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Abstract 
It is increasingly recognized that maternal health and nutritional status prior to and 
during pregnancy are important determinants of fetal outcome. Fetuses exposed to a 
suboptimal in utero environment are at higher risk of developing adult onset diseases 
including: type 2 diabetes, insulin resistance and obesity. Maternal alcohol intake 
has been extensively studied when consumed during pregnancy, at different doses, 
and different exposure periods. Many of these – including studies investigating low 
levels of prenatal alcohol consumption – have demonstrated abnormal development 
of fetal organs and alterations in metabolic pathways that persists into adulthood and 
commonly result in insulin resistance and glucose intolerance. Many women who 
consume alcohol do however cease upon pregnancy recognition – but the effects of 
alcohol consumption during the periconceptional period (defined as prior to 
conception until preimplantation) on adult offspring metabolism are still to be 
investigated. Therefore, the focus of this thesis was to ascertain whether 
periconceptional alcohol exposure (PC:EtOH-exposure) results in persisting 
metabolic effects in the adult offspring; and whether this was mediated via placental 
dysfunction. In addition, as adult onset disease initially programmed in utero can be 
potentiated or first revealed by a mismatch between the pre- and postnatal 
environment, or a ‘second hit’, this thesis also investigated the interaction between 
PC:EtOH-exposure and a postnatal consumption of a western diet (WD). 
 
As a part of this thesis, a rat model of maternal alcohol consumption (moderate to 
high) was developed. 12.5% alcohol (v/v) was administered via a liquid diet to dams 
from 4 days pre-conception until 4 days after confirmation of pregnancy (PC:EtOH 
group). Control dams were given a nutritional equal liquid diet but without alcohol 
during the exposure period (untreated (U) group). Separate cohorts of rats were 
generated to study the offspring at different ages: one subset of dams was assigned 
for studies of the late gestation fetus and investigation of the placenta on embryonic 
day (E)20 (Chapter 3); another subset of dams littered down naturally to allow for 
examination of physiological parameters at 6-8 months of age in offspring consuming 
a control diet (C) (U:C and PC:EtOH:C), and in combination with a WD (U:WD and 
PC:EtOH:WD) (Chapter 4 & 5). Physiological parameters in the offspring included 
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investigation of glucose- and insulin homeostasis via a glucose tolerance test (GTT) 
and an insulin tolerance test (ITT); and assessment of the body composition via a 
dual X-ray (DXA)-scan. Plasma at different ages throughout development was 
assessed and tissue (predominantly the placenta, liver, adipose tissue and muscle) 
were investigated with quantitative polymerase chain reaction (qPCR), western 
blotting and histology. 
 
PC:EtOH-exposure resulted in fetal growth restriction, increased the placenta:body 
weight ratio, and increased placental length and width in both males and females. 
Morphological analyses of the placenta revealed that the increase in placental size 
primarily was accounted for by increases in the junctional zone and sex-specific 
increases in the cross-sectional area of apparent glycogen cells. These changes 
were associated with sex-specific alterations in a wide array of placental genes and 
proteins involved in nutrient transportation and vasculogenesis. Importantly, the 
protective enzyme 11-beta hydroxysteroid dehydrogenase (11βHsd-2) was 
expressed at higher levels in the labyrinth zone of the placenta, which is suggestive 
of an augmented stress-response, apparent well beyond the exposure window. 
mRNA levels of DNA methyltransferases were also increased in the fetal liver, 
suggesting a potential epigenetic involvement.  
 
In adulthood – regardless of postnatal diet – both male and female offspring were 
glucose intolerant and insensitive to exogenous insulin. This was associated with 
increased hepatic gluconeogenesis and sex-specific alterations in peripheral insulin 
signaling. Male, but not female offspring had an increased percentage of total- and 
abdominal fat mass; and had developed a more advanced stage of hepatic steatosis. 
The plasma lipid composition was abnormal; and the levels of gene expression of 
inflammatory genes were increased in both sexes. While the interactive effects of 
PC:EtOH and a postnatal WD were negligible in female offspring, a WD exacerbated 
the degree of insulin insensitivity and hepatic steatosis in PC:EtOH-exposed male 
offspring. Often, the phenotypes created by PC:EtOH and a WD were similar – 
suggesting the effects of PC:EtOH on adult metabolism in some circumstances are 
comparable to those seen after consuming a WD for the major part of adult life. 
 
This thesis has provided compelling experimental evidence that maternal 
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periconceptional alcohol consumption can program the offspring to adult onset 
disease. This information should be taken into account when developing public 
policy guidelines regarding alcohol intake prior to and during early pregnancy and 
made available to women of childbearing age. 
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CHAPTER 1 
 
Review of Literature 
 
1.1 Introduction  
The metabolic syndrome is a cluster of conditions that includes insulin resistance, 
hypertension, dyslipidaemia and central obesity (Eckel et al., 2005, Grundy, 2008). 
This disease is often accompanied by other medical conditions such as fatty liver, 
depression, obstructive sleep apnoea and cholesterol gallstones (Grundy, 2008) – all 
of which constitutes an economic burden for both the individual and society. 
Although the prevalence of metabolic syndrome declined over the last year, 56% of 
the U.S population are currently obese, and insulin resistance is projected to affect 
366 million Americans by 2030 (Beltran-Sanchez et al., 2013, Wild et al., 2004). 
Many factors contribute to this: a sedentary lifestyle; low energy expenditure; and the 
easy access to highly calorific food (Bell et al., 2005). However, epidemiological and 
experimental studies now highlight the periconceptional (PC) and prenatal periods as 
critical for long-term development – suggesting a suboptimal in utero environment 
may program adult disorders. This idea originates in the ‘Barker hypothesis’ after 
David Barker with colleagues discovered a link between low birth weight, mortality 
rates from stroke and cardiovascular disease (CVD) and poor maternal nutrition in 
the UK (Barker and Osmond, 1986). The ‘Barker hypothesis’ – now referred to as 
‘developmental origin of health and disease’ (DOHaD) – escalated to include other 
maternal perturbations (present both during pregnancy and/or during early postnatal 
life) including: maternal obesity (Samuelsson et al., 2008), diabetes (Honda et al., 
1990, Moley, 1999) overnutrition (Rattanatray et al., 2010), glucocorticoid exposure 
(Cuffe et al., 2012), micronutrient deficiency (Maloney et al., 2011) and alcohol 
intake (Chen and Nyomba, 2004, Lopez-Tejero et al., 1989). Altered birth 
phenotypes, including low birth weight (Langley and Jackson, 1994, Kwong et al., 
2000, Watkins et al., 2011, Probyn et al., 2012, Chen and Nyomba, 2003a, 
Pennington et al., 2002) and altered organ development, either independently or in 
association with other maternal perturbations (Louey et al., 2000, Wlodek et al., 
Chapter 1 Review of Literature 
 
2 
 
2007) is commonly seen in these models, increasing the susceptibility to adult 
diseases such as insulin resistance, CVD, anxiety, fatty liver. Interestingly, many of 
these phenotypes have been demonstrated following maternal alcohol consumption 
(Chen and Nyomba, 2003b, Chen and Nyomba, 2004, Yao et al., 2006, Pennington 
et al., 2002), a common social habit amongst women of childbearing age. These 
studies (like most DOHaD studies) examined the effects of alcohol when consumed 
prenatally, often throughout pregnancy, although women are far more likely to drink 
in the PC period, before awareness of their pregnancy (Nykjaer et al., 2014, 
Kesmodel, 2001, Carmichael et al., 2003, Colvin et al., 2007, Mullally et al., 2011).  
The PC period (defined in this thesis as the time prior to conception until blastocyst 
implantation) is now regarded as a ‘critical window of development’ as it coincides 
with important stages of embryonic development including: cell division, genome 
activation and epigenetic reprogramming. Animal models examining PC insults 
(often nutritional perturbations, such as under- and overnutrition, low protein diets 
and vitamin deficiency) demonstrate similar adult outcomes as those exposing the 
fetus during the entire pregnancy (Watkins et al., 2011, Joshi et al., 2003, Jaquiery et 
al., 2012, Rattanatray et al., 2010, Sinclair et al., 2007). Alcohol has the ability to 
diffuse into the oviduct and uterus (Mitchell, 1994) and affect blastocyst development 
and implantation (Mitchell, 1994, Mitchell and Goldman, 1996, Cebral et al., 1999, 
Cebral et al., 2000). However, no one has examined the long-term effects of 
periconceptional alcohol consumption (PC:EtOH) in developmental programming.  
This thesis reviews the literature regarding DOHaD, focusing on maternal alcohol 
intake (both prenatal and periconceptional) as the maternal insult. Consideration is 
then given to placental insufficiency as a mechanism, and metabolic outcomes in the 
adult offspring. Many experimental studies suggest females to be ‘protected’ from 
programmed adult disease as prenatal insults typically generates sexually dimorphic 
differences – with stronger phenotypes frequently seen in male offspring (Di Renzo 
et al., 2007, Smith et al., 2010, Watkins et al., 2011, Maloney et al., 2011). More 
recent evidence suggest that postnatal stressors and ‘second hits’ (for example 
dietary modifications, pregnancy itself, stress or disease) can reveal or exacerbate a 
programmed phenotype, often in both males and females (Rueda-Clausen et al., 
2011, Chen and Nyomba, 2003b). This highlights the significance to consider both 
sexes in experimental studies; and the influence of environmental factors on the 
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future disease picture. This will serve as a rationale for the subsequent studies in this 
thesis, which aimed to determine whether maternal PC alcohol intake: (1) affects 
placental biochemistry; (2) increases the susceptibility of the adult rat offspring to 
develop metabolic dysfunction; and (3) interacts with a postnatal consumption of a 
western diet (WD) to reveal or exacerbate this phenotype. 
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1.2 Developmental origins of health and disease (DOHaD) 
Over the last 20-25 years, a concept has developed that maternal insults during 
pregnancy can program the risks for adult diseases in the offspring (Barker, 2004). 
David Barker and his colleagues in the United Kingdom were the first group to 
publish the theory of ‘early’ or ‘fetal origins of adult disease’, after discovering a link 
between low birth weights and mortality rates from stroke and CVD in specific 
geographical regions. The group suggested that poor maternal nutrition and health 
contributed to a high rate of neonatal death, and that surviving children (often born 
small) had a greater risk of dying from CVD as adults compared with children born to 
healthy mothers (Barker and Osmond, 1986). The ‘Barker hypothesis’ generated 
large interest worldwide and was soon replicated in a number of other studies 
(Frankel et al., 1996, Rich-Edwards et al., 1997, Leon et al., 1998, Stein et al., 1996). 
Barker later proposed humans to be ‘plastic’ and able to adapt to the intrauterine 
environment. He explained ‘developmental plasticity’ as the ability of a genotype to 
respond to a critical intrauterine environment and produce more than one alternative 
phenotype (Barker, 2004).  
1.2.1 The thrifty phenotype 
The ‘thrifty phenotype’ hypothesis extends developmental plasticity further. This 
theory suggests that the fetus can respond to a suboptimal intrauterine environment 
by preserving the growth of key organs (eg, the brain) on the expense of less 
important organs, (eg, the liver, pancreas and muscle) to increase its chance to 
survive in the poor in utero conditions. (Gluckman et al., 2005, Barker, 2004, Hales 
and Barker, 2001). These responses, however, may induce permanent alterations in 
tissue gene expression, metabolic pathways and epigenetic regulations that affects 
the offspring’s risk of developing diseases in adulthood (Lucas, 1991) (Figure 1.1). 
Gluckman and Hanson (2006) have presented ‘the predictive adaptability 
hypothesis’, which states that the fetus, based on its intrauterine environment can 
‘predict’ its postnatal environment to gain a competitive advantage postnatally. When 
the fetus experiences a mismatch between the pre- and postnatal environments, 
these early adaptations becomes unfavorable.  
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Used interchangeably, these theories describe and highlight the importance of how 
suboptimal in utero environments can result in adult diseases. 
 
 
Figure 1.1 – A schematic presentation of developmental origin of health and disease  
The concept ‘developmental origin of health and disease’ states that maternal insults during 
pregnancy can interfere with fetal development via a range of different mechanisms that 
independently, or in combination can increase the susceptibility, or ‘program’ the fetus for adult 
onset disease.  
  
 
1.2.2 Prenatal famine exposure 
 
Although tragic, one of the best human ‘experiments’ of programming of disease 
which provides supportive evidence to the 'thrifty phenotype hypothesis' and 
highlights the importance of the timing of exposure is the ‘Dutch hunger winter’. 
Between September 1944 and May 1945, the Netherlands were facing an extremely 
severe winter which combined with war rations resulted in people, including pregnant 
women, having a daily energy intake of 400-1600 calories (Hart, 1993). The pattern 
of undernutrition differed between pregnancies: some women were undernourished 
Maternal insults
Global over/undernutrition, gestational diabetes, obesity, anemia, stress,  smoking, 
alcohol intake, drug abuse, protein malnutrition, hypoxia, vitamin deficiency
Fetal programming
Organ remodeling, altered growth patterns, 
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throughout pregnancy, others during one specific trimester, or prior to or after birth. 
Long term follow up studies on offspring has provided significant insights regarding 
the timing of exposure, as different exposure periods generated different health 
outcomes. For example, babies exposed to starvation during early but not late 
gestation were more likely to develop obesity and CVD as adults (Barker et al., 
1990), whereas the lipid profile was altered in all exposure groups of the Dutch 
famine (Glazier et al., 1992). It was also found that adverse adult health outcomes 
could arise despite normal birth weights (Barker et al., 1990). Other observational 
studies following natural famine events showed similar results: many babies exposed 
to the 19th century crop failure in Sweden (Moore et al., 1996), or to the Great Leap 
famine in China (Roberts et al., 2008) developed adult CVD and diabetes; and 
individuals prenatally exposed to malnutrition in the Leningrad siege study had an 
increased risk of adult obesity (Winder et al., 2011). Collectively, prenatal famine 
outcomes strengthen the evidences that elements of metabolic disease can be 
programmed. 
 
1.2.3 Intrauterine growth restriction 
Intrauterine growth restriction (IUGR) refers to a condition in which the fetus is 
smaller than it should be at a certain gestational age (Varvarigou, 2010). This is 
dissimilar to preterm infants, whom are not always born small for their gestational 
age (Wilcox, 2001). Small for their gestational age (SGA) infants may however be 
small because of IUGR – or they may be small despite following a normal growth 
pattern in utero (Varvarigou, 2010). Thus IUGR and SGA should not be used 
interchangeably. Low birth weight – which is a good indication of IUGR – is defined 
as birth weight and/or length being at least two standard deviations below the mean 
for gestational age of the overall reference population (Gluckman et al., 2007). The 
number of babies born with low birth weight increased by nearly 20% between 1990 
and 2006 and affected ~8% of all babies worldwide in 2009 (Martin et al., 2011). As 
a baby’s birth weight is influenced by complex interactions between maternal, 
placental and fetal factors (Varvarigou, 2010), a low birth weight – which is 
associated with adult disease (Eriksson et al., 2000, Stein et al., 1996) – can result 
from dysregulations in all these factors. 
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1.2.4 Catch-up growth 
~85% of SGA babies experience ‘catch-up growth’ postnatally (Albertsson-Wikland 
et al., 1993), accelerating their growth rate to restore weight, length and head 
circumference by late childhood (Eriksson et al., 1999). This increases the risk for 
high body mass index (BMI), blood pressure and insulin resistance already during 
adolescence (Jaquet et al., 2000, Crowther et al., 1998). Crowther et al. (1998) 
reported that SGA children who underwent a rapid catch-up growth became glucose 
intolerant already at age 7 in a South African cohort. Similar result were found by 
Eriksson et al. (1999), who also demonstrated that boys born thin (a factor of IUGR) 
in conjunction with accelerated postnatal growth had the highest mortality rate from 
coronary heart disease (Eriksson et al., 1999).  
It is likely that SGA babies accelerate their postnatal growth to compensate for the 
previously constrained growth pattern, but the mechanism linking catch-up growth to 
adult disease is unclear. One suggestion is that increased adiposity contributes to 
the adverse metabolic phenotypes commonly seen in these children, as an 
accelerated growth pattern is more beneficial for fat mass than lean mass (Hediger 
et al., 1998). This is supported by Leunissen et al. (2008) who suggest that fat 
accumulation – independent of birth size – is the only significant marker of insulin 
insensitivity. The group refers to this as the ‘fat accumulation hypotheses’ and 
proposes that growth acceleration only becomes problematic when it causes fat 
accumulation (Leunissen et al., 2008), because increased fat mass is associated 
with dysregulation of free fatty acids and adipocytokines (Van Gaal et al., 2006) 
which affect insulin sensitivity (see section 1.7.2.2.2). 
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1.3 Timing of exposure to a sub-optimal environment  
As evident from the famine studies, the timing of exposure to an insult plays a large 
role in determining the outcome of disease. There are many ‘critical developmental 
windows’ in which the embryo or fetus is at higher risk of being programmed to adult 
disease (Figure 1.2). Some of the better understood ones are organogenesis and 
early postnatal growth – as the exposure period often coincides with the 
developmental stage of a particular organ or organ system. More recent studies 
have also started to recognize the PC period (prior to conception until blastocyst 
implantation) as a critical developmental window. The following sections review the 
importance of the timing of exposure. 
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Figure 1.2 – Critical windows of development susceptible to programmed disease 
A summary of some of the critical developmental windows identified as vulnerable to maternal 
perturbations. This highlights the susceptible events and potential mechanisms which may program 
adult disease.  
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1.3.1 The periconceptional period  
The PC period is defined as a time prior to conception until blastocyst implantation. 
In this thesis, this time span is defined as 4 days prior to conception until embryonic 
day (E)4. This definition does however differ between studies, and the length of the 
preimplantation development varies between species, which complicates the 
comparison of results. 
To fully understand the concept of PC programming, it is important to be familiar with 
the preimplantation development. Therefore, before discussing the PC period in 
programming of disease, a brief presentation of embryonic development is provided. 
1.3.1.1 Preimplantation development 
 
 
 
 
 
Figure 1.3 – Human versus rat preimplantation development 
A comparison between the preimplantation blastocyst in human (pink) compared with rats (blue).  
 
In mammals, the fertilization of the oocyte and sperm occur in the ampulla of the 
oviduct, from which the fertilized zygote must travel to the uterus to implant as a 
blastocyst. This time span – referred to as ‘preimplantation development’ – marks 
the beginning of embryogenesis and precedes pregnancy recognition (Watson, 
1992). Complex hormonal and metabolic interactions are occurring between the 
embryo and maternal environment at this stage (Watson, 1992, Watson and 
Barcroft, 2001). Processes fundamental for a successful preimplantation 
development including: zygote cleavage divisions, genomic activation, compaction 
and cavitation, ultimately result in an attachment-competent blastocyst on E4 
(Watson, 1992, Watson and Barcroft, 2001). 
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The replication of cell numbers up to the 8-cell stage in which compaction – the initial 
event of morphological transition and cellular differentiation – begins in both human 
and rat are relatively synchronous (Hardy et al., 1989, Reeve, 1981, Pratt et al., 
1982). During compaction, the cells become compressed to maximize cell contact 
and to develop intercellular junctions (Watson, 1992). At the 16-cell stage, the 
embryo becomes double layered with two distinct cell populations; the polarized 
blastomeres on the outside; and the apolar blastomeres on the inside (Watson, 
1992). In a successful implantation, the cell mass becomes uniform to form a morula 
(Ducibella and Anderson, 1975). In the morula, the outer cells give rise to specialized 
trophectoderm cells (TE) (which later differentiate into trophoblasts to mediate 
attachment to the uterine wall); and the inner cells forms the inner cell mass (ICM) 
(which later form all the tissues of the embryo’s body) (Jones and Thomson, 2000, 
Watson and Barcroft, 2001, Watson, 1992). The trophoblast lineage is also essential 
for placental development – the first organ to be formed in embryogenesis 
(Scharfmann, 2000).  
During cavitation (following compaction and the differentiation of the TE from the 
ICM), the morula becomes a blastocyst (Watson, 1992, Watson and Barcroft, 2001). 
At E4 in rat and E5-7 in human, the blastocyst reaches the uterus, however since it 
is not yet implanted in the uterine wall, it is still considered a preimplantation embryo 
(Aplin, 2000). In the uterus, the blastocyst ‘hatches’ out of the zona pellucida, which 
protectively has surrounded the oocyte to prevent implantation in the oviduct wall. 
Implantation usually starts late on E5 in the rat and is completed late on E6 (Mitchell, 
1994). In the human, implantation normally occurs between 7-11 days after ovulation 
(Aplin, 2000). Pregnancy is not recognized until successful implantation, thus 
successful blastocyst formation is crucial for the establishment of pregnancy. The 
similar temporal embryonic development between human and rat is demonstrated in 
Figure 1.3.  
1.3.1.2 Programming of metabolic outcomes by periconceptional exposures 
Via largely unknown mechanisms, the preimplantation embryo is able to sense and 
react to the maternal environment. Animal models of PC programming have started 
to provide evidence of how maternal insults; preceding both implantation and 
conception are capable to program adult disease. These studies have mainly 
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focused on maternal dietary modifications including: low protein diets (Watkins et al., 
2011, Kwong et al., 2000), global undernutrition (Gardner et al., 2004), increased 
energy intake (Rattanatray et al., 2010) and methionine deficient (MD) diets 
(Maloney et al., 2011, Sinclair et al., 2007). Table 1.1 summarizes maternal PC 
perturbations and the programmed metabolic phenotype. 
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Table 1.1 Periconceptional programming of disease  
PC insult Species Exposure period Timing of exposure Phenotype Reference 
Lo
w
 p
ro
te
in
 d
ie
t 
Mouse 
9% compared with isocaloric 
normal protein controls (18%) 
0-3.5 days gestation Increased systolic blood pressure in adults Increased body weight (adult females only) 
(Watkins et al., 
2011) 
Mouse -3.5 days until mating Increased systolic blood pressure at 21 weeks  Attenuated vasodilation 
(Watkins et al., 
2008) 
Rat 0-4.25 days gestation 
Low birth weight 
Accelerated postnatal growth 
Adult hypertension 
(Kwong et al., 2000) 
Rat 50% of normal protein intake -8 weeks until mating Increased blood glucose levels at 94 days Increased blood cholesterol at 180 days (Joshi et al., 2003) 
U
nd
er
nu
tr
iti
on
 
Sheep 
50% of normal calorie intake 0-30 days gestation 
Increased pulse pressure 
Reduced rate pressure product 
(Gardner et al., 
2004) 
Sheep No effect on glucose tolerance (Gardner et al., 2005) 
Sheep 
Fasted for 2 days, then 
concentrates of 1-2% of body 
weight per day (control group 
received 3-4% and no fasting) 
-61-30 days gestation 
Increased plasma insulin response to a glucose 
load (E115 fetus) 
Increased plasma taurine levels (E115 fetus) 
(Oliver et al., 2001) 
Sheep Individually adjusted feeding regimen to achieve and 
maintain a weight loss of 10-
15% body weight 
-61-0 days and -2-30 days 
gestation 
Greater % fat mass and perirenal rat at 3-4 
years of age (males only)  
(Jaquiery et al., 
2012) 
Sheep -61-30 days gestation Glucose intolerance at 10 months of age (Todd et al., 2009) 
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Table 1.1 Periconceptional programming of disease (cont.)  
PC insult Species Exposure period Timing of exposure Phenotype Reference 
U
nd
er
nu
tr
iti
on
 
Sheep 70% of energy requirement -28-7 days gestation 
Lower plasma glucose and higher plasma 
insulin levels at birth (males only) 
Increased insulin response to a glucose load 
(males only) 
(Smith et al., 2010) 
Sheep 70% of the energy requirement during treatment period -60-6 days and 0-6 days 
Altered expression of microRNAs associated 
with alterations in the insulin signaling 
pathway 
(Lie et al., 2014) 
O
ve
r-
nu
tr
iti
on
 
Sheep 170-190% maintenance energy requirements 
-5 months-preimplantation 
when embryos were 
transferred to non-obese 
ewes 
Increased body fat mass in females at 4 
months of age 
(Rattanatray et al., 
2010) 
Vi
ta
m
in
 d
ef
ic
ie
nc
y 
Sheep Folate, vitamin B12 and methionine deficient diet 
-2 months-6 days 
gestation when embryos 
were transferred to 
normal fed surrogate 
mothers 
Increased body weight and body fat in 
adulthood 
Insulin resistance 
Elevated blood pressure 
(Sinclair et al., 
2007) 
Rat Folate, choline and methionine deficient diet -3 weeks-5 days gestation Glucose intolerance at 6 months (males only) 
(Maloney et al., 
2011) 
      
PC, periconceptional
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1.3.1.3 Mechanisms of programming in the periconceptional period 
A few research groups have attempted to mechanistically describe programming of 
disease following periconceptional insults. Kwong et al. (2000) showed that PC low 
protein diets in rat caused hypertension in the offspring. They linked this to changes 
in both the maternal environment (dams were mildly hyperglycaemic and deficient in 
insulin and essential amino acids); and to the blastocyst development (the early 
blastocyst displayed reduced cell numbers within the ICM and the mid/late stage 
blastocyst had reduced cell number in the TE linages). Maternal hyperglycaemia has 
previously been shown to impact on the preimplantation embryo (Moley, 1999). For 
example, rat blastocysts (E5) incubated in a hyperglycaemic environment in vitro 
have overall a reduced number of cells (but more apoptotic cells) in the ICM 
(Pampfer et al., 1997).  
The preimplantation embryo is extremely responsive to its environment and 
susceptible to epigenetic perturbations, mechanisms believed to play a role in 
programming of disease (Ikeda et al., 2012). Sinclair et al. (2007) exposed female 
sheep to a folate, vitamin B12 and MD diet 8 weeks prior to until 6 days after 
conception, before transferring the embryos to normal fed surrogate mothers. The 
birth weights were unaffected by the MD diet, but the older offspring weighed more, 
had increased body fat percentage, elevated blood pressure, and were insulin 
resistant. All phenotypes were exaggerated in male offspring. A restriction landmark 
genome scanning in liver of 90d old offspring demonstrated altered methylation 
status of 4% of the 1.400 CpG loci studied, with 88% of the loci being unmethylated 
or hypometylated (Sinclair et al., 2007). This supports the concept that an insult 
exclusively present during the PC period can cause epigenetic alterations in 
offspring deoxyribonucleic acid (DNA). Similarly, a MD diet administered to rats in 
the PC period (3 weeks prior to conception until 5 days after) caused glucose 
intolerance in male offspring aged 26 weeks (Maloney et al., 2011).  
The origins of periconceptionally programmed disease may also be due to events 
occurring well beyond the exposure time. Watkins et al. (2011) showed increased 
gene expression of insulin receptor and the insulin like growth factor 1 receptor 
(Igf1R) in white adipose tissue and reduced uncoupling protein 1 (Ucp1) in brown 
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adipose tissue in adult female mice following PC low protein diet, which they 
suggested explained the energy storing phenotype.  
Alcohol in periconceptional programming is discussed in section 1.6.6.1. 
1.3.2 Prenatal programming of metabolic outcomes  
Prenatal perturbations have been extensively investigated in DOHaD to study 
programming of metabolic disease and shall not be reviewed here is great detail (for 
review see (Brenseke et al., 2013, Langley-Evans and McMullen, 2010)). Soon after 
Barker proposed his hypothesis, Langley and Jackson (1994) reported that rat 
offspring of protein restricted dams (9 or 6% throughout pregnancy) had elevated 
systolic blood pressure at 9 and 21 weeks. This was associated with increases in 
pulmonary angiotensin-converting enzyme activity. Similar increases in systolic 
blood pressure at various ages have been demonstrated in a number of protein 
restricted animal models in which the diet has been maintained throughout 
pregnancy (Langley-Evans et al., 1996a, Langley-Evans et al., 1996b, Nwagwu et 
al., 2000, Brawley et al., 2003, Langley-Evans et al., 1999), often accompanied by 
changes in kidney nephron number (Langley-Evans et al., 1999) and altered kidney 
function (Langley-Evans et al., 1999, Nwagwu et al., 2000, Langley-Evans et al., 
1996a). Other components of programmed metabolic diseases following a prenatal 
perturbation includes insulin insensitivity and glucose intolerance which has been 
demonstrated in models of maternal undernutrition (Vickers et al., 2000), 
glucocorticoid exposure (Drake et al., 2005) and maternal protein restriction (Ozanne 
et al., 2003). Underlying mechanisms to programmed glucose- and insulin 
homeostasis, the main focus of this thesis, are discussed further in section 1.6.6.2 
and in section 1.7.1.4. 
1.3.3 Interactions between prenatal and postnatal environments 
As discussed in section 1.2.1, a suboptimal fetal environment alone can be 
detrimental – but it is often the mismatch between the predicted and experienced 
postnatal environment that causes permanent changes in offspring physiology. 
Evidence for this is derived from cross-fostering studies. Ozanne et al. (2004) 
showed that prenatally protein restricted male mice cross-fostered to control dams 
experienced a fast catch-up growth despite being born small, whereas control pups 
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cross-fostered to low protein fed dams were growth restricted at weaning. Similarly, 
Gorski et al (2006) showed that obese-prone rat pups cross-fostered to obese-
resistant dams improved their insulin sensitivity, despite remaining obese. 
Correspondingly, obese-resistant pups cross-fostered to genetically obese dams 
increased their adiposity, and insulin and leptin receptors (Gorski et al., 2006).  
Also a later deviant postnatal environment can exacerbate or unmask disease 
originally programmed in utero (Eriksson et al., 1999). Most studies investigating this 
have focused on the postnatal diet, including diets rich in salt or fat, however this 
‘second hit’ can also be exposure to other factors such as stress, pregnancy or 
disease. Yan et al (2014) showed that male offspring of dams with induced 
gestational diabetes had an accelerated blood pressure change at 20 weeks of age 
when fed a high salt diet (8%) after weaning. Petry et al (2007) showed that rats 
exposed to a low-protein diet (8%) in utero and during lactation had an additive risk 
of developing high blood pressure when consuming a cafeteria style diet for 70 days 
at 1 year of age compared with rats of either one exposure. Consistently, rats 
exposed to undernutrition (30%) throughout gestation and fed a hyper-caloric diet 
(30% fat) from weaning had higher systolic blood pressure at 14 weeks of age 
compared with rats of either one exposure (Vickers et al., 2000). Chen and Nyomba 
(2003b) found an interactive effect of in utero EtOH-exposure and a postnatal high-
fat diet, in which rats exposed to both conditions displayed an exacerbated increase 
in glucose intolerance and insulin secretion following a glucose load. More recently, 
Shen et al (2014) demonstrated a significantly increased susceptibility to non-
alcoholic fatty liver disease (NAFLD) in female rat offspring prenatally exposed to 
EtOH (E11-E20) after consuming a high-fat diet since weaning. 
The influence of the postnatal environment is important as it may reveal in utero 
programmed diseases, but also because food preferences themselves can be 
programmed (Brenseke et al., 2013). Bellinger et al (2004) found that rat offspring 
exposed to protein restriction in utero preferred a high-fat diet over diets rich in 
carbohydrates or protein at 12 weeks of age. While this demonstrates how a certain 
food pattern might be the preferred one (and therefore a likely change of the 
postnatal environment), it is important to emphasize that the dosage used in animal 
studies are not always comparable to a human scenario. For example, the 8% 
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sodium diet used in the study by Yan et al (2014) has 16-fold higher sodium levels 
compared with the recommended rodent diet of 0.5% sodium (Martus et al., 2005). 
For a human, that would be equivalent to a daily intake of 32g sodium 
(recommended intake is <2g/d). The mean sodium intake (globally) was however 
estimated to 3.95g daily in 2010 (Powles et al., 2013) and therefore the physiological 
relevance of such experiment is limited. Secondly, the time point by which the 
‘second hit’ is introduced is not always realistic. It is for example questionable that a 
30% undernutrition throughout pregnancy changes to a hyper-caloric diet containing 
30% fat from the day of weaning, as was the case in Vickers et al (2000) study; or 
that a normal diet during weaning changes to a high-fat diet after weaning (when the 
rat is only 28-30 days old) as in the study of Shen et al (2014). Introducing a dietary 
intervention (as a second hit) is more realistic later in life, for example at a time point 
equivalent to a teenager moving out of home. 
1.4 Sex differences in fetal programming 
There is a general belief that male fetuses are more vulnerable to the in utero 
environment, while females have been assumed to be ‘protected’ from programmed 
disease. This is because adverse pregnancy outcomes including miscarriage, 
rupture of the fetal membranes and premature birth, are more common when the 
fetus is a male (Di Renzo et al., 2007). Women carrying male fetuses also have 
higher rates of gestational diabetes mellitus, fetal macrosomia, cord prolapse and 
true umbilical cord knots (Sheiner et al., 2004) and are more likely to deliver via 
caesarean section (Ingemarsson, 2003). Some of these sex differences may be 
attributable to the fact that male fetuses grow more quickly – even during 
embryogenesis (Mittwoch, 1993) – and have higher nutritional demands during 
pregnancy compared with females (Pedersen, 1980). 
Many epidemiological studies support gender disparities in fetal programming. 
Flanagan et al (2000) showed that men who were lighter or shorter at birth were 
insulin insensitive at 20 years of age, but the same correlation was not found in 
growth restriction females. This is consistent with other epidemiological (Fall et al., 
1995, Hales et al., 1991) and animal studies (Desai et al., 1997). Desai et al (1997) 
showed that male, but not female offspring prenatally exposed to protein restriction 
were glucose intolerant at 12 weeks of age. Gender disparities have also been 
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demonstrated following PC perturbations. For example, in the study of Sinclair et al 
(2007) with the MD diet (see section 1.3.1.3) the insulin resistance and increased 
blood pressure were more pronounced in male offspring. A PC MD diet has also 
been shown to increase the homeostatic model for assessment of insulin resistance 
(HOMA-IR) and cause glucose intolerance in male, but not female rat offspring 
(Maloney et al., 2011). In the study by Kwong et al (2000), the PC low protein diet 
increased the systolic blood pressure in male offspring only.  
Because of these and other studies, males are believed to “live dangerously in the 
womb”. In their efforts to maximize overall body weight and size (in the presence of 
an in utero perturbation) other organs and tissues may become compromised and 
increase the susceptibility to disease. Differences in the levels of sex hormones are 
believed to contribute to sex-specific effects, as they may have an influence both 
during fetal and postnatal life (Reckelhoff et al., 1998). Ojeda et al (2007a) found that 
IUGR male rat offspring became hypertensive at 16 weeks of age due to elevated 
testosterone levels whereas their female counterparts were protected by estrogen. 
Furthermore, they demonstrated how castration alleviated male hypertension (Ojeda 
et al., 2007b). These results have caused many researchers to only study male 
offspring in developmental programming. Many researchers also only consider 
offspring at a younger age, while studying female offspring may be more important 
later in life considering the change in estrogen levels in menopausal women. Indeed, 
the hypertension incidence increases in humans after menopause (Schulman et al., 
2006); and ovariectomy induces hypertension in IUGR female rat offspring already at 
a younger age (Ojeda et al., 2007a). 
The mechanisms underpinning the sex differences in programming are unknown but 
current research has focused on differential placenta responses of males and 
females to a gestational insult. In order to understand the role of the placenta in sex-
specific programming, it is important to understand how the placenta develops and 
functions. 
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1.5 The role of the placenta in fetal programming 
Adult disease can be programmed by alterations in the development of specific 
organs or organ systems that are developing at time of exposure. The placenta – the 
first organ to form in embryogenesis – unites the fetal and maternal environments, 
produces hormones and serves as a site for exchange of nutrients, gases and waste 
products between the mother and the fetus (Salafia et al., 2007). Thus disrupted 
placental function will greatly impact on development and birth weight. It is 
suggested that any genetic or environmental insult that interferes with placental 
development, nutrient transport or vascularization at any stage of gestation can 
cause placental insufficiency, fetal growth retardation and death (Scharfmann, 2000). 
Thus a healthy and normally functional placenta is essential for a successful 
pregnancy outcome. 
Although PC exposures precede organogenesis, it may still impair the initial 
clustering of embryonic cells that later will form both the placenta and embryo 
proper. As this thesis investigated the role of the placenta in PC programming, a 
brief introduction to placentation, utero-placental insufficiency, and placenta in fetal 
programming will be provided in the following sections.  
1.5.1 Placentation in human and rat 
Rat models have become important in placental studies due to the strikingly 
similarities to human placentation and organization: both have a hemochorial 
placenta where the maternal blood has direct contact with the chorion; the placentas 
are discoid shaped; the intrauterine trophoblast invasion is deep (compared with the 
mouse placenta) (Ain et al., 2003); and the uterine implantation is similar (Soares et 
al., 2012). There are, however still some differences in the timing of placentation and 
in placental structure. The following paragraphs will therefore compare some of the 
main events in rat and human placentation.   
In human development, the trophoblast cell line starts to differentiate 4-5 days post-
conception (between the morula and blastocyst stage). Following differentiation, the 
blastocyst consists of an ICM (which later forms the embryo, umbilical cord and 
placental mesenchyme); and a surrounding layer of mono-nucleated trophoblasts 
(which later forms the placenta and fetal membranes) (Huppertz, 2008). Placentation 
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(and the implantation period) starts 6-7 days post-conception, when the blastocyst 
hatches from the surrounding zona pellucida and attaches to the uterine epithelium 
(Aplin, 2000). During the pre-lacunar stage (first stage of implantation) the polar 
trophoblasts (the outer layer of trophoblast cells) orient the blastocyst and fuse with 
the uterine and syncytial epithelium to form an oligo-nucleated syncytiotrophoblast – 
the first embryonic tissue with direct contact to maternal cells and fluids (Huppertz, 
2008). Remaining cytotrophoblast cells (from the mono-nucleated trophoblast linage) 
act as stem cells, fusing with and expanding the syncytiotrophoblast (Potgens et al., 
2002). In the lacunar stage (8 days post-conception), the syncytiotrophoblast exhibits 
fluid filled spaces which merges to generate larger lacunae; while the spaces around 
and between the lacunae (the trabeculae) forms the placental villous tree. The 
lacunae/trabeculae later develop into the intervillious space. At this stage, the 
placenta also consists of an early chronic plate (facing the embryo), and the primitive 
basal plate (facing the maternal endometrium) (Huppertz, 2008). Invading 
syncytiotrophoblast cells starts to penetrate the interstitium of the endometrium, to 
create contact with maternal capillaries. To prepare the maternal system for 
pregnancy, these cells starts to surround the uterine spiral arteries and stimulate 
maternal blood flow to the implantation site via endocrine signaling (Hertig et al., 
1956). Implantation is finalized at around 12 days post-conception, when the embryo 
and surrounding tissues are completely embedded in the endometrtium (Huppertz, 
2008). During the villous stage of placental development (13 days post-conception), 
the trophoblasts starts to differentiate into primary villi. As the mesenchyme invades 
the primary villi, their size increases to generate secondary chorionic villi (21 days 
post-conception) (Kingdom et al., 2000). This coincides with the formation of the first 
placental blood- and endothelial cells, independent of the vascular system 
(Dempsey, 1972). As the secondary villi undergo vasculogenesis to form tertiary 
chorionic villi, the villous trees – the major regulatory site for transplacental transport 
of nutrients and waste – are complete (Kingdom et al., 2000, Chaddha et al., 2004).  
In contrast to human placentation, rat placentation starts on E3.5 (Watson and 
Cross, 2005). Embryo implantation occur at the anti-mesometrial side of the uterus 
already around E4.5, whereas the placental formation takes place at the mesometrial 
side (de Rijk et al., 2002) (Figure 1.4). The placenta develops from the 
extraembryonic ectoderm (the outer layer of the blastocyst, also referred to as the 
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TE), as it differentiates into chorionic ectoderm (which later forms the labyrinth) and 
the ecoplacental cone (which later forms the spongiotrophoblast) (Soares et al., 
2012, Bissonauth et al., 2006). Around E8.5, the chorionic ectoderm and allantoic 
mesoderm fuse together to form the labyrinth zone – the exchange region in the rat 
placenta (analogous to the human villous tree) (Bissonauth et al., 2006). The 
labyrinth zone consists of: maternal and fetal blood vessels, endothelial cells, and 
the syncytiotrophoblasts and cytotrophoblasts which together form the interhemal 
membrane – a selectively permeable barrier between the maternal and fetal 
circulation (Coan et al., 2004). The junctional zone develops from trophoblast 
progenitor cells which differentiated into four distinct cell linages: trophoblast giant 
cells, spongiotrophoblast cells, glycogen cells, and invasive trophoblast cells 
(Simmons and Cross, 2005). These cells form two distinct layers of the junctional 
zone: the spongiotrophoblasts which mainly provide structural support; and the 
trophoblast giant cells which are involved in endocrine functions and implantation of 
the placenta into the surrounding decidua. The glycogen cells and the invasive 
trophoblast cells appear first during mid-gestation. The invasive trophoblast cells 
invade the mesometrial uterine compartment where they penetrate and surround the 
uterine spiral arteries (Soares et al., 2012). Around E16, the main structures on the 
placenta are fully formed, however the villi continues to branch throughout 
pregnancy until birth (Watson and Cross, 2005) (Figure 1.5). 
Despite some gross differences in placental morphology and development between 
rat and human, developmental processes and cell fate is similar, making the rat a 
good model to study placental programming. 
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Figure 1.4 – An illustration of the in utero 
orientation of the fetus and placenta in rat 
 The embryo is facing the anti-mesometrial side 
and the placenta formation occurs at the 
mesometrial side in rat. 
Figure 1.5 – Rat placentation at E6, E8, E10, E13 and E16. On E16, all the major structures of the 
placenta are fully formed.  
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1.5.2 Placental nutrient transfer 
 
1.5.2.1 Glucose 
The amount of nutrients that can be transferred to the fetus depends on the vascular 
surface area of the placenta, and the availability of nutrients and nutrient 
transporters. As fetal gluconeogenesis is very limited (Marconi et al., 1993), the fetus 
rely on transplacental glucose transport from the maternal system. Although 
nutrients can both diffuse or be transported actively (Neerhof and Thaete, 2008), the 
facilitated glucose transporter (GLUT)1 and GLUT3 are responsible for 
transplacental glucose transfer. GLUT1 is located on the microvillus and basal 
membranes of the syncytium and transports glucose from the mother into the 
placenta (Neerhof and Thaete, 2008); and GLUT3 is expressed on the arterial 
endothelium and transports glucose from the placenta to the fetus (Shin et al., 1997). 
Importantly, glucose can also be transported from the fetal circulation back into the 
placenta, as the placenta is the only fetal tissue capable of storing excess fetal 
glucose (Schneider et al., 2003). Both glucose backflow, which normally generates 
increased glycogen pooling (Thomas et al., 1990, Barash et al., 1985), and Glut3 
gene expression are increased in placenta of diabetic rats (Boileau et al., 1995), 
perhaps to protect the fetus from being exposed to excessive glucose levels. The 
maternal glucose concentration is generally slightly higher than fetal glucose 
concentration, creating a maternal-fetal glucose gradient (Neerhof and Thaete, 
2008). In fetal growth restricted humans, the difference in this gradient is increased 
(Marconi et al., 1996) and is likely due to altered placental size and transport 
capacity, as well as changes in the concentration of placental glucose transporters 
(Jansson et al., 1993).  
1.5.2.2 Amino acids 
As the concentrations of amino acids are normally higher in the fetal- compared with 
the maternal blood circulation in humans, amino acids are believed to cross the 
placenta via active transport (Philipps et al., 1978). This transport is mainly facilitated 
by the system-A sodium-dependent amino acid transport system in the labyrinth 
zone and is reduced in cases of placental growth restriction (Cetin et al., 1990, 
Paolini et al., 2001). The system-A subtypes of amino acid transporters accept a 
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fairly wide range of amino acids for transport, however solute carrier family 38 
member 2 (Slc38a2) is the only one carrying the essential amino acid methionine 
(Mackenzie and Erickson, 2004). Methionine is involved in methylation of DNA and 
histones and is therefore implicated in epigenetic regulation of genes (Ikeda et al., 
2012). As discussed previously, the preimplantation embryo is very susceptible to 
epigenetic perturbations (Ikeda et al., 2012), which again is supported by the PC MD 
study performed by Sinclair et al (2007) (discussed in section 1.3.1.3). 
1.5.3 Vasculogenesis 
The placenta’s vascular system is complex and provides a network of capillaries 
through which nutrients, waste and oxygen can be transported. These blood vessels 
forms via two processes: vasculogenesis (de novo), and angiogenesis (generation of 
blood vessels from existing ones) (Arroyo and Winn, 2008).  
 
In vasculogenesis, as shown in Figure 1.6, mesenchymal cells form hemangiogenic 
stem cells under control of the vascular endothelial growth factor A (VEGFA) (Coan 
et al., 2004). These cells give rise to hemangioblastic stem cells, which differentiate 
into endothelial cells to form the vascular networks (Huppertz and Peeters, 2005). 
The endothelial tubes then fuse with vascular smooth muscle cells from the 
mesenchyme (pericytes); which start to proliferate and migrate to cover the 
endothelial cells to form the vessels (Huppertz and Peeters, 2005). 
 
 
 
 
 
Figure 1.6 – A diagram demonstrating 
cell differentiation in vasculogenesis 
 During vasculogenesis, mesenchymal 
cells form hemangiogenic stem cells, 
which form hemangioblastic stem cells, 
which differentiate into endothelial cells 
to form the vascular networks. 
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A large number of enzymes are involved in the formation of a vascular network in the 
placenta: the vascular endothelial growth factor (VEGF) family; placental growth 
factor (PGF); FMS-related tyrosine kinase 1 (FLT-1) (also called vascular endothelial 
growth factor receptor-1 (VEGFR-1); and the kinase insert domain receptor (KDR, or 
VEGFR-2) (Huppertz and Peeters, 2005). These enzymes need to be available and 
functional to meet the requirements of the developing fetus, as failure to develop a 
capillary network often results in IUGR (Torry et al., 2004) and embryonic death 
(Meegdes et al., 1988). 
 
1.5.4 Utero-placental insufficiency  
A low birth weight can be generated by a number of factors and combination of 
factors, including: maternal stress, gestational diabetes, nutritional status, drug 
abuse, smoking, alcohol consumption, and utero-placental insufficiency (Neerhof 
and Thaete, 2008). Utero-placental insufficiency which is a degenerative process 
depriving oxygen and nutrient transfer to the fetus (Gagnon, 2003), is one of the 
major factors contributing to fetal growth restriction (Tapanainen et al., 1994). This is 
caused by defects in vascular remodeling (Labarrere and Althabe, 1987) and 
abnormal vasculogenesis (Torry et al., 2004) which in turn can be attributed to 
abnormal angiogenesis (Chen et al., 2002) or decreased placental surface area, 
volume and number of terminal villi and capillaries (Jackson et al., 1995, Teasdale, 
1984). Overall, defects in the vascular system of the placenta are likely to impact 
negatively on the developing fetus.  
1.5.5 Placental size 
Researchers have showed increased interest in the placenta as a mediator of fetal 
programming (Maloney et al., 2011, Winder et al., 2011, Moore et al., 1996, Barker 
et al., 1990, Barker et al., 2010, Burd et al., 2007) and both absolute placental weight 
and placenta-to-body weight-ratio have been independently associated with adult 
disease. Studies suggest a U-shaped curve in which subjects with either a low or 
high placental weight or ratio are more prone to disease (Godfrey, 2002). Barker et 
al (1990) were the first to show this by correlating placental and fetal size with blood 
pressure in 50 year old humans. The group demonstrated that those with the lowest 
birth weight and highest placental weight had the highest blood pressure as adults 
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(25 mmHg higher than a control group with normal body and placental weight). 
Risnes et al (2009), found similar results in a study covering 31000 humans in 
Norway in which individuals born with the highest placenta-to-body weight-ratio had 
the highest death rates from coronary artery disease. After reviewing existing human 
studies, Godfrey et al (2002) suggested that any deviation in the placenta-to-body 
weight-ratio greater than 20% increases the risk of cardiac death.  
Importantly however, a measurement of placental weight does not consider the 
surface area or thickness – other important determinants of fetal outcome (Winder et 
al., 2011). The length and width of the placenta represent placental growth along the 
major and minor axis (of a circular placenta). The width, which is often affected in 
programming models of altered maternal nutrition, is influenced by the availability of 
nutrients (Barker et al., 2011). The length is instead closely correlated with the length 
of the fetus (Roseboom et al., 2011) and is generally unaffected by poor nutrition. 
Human studies have associated altered placental dimensions with increased systolic 
blood pressure in the adult offspring, but the association is complex. Adult offspring 
of short mothers are more likely to have increased systolic blood pressure if they had 
a wide placenta with a big surface area; whereas a similar correlation in offspring 
from tall mothers was only found if the placenta was more oval (Winder et al., 2011) 
or small (Eriksson et al., 2011, Barker et al., 2011).  
The correlation between the dimensions and programmed disease is more complex 
than just measuring the placenta, which is composed of multiple layers: the labyrinth 
layer, the interhemal membrane, and the spongiotrophoblast layer. As the labyrinth 
layer constitutes the major site of nutrient transfer (Coan et al., 2008) a thicker 
labyrinth is easily assumed to be beneficial for nutrient and waste exchange; 
however reduced nutrient availability, which can increase thickness, may be 
detrimental because of increased nutritional cost of producing the larger tissue. This 
applies to the total size of the placenta too. A small placenta would theoretically be 
less capable of transferring nutrients to the fetus (Harding, 2001), but can adapt to 
the fetal requirements (Burton and Fowden, 2012) and instead increase the 
abundance of nutrient transporters, thus transplacental transport (Constancia et al., 
2005, Coan et al., 2008). Similarly, a large placenta may be more inefficient because 
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it has a higher metabolic demand (Gu et al., 1987) and may divert more nutrients to 
itself on the behalf of the fetus (Harding, 2001, Angiolini et al., 2006). 
 1.5.6 The effect of alcohol on the placenta 
There has been surprisingly little research on the effects of alcohol consumption on 
the placenta. When alcohol is consumed throughout pregnancy, placental weight has 
been shown to be either reduced (Andersson et al., 1989, Niemela et al., 1991) or 
unaffected (Westney et al., 1991). EtOH perfusion has also been shown to impair 
placental metabolism by decreasing glucose utilization, increasing the levels of 
lactate and triglyceride (TG) (Rice et al., 1986), introducing defects in protein 
synthesis (Tal et al., 1985), and reducing DNA and total protein content (Karl et al., 
1996). Not surprisingly, alcohol intake increases the rate of placental abruption, fetal 
growth impairment, and still birth (Burd et al., 2007).  
Whether the future growth and function of the placenta is affected by PC alcohol 
intake is currently unknown. Evidence does however suggest that preimplantation 
development can be disturbed in the presence of alcohol, and as the placenta arises 
from the rapidly dividing TE cells, PC alcohol intake is likely to impact on placental 
development. If it does, adult onset disease similar to other in utero perturbations 
may arise.  
1.6 Alcohol 
1.6.1 Alcohol intake during pregnancy 
The guidelines given by the National Health and Medical Research Council 
(NHMRC) of Australia regarding alcohol consumption during pregnancy have varied 
during the last decades. In 1992, women were advised abstinence while pregnant; 
but in 2001 the guidelines changed to allow <7 standard drinks per week (with a 
maximum intake of 2 drinks per day). In 2009 however, the guidelines were revised 
and currently states that: “For women who are pregnant or planning a pregnancy, not 
drinking is the safest option” (NHMRC, 2009). Despite this, drinking prior to and 
during pregnancy is relatively common. An Australian study reported that only 41% 
of pregnant women abstained alcohol consumption throughout pregnancy (O'Leary 
et al., 2009). The percentage of women drinking prior to and during early pregnancy 
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(the periconceptional period) is considerably higher in some countries: 80% of 
Western Australian, and Irish women; (Colvin et al., 2007, Mullally et al., 2011); and 
around 50% of Danish and American women (Kesmodel, 2001, Carmichael et al., 
2003) admit to alcohol consumption in the months leading up to pregnancy. Binge 
drinking (consuming five or more drinks per session) also increased from 6.2 million 
to 7.2 million women (of childbearing age) between 2001 to 2003 in The United 
States (Tsai et al., 2007). Estimating alcohol consumption before and during 
pregnancy is however difficult due to various factors such as: ethnicity (Floyd et al., 
1999), the woman’s own understanding of what a standard drink is, drinking patterns 
in different countries (O'Leary et al., 2007), and underreporting (Ernhart et al., 1988).  
The prevalence of binge-like drinking patterns is highest amongst men and women 
of reproductive age (Naimi et al., 2003) and there is a strong association between 
binging, unprotected sexual activity and unplanned pregnancies (Maier and West, 
2001). Being unaware of pregnancy in turn explains the higher rates of alcohol intake 
in early pregnancy, as women who do not plan to become pregnant are less likely to 
recognize early signs of pregnancy (Naimi et al., 2003, Kost et al., 1998). Around 
45% of all pregnancies in Australia and The United States are unplanned (Naimi et 
al., 2003, Colvin et al., 2007). The median number of days elapsed before 
recognition of pregnancy is 31 (with a variation between 7-227 days) (Edwards and 
Werler, 2006). Most women cease alcohol consumption completely when they 
realize they are pregnant; and amongst those who continue to drink, the intake is 
reduced (Floyd et al., 1999). The number of women drinking before pregnancy is 
however still higher than the number of unplanned pregnancies (Colvin et al., 2007), 
suggesting that women consume alcohol despite planning a pregnancy. Peadon et al 
(2011) recently confirmed this when they reported that 32% of women admitted they 
would continue to drink despite trying to get pregnant.  
The high percentage of women drinking prior to pregnancy, the time elapsed before 
pregnancy recognition, and women’s attitudes regarding drinking behaviour during 
pregnancy planning strongly indicates that many fetuses are exposed to alcohol 
around conception and during early gestation. 
 
Chapter 1 Review of Literature 
 
30 
 
  
1.6.2 The effect of alcohol on the fetus and fetal alcohol syndrome  
Alcohol crosses the placenta and can directly affect the fetus, or provoke changes in 
maternal endocrine functions that secondarily can interfere with fetal development 
and cause metabolic, physiological and endocrine disruptions – or result in 
miscarriage (Weinberg et al., 2008). Alcohol-induced birth defects may be 
established before the woman is aware of her pregnancy (Floyd et al., 1999), 
therefore women drinking both before pregnancy confirmation and during pregnancy 
are at risk of delivering a baby with fetal alcohol spectrum disorder (FASD) (Abel, 
1999). The more severe condition of FASD, fetal alcohol syndrome (FAS), is a result 
of chronic alcohol consumption during pregnancy. The diagnosis for FAS includes: 
facial dysmorphology, intellectual impairment, neurological abnormalities and 
developmental delays (Jones and Smith, 1973). The features seen in FASD are 
similar to these seen in FAS but more subtle (Abel, 1999).  
1.6.3 Timing, drinking pattern and drinking level 
Babies exposed to alcohol prenatally respond differently, suggesting the 
programmed characteristics are conditional to the insult, as well as the timing of 
exposure (O'Leary, 2004). Some have argued the effects alcohol has on the fetus 
are only dose dependent if a particular threshold is exceeded (Abel, 1999). Binge 
drinking, which easily causes these levels to be exceeded by creating high plasma 
alcohol concentration (PAC), are particularly harmful for fetal brain development 
(Naimi et al., 2003). Yet even moderate levels of alcohol are associated with adverse 
health outcomes including: IUGR, decreased birth weight (Windham et al., 1995), a 
greater risk for congenital anomalies, and reduced intelligence quotient (IQ) 
(Martinez-Frias et al., 2004). The specific effect alcohol has on the fetus also 
depends on the gestational time at which it is consumed. The fetus is most severely 
affected during the first trimester – the major period of organogenesis (West and 
Goodlett, 1990). Alcohol during the first, but not second or third trimester, increases 
the risk of spontaneous abortion in humans (Windham et al., 1997); whereas alcohol 
during the third, but not second trimester increases the risk of preterm delivery 
(Kesmodel et al., 2000). Thus alcohol is harmful throughout and in all trimesters of 
pregnancy but different organs and cell populations are more or less vulnerable at 
different times of exposure (West and Goodlett, 1990).  
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Animal models of maternal EtOH intake suggest the peak PAC is more harmful than 
the average intake (Pennington and Kalmus, 1987, Bonthius et al., 1988, Zajac and 
Abel, 1992). A high PAC is attained by consuming large amounts of alcohol on one 
single occasion (binge drinking) (Tsai et al., 2007). One research group administered 
the same amount of EtOH to neonatal rats during postnatal day (PN)4-10 
(corresponding to the third trimester of pregnancy in humans) in two different 
patterns and studied their brain weights. One group were continuously exposed over 
the day (producing PAC of 0.05%); whereas the other group were given EtOH in a 
binge-like pattern (generating a high and sudden PAC of 0.27%). The binge group 
had significantly lower brain weight on PN10 (Pierce and West, 1986). Even a lower 
daily dose of EtOH given in a binge-like pattern induced more severe microcephaly 
and neuronal loss than a larger dose given continuously during PN4-10 (Bonthius 
and West, 1990). Another group gavaged pregnant dams with high doses of EtOH 
(1g/kg body weight) once daily on E13.5 and E14.5 (generating blood alcohol 
concentrations (BAC) of 0.12%). The offspring of the EtOH-gavaged dams where 
growth restricted, had reduced nephron number and higher mean arterial pressure at 
1 month compared with control offspring (Jansson et al., 1999). These studies 
demonstrate how a binge-like drinking pattern, creating a higher PAC, can be more 
severe than chronic alcohol intake.  
1.6.4 Alcohol elimination during pregnancy – the mother, placenta and fetus 
As discussed in the previous paragraphs, alcohol can cross the placental barrier and 
affect the fetus. The dosimetry of alcohol exposure depends on: the total body water 
content (approximately 49%, but more in pregnancy as it contains the fetus’s water 
content and the amniotic fluid), the amount of alcohol consumed, available 
metabolizing enzymes, and the duration of the drinking episode (Lukaski et al., 
1994). For a woman weighing 63 kilos who consumes four standard drinks over 4 
hours (assuming one standard drink contains 14 grams of alcohol) (NIH, 2007), it will 
take around 8.5 hours to restore the blood alcohol levels to zero. If she instead 
drinks 12 standard drinks, elimination would take 25.6 hours (Paintner et al., 2012). 
Importantly, if a second drinking episode begins before the blood alcohol 
concentration from the previous one is restored, the BAC will be higher and the 
exposure period even longer (Paintner et al., 2012).  
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The placenta’s ability to metabolize EtOH is very limited and produces acetaldehyde 
(Brien et al., 1983). Within an hour of maternal drinking, the fetus experiences 
alcohol levels comparable to those in the maternal circulation (Idanpaan-Heikkila et 
al., 1972) – but the acetaldehyde levels are considerably higher (Brien et al., 1983). 
The fetus eliminates alcohol very slowly (Brien et al., 1983, Seppala et al., 1971) 
extending the fetal exposure period even further.  
It is however important to remember that the exposure period to alcohol in this thesis 
precede the development of both a fetus and a placenta. The effects of alcohol 
during early development are discussed further in section 1.6.6. 
1.6.5 Alcohol metabolism 
Alcohol (EtOH) is a toxic substance which is readily absorbed in the gastrointestinal 
tract and mainly metabolized in the liver (Lieber, 2005). As the body is unable to 
store EtOH, it becomes the preferred fuel for metabolism at the expense of other 
nutrients, causing metabolic imbalances (Shelmet et al., 1988, Lieber, 2005). EtOH 
can be metabolized via three different pathways: the alcohol dehydrogenase 
pathway (ADH); the microsomal ethanol oxidizing system (MEOS); and by catalase 
in the liver peroxisomes (Figure 1.7), all of which produce the extremely toxic 
metabolite acetaldehyde. As catalase metabolism only has a minor influence on 
EtOH metabolism, it will not be discussed in this report. 
The ADH pathway accounts for 90-95% of hepatic EtOH metabolism (Hernandez-
Munoz et al., 1990). In this process, a hydrogen atom is removed from EtOH by 
mitochondrial aldehyde dehydrogenase (ALDH), producing acetaldehyde. This 
converts nicotineamide adenine dinucleotide (NAD) to its reduced form; 
nicotineamide adenine dinucleotide hydrate (NADH) and one hydrogen atom 
(Hernandez-Munoz et al., 1990). Acetaldehyde is then quickly metabolized to 
acetate (or acetyl coenzyme A, acetyl-CoA), which produces another hydrogen atom 
for NAD (Lieber, 2005). The increase in the NADH/NAD-ratio creates a surplus of 
hydrogen atoms as NAD becomes saturated (Lieber, 2005). The mitochondria 
(which normally uses hydrogen derived from fatty acid oxidation) starts to utilize 
hydrogen produced in EtOH metabolism instead, and lipids start to accumulate in the 
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liver. The acetyl-CoA is eventually converted to carbon dioxide (CO2) and water and 
is eliminated by the body. 
When alcohol consumption is high, hepatic ADH becomes saturated, and the MEOS 
system (5-10% of EtOH metabolism), controlled by cytochrome P450 2E1 (CYP2E1) 
becomes activated. MEOS Km for EtOH is higher than the Km of the ADH pathway 
(8-10 mM as compared with 0.2-2 mM) (Lieber, 2005), and increases the EtOH 
tolerance. Activation of the MEOS system does however result in increased 
acetaldehyde production, which when oxidized releases free radicals (Lieber, 2005). 
Acetyl-CoA 
NAD 
NADH + H+ 
CoA 
Aldehyde dehydrogenase 
Mitochondrial 
electron transport 
chain to generate 
energy 
 
- Fatty acid synthesis 
- Hyperlipidaemia  
- Hypoglycaemia 
 
Ethanol Acetaldehyde 
NAD NADH + H+ 
ADH - Deactivate proteins 
- Inhibit protein repair 
- Mutations and cell death 
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mitochondrial electron transport chain 
- Oxidative stress 
- Cell and tissue damage 
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MEOS – ingestion of high 
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NADPH + H+ NADP 
O2 2H2O 
Figure 1.7 – Metabolism of ethanol via the alcohol dehydrogenase pathway and the MEOS system 
A schematic presentation of alcohol metabolism via the alcohol dehydrogenase (ADH) pathway and the 
microsomal ethanol oxidizing system (MEOS). 
Chapter 1 Review of Literature 
 
34 
 
  
1.6.5.1 Alcohol metabolism in rats compared with humans 
Rats metabolize EtOH faster than humans. Zorzano and Herrera (1990) gave 
humans and rats the same amount of EtOH (per kilogram body weight) and 
measured the concentrations of EtOH and acetaldehyde in their blood over time. In 
humans, the concentrations were low at 5 minutes (close to 1 mM), peaked at 30 
minutes (5 mM) – and remained at 5 mM 3 hours after administration. In Wistar rats 
however, the concentrations were higher than 5 mM at 5 minutes, stayed constant 
for the first 30 minutes, and subsequently declined to reach a level of 0.8 mM 90 
minutes after dosage. This needs to be considered when studying alcohol in rat 
models. 
1.6.6 Animal models of maternal alcohol intake and programming of disease 
The developmental programming research and the mechanisms by which 
programming occurs have been advanced by the development of animal models, as 
it is ethically inappropriate to use human models for this purpose. The uses of animal 
models are advantageous as they overcome many limitations of epidemiological 
study designs. The environment can be strictly controlled throughout the animals’ 
lifespan, enabling confounding factors to be kept low. 
1.6.6.1 Periconceptional alcohol consumption  
Periconceptional programming following maternal alcohol has received very little 
attention in experimental studies. It is however known that EtOH can diffuse into 
watery compartments of the body – including the oviduct and the uterus and be 
deleterious for the developing embryo (Mitchell, 1994). For example, Mitchell (1994) 
showed that EtOH (2g/kg body weight per day from E1-E4) advances the onset of 
blastocyst implantation and causes post-implantation embryo loss without affecting 
fecundity in rat. The same authors later speculated that these changes may be due 
to the ability of EtOH to increase blood flow to the vascular bed of blastocyst 
implantation sites (Mitchell and Goldman, 1996). Contradictory to these findings, 
mouse oocytes from EtOH-treated dams that were inseminated with spermatozoa in 
vitro had a significantly lower fertilization rate and faced an abnormal embryo 
development that resulted in fewer oocytes reaching the expanded blastocyst and 
hatching blastocyst stage on E6 (Cebral et al., 1999). This was later replicated with 
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similar results in a mouse in vivo study (Cebral et al., 2000). When extending these 
experiments further, the research group showed that EtOH-exposed female mice 
had fewer embryos on E10, reduced implantation site numbers, increased 
resorption, delayed embryonic development and abnormal neural tube closure (Coll 
et al., 2011). In this study however, the PC period was defined as 17 days prior to 
conception until E10 (Coll et al., 2011), which is after embryonic implantation in mice.  
Collectively, these studies confirm that the early embryo is affected by EtOH, yet no 
one has investigated the long term consequences of PC alcohol.  
1.6.6.2 Prenatal alcohol consumption 
The long term effects of prenatal alcohol exposure have – in contrast to PC alcohol – 
been extensively investigated. Many characteristics seen in humans with FAS have 
been observed in rodent models of prenatal EtOH-exposure (Lee and Wakabayashi, 
1985, Addolorato et al., 1997), but also other effects are documented including: low 
birth weight and IUGR (Chen et al., 2004, Chen and Nyomba, 2003b, Lopez-Tejero 
et al., 1989, Villarroya and Mampel, 1985, Chen and Nyomba, 2003a); altered fetal 
glucose and insulin homeostasis (Chen and Nyomba, 2004, Chen and Nyomba, 
2003a, Lopez-Tejero et al., 1989, Chen and Nyomba, 2003b, Villarroya and Mampel, 
1985); decreased glucose tolerance (Chen and Nyomba, 2004, Chen and Nyomba, 
2003b, Chen and Nyomba, 2003a); and decreased insulin sensitivity (Chen et al., 
2004, Chen and Nyomba, 2003a, Yao et al., 2006). Table 1.2 provides a 
comprehensive summary of how prenatal alcohol affects the metabolic status of the 
offspring. 
Researchers attempting to mechanistically describe the metabolic alterations in the 
offspring following prenatal EtOH-exposure have traditionally focused on changes in 
gene expression and molecular pathways. Alterations in gluconeogenic genes 
(causing deregulated hepatic glucose output) (Chen et al., 2004, Yao et al., 2006), 
the insulin signaling pathways (Chen et al., 2005), and in the level of circulating 
adipokines (Chen and Nyomba, 2003a, Chen and Nyomba, 2003b) are commonly 
shown in these models. More recent studies have started to examine possible 
epigenetic modifications and suggested that the origin to the common changes in 
molecular pathways and endocrine functions may recede in very early ‘metabolic 
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imprints’. For example, Yao et al (2013) demonstrated changes in histone acetylation 
which they associated with adult glucose intolerance. Although investigating 
epigenetic modifications were beyond the scope of this thesis, it should be 
emphasized that epigenetics may have contributed to the phenotype seen in the rats 
in this thesis (discussed in section 6.6). 
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Table 1.2 Animal models of prenatal alcohol exposure and programming effect 
Species Dosage and method of alcohol administration 
Timing of 
exposure 
Human 
trimester 
equivalent 
Mechanism Phenotype Reference 
Wistar 
rats 
10% EtOH (w/v) during 
week 1 of pregnancy 
and 25% EtOH (w/v) 
during week 2-4 of 
pregnancy 
Throughout 
gestation 1-2  
↑ Fasting plasma insulin but ↔ in glucose 
(birth) 
Glucose intolerance with ↔ in insulin 
response (birth) 
Normal glucose response with ↑ insulin 
response (PN3) 
(Villarroya and 
Mampel, 1985) 
SD rats 
35% EtOH derived 
calories administrated 
via a liquid diet 
(BAC 100-150mg/dL) 
Throughout 
gestation 1-2  
↑TG levels with increasing age 
↑VLDL 
(Pennington et 
al., 2002) 
SD rats 
35% EtOH derived 
calories administrated 
via a liquid diet 
(BAC 100-150mg/dL) 
Throughout 
gestation 1-2  
↓basal and insulin-dependent glucose uptake 
by muscle tissue in vitro (PN75-95, male only) 
↔in vivo insulin sensitivity 
(Elton et al., 2002) 
SD rat* 
2g/kg/d (36%) by 
gavage twice daily 
(~1.5g/d or 10.5kcal/d) 
Throughout 
gestation 1-2 
↑adipose tissue mRNA resistin 
↑plasma resistin 
↓GLUT4 in muscle membrane following 
glucose administration 
↓birth weight 
Glucose intolerance (13 weeks) 
(Chen and 
Nyomba, 2003b) 
SD rat* 
2g/kg/d (36%) by 
gavage twice daily 
(~1.5g/d or 10.5kcal/d) 
BAC 114.4mg/dL 
Throughout 
gestation 1-2 
PN1: ↓leptin mRNA and plasma insulin but 
↔ β-cell mass 
13weeks: ↑resistin mRNA in adipose 
↓skeletal muscle GLUT4 
↔ in leptin mRNA, or plasma leptin 
PN1: ↓birth weight 
Catch up growth after 7weeks  
13 weeks: ↔ in adipose tissue weight 
glucose intolerance 
↑plasma insulin 
(Chen and 
Nyomba, 2003a) 
SD rat* 
2g/kg/d (36%) by 
gavage twice daily 
(~1.5g/d or 10.5kcal/d) 
Throughout 
gestation (1) or 
PN1-PN21 (2) 
1-2 (1) or 3 
(2) 
↔plasma FFA  
↑Plasma, muscle and liver TG content at 16 
weeks (1a), ↔ in other groups 
 
↓birth weight (~50% of pups, 1a) 
Catch up growth after 4 weeks 
Insulin resistance and glucose intolerance in all 
EtOH-groups (16 weeks) 
(Chen and 
Nyomba, 2004) 
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Table 1.2 Animal models of prenatal alcohol exposure and programming effect (cont.) 
Species Dosage and method of alcohol administration 
Timing of 
exposure 
Human 
trimester 
equivalent 
Mechanism Phenotype Reference 
SD rat* 
2g/kg/d (36%) by 
gavage twice daily 
(~1.5g/d or 10.5kcal/d) 
Throughout 
gestation 1-2 
↔baseline hepatic mRNA levels of Pck1, 
G6pc, Pgc-1α or Gck 
↓ Pck1 and ↑Pgc-1α 30 minutes after 
insulin  
ND in adipose tissue mRNA or serum levels 
of adiponectin  
↓birth weight, ↓body length 
↔basal plasma glucose or insulin (PN1) 
Insulin insensitive (PN1) 
(Chen et al., 2004) 
SD rat* 
2g/kg/d (36%) by 
gavage twice daily 
(~1.5g/d or 10.5kcal/d) 
Throughout 
gestation 1-2 
↓Muscle GLUT4 on membrane following 
insulin administration at 16 weeks 
Insulin treatment had no effect on tyrosine 
phosphorylation of insulin receptor β-subunit  
or IRS-1 
↓PI3K activity 
↔AKT activity 
 (Chen et al., 2005) 
SD rat* 
2g/kg/d (36%) by 
gavage twice daily 
(~1.5g/d or 10.5kcal/d) 
BAC 114.4mg/dL 
Throughout 
gestation 1-2 
PN7: ND in basal Pck1 and Pgc-1α mRNA or 
protein  
↔ response of Pck1 or Pgc-1α  mRNA and 
protein to insulin administration 
3 months: ↑Basal mRNA and protein levels 
of PCK1 and PGC-1α 
↔response of Pck1 or Pgc-1α mRNA and 
protein to insulin administration 
↓birth weight 
↑fasting plasma insulin, ND in glucose (PN7 
and 3 months) 
↔ response in glucose when tested after 
insulin administration (PN7 and 3 months) 
↑Gluconeogenesis (measured by a pyruvate 
tolerance test) 
(Yao et al., 2006) 
Guinea 
pig 
4g/kg/d (30% v/v) in 
tap water 
(BAC ~281mg/dL) 
5 days per 
week 
throughout 
gestation 
1-3 
↓β-cell insulin-like immunopositive area 
(indicative of ↓pancreatic insulin production 
and/or secretion) 
↑ gestational length 
↓birth weight 
Catch up growth (PN1-PN7) 
↑visceral and subcutaneous adiposity (PN100-
140) 
↑pancreatic adiposity (PN150-200) 
(Dobson et al., 
2012) 
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Table 1.2 Animal models of prenatal alcohol exposure and programming effect (cont.) 
Species Dosage and method of alcohol administration 
Timing of 
exposure 
Human 
trimester 
equivalent 
Mechanism Phenotype Reference 
SD rat 
6% EtOH (v/v) via a 
liquid diet 
(BAC ~30mg/dL) 
Throughout 
gestation 1-2 
↔ β-cell density, islet density, β-cell mass or 
islet mass (PN30) 
↔ in hepatic Glut4, Pck1, PGC-1α, Gck or 
insulin receptor 
↔ in adipose resistin, adiponectin, Glut4 or 
insulin receptor 
↔ in muscle Pgc-1α or Glut4 
↔ birth weight 
↑ plasma insulin and HOMA-IR (4 months) 
↔ glucose tolerance but males had  ↑ 1st 
phase insulin secretion in response to glucose 
↔ body composition 
↓ plasma TG (males) (7 months) 
(Probyn et al., 
2013c) 
SD rat* 
2g/kg/d (36%) by 
gavage twice daily 
during treatment 
period 
Early (E1-7), 
mid (E8-14) or 
late gestation 
(E15-21) 
1 or 2 
(critical 
periods) 
↑PCK1 and G6PC (mRNA and protein) 
↑in HDAC activity (4, 5 and 7) 
↑SIRT2 protein 
↑free radicals in liver 
↓birth weight (early and late) 
Time specific alterations in glucose handling 
↑endogenous insulin production after GTT 
↑gluconeogenesis 
(Yao et al., 2013) 
Wistar 
rats † 
4g/kg/d via gavage 
(BAC ~395mg/dL) E11-E20 2 
↓ serum corticosterone 
↑IGF1 and glucose 
↔ mRNA levels of Igf1R, Irs2, Glut2, Pparα, 
Fox01 or G6pc 
↓birth weight 
↑ hepatic microvesicular steatosis around the 
central vein 
(Shen et al., 2014) 
       
AKT, protein kinase B; BAC, blood alcohol concentration; E, embryonic day; d, day; FFA, free fatty acids; FOXO1, forkhead box protein O1; G6pc, glucose-6-
phosphatase; Gck, glucokinase; GLUT4, glucose transporter 4; HDAC, histone deactylases; PN, postnatal day; Pck1, phosphoenolpyruvate carboxykinase; 
Pgc-1α, peroxisome proliferator-activated receptor gamma, coactivator 1α; PPARα, peroxisome proliferator-activated receptor alpha; SD, Sprague Dawley 
rats; SIRT2, NAD-dependent deacetylase sirutin-2; TG, triglyceride; VLDL, very low density lipoprotein. *Did not specify sex or males only; †Females only; 
↔, (no difference); ↑, (significantly increased); ↓, (significantly decreased).  
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1.7 The metabolic syndrome 
‘Metabolic disease’ was first described by a Swedish physician 80 years ago as the 
clustering of hypertension, hyperglycaemia and gout (Studien, 1923). Today 
metabolic disease characteristics also generally include: insulin resistance, 
hyperinsulenemia, central obesity, dyslipidaemia, impaired glucose tolerance, 
hypertension and/or atherosclerosis – all of which are associated with the 
development of both diabetes and CVD (Miranda et al., 2005, Eckel et al., 2005, 
Levitan et al., 2004). These risk factors have generated several diagnosis criteria 
where the most widely used ones: the World Health Organization (WHO) (Alberti and 
Zimmet, 1998); the US National Cholesterol Education Program (NCEP) (NCEP, 
2001); and the adult treatment panel III (ATPIII) (ATPIII, 2002) are summarized in 
Table 1.3.  
Table 1.3 The metabolic disease: Criteria and definitions 
WHO NCEP ATPIII 
Type 2 diabetes, impaired glucose 
tolerance, or insulin resistance by 
HOMA-IR 
Fasting plasma glucose 110-
125mg/dL 
Fasting plasma glucose ≥ 110 
mg/dL 
 
 BMI > 30 or waist hip ratio > 0.90 
(men) or > 0.85 (women) 
Waist circumference > 102 (men) or 
> 88 (women) 
Waist circumference > 102cm 
(men) or > 88cm (women)  
Dyslipidemia: TG ≥ 150mg/dL, HDL 
< 35 (men) or < 39 (women) 
TG ≥ 150mg/dL, HDL < 40 (men) or 
< 50 (women) 
TG ≥ 13mg/dL, HDL < 1.0mmol/L 
(men) or < 1.3mmol/L (women) 
Hypertension: on medication or 
untreated blood pressure ≥ 160/90 
mm Hg 
Blood pressure ≥ 130/85 mm Hg Blood pressure ≥ 130/85 mm Hg 
or medication 
 
ATPIII, adult treatment panel III; BMI, body mass index; HDL, high density lipoprotein; HOMA-IR, 
homeostatic model for assessment of insulin resistance; LDL, low density lipoprotein; TG, 
triglycerides; WHO, world health organization. WHO; must meet glucose/insulin criterion and 2 
more. NCEP; must meet 3 of 5 criteria (low HDL and high TG are 2 criteria). ATPIII; must meet 3 or 
more (low HDL and high TG are 2 criteria).  
 
Establishing an internationally recognized definition is complex because the degree 
of risk factors differ heavily between populations and age groups (Eckel et al., 2005), 
and therefore it is difficult to determine the prevalence accurately. Approximately 
25% of the world’s population had metabolic syndrome by NCEP criteria in 1994, but 
this number increases parallel to the rise in obesity – one of the main drivers of 
metabolic syndrome (Grundy, 2008). WHO estimates that 300 million people 
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worldwide will be diagnosed with metabolic syndrome or associate disorders by 2025 
(Seidell, 2000). Although metabolic syndrome used to be prevalent mainly in older 
age groups (Eckel et al., 2005), the disease is now alarmingly increasing in children 
too (Sinha et al., 2002, Weiss et al., 2004). Figure 1.8 shows the prevalence of the 
metabolic syndrome in various countries in 2004.  
 
 
 
Figure 1.8 – Prevalence of the metabolic syndrome in a worldwide population 2004                              
Percentage of men and women affected by the metabolic syndrome in various countries.  
Adapted from (Cameron et al., 2004). 
 
Poor nutrition and environmental factors majorly contribute to the increase in 
metabolic syndrome; but accumulating evidence suggests developmental 
programming to be a strong contributor too. Therefore, programming of glucose- and 
insulin homeostasis and adiposity – the major focus of this thesis – are discussed in 
the following sections (whereas blood pressure and CVD will not be targeted).  
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1.7.1 Diabetes 
 
Figure 1.9 – Projected numbers of diabetics in a worldwide population by 2025     .     . 
Projected numbers of people over 20 years old suffering from diabetes year 2000 (grey bars) and 
2025 (black bars) compared with documented numbers year 1995 (white bars) in developed 
countries, developing countries and the World.  Adapted from (King et al., 1998). 
 
Type 2 diabetes – which is defined as fasting hyperglycaemia and glucose 
intolerance in response to insulin secretion and impaired insulin action – accounts for 
90-95% of all cases of diabetes (Bell and Polonsky, 2001, Eckel et al., 2005). It is 
estimated to affect 300 million people (adult population) by 2025 (King et al., 1998) 
and 366 million people by 2030 (Wild et al., 2004), with the biggest increase 
incidence in developing countries (Figure 1.9) (King et al., 1998). In healthy subjects, 
insulin is produced and secreted by the pancreas in response to 
hyperglycaemia/postprandial raise in blood glucose, to facilitate glucose disposal in 
peripheral tissues and to attenuate hepatic gluconeogenesis (lowering blood glucose 
levels) (Huang, 2009). In insulin insensitivity, the tissues’ ability to respond to insulin 
is reduced and can progressively cause insulin resistance. Importantly, insulin 
resistance is an early metabolic defect that often, but not always, results in type 2 
diabetes (Huang, 2009).  
The following paragraphs discuss some of the common complications from which 
insulin resistance generally arise. 
 
Chapter 1 Review of Literature 
 
43 
 
 
1.7.1.1 Pancreatic insulin secretion 
Pancreas organogenesis starts at 8-10 weeks of gestation and continues throughout 
pregnancy in humans (Mitchell et al., 2009); and occurs between E10 and E19 in 
rats (Navarro-Tableros et al., 2007). Pancreas develops from two buds derived from 
the epithelium of the digestive tracts, that fuse together and differentiate into 
endocrine (islets of Langerhans) and exocrine (acini) cells (Scharfmann, 2000). The 
endocrine pancreas comprises four distinct cell types secreting different substances: 
α-cells (glucagon); β-cells (insulin); δ-cells (somatostatin); and PP-cells (pancreatic 
polypeptide) (Fowden and Hill, 2001, Scharfmann, 2000, Clark and Rutter, 1972). 
The secretion of insulin from the β-cells is dynamic as such it can be adjusted to the 
levels of extracellular glucose. This occurs by expansion of the β-cells mass (the 
product of the number and size of β-cells) in pregnancy and has been shown in 
obese, old and insulin resistant women (Bonner-Weir, 2000). Improper regulation of 
β-cells, and β-cell dysfunction contributes to the pathogenesis of type 2 diabetes 
(Wild et al., 2004). 
1.7.1.2 Peripheral insulin signaling  
Insulin released by the pancreatic β-cells binds via a saturable process to the insulin 
receptor, a receptor tyrosine kinase which regulates multiple signaling pathways via 
sequences of phosphorylation cascades (Figure 1.10). The insulin receptor (a 350 
kD transmembrane glycoprotein) comprises four subunits held together by disulphide 
bonds as a hetero-tetramer: two extracellular ligand binding (regulatory) α-subunits; 
and two (catalytic) β-subunits which each contains a tyrosine kinase domain. The α- 
and β-subunits are encoded for by the same gene and originate from the same 
precursor molecule (proreceptor).  
When insulin binds to the α-subunits, the β-subunits are rapidly auto-phosphorylated 
at five tyrosine residues (Kahn and Goldfine, 1993), triggering two parallel pathways: 
the phosphoinositide 3-kinase (PI3K) pathway, and the mitogen-activated protein 
(MAP)-kinase pathway. Insulin resistance inhibits the PI3K pathway (thus endothelial 
nitric oxide production and GLUT4 mediated glucose uptake) – but leaves the MAP-
kinase pathway and endothelin-1 production (which induces vasoconstriction) intact 
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– introducing imbalances between the two. Insulin resistance therefore often coexists 
with vascular abnormalities (Huang, 2009).  
 
Figure 1.10 – Schematic presentation of the insulin regulated intracellular signal transduction 
cascade 
Binding of insulin to the insulin receptor causes translocation of the intracellular GLUT4 enzyme to 
the cell membrane for insulin-mediated glucose uptake. Adapted from (Frojdo et al., 2009). 
 
The PI3K pathway starts with phosphorylation of the insulin like receptor substrate 1 
(IRS-1); a 185 kD cytosolic protein with several serine and tyrosine phosphorylation 
sites. IRS-1 is both positively and negatively regulated by insulin: increased serine 
phosphorylation deactivates (Li et al., 1999) and degrades PI3K (Pederson et al., 
2001); whereas increased tyrosine phosphorylation activates PI3K and the PI3K/AKT 
complex (Rayasam et al., 2009). Similar to the insulin receptor, PI3K has one 
catalytic (p110α-δ) and one regulatory (p85α-β, which exists in three splice variants: 
AS53, p55α and p50α) subunit (Mauvais-Jarvis et al., 2002). p85α is believed to be 
involved in attenuation of insulin responses (Terauchi et al., 1999) as cultured cells 
overexpressing p85α decreases both the amount of p85/110 dimer, and the catalytic 
activity of the p110 subunit (Rameh et al., 1995). PI3K catalyzes the production of 
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phosphatidylinositol-3,4,5-triphosphate (PIP3) by phosphorylating second 
messengers of insulin signaling: phosphatidylinositol (PI), phosphatidylinositol-4-
phosphate (PIP), and phosphatidylinositol-4,5-bisphosphate (PIP2) (Tsakiridis et al., 
1995). PIP3 phosphorylates, thus activates the v-akt murine thymoma viral oncogene 
homolog (AKT) (also referred to as PKB or Rac), another serine/threonine kinase. 
AKT exists in three isoforms: AKT1, 2 and 3 (PKBα, β and γ) encoded for by three 
different genes. Mice knockout studies have shown that AKT1 and AKT3 are 
predominantly involved in growth and development, whereas AKT2 regulates energy 
homeostasis (Schultze et al., 2011). Human studies have confirmed this as skeletal 
muscle and adipocytes (which expresses all three forms of AKT) only reduces 
insulin-stimulated glucose uptake in response to Akt2 deletion (Cho et al., 2001). 
Phosphorylation of AKT2 occurs at two different sites: first on Thr309 by 3-
phosphoinositide-dependent protein kinase 1 (PDK1) resulting in basal kinase 
activity; and then on Ser474 by the mechanistic target of rapamycin complex 2 
(MTORC2), resulting in full kinase activity (Schultze et al., 2011). In skeletal muscle 
and adipocytes, activated AKT2 disassociate from the plasma membrane to 
phosphorylate intracellular vesicles of GLUT4, which translocates to the cell surface 
and catalyse glucose uptake (Devaskar and Thamotharan, 2007, Huang, 2009).  
1.7.1.2.1 Glycogen synthase kinase-3 beta 
Downstream of AKT is glycogen synthase kinase-3 beta (GSK3β), a constantly 
active kinase (generally keeping its substrates in an inactivated state via 
phosphorylation) which is inactivated in response to cellular signals (Rayasam et al., 
2009). GSK3β is involved in processes that also allows for blood glucose lowering 
effects and improved insulin sensitivity. When AKT phosphorylates (thus inactivates) 
GSK3β on Ser21 and Ser9, serine residues (Ser)(641, 645, 549, 653) of glycogen 
synthase (GS) becomes de-phosphorylated (thus activated) and GS can mediate the 
conversion of glucose to glycogen (Cross et al., 1995, Rayasam et al., 2009). GSK3 
also regulates hepatic gluconeogenesis via suppression of gluconeogenetic 
enzymes such as phosphoenolpyruvate carboxykinase (Pck1) and glucose-6-
phosphatase (G6pc) (Lochhead et al., 2001). Additionally, GSK3 can phosphorylate 
IRS-1 on Ser332 and 336 residues (Eldar-Finkelman and Krebs, 1997) as such 
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overexpression of GSK3 may contribute to reduced insulin sensitivity, as discussed 
in the following paragraphs.  
The PI3K/AKT-pathway also controls hepatic glucose metabolism in hepatocytes by 
inhibition of the forkhead box protein O1 (FOXO1). FOXO1 normally exists in an 
active (non-phosphorylated) form in the cell nucleus where it binds to the G6pc 
promoter and stimulates G6pc transcription (Nakae et al., 2001, Taniguchi et al., 
2006). When AKT phosphorylates FOXO1 it becomes inhibited and hepatic glucose 
production decreases. Both AKT1 and AKT2 are expressed in the liver and it may 
therefore be a functional overlap between the two isoforms, although this is unclear 
(Schultze et al., 2011). Collectively, the levels of AKT phosphorylation in skeletal 
muscle, adipocytes and hepatocytes following insulin stimulation is often considered 
as a benchmark for insulin sensitivity (Schultze et al., 2011). 
1.7.1.3 Hepatic glucose homeostasis 
Apart from the pancreas and peripheral insulin signaling, the liver plays a critical role 
in regulation and maintenance of glucose homeostasis. This occurs via: uptake 
(glycogenesis); storage (glycolysis); production (glycogenolysis); and release 
(gluconeogenesis) of glucose (Figure 1.11) under the influence of hormones, 
particularly insulin, glucagon and epinephrine.  
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Figure 1.11 – The regulation of glycogenolysis, glycogenesis, glycolysis and gluconeogenesis 
In glycogenolysis glucose-6-phosphate is generated from glycogen, whereas in glycogenesis, 
glycogen is synthesized from glucose-6-phosphate. In glycolysis, glucose is metabolized to pyruvate 
with the concomitant net production of two adenosine triphosphate (ATP) molecules. In 
gluconeogenesis, glucose is generated by the liver from non-carbohydrate precursors such as 
pyruvate and lactic acid.     
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The initial development of the liver is similar in human and rat. Cellular differentiation 
starts at somite stage 11 in both species (corresponds to E24 in human and E10.5 in 
rat). During the following stages, up to the embryonic stage 23 (corresponds to E57 
in human and E16 in rat) the same hepatic structures are present in both species. At 
embryonic stage 23, more than 90% of the hepatic structures are present in both 
human and rat (Godlewski et al., 1997), suggesting that the rat is a good animal 
model for liver investigation.  
1.7.1.3.1 Hepatic glucose homeostasis in response to fasting 
Both glycogenolysis and gluconeogenesis are activated during fasting or 
hypoglycaemia via post-translational modifications and allosteric activation of rate-
limiting enzymes (Oh et al., 2013). During initial fasting, glucose is primarily made 
available via glycogenolysis, which is dependent on the activities of GS and 
glycogen phosphorylase (Gerich, 1993). In prolonged fasting, glycogenolysis 
becomes less important and glucose is instead produced de novo from precursors 
such as lactate, glutamine and alanine during prolonged fasting (Aronoff et al., 2004, 
Konig et al., 2012). The rate of gluconeogenesis increases gradually as blood 
glucose levels falls (Konig et al., 2012). DeFronzo et al (1992) suggested that 
plasma glucose levels following an overnight fasting period (~10 hrs) reflects 
endogenous glucose production (gluconeogenesis): but according to more recent 
evidence, fasting has to be maintain for up to ~40 hours to truly reflect 
gluconeogenesis (Konig et al., 2012) as it takes approximately 40 hours for 
glycogenolysis to deplete the glycogen stores (Konig et al., 2012). Gluconeogenesis, 
which comprises a series of eleven enzyme-catalysed reactions, is dependent on the 
amount of glucogneogenic substrates and their regulatory enzymes. These genes 
are controlled at transcriptional level by hormones such as insulin, glucagon and 
corticosteroid (Yoon et al., 2001) as such gluconeogenesis and glycogenolysis 
increases when pancreas excretes glucagon, and decreases when insulin is present 
(Hanson and Reshef, 1997). The liver can also utilize free fatty acids as a source for 
glucose production (Postic et al., 2004). Hepatic lipid oxidation increases the levels 
of acetyl-CoA/CoA, NADH/NAD+ ratios, and acetyl-CoA esters, which reciprocally 
inhibits glycolytic enzymes and further stimulates gluconeogenic enzymes (Gerich, 
1993). As discussed in the following sections, insulin resistance generally leads to an 
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inability to control the expression of gluconeogenic enzymes, which results in 
increased hepatic glucose production.  
1.7.1.3.2 Hepatic glucose homeostasis in response to a meal 
Following a meal, blood glucose levels rise within 15 minutes, peak at around 30 
minutes and decline to base levels after around 4-5 hours (depending on meal size 
and glucose content). The rapid increase in glucose levels, together with neurogenic 
stimuli and gastrointestinal hormones stimulate insulin and suppresses glucagon 
secretion (Gerich, 1993). Insulin is released in a biphasic manner: phase one, a 
rapid release of stored insulin; and phase two, a slower release of newly synthesised 
insulin (Gerich, 1993, Del Prato and Tiengo, 2001). First-phase insulin secretion 
exerts an important effect on the liver (Steiner et al., 1982, Luzi and DeFronzo, 1989) 
as it acutely suppresses endogenous glucose production (by decreasing gene 
transcription of Pck1 and G6pc (Barthel and Schmoll, 2003)); and reciprocally 
increases peripheral glucose disposal, as demonstrated by hyperglycaemic clamp 
studies (Luzi and DeFronzo, 1989). If first-phase insulin release is suppressed, 
peripheral glucose utilization will not be stimulated, and endogenous glucose 
production will only decrease by 50% (Luzi and DeFronzo, 1989). In healthy people, 
glucose enters the hepatocytes via GLUT2, become phosphorylated to glucose-6-
phosphate via glycolysis, and subsequently enters the Krebs cycle to produce 
energy (Gerich, 1993). If a surplus of glucose is ingested, glycogenesis is initiated by 
GSK3 inactivation, (thus GS activation) to produce glycogen (Oh et al., 2013). The 
immediate response to increased blood glucose levels is thereby mediated by 
insulin-mediated glucose uptake in peripheral tissues and in the liver; but the 
removal of glucose from the circulation also results from suppressed endogenous 
glucose production (Aronoff et al., 2004, Oh et al., 2013).  
1.7.1.4 Insulin and glucose homeostasis in diabetes 
The rate of insulin-mediated glucose disposal varies greatly within the population 
due to genetic variation, fitness and adiposity. Impaired glucose homeostasis can 
arise from either: fasting hyperglycaemia (most common), which results from 
increased hepatic glucose release (gluconeogenesis); or postprandial 
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hyperglycaemia, caused by failure to suppress gluconeogenesis and/or impaired 
peripheral uptake of glucose; or a combination of both.  
1.7.1.4.1 Insulin homeostasis in diabetes 
Insulin resistance occurs when the sensitivity to insulin is decreased in peripheral 
tissues (skeletal muscle, adipose tissue and liver) (Huang, 2009), and is often due to 
dysregulations in the insulin signaling pathway (Czech and Corvera, 1999, Morino et 
al., 2006, Schultze et al., 2011). Many insulin signaling substrates can be affected in 
insulin resistance, but  activation of the insulin receptor is generally fully functional 
(Frojdo et al., 2009). Both animal and human studies have shown that reduced IRS-1 
protein can contribute (Saad et al., 1992, Kerouz et al., 1997, Cusi et al., 2000, 
Danielsson et al., 2005): mice lacking IRS-1 exhibit insulin resistance in the absence 
of diabetes (Araki et al., 1994); and  obese and type 2 diabetic humans have 
diminished IRS-1 phosphorylation in skeletal muscle (Cusi et al., 2000) and 
adipocytes (Danielsson et al., 2005). PI3K activation is difficult to measure and its 
role in insulin resistance is controversial  (Frojdo et al., 2009). Mice lacking all splice 
variants of p85α exhibit improved insulin sensitivity (Terauchi et al., 1999), lower 
fasting plasma glucose concentrations, and have a lower diabetes incidence 
(Mauvais-Jarvis et al., 2002). This may be due to a more beneficial stoichiometry of 
the p85/p110/IRS complex, and/or increased PI3K-dependent signaling (as p85 
overexpression inhibits PI3K signaling, whereas p85 deficiency facilitates bridging of 
the IRS-1 with the catalytic p110 subunit) (Mauvais-Jarvis et al., 2002). Others have 
confirmed impaired activation of PI3K when measured in vitro as IRS-1 associated 
activity (Beeson et al., 2003, Kim et al., 2003). The role of AKT in diabetes is also 
debatable. Down-regulation of AKT2 inhibits insulin induced GLUT4 translocation to 
the cell surface (Jiang et al., 2003), Akt2 knockout mice are insulin resistant and 
mildly glucose intolerant (Schultze et al., 2011), and AKT2 overexpression rescues 
impaired glucose transport in AKT2-deficient adipocytes (Bae et al., 2003). In 
agreement with this, many have reported decreased muscle Ser474 and Thr309 
phosphorylation of AKT in diabetic patients (Cozzone et al., 2008, Frojdo et al., 
2009). Others did however find AKT2 activation to be unaltered in insulin resistance 
(Kim et al., 2003, Cusi et al., 2000, Nikoulina et al., 2001), but discovered reductions 
in insulin-induced PI3K activity instead (Beeson et al., 2003, Kim et al., 2003). 
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Importantly, all groups did not specify which isoform of AKT they measured, and/or 
the origin of skeletal muscle biopsies, and the severity of obesity/diabetes differed in 
these studies. More consistent findings of reduced AKT phosphorylation and activity 
are reported in adipose tissue (Rondinone et al., 1999, Carvalho et al., 2000). 
Researchers have also found increased GSK3β activity in skeletal muscle of type 2 
diabetes patients (Nikoulina et al., 2000) and in diabetic mice (Eldar-Finkelman et al., 
1999). Correspondingly, GSK3β inhibition improves insulin signaling and glucose 
tolerance (Meijer et al., 2004). Other substrates in insulin signaling, including GLUT4 
and protein kinase C, are also commonly impaired in type 2 diabetic patients (Frojdo 
et al., 2009).  
Collectively, these studies suggest that impairments of most substrates in the insulin 
signaling pathway can result in insulin resistance and/or diabetes.  
1.7.1.4.2 Glucose homeostasis in diabetes 
In insulin resistance, hepatic glucose output remains high despite the presence of 
insulin (Mitrakou et al., 1992, DeFronzo et al., 1989), contributing to both 
postprandial and fasting hyperglycaemia (Yoon et al., 2001, Del Prato and Tiengo, 
2001). Both increased accessibility to glucose precursors and dysfunctions at the 
enzymatic level contribute to this. For example, type 2 diabetic patients produce 
more lactate, and their livers converts lactate to glucose more efficiently (Zawadzki 
et al., 1988); and the rate of the Cori cycle is increased in obese patients with 
diabetes compared with healthy controls (Consoli et al., 1990).  
Regarding enzymatic dysregulation, one of the most characterized alterations in 
diabetic patients is increased gene expression of the rate-limiting gluconeogenic 
enzyme Pck1 (Rognstad, 1979), as it can affect gluconeogenesis already at 
relatively small changes (Sun et al., 2002). Hyperglycaemic, transgenic mice 
overexpressing the Pck1 gene (under control of its own promoter), exhibit increased 
steady state levels of both hepatic Pck1 and G6pc (but normal Glut2 and 
glucokinase (Gck)), and these increased levels remains unaltered even when the 
insulin levels are decreased (Sun et al., 2002). Previously, Valera et al (1994) had 
shown that mice overexpressing Pck1 develop impaired glucose tolerance, fasting 
hyperglycaemia and hyperinsulinemia. Other experiments have revealed that Zucker 
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diabetic rats – which have an impaired suppression of hepatic glucose output 
genetically – have perturbed whole body glucose homeostasis in association with 
increased G6PC activity (Trinh et al., 1998). In agreement with this, GCK (which 
catalyses the opposite reaction to G6PC) lowers plasma glucose concentration when 
up-regulated (Niswender et al., 1997).  
Thus the increase in endogenous glucose output is complex and likely to be 
multifactorial in its origin. Intriguingly, as described in section 1.6.6, dysregulation of 
gluconeogenesis is common in fetal programming of adult disease.  
1.7.2 Overweight and obesity 
The prevalence of obesity has increased more than 2-fold worldwide over the past 
30 years. According to WHO, over 200 million men and 300 million women were 
classified as obese in 2008 (Withrow and Alter, 2011). Adiposity and/or obesity, 
which often coexists with type 2 diabetes, hypercholesterolemia, 
hypertriglyceridemia, CVD and cancers (Mokdad et al., 2003), is a major public 
health issue. It also burdens the economy as it accounts for an average of 0.7-2.8% 
of a country’s total healthcare expenditures – and the medical cost for obese 
individuals are approximately 30% higher compared with normal weight people 
(Withrow and Alter, 2011). Just like diabetes, accumulating evidence suggests the 
intrauterine environment and IUGR are strongly associated with the onset of 
adiposity and obesity in adult life (Sarr et al., 2012).  
1.7.2.1 Obesity in developmental programming 
Many animal models that have examined in utero insults have showed a link 
between the maternal environment, IUGR and adult adiposity. Birth weight strongly 
correlates with adult fat mass (Fall et al., 1995, McMillen and Robinson, 2005) in a J- 
or U-shaped manner, where the obesity risk is highest in babies with low or high birth 
weights. Intriguingly, both diabetic (including type 2 diabetes, gestational diabetes 
and mildly glucose intolerant) (Buchanan and Kjos, 1999, Dorner and Plagemann, 
1994) and overweight mothers (Parsons et al., 2001) are more likely to give birth to a 
heavy baby, potentially creating a vicious cycle. Babies born with a low birth weight 
usually have a lower BMI in adulthood – but they have more body fat which is often 
abdominally distributed (Fall et al., 1995, Singhal et al., 2003, Law et al., 1992). Also 
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the well-established maternal low protein diet (50% protein restriction during 
pregnancy) leads to offspring obesity (Langley-Evans, 2001, Zambrano et al., 2006). 
Female but not male offspring exposed to protein restriction in utero had increased 
body fat and decreased lean mass at 70 days of age (Langley-Evans et al., 1996b). 
Maternal global undernutrition during the first 2 weeks of intrauterine life caused 
similar outcomes, but in offspring of both sexes (Anguita et al., 1993). Also placental 
insufficiency resulted in increased adiposity in male adolescent rat offspring (Joss-
Moore et al., 2010). In agreement with this, human studies from the Dutch Winter 
famine resulted in low birth weight and subsequent obesity (Ravelli et al., 1976) (see 
section 1.2.2).  
1.7.2.2 Adipose tissue as an endocrine organ 
White adipose tissue consists of unilocular adipocytes with one large lipid filled 
vacuole and a cell nucleus pressed closely against the plasma membrane. Its 
fundamental role is to store energy (as triaglycerols) which can be released as fatty 
acids during food deprivation (Fantuzzi, 2005). It was long believed that adipose 
tissue was devoted to energy storage only, but during the last decades, it has 
become evident that it is highly metabolically active and regulates both physiologic 
and pathologic processes. It produces and secretes both pro-inflammatory and anti-
inflammatory factors including: cytokines and chemokines (tumor necrosis factor 
alpha (TNF-α), interleukin 6 (IL-6)) and adipokines (adiponectin, leptin) (Fantuzzi, 
2005). As many of these have been implicated in the development of insulin 
resistance and CVD, and were examined in chapter 5 of this thesis, the following 
paragraphs discuss some of them briefly. Table 1.4 summarizes some of the 
established effects of cytokines and adipokines in metabolic dysfunction. 
1.7.2.2.1 Inflammation 
During obesity, the adipose tissue becomes inflamed via macrophagic infiltration and 
cytokine secretion (by adipocytes) (Wellen and Hotamisligil, 2005). The functional 
capability of adipocytes and marcophages overlaps as macrophages can 
accumulate lipids and become atherosclerotic foam cells (Wellen and Hotamisligil, 
2005) – a crucial process in the development of peripheral insulin resistance. 
Obesity thereby itself promotes both a chronic low-grade inflammatory and insulin 
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resistant state, but infusion of cytokines to non-obese animals also causes insulin 
resistance (Yu et al., 2002). Similarly, humans with chronic inflammatory conditions 
(including hepatitis C (Knobler et al., 2003) and rheumatoid arthritis (Sattar et al., 
2003)), are more likely to develop diabetes, and removal of inflammatory pathways 
protects against insulin resistance (Wellen and Hotamisligil, 2005), supporting 
inflammation to be a primary cause of obesity-linked insulin resistance. 
TNF-α was the first molecular link found between obesity and inflammation in both 
rodents (Sethi and Hotamisligil, 1999, Hotamisligil et al., 1993) and humans (Kern et 
al., 1995). Mice lacking TNF-α or its receptors exhibit improved insulin sensitivity 
compared with wild-type mice (Hotamisligil et al., 1993, Uysal et al., 1997). Many 
human studies have also correlated TNF-α messenger ribonucleic acid (mRNA) and 
protein levels in adipose tissue (Kern et al., 1995, Hotamisligil et al., 1995, Arner, 
1996), and circulating TNF-α (Corica et al., 1999, Winkler et al., 1999) with insulin 
resistance. TNF-α phosphorylates serine residues and inactivates IRS-1, which 
reduces the relocation of GLUT4 to the cell membrane (Hotamisligil et al., 1996). 
Importantly, although circulating TNF-α modifies molecules in the insulin signaling 
pathway via posttranslational modifications, Tnf-α overexpression are seen in 
adipocytes from both obese rodents (Hotamisligil et al., 1993) and humans 
(Hotamisligil et al., 1995, Rotter et al., 2003). TNF-α also increases plasma TG, very 
low density lipoprotein (VLDL) (Peraldi and Spiegelman, 1998) and IL-6 (Kern et al., 
1995).  
Similar to TNF-α, plasma IL-6 is increased, and adipose expression levels up to 10-
fold higher in obese and diabetic subjects compared with healthy controls (Fried et 
al., 1998, Kern et al., 1995). A range of factors, including nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) (Ahn and Aggarwal, 2005), TNF-α, IL-6 
itself (Fasshauer and Paschke, 2003, Rotter et al., 2003), stress and sex hormones 
(Eder et al., 2009) affects gene expression and circulating levels of IL-6. IL-6, a 21-
28 kDa polypeptide (depending on phosphorylation and glycosylation state) (May et 
al., 1988) exhibits both pro- and anti-inflammatory effects (Xing et al., 1998). Adipose 
tissue and adipocytes cultured in IL-6 also exhibit increased lipolysis (Eder et al., 
2009, Trujillo et al., 2004) and IL-6 administration to non-obese humans increases 
systemic lipolysis (van Hall et al., 2003), which indirectly may induce insulin 
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resistance (van Hall et al., 2003, Eder et al., 2009). Unlike TNF-α, IL-6 does not alter 
the phosphorylation status of IRS-1, but inhibits Irs-1, Glut4 and Pgc-1α on a 
transcriptional level (Rotter et al., 2003). Unsurprisingly, both insulin resistant 
(Pickup et al., 1997) and obese subjects (Mohamed-Ali et al., 1997, Fried et al., 
1998) often have increased circulating levels of IL-6, which correlates with a 
prospect risk of developing type 2 diabetes – irrespective of amount body fat 
(Pradhan et al., 2001). According to a review by Eder et al (2009), although IL-6 
increases plasma insulin, it reduces hepatic insulin sensitivity, insulin dependent 
glycogen synthesis, and glucose uptake in adipocytes – thus contributes to 
hyperglycaemia and hyperlipidaemia. 
It is speculated that the inflammatory response is initiated in the cells first affected by 
adiposity – the adipocytes (Wellen and Hotamisligil, 2005). The adipocytes may 
trigger this inflammatory response via endoplasmic reticulum stress (which activates 
inflammatory pathways) (Ozcan et al., 2004); or via oxidative stress (caused by 
augmented glucose delivery to adipocytes and endothelial cells). The second 
mechanism produces reactive oxygen species in the mitochondria, inflicting oxidative 
damage and activation of inflammatory pathways (Brownlee, 2001). Inflammation is 
therefore both the cause and the result of obesity and diabetes, forming a vicious 
cycle in which either condition once, established can further contribute to the 
production of the other.  
1.7.2.2.2 Adipokines 
Altered levels of adipokines often coexist with inflammatory conditions, but our 
understanding of their mechanisms and pathogenic roles are incomplete.  
Leptin 
Leptin (a 16kD adipocyte-derived peptide hormone) circulates at levels proportional 
to fat and regulates fat mass and appetite by acting on the central nervous system 
(Trujillo et al., 2004). As reviewed by others (Friedman, 2002, Coleman, 1978), mice 
and humans with a mutation in the leptin gene (ob/ob mice), or in the leptin receptor 
gene (db/db mice) develop obesity (from hyperphagia), as the absence of leptin fail 
to communicate that there are adequate fat stores. In obesity, however, leptin levels 
are elevated due to leptin resistance, and plasma levels normally correlate positively 
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with adipose tissue mass (Maffei et al., 1995), and increased IL-6 expression (Trujillo 
et al., 2004). Leptin’s role in developmental programming has been highlighted in 
several studies (Mantzoros et al., 2009, Martinez-Cordero et al., 2006). Leptin cord 
levels and fetal serum levels are lower in SGA children compared with normal weight 
infants; and neonatal leptin treatment of growth restricted piglets reverse both the 
high levels of cell proliferation in fetal adipose tissue, and the adult increase in 
adiposity (Vickers et al., 2005). It is therefore suggested that leptin regulates 
substrate utilization and maintenance of adipose tissue prior to birth; and that altered 
levels contribute to adult adiposity (McMillen and Robinson, 2005).  
Adiponectin 
Adiponectin is another adipose dervived adipokine synthesized from 4-6 trimers. 
Both the polymerized form and free trimers circulate in the plasma (Fantuzzi, 2005). 
Because the adiponectin gene locus overlaps with a diabetes susceptible locus (on 
human chromosome 3q27), adiponectin levels is suggested to affect the 
development of type 2 diabetes (Saito et al., 1999). In contrast to leptin, circulating 
adiponectin and mRNA expression tend to decrease with increased adiposity and 
diabetes (Hu et al., 1996, Arita et al., 1999); and correspondingly, high adiponectin 
levels are associated with a lower relative risk of type 2 diabetes (Spranger et al., 
2003). Adiponectin also inhibits the activity of TNF-α and IL-6 (Fantuzzi, 2005, 
Masaki et al., 2004); and TNF-α and IL-6 suppress adiponectin secretion (Rotter et 
al., 2003). The literature regarding adiponectin levels in fetal programming is 
however inconsistent. Cianfarani et al (2004) reported adiponectin levels to be lower 
in SGA children and further reduced in the ones experiencing a postnatal catch-up 
growth, whereas others have shown a reverse relationship between adiponectin 
levels and birth weight (Lopez-Bermejo et al., 2004), or no changes at all (Chen et 
al., 2004). This inconsistency may result from differences in the study design and/or 
in the data analysis. For example, the study by Cianfarini et al (2004) did not adjust 
the levels of adiponectin the degree of insulin resistance or height (Cianfarani et al., 
2004), whereas Lopez-Bermejo et al (2004) considered the inversely correlation 
between adiponectin levels and height in their study. Houde et al (2013) recently 
examined DNA methylation in the placenta and found that maternal glycaemia 
correlated with DNA methylation changes at two adipokine gene loci. However the 
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involvement of epigenetics in fetal programming of adipokines requires more 
investigation.    
Table 1.4 The effects of cytokines and adipokines in regulation of metabolism 
Factor Effect of obesity Mechanism 
TNF-α Increased in obesity Promotes insulin resistance 
Reduces adiponectin 
 
 IL-6 Increased in obesity Reduces hepatic insulin sensitivity and glycogen synthesis 
Reduces glucose uptake in adipocytes 
Increases plasma insulin and glucose levels 
Causes hyperlipidaemia  
Reduces adiponectin 
Increases leptin 
Leptin Increased in obesity Suppresses appetite 
Protects T-lymphocytes from apoptosis 
Adiponectin Decreased in obesity Anti-inflammatory; promotes insulin sensitivity 
Inhibits the activity of TNF-α and IL-6 
 
TNF-α, tumour necrosis factor alpha; IL-6, interleukin 6. 
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1.8 The scope of this thesis 
Previous studies have shown that maternal alcohol when consumed prenatally, or 
throughout gestation harms the developing fetus and causes long-lasting changes in 
offspring physiology. The significance of the periconceptional period as a critical 
window of development has been emphasized in many studies; however the impact 
of periconceptional alcohol consumption on offspring metabolism has not been 
explored. This study therefore aimed to provide novel knowledge in the field of 
periconceptional alcohol exposure, particularly with respect to the developmental 
programming of metabolic outcomes.  
1.8.1 Aims and hypotheses  
1.8.1.1 Overall aims  
The overall aims of this thesis were to:  
1) Develop a rat model of maternal periconceptional alcohol consumption to 
investigate the role of the placenta in fetal programming and the metabolic 
phenotype of the adult offspring. 
2) Examine whether a consumption of a western diet postnatally would unmask 
or exacerbate the programmed phenotype.   
1.8.1.2 Overall hypotheses 
We hypothesized that periconceptional exposure to alcohol would: 
1) Impact on fetal growth via changes in placental biochemistry and 
morphology. 
2) Result in sex-specific outcomes in glucose and lipid homeostasis in adult 
offspring. 
3) Interact with a postnatal western diet to exacerbate the adult phenotype. 
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1.8.2 Aims and hypotheses for chapter 3 
Other studies of developmental programming demonstrate the importance of the 
placenta in the regulation of fetal body and organ development. Any alteration in 
placental physiology and function may contribute to adult onset disease – but 
whether periconceptional alcohol impacts on the placenta is unknown. The 
periconceptional period precedes placental development, but accompanying 
changes (secondary to PC:EtOH-exposure) may still affect the placenta, thus the 
developing fetus. Placental biochemistry and morphology were therefore examined 
as a possible mechanism to the adult phenotype in chapter 3. 
The specific aims addressed in chapter 3 were to determine if periconceptional 
alcohol exposure: 
i. Altered fetal phenotype in late gestation. 
ii. Was associated with any morphological changes in the placenta. 
iii. Affected placental gene expression of nutrient transporters or 
vasculogenesis. 
iv. Resulted in sexually dimorphic differences.  
We hypothesized that periconceptional exposure to alcohol would: 
i. Result in utero growth restriction. 
ii. Affect the morphology and biochemistry of genes involved in nutrient 
transport and vasculogenesis in the placenta. 
iii. Affect placentas and fetuses in a sexually dimorphic manner.  
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1.8.3 Aims and hypotheses for chapter 4 
Fetal programming studies commonly demonstrate metabolic dysfunction following 
both prenatal and periconceptional insults. Often, these changes can be unmasked 
or exacerbated when a mismatch between the in utero and postnatal environment is 
introduced. Chapter 4 examined whether offspring of dams fed alcohol 
periconceptionally develop glucose intolerance and/or insulin resistance in 
adulthood; and whether a postnatal western diet exacerbated this phenotype. 
The specific aims addressed in chapter 4 were to determine if periconceptional 
alcohol exposure: 
i. Caused glucose intolerance and/or insulin insensitivity in offspring 
aged 6 months. 
ii. Affected hepatic gluconeogenesis by examining mRNA expression of 
key gluconeogenic enzymes. 
iii. Resulted in peripheral changes in the insulin signaling pathway. 
v. Resulted in sexually dimorphic differences.  
And; 
iv. To examine if a postnatal western diet revealed or exacerbated any 
phenotype caused by periconceptional alcohol. 
We hypothesized that: 
i. Periconceptional alcohol would cause glucose intolerance and 
peripheral insulin sensitivity, accompanied by alterations in the insulin 
signaling pathway and increases in hepatic gluconeogenesis. 
ii. Male offspring would be more susceptible to periconceptional alcohol, 
displaying a more severe phenotype than their female counterparts. 
iii. A postnatal western diet would interact with periconceptional alcohol 
and exacerbate disease outcomes. 
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1.8.4 Aims and hypotheses for chapter 5 
While chapter 4 examined the propensity for a diabetic programmed phenotype 
following periconceptional alcohol exposure and a postnatal western diet; chapter 5 
investigated the same combination on the development of adiposity and fat synthesis 
in offspring at 8 months of age.  
The specific aims addressed in chapter 5 were to determine if periconceptional 
alcohol exposure: 
i. Affected body composition in adult offspring. 
ii. Induced changes in liver morphology and inflammation. 
iii. Altered the plasma lipid profile. 
iv. Resulted in sexually dimorphic differences.  
And; 
v. To examine if a postnatal western diet revealed or exacerbated any 
phenotype caused by periconceptional alcohol. 
We hypothesized that: 
i. Periconceptional alcohol would cause changes in offspring body 
composition, associated with changes in the plasma lipid profile and 
changes in liver morphology. 
ii. Consumption of a postnatal western diet would exacerbate the 
programmed phenotype, especially in male offspring.  
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CHAPTER 2 
 
 General Methods and Materials  
2.1 Ethics 
All animal experiments and procedures were approved by The University of 
Queensland Anatomical Bioscience Animal Ethics Committee (AEC approval 
number SBS/022/12/NHMRC) prior to commencement of this study.  
2.2 Animal husbandry  
Outbred, virgin female Sprague Dawley rats 6-8 weeks of age were obtained from 
The Animal Resource Centre (Canning Vale, WA, Australia) and housed at the 
animal facility in the Australian Institute for Bioengineering and Nanotechnology at 
the University of Queensland. All rats were allowed to acclimatize to the new 
environment for at least one week and were exposed to the experimental control diet 
during a five hour period on two separate occasions to ensure acceptance. 3-4 rats 
were housed together in plastic cages with stainless steel wire lids under controlled 
temperature (20-22oC), relative humidity (40-50%) and an artificial 12 hour light-dark 
cycle. Of particular importance, the dark cycle was between 12.00 and 24.00 hours). 
All rats received standard rat chow (4.0% fat, 13.6% protein, 64.3% carbohydrates; 
15.5 MJ/kg) (SF-08-020 Specialty feeds, Glenforrest, WA, Australia) and had access 
to ad libitum access to tap water. 
2.2.1 Mating and start of the experimental protocol 
For a summary of the experiment protocol, see Figure 2.1. Vaginal impedance was 
measured with an EC40 estrous cycle monitor (Fine Science Tools, Foster City, CA, 
USA) to determine the appropriate stage of the estrous cycle for mating. Vaginal 
secretions with a resistance of > 4.5×103 Ω at 9.00 hours indicated pro-estrous (and 
a high likelihood that the female rat would be in estrous within the following 12 
hours). As the estrous cycle of a rat lasts for four days (Marcondes et al., 2002), 
dams were randomly allocated either a control liquid diet or a liquid diet containing 
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12.5% EtOH (v/v) (13.8 EtOH-derived kcal/day, or ~22 energy percentages (E%) 
from EtOH). From this day, dams were housed individually and the allocated diet 
was provided. Dams that were in pro-estrous again four days after entering the 
experimental protocol were paired with a male Sprague-Dawley rat overnight (mating 
window 12.00 until 8.00 hours). Mating was confirmed by the presence of a seminal 
plug and this day was designated as E1. In cases where no plug was observed, a 
second mating was performed the following day. If mating was unsuccessful even 
the second time, the dam was excluded from the experimental protocol. Pregnant 
dams were returned to their individual cages on E1 and remained on their allocated 
experimental diets until E4. On E5, dams returned to standardized rat chow. All 
dams were weighed daily throughout the experimental protocol. 
2.2.2 Experimental diet and chow 
The liquid diet consisted of Sustagen® hospital formula (Mead Johnson® 
Nutritionals, Auckland, New Zealand), reduced fat milk (Coles supermarket, 
Australia) and corn flour (Coles supermarket, Australia). Minerals (ferric citrate, 
copper II sulphate and magnesium sulphate were obtained from Sigma-Aldrich 
(Missouri, USA) and selenium yeast from Selmenite®Blackmore (Balgowlah, NSW, 
Australia). The energy content of the EtOH liquid diet was modified to give similar 
energy percentages of protein, fat and calories compared with the control diet (Table 
2.1). This diet was adapted following preliminary experiments that showed that dams 
consuming an EtOH containing diet drank a relative smaller volume than dams 
consuming a control diet (~22 mL/day vs. ~30 mL/day) (see section 6.2). The 
experimental liquid diets were made up daily. Absolute EtOH was added separately 
to each bottle to generate a diet consisting of 12.5% EtOH (v/v). This was achieved 
by adding 10 mL absolute EtOH to 70 mL liquid diet. The liquid diets were weighed 
prior to presenting them to the dams at 12.00 hours, and again 5 and 21 hours after. 
Standard curves were generated for both diets in order to determine the volume of 
diets consumed from the recorded weights, and EtOH and caloric intake were 
calculated from these curves. Dams had ad libitum access to the diet for 21 hours 
(between 12.00 and 9.00 hours). Tap water was offered between 9.00 and 12.00 
hours. Water consumption was monitored throughout pregnancy by weighing the 
water bottles prior to and after administration of water. Following the 8 day exposure 
Chapter 2 General Methods and Materials 
 
64 
 
 
period, dams were returned to standardized rat chow and ad libitum access to water. 
Food intake over the remainder of pregnancy was recorded daily by subtracting the 
weight of remaining chow including any spill from the amount offered. 
Table 2.1 Experimental liquid diet for untreated and ethanol treated  dams 
Control diet (7.7 MJ/kg) 
Component Amount Energy (cal) Protein (g) Fat (g) Starch (g) 
Sustagen hospital formula 19.5 g 74.1 4.5 0.5 12.7 
Corn flour 15.7 g 62.8 0.1 0.1 15.7 
Selenium yeast 0.03 g 0.1 0.01 0.0 0.0 
Low fat milk 58.3 mL 30.9 2.5 0.8 0.0 
Sunflower oil 0.8 mL 6.7 0.0 0.8 0.0 
Copper sulphate (50mM) 33.3 µL 0.0 0.0 0.0 0.0 
Ferric citrate (199mM) 33.3 µL 0.0 0.0 0.0 0.0 
Manganese sulphate (303mM) 33.3 µL 0.0 0.0 0.0 0.0 
Absolute ethanol 0.0 mL 0.0 0.0 0.0 0.0 
Total ~80.0 mL 174.7  7.1 2.2 28.4 
Energy%   17.0 11.3 68.2 
      
Ethanol diet (11.8 MJ/kg) 
Sustagen hospital formula 22.0 g 83.6 5.0 0.6 14.3 
Corn flour 15.0 g 60.0 0.1 0.1 15.0 
Selenium yeast 0.03 g 0.1 0.01 0.0 0.0 
Low fat milk 50.0 mL 26.1 2.1 0.7 0.0 
Sunflower oil 2.0 mL 16.2 0.0 1.8 0.0 
Copper sulphate (50mM) 33.3 µL 0.0 0.0 0.0 0.0 
Ferric citrate (199mM) 33.3 µL 0.0 0.0 0.0 0.0 
Manganese sulphate (303mM) 33.3 µL 0.0 0.0 0.0 0.0 
Absolute ethanol 10.0 mL 56.1 0.0 0.0 0.0 
Total ~80.0 mL 242.5 7.3 3.2 29.3 
Energy%   12.6 11.9 50.7 
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2.2.3 Plasma alcohol concentration cohort 
To avoid inducing stress to dams used for fetal and offspring studies, a separate 
cohort of dams (PC:EtOH-exposed dams (nPC:EtOH) = 10; untreated dams (nU) = 10) 
were generated to determine the PAC reached by the EtOH diet. This set of dams 
had blood collected from a tail vein (see section 2.5.1) two days prior to conception 
(E-2) and on day two of pregnancy (E2). Blood samples were collected prior to, and 
at 0.5, 1, 3, 5 and 21 hours after administration of the liquid diet. To limit stress to the 
dam and minimize blood loss, only two blood samples were taken from any one 
animal. These animals were not used for any other experiments.  
2.2.4 Embryonic day 20 cohort 
All animals from this cohort followed the experimental protocol outlined in sections 
2.2-2.2.2. Dams allocated to this cohort were sacrificed for tissue collection on E20 
(nPC:EtOH = 11; nU = 9) (see section 2.4.1). 
2.2.5 Offspring cohort 
All animals from this cohort followed the experimental protocol outlined in sections 
2.2-2.2.2. Dams allocated to this cohort (nPC:EtOH = 12; nU = 12) delivered their pups 
naturally ~22 days after conception (designated as PN1). All pups were toe clipped 
for identification on PN6-PN8. Pups were weaned on PN28 and separated into 
plastic cages with stainless steel wire lids together with 3-4 littermates from the same 
sex. Offspring were allocated to various thesis experiments at the time of weaning. 
Offspring were kept under controlled temperature (20-22oC), relative humidity (40-
50%) and an artificial 12 hour light-dark cycle (dark cycle maintained between 12.00 
and 24.00 hours). Offspring received standard rat chow (4.0% fat, 13.6% protein, 
64.3% carbohydrates; 15.5 MJ/kg) (SF-08-020 Specialty feeds, Glenforrest, WA, 
Australia) until the age of 3 months. Water was offered ad libitum. 
At 3 months of age, all rats were transferred to the animal house facility in the OTTO 
Hirschfield Building at The University of Queensland, with controlled temperature 
(20-22oC), relative humidity (40-50%) and an artificial 12 hour light-dark cycle (dark 
cycle maintained between 18.00 and 6.00 hours). Rats were allowed 1.5-2 weeks to 
acclimatize to the new environment and light-dark cycle. Following acclimatization, 
one subset of offspring from both sexes were randomly assigned a WD wth 
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increased fat and cholesterol (21% fat, 0.15% cholesterol, 19% protein, 59.9% 
carbohydrates; 19.4MJ/kg) (SF00-219 Specialty feeds, Glenforrest, WA, Australia) 
while one remained on the standardized chow. All groups had ad libitum access to 
allocated diet and water until termination of the study. 
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Figure 2.1 – Timeline of experimental protocol from treatment to 8 months post mortem     .    .    .    
. 
Dams were exposed to 12.5% alcohol (v/v) from 4 days prior to mating (E-4) until embryonic day (E)4 
when all dams were offered standard chow. The fetal cohort was collected on E20. The offspring 
cohort was born on day 22 of gestation. One subset of offspring was sacrificed 2 days after weaning, 
on postnatal day (PN)30. At 3 months, half of the remaining offspring started a western diet (WD). 
Blood sampling was performed at 1, 2, 4, 6 and 8 months. An intraperitoneal glucose tolerance test 
(IPGTT) and insulin tolerance test (ITT) were performed on rats at 6 months; and a dual-energy X-ray 
absorptiometry (DXA-scan) of body composition at 7 months. At 8 months, the last subset of animals 
for this thesis was sacrificed for tissue collection. 
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2.3 Offspring weight 
Body weight of individual pups were taken daily from PN1-PN30. Weights for 
postnatal growth studies were taken as an average of the entire litter for each sex. 
Offspring > the age of PN30 were weighed weekly until the end of the experimental 
protocol, and postnatal growth studies used the average of the entire litter for each 
particular sex (and diet when age > 3 months). 
2.4 Post mortem and tissue collection 
2.4.1 Embryonic day 20 cohort 
Figure 2.2 – Fetal and placental collection procedure on embryonic day 20            .      . 
Deeply anesthetized pregnant dam with the two uterine horns exposed (A), embryonic day (E)20 
fetus attached to its placenta (B) and the placenta separated into the labyrinth (left) and the 
junctional layer (right) (C). 
 
A B
C
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On E20, maternal blood was collected via a tail vein (see section 2.5.1) prior to being 
deeply anesthetized with an intraperitoneal (i.p.) injection of a mixed solution 
containing 50/50 Ketamine/Xylazile (Lyppard Australia Ltd., Northgate, QLD, 
Australia) (0.1 mL/100g body weight) to ensure maternal blood supply continued to 
the fetuses during fetal and placental collection. Once the dam was adequately 
anesthetized and displayed no corneal and pedal reflexes, it was placed supine and 
the abdominal cavity open to expose the uterus (Figure 2.2 A). The uteri were placed 
on saline soaked gauze while each horn was cut open to expose fetuses in their 
amniotic sacs. Amniotic fluid was extracted from the amniotic sac with a syringe prior 
to being opened to expose the fetus. Fetal sex was at first determined anatomically 
by visual observation of the ano-genital distance and was later confirmed via 
genotyping (see section 2.9.7). A small incision was made in the fetal chest and 
blood drawn with a hematocrit capillary (see section 2.5.3) and pooled with blood 
collected from the same litter and sex. All fetuses and placentas (Figure 2.2 B) were 
separated and weighed to the nearest 0.1 µg. Fetal body dimensions (head width, 
measured from the front of the ears across the head; hind limb, measured from the 
base of the left heel to the knee; crown-to-rump length, measured from the middle of 
the ears in the center of the head to the hair line of the tail; snout-to-rump length, 
measured from the tip of the nose to the hair line of the tail) were taken using digital 
vernier calipers (accurate to 0.01 mm) (Figure 2.3 A-C). Placental dimensions (width, 
length and thickness) were measured to the nearest 0.01 mm (Figure 2.3 D-G) and 
immediately separated into the labyrinth and junctional zone (Figure 2.2 C). 
Placentas, fetal heart, kidneys and liver were quickly extracted and weighed, and 
either snap-frozen in liquid nitrogen and stored at -80oC for molecular analyses, or 
fixed in 4% paraformaldehyde (PFA) for histological analyses. Fetal tails were 
collected and snap-frozen in liquid nitrogen for genotyping. Following fetal collection, 
the dam was euthanized by diaphragm puncture, blood collected via cardiac 
puncture (see section 2.5.3) and liver collected and snap frozen in liquid nitrogen 
and stored at -80oC.  
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Figure 2.3 – Measurement of fetal and placental dimensions on embryonic day 20                              . 
Measurement of fetal snout-to-rump length (A), head width (B) and hind limb length (C). A placenta 
separated from the fetus (D) for measurements of length (E), width (F) and depth (G). 
A B
C
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2.4.2 Offspring cohort 
 
Rats were anaesthetized with an i.p. injection of a mixed solution containing 50/50 
Ketamine/Xylazile (Lyppard Australia Ltd., Northgate, QLD, Australia) (0.5 mL/100g 
body weight) between 8.00-11.00 hours, following an overnight fast. Body 
dimensions (head width, measured from the front of the ears across the head; hind 
limb, measured from the base of the left heel to the knee; crown-to-rump length, 
measured from the middle of the ears in the center of the head to the hair line of the 
tail; snout-to-rump length, measured from the tip of the nose to the hair line of the 
tail) were taken using digital Vernier calipers (accurate to 0.01 mm). Abdominal 
circumferences were determined by placing a thread around the middle of the waist 
and measure the length of the thread with a ruler (accurate to 1 mm). Ponderal index 
were later calculated by using the following formula: 
𝑃𝑜𝑛𝑑𝑒𝑟𝑎𝑙 𝑖𝑛𝑑𝑒𝑥 =
𝑤𝑒𝑖𝑔ℎ𝑡
𝑠𝑛𝑜𝑢𝑡 − 𝑡𝑜 − 𝑟𝑢𝑚𝑝 𝑙𝑒𝑛𝑔𝑡ℎ3
 𝑥 100 
where weight is expressed in grams and snout-to-rump length in cm. 
The rat was placed supine and the chest cavity opened. Blood was collected by 
cardiac puncture with a heparinized and ethylenediaminetetraacetic acid (EDTA) 
coated syringe (see section 2.5.3). Following blood collection, all major organs and 
intra-abdominal visceral fat were extracted and weighed. All tissues were either 
snap-frozen in liquid nitrogen and stored at -80oC for molecular analyses, or fixed in 
4% PFA for histological analyses. In all cases, only one male and one female from 
each litter were used for each outcomes measure in all adulthood experiments. 
2.4.3 Placental dry weight 
Placental labyrinth and junctional zone dry weights were obtained by oven drying. 
For this purpose, the initial weight of labyrinth and junctional zones were recorded, 
the tissue placed in a weigh boat, covered with aluminum foil and dehydrated at 
37oC. Tissues were weighed daily until weight did no longer change. 
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2.5 Blood collection  
Blood sampling was performed via tail tipping on rats in the PAC cohort and on 
offspring at 2, 4, and 8 months of age. Offspring aged 8 months were fasted 
overnight prior to blood sampling. Blood sampling was performed via tail slicing for 
the glucose tolerance test (GTT) (following an overnight fasting period of 15 hours) 
and insulin tolerance test (ITT) (following a fasting period of 1 hour) on offspring 
aged 6 months. Blood sampling was performed via cardiac puncture on fetuses, 
dams and offspring on all post mortems (PM). 
2.5.1 Tail tipping 
An analgesic cream containing lidocaine and prilocaine was applied to the tip of the 
tail 5-15 minutes prior to the procedure. The rat was wrapped into a towel to restrict 
movements and placed in prone position with the tail exposed. Approximately 1 mm 
of the tip of the tail was cut of using a sterile surgical blade (Figure 2.4 A-B). A blood 
sample of 300-700 µL was collected into either a Microvette® lithium heparin coated 
tube or EDTA coated tube (1.6 mg EDTA per 1 ml blood) (Sarstedt Pty, Ltd., 
Technology Park, SA, Australia). 
2.5.2 Tail slicing  
Tail slicing was only performed for blood sampling during the GTT and ITT. All tail 
slicing procedures were performed in a quiet room with a temperature of 28-30oC to 
assist blood circulation. 10-20 minutes prior to the procedure, an analgesic cream 
containing lidocaine and prilocaine was applied to the tail. The rat was wrapped into 
a towel to restrict movements and placed in prone position with only the tail exposed. 
A small incision (~2 mm long and ~1 mm deep) was made with a sterile surgical 
blade in a lateral caudal vein to allow blood sampling. Blood samples of 200-300 µL 
were collected into Microvette® lithium heparin coated tube (Sarstedt, Pty, Ltd., 
Technology Park, SA, Australia) (Figure 2.4 C-D). For blood sampling over an 
extended period of time, the scab on the initial incision was removed by using a 
cotton bud soaked in heparinized saline. Whole blood glucose concentration was 
tested with Accu-Check® Performa (Roche Diagnostics, Pty, Ltd., Castle Hill, NSW, 
Australia) at every sampling to monitor blood glucose concentration during the 
procedure. Details of the GTT and ITT are described in section 2.6. 
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2.5.3 Cardiac puncture 
During all PMs, blood was collected via cardiac puncture. With the rat placed supine, 
the chest cavity was opened and exposed. Blood was drawn into a heparinized 
syringe by inserting the syringe needle in the left ventricle and transferred to 
Microvette® lithium heparin coated tube (Sarstedt, Pty, Ltd., Technology Park, SA, 
Australia). Blood was also drawn into a non-heparinized coated syringe and 
transferred to EDTA coated tube (1.6 mg EDTA per 1 ml blood) (Sarstedt, Pty, Ltd., 
Technology Park, SA, Australia). For cardiac puncture on fetuses, the chest cavity 
was cut open, a small incision made in the heart and blood drawn with a hematocrit 
capillary (Hirschmann® Eberstads, Germany).   
Figure 2.4 – Blood collection via tail tipping and tail slicing                            .    . 
Tail tipping (A-B) was performed for all monthly blood collections and tail slicing (C-D) was 
performed for blood collections during the glucose- and insulin tolerance tests (GTT and ITT). 
C
A B
D
Chapter 2 General Methods and Materials 
 
74 
 
 
2.6 Assessment of glucose- and insulin homeostasis 
2.6.1 Glucose tolerance test (GTT) 
A GTT was performed on rats aged 6 months. Rats were fasted overnight (for 15 
hours) and transferred to a quiet room with a temperature of 28-30oC. All GTTs were 
initiated between 8.00 and 9.00 hours. During the procedure, rats were housed 
individually in small plastic cages with a stainless steel lid and had ad libitum access 
to water. Following basal blood collection via tail slicing (see section 2.5.2), 1 g/kg 
body weight of glucose (Sigma-Aldrich, Sydney, NSW, Australia) (made up in saline) 
was administered via an i.p. injection. Further blood sampling took place at 5, 10, 20, 
40, 60 and 90 minutes following the glucose administration. After the procedure, rats 
had access to standardized chow and water and were allowed to recover individually 
for one day, before being transferred back to their home cage.  
2.6.2 Insulin tolerance test (ITT) 
An insulin tolerance test was performed on a different subset of rats aged 6 months 
in order to avoid stressing the rats. Rats were fasted for 1 hour and transferred to a 
quiet room with a temperature of 28-30oC. All ITTs were initiated between 10.00 and 
10.30 hours. During the procedure, rats were housed individually in small plastic 
cages with a stainless steel lid and had ad libitum access to water. Following basal 
blood collection via tail slicing (see section 2.5.2), 0.75 U/kg body weight of insulin 
(Actrapid, Novo Nordisk Pharmaceuticals Pty. Ltd., Baulkham Hills, NSW, Australia) 
made up in saline was administered via an i.p. injection. Further blood sampling took 
place at 5, 20, 40, 60, 90 and 120 minutes following the insulin administration. After 
the procedure, rats had access to standardized chow and water and were allowed to 
recover individually for one day, before being transferred back to their home cage. 
2.6.3 Calculations for area under curves generated in the GTT and ITT 
Basal glucose and insulin concentration from the GTT were used to calculate 
HOMA-IR (Duncan et al., 1995): 
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𝐻𝑂𝑀𝐴 − 𝐼𝑅 =
𝑓𝑎𝑠𝑡𝑖𝑛𝑔 𝑝𝑙𝑎𝑠𝑚𝑎 𝑖𝑛𝑠𝑢𝑙𝑖𝑛 (𝜇𝑈𝑚𝐿) 𝑥 𝑓𝑎𝑠𝑡𝑖𝑛𝑔 𝑝𝑙𝑎𝑠𝑚𝑎 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 (
𝑚𝑚𝑜𝑙
𝐿 )
22.5
 
The HOMA-IR index is often used to estimate hepatic insulin sensitivity (Wallace et 
al., 2004) and although controversial, it has been shown to be a good predictor of 
insulin sensitivity in Sprague-Dawley rats (Cacho et al., 2008). To further validate the 
insulin resistance score, a quantitative insulin sensitivity check index (QUICKI) was 
calculated (Katz et al., 2000): 
𝑄𝑈𝐼𝐶𝐾𝐼 =
1
log (𝑓𝑎𝑠𝑡𝑖𝑛𝑔 𝑝𝑙𝑎𝑠𝑚𝑎 𝑖𝑛𝑠𝑢𝑙𝑖𝑛 (𝜇𝑈𝑚𝐿) 𝑥 log (𝑓𝑎𝑠𝑡𝑖𝑛𝑔 𝑝𝑙𝑎𝑠𝑚𝑎 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 (
𝑚𝑔
𝑑𝐿 )
 
A low QUICKI indicates low insulin sensitivity and a high QUICKI indicates high 
insulin sensitivity.  
The area under the glucose curve (AUGC) and the area under the insulin curve 
(AUIC) for the IPGTT were calculated using the trapezius method with baseline 
defined as zero (Allison et al., 1995) using GraphPad Prism 6 Software (GraphPad 
Software Inc., San Diego, CA, USA). The AUGC was calculated as the incremental 
glucose area under the curve (AUC) from basal to 90 minutes (Figure 2.5 A). Total 
AUIC was calculated as the total incremental insulin AUC from basal to 120 minutes, 
or as first- plus second-phase insulin secretion (Figure 2.5 C-D). Before calculating 
AUGC following the ITT, the curves were inverted (Figure 2.5 B) and the total 
incremental area calculated from basal to 120 minutes. The insulin secretory 
response to glucose, or the ratio of AUIC to AUGC following the IPGTT, was 
calculated by dividing the total AUIC by the total AUGC.  
Acute first-phase insulin secretion, which is indicative of acute insulin release from 
the pancreas in response to a glucose load (Del Prato and Tiengo, 2001, Kahn et al., 
2008) was calculated as the incremental AUIC from basal to 5 minutes (Figure 2.5 
C). Second-phase insulin secretion comprises a sustained, slow release of newly 
formed insulin from the β-cells in order to normalize the blood glucose concentration, 
and was calculated as the incremental AUIC from 5 to 120 minutes (Figure 2.5 D). 
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Figure 2.5 – Area under glucose and insulin curves           .          .       .            ..  .         
Area under the glucose curve (AUGC) following the IPGTT was calculated as the total incremental 
area from basal to 90 minutes (A). To determine the AUGC following the ITT, graphs were inverted 
and the total incremental area calculated from basal to 120 minutes (B). First phase-insulin secretion 
was calculated as the incremental AUIC from basal to 5 minutes (C) and second-phase insulin 
secretion as the incremental AUIC from 5 to 90 minutes (D).  
 
2.7 Blood handling and plasma analyses 
All blood samples were spun down at 3500 rpm for 15 minutes at 4oC using a 
refrigerating Eppendorf microcentrifuge 5417R (Quantum scientific, Eppendorf South 
Pacific, NSW, Australia) to allow for plasma separation. The plasma supernatant was 
transferred into aliquots to avoid repeated freeze thawing, and stored at -20 or -80oC 
depending on specific assay requirements until further analysis. Plasma used for 
PAC determination was stored in 0.5 mL PCR tubes, filled up to the lid to avoid 
evaporation, and snap-frozen in liquid nitrogen prior to being stored in -80oC until 
assayed.  
Glucose injection
A
Glucose injection
C
Glucose injection
D
1st phase insulin secretion 2nd phase insulin secretion
Insulin injectionB
6
0 -
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2.7.1 Cobas Integra analyses 
A Cobas Integra 400 Plus Chemistry Analyzer system (software version 3.5) (Block 
Scientific, NY, USA) was used for determining plasma concentrations of enzymes 
and ions. Plasma glucose, TG, total cholesterol, low density lipoprotein (LDL) and 
high density lipoprotein (HDL) were measured in duplicates by absorbance 
photometry. Plasma sodium, potassium and chloride were measured in duplicates by 
ion-selective electrode potentiometry with assay detection. Catalogue number, 
detection range and sub- and main reference length for tested parameters are 
summarized in Table 2.2. 
Table 2.2 Assay specifics for parameters analysed with Cobas Integra 400 plus 
Plasma parameter Instrument number Detection limit (mmol/L) Sub/main wavelength 
†Glucose #04404483190 0.11-41.6 700/340 
†Triglycerides #20767107322 0.1-10 700/505 
†Total cholesterol #03039773190 0.1-20.7 800/505 
†LDL #03038866322 0.10-14.2 700/600 
†HDL #04399803190 0.08-3.10 700/600 
*Sodium #21029371001 N/A N/A 
*Potassium #21029355001 N/A N/A 
*Chloride #03246353001 N/A N/A 
 
HDL, high density lipoprotein; LDL, low density lipoprotein; †tested with absorbance photometry; 
*tested with ion-selective electrode potentiometry. 
 
2.7.2 Plasma alcohol determination 
PAC was determined by the enzymatic colorimetric (565 nm) method using the 
EnzyChromTM EtOH assay kit and protocol (ECET-100) (Bio Assay Systems, 
Hayward, CA, USA) according to the manufacturer’s instructions. The EnzyChromTM 
EtOH assay kit is based on ADH catalyzed oxidation of EtOH, in which the NADH 
produced is coupled to the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT)/phenazine methosulfate (PMS) reagent. The color produced is 
proportionate to the EtOH concentration in the sample when measured at 565 nm. 
Briefly, 10 µL plasma sample was added to each reaction well in a clear bottom 96-
well plate. 90 µL working reagent (consisting of 60 µL assay buffer, 1 µL enzyme, 10 
µL NAD, 14 µL PMS and 14 µL MTT reagent) was added and solutions mixed by 
gently tapping the plate. Optical density (OD) was measured at time point zero (OD0) 
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and after 5 minutes incubation in room temperature (OD5). A ΔOD was calculated by 
subtracting OD0 from OD5 for standards and sample wells and used to determine 
sample EtOH concentration from the standard curve generated. All samples were 
tested in duplicates.  
2.7.3 Hormone analyses 
Plasma insulin and leptin was determined using a high sensitivity rat insulin or leptin 
Radioimmunoassay (RIA) kit containing the radioactive gamma isotope of iodine-125 
(125I). Insulin concentrations were determined in plasma collected during the GTT at 
6 months, and leptin concentration in plasma collected at PN30 and at 8 months. 
The RIA assay is based on the competitive binding between unlabelled insulin/leptin 
antigen (in plasma samples) and radiolabelled insulin/leptin antigen to the 
insulin/leptin antibody. A tracer antigen, labelled with 125I-Insulin or 125I-Human-Leptin 
is added in a known concentration. The radiolabelled antigen tracer is incubated with 
a known amount of the antibody for that specific antigen, allowing for chemical 
binding between the two. As plasma samples with an unknown concentration 
(unlabelled antigen) is added, labelled antigen tracer and unlabelled antigen will 
compete for the limited (but constant) number of binding sites on the antibody. As 
the concentration of unlabelled antigen (from the test sample) increases, it displaces 
the amount of labelled antigen tracer that is bound to the antibody. As such the ratio 
of antibody bound labelled antigen to free labelled antigen decreases as the antigen 
concentration in the test sample increases. After separating bound antigens from 
unbound fractions, the bound fractions can be counted with a gamma counter and 
radioactivity measured. By generating a binding curve with standards provided in the 
kit (Figure 2.6), the amount of antigen in test samples are calculated as the inverse 
proportion to the amount of unlabelled insulin/leptin in the sample.   
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Figure 2.6 – Insulin RIA standard curve generated with Assay Zap               .          . 
A weighted 4-parameter curve graphing the percentage bound (%B/B0) for each standard on the y-
axis versus the known concentration of each standard on the x-axis. The insulin concentrations for 
the test samples were determined by interpolation of the reference curve. The procedure for 
calculating plasma leptin concentrations is the same. 
 
2.7.3.1 Plasma insulin determination 
Insulin concentrations were determined following the manufacturers protocol, but 
modified by reducing all reagents and samples by half due to small sample volumes 
(Cat.#RI-13K, Millipore, Pty. Ltd., Kilsyth, VIC, Australia) (Table 2.3). All samples for 
this assay were run in duplicates. Non-specific binding (NSB) tubes were prepared 
by adding 100 µL assay buffer with 50 µL hydrated 125I-Insulin; reference (B0) tubes 
by adding 50 µL assay buffer with 50 µL hydrated 125I-Insulin; and insulin standards 
(0.16, 0.31, 0.63, 1.25, 2.5, 5.0 and 10.0 ng x mL-1) and quality controls (QCs) were 
prepared by adding 50 µL assay buffer, 50 µL hydrated 125I-Insulin and 50 µL insulin 
antibody (guinea pig anti-rat insulin serum in assay buffer) together. Plasma samples 
(25 µL) were diluted 1:2 or 1:4 as appropriate with assay buffer. 50 µL hydrated 125I-
Insulin and 50 µL insulin antibody was added before vortexing and incubating in 4oC 
for 20-24 hours. Following incubation, 500 µL cold precipitating reagent (goat anti-
guinea pig immunoglobulin G (IgG) serum) was added to all tubes except the total 
Insulin RIA standard curve
Standard concentration (ng/ml)
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counts tubes, samples vortexed and incubated in 4oC for another 20 minutes. Insulin 
gamma count was performed with a 2470 Wizard2TM automatic gamma counter 
(PerkinElmer, Inc. Massachusetts, USA) following a 45 minutes centrifugation at 
3500 g at 4oC in a refrigerating Beckman C5-6R centrifuge (Beckman Coulter, Pty 
Ltd., Lane Cove, NSW, Australia) and decantation of supernatant. Plasma insulin 
concentrations were then calculated by automated data reduction procedures.  
Table 2.3 Modified assay standard procedure for insulin radioimmunoassay 
Day 1 Day 2 
               Step 
Set up 
1 2-3 4 5 6 7 8 9-11 
Tube content 
(x2) 
Assay 
buffer 
Std/QC/test 
samples 
125I-tracer 
Rat insulin 
AB 
Vo
rt
ex
, c
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 w
ith
 a
lu
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um
 fo
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 a
nd
 in
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ba
te
 fo
r  
20
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4 
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Total counts  - - 50µl - - 
NSB  100µl - 50µl - 500µl 
B0  50µl - 50µl 50µl 500µl 
Std 0.16 - 50µl of 0.16ng/ml 50µl 50µl 500µl 
Std 0.31 - 50µl of 0.31ng/ml 50µl 50µl 500µl 
Std 0.63 - 50µl of 0.63ng/ml 50µl 50µl 500µl 
Std 1.25 - 50µl of 1.25ng/ml 50µl 50µl 500µl 
Std 2.50 - 50µl of 2.5ng/ml 50µl 50µl 500µl 
Std 5.00 - 50µl of 5.0ng/ml 50µl 50µl 500µl 
Std 10.0 - 50µl of 10.0ng/ml 50µl 50µl 500µl 
QC1  - 50µl of QC1 50µl 50µl 500µl 
QC2  - 50µl of QC2 50µl 50µl 500µl 
Test sample 1 25µl 25µl test sample 50µl 50µl 500µl 
Test sample 2 25µl 25µl test sample 50µl 50µl 500µl 
         
B0, reference tube; NSB, non-specific binding; QC, quality control; std, standard. All procedures were 
following the manufacturers’ protocol but modified by reducing all reagents and samples by half as 
shown in the table. Adapted from (Cat.#RI-13K, Millipore, Pty. Ltd., Kilsyth, VIC, Australia). 
2.7.3.2 Plasma leptin determination 
Leptin concentrations were determined following the manufacturers protocol 
(Cat.#XL-85K, Millipore, Pty. Ltd., Kilsyth, VIC, Australia) (Table 2.4). All samples for 
this assay were run in duplicates. On day one, 300 µL assay buffer were added into 
NSB tubes. B0 tubes were prepared by adding 200 µL assay buffer with 100 µL leptin 
antibody (guinea pig anti-multi-species leptin antibody in assay buffer); and leptin 
standards (0.20, 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25.0, 50.0 and 100.0 ng x mL-1) 
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and QCs by adding 100 µL assay buffer with 100 µL standard/QC and 100 µL leptin 
antibody. Plasma collected from rats aged 8 months were run in a 1:3 dilution (50 µL 
sample + 150 µL assay buffer), and plasma collected at PN30 in a 3:1 dilution (150 
µL sample + 50 µL assay buffer). 100 µL leptin antibody was added to test samples. 
Tubes were mixed by vortexing and incubated in 4oC for 20-24 hours. Following 
incubation, on day two, 100 µL 125I-Human-Leptin tracer was added to all tubes, and 
tubes were mixed again by vortexing and incubated in 4oC for 20-24 hours. On day 
three, 1 mL cold precipitating reagent (goat anti-guinea pig IgG serum) was added to 
all tubes except the total counts tubes. Tubes were gently vortexed and incubated in 
4oC for another 20 minutes. Leptin gamma count was performed with a 2470 
Wizard2TM automatic gamma counter (PerkinElmer, Inc. Massachusetts, USA) 
following a 30 minutes centrifugation at 3000 g at 4oC in a refrigerating Beckman C5-
6R centrifuge (Beckman Coulter, Pty Ltd., Lane Cove, NSW, Australia) and 
decantation of supernatant. Plasma leptin concentrations were then calculated by 
automated data reduction procedures.  
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Table 2.4 Modified assay standard procedure for leptin radioimmunoassay 
Day 1 Day 2 Day 3 
               Step 
Set up 
1 2-3 4 5 6 7 8 8 9-11 
Tube content 
(x2) 
Assay 
buffer 
Std/QC/test 
samples 
Leptin 
AB 
Vo
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ex
, c
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125I-tracer 
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Total counts  - - - 100µl - 
NSB  300µl - - 100µl 1000µl 
B0  200µl - 100µl 100µl 1000µl 
*Std 0.20 100µl 100µl of 0.20ng/ml 100µl 100µl 1000µl 
*Std 0.39 100µl 100µl of 0.39ng/ml 100µl 100µl 1000µl 
*Std 0.78 100µl 100µl of 0.78ng/ml 100µl 100µl 1000µl 
Std 1.56 100µl 100µl of 1.56ng/ml 100µl 100µl 1000µl 
Std 3.13 100µl 100µl of 3.13ng/ml 100µl 100µl 1000µl 
Std 6.25 100µl 100µl of 6.25ng/ml 100µl 100µl 1000µl 
Std 12.5 100µl 100µl of 12.5ng/ml 100µl 100µl 1000µl 
Std 25.0 100µl 100µl of 25.0ng/ml 100µl 100µl 1000µl 
Std 50.0 100µl 100µl of 50.0ng/ml 100µl 100µl 1000µl 
*Std 100.0 100µl 100µl of 100ng/ml 100µl 100µl 1000µl 
QC1  100µl 100µl of QC1 100µl 100µl 1000µl 
QC2  100µl 100µl of QC2 100µl 100µl 1000µl 
Test sample 1 50µl 150µl test sample 100µl 100µl 1000µl 
Test sample 2 50µl 150µl test sample 100µl 100µl 1000µl 
          
B0, reference tube; NSB, non-specific binding; QC, quality control; std, standard. All procedures were 
following the manufacturers’ protocol. Standard curve was extended (*) to allow for a wider 
detection limit. The table is showing a 1:3 dilution of test samples. Adapted from (Cat.#XL-85K, 
Millipore, Pty. Ltd., Kilsyth, VIC, Australia). 
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2.7.3.3 Automated data reduction procedures  
For determination of plasma insulin and leptin concentrations, a weighted 4-
parameter curve was generated in Assay Zap (Biosoft® version 3.2) (Figure 2.6). 
The average count per minute (cpm) of the NSB tubes were subtracted from the 
average cpm of each sample and test sample to generate a total binding counts 
value. This value was then used to determine the percentage of tracer bound, which 
was calculated by: 
 
% 𝑡𝑟𝑎𝑐𝑒𝑟 𝑏𝑜𝑢𝑛𝑑 =
𝑇𝑜𝑡𝑎𝑙 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 𝑐𝑜𝑢𝑛𝑡𝑠
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑢𝑛𝑡𝑠
 𝑥 100 
where the total counts are the current cpm measured from the hydrated 125I-tracer. 
The percentage tracer bound should be between 35-50%. 
The percentage of total binding (%B/B0) for each standard and sample was the 
calculated by: 
%𝐵/𝐵0 =  
𝑆𝑎𝑚𝑝𝑙𝑒 𝑜𝑟 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
𝑇𝑜𝑡𝑎𝑙 𝑏𝑖𝑛𝑑𝑖𝑛𝑔
 𝑥 100 
The %B/B0 was plotted using the standard values on the y-axis and the known 
concentrations of the standards on the x-axis. The insulin and leptin concentrations 
in the test samples and QCs were determined in ng x mL-1 by interpolation of the 
reference curve. Appropriate mathematical adjustment were made to accommodate 
for the dilution factor, in this case, the value from a 1:2 dilution was multiplied by 2, 
the value from a 1:3 dilution by 3, the value from a 1:4 dilution by 4 and a value from 
a 3:1 dilution was divided by 3.  
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2.7.3.4 Plasma adiponectin determination 
Plasma adiponectin was determined with enzyme-linked immunosorbent assay 
(ELISA) (limit of sensitivity 0.4 ng/mL) (Cat#EZRADP-62K, Millipore, Pty. Ltd., 
Kilsyth, VIC, Australia) according to the manufacturers instructions (Table 2.5). Test 
samples were diluted to 1:500 in 1x assay buffer. The dilution was made in two 
steps. First, 10 µL test sample was added to 990 µL assay buffer (dilution A; 1:100), 
and then 100 µL of dilution A was added to 400 µL assay buffer (dilution B; 1:500). 
All reagents were pre-warmed to room temperature before use. Assay strips were 
placed in a microliter assay plate and washed three times with 300 µL provided wash 
buffer. Wash buffer and residual amount was decanted from the wells between every 
wash by inverting the plate and tapping it onto absorbent towels several times. 80 µL 
assay running buffer was added to each well together with 20 µL standards, QCs or 
test sample. The assay plate was covered with plate sealer and incubated in room 
temperature for 2 hours on a Heidolph Titramax 100 orbital microliter plate shaker at 
500 rpm (John Morris Scientific Pty, Ltd., Chatswood, NSW, Australia). Following 
incubation, the plate was washed a second time (same washing procedure as the 
first time). 100 µL rat pre-titered bioinylated monoclonal anti-Adiponectin antibody 
was added to each well using a multi-channel pipette and the plate was sealed and 
incubated for 1 hour in room temperature at 500 rpm. The plate was then washed a 
third time before adding 100 µL enzyme solution (pre-titered streptavidid-horseradish 
peroxidase conjungate in buffer) using a multi-channel pipette. After another 30 
minutes incubation in room temperature at 500 rpm, and another three washes, 100 
µL substrate solution (containing 3,3’,5,5’-tetramethylbenzidine in buffer) was added 
to each well. The plate was placed in room temperature on the plate shaker at 500 
rpm for 8-15 minutes to allow for color change (intensity proportional to increasing 
concentrations of the rat adiponectin standards). 100 µL of stop solution (containing 
0.3 M hydrochloric acid (HCl)) was added to each well and the plate gently agitated. 
Absorbance was immediately read at 450 nm and 590 nm in a Tecan SunriseTM 
Micro plate Absorbance reader (Tecan Pty, Ltd., Port Melbourne, VIC, Australia) and 
the difference of absorbance units recorded.  
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Table 2.5 Assay procedure for plasma adiponectin ELISA 
Step 1 2 3 4 5 6 7 8 9 10 11 12 
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Stop 
solution 
Re
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nc
e 
at
 4
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m
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m
. 
Std 0 100µl - 100µl 100µl 100µl 100µl 
Std 3.1 80µl 20µl of 3.1ng/ml 100µl 100µl 100µl 100µl 
Std 6.3 80µl 20µl of 6.3ng/ml 100µl 100µl 100µl 100µl 
Std 12.5 80µl 20µl of 12.5ng/ml 100µl 100µl 100µl 100µl 
Std 25 80µl 20µl of 25ng/ml 100µl 100µl 100µl 100µl 
Std 50 80µl 20µl of 50ng/ml 100µl 100µl 100µl 100µl 
Std 100 80µl 20µl of 100ng/ml 100µl 100µl 100µl 100µl 
Std 200 80µl 20µl of 200ng/ml 100µl 100µl 100µl 100µl 
QC2 80µl 20µl of QC2 100µl 100µl 100µl 100µl 
Sample1 80µl 20µl of sample 1 100µl 100µl 100µl 100µl 
Sample 2 80µl 20µl of sample 2 100µl 100µl 100µl 100µl 
 
QC, quality control; RT, room temperature; Std, standard. All procedures were following the manufacturers’ protocol. Adapted from (Cat.#EZRADP-62K, 
Millipore, Pty. Ltd., Kilsyth, VIC, Australia). 
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A sigmoidal 4-parameter logistic equation was generated in Assay Zap (Biosoft® 
version 3.2) (Figure 2.7) and the concentration of adiponectin in test samples 
calculated based on the values of the standards.  
Figure 2.7 – Standard curve generated with Assay Zap for determination of adiponectin      .   .   .     
A sigmoidal 4-parameter logistic equation graphing the logarithm of the difference of absorbance 
units between 590 and 450 nm for each standard on the y-axis versus the known concentration of 
each standard on the x-axis. The adiponectin concentrations for the test samples were determined 
by based on the standard values.  
 
2.7.4 Plasma osmolality determination 
Plasma osmolality is a measurement of the body’s electrolyte-water balance and 
was determined using a Vapor Pressure Osmometer (5520 WESCOR, Helena 
Laboratories, Australia) (detection range 20-3200 mmol/kg).  
2.8 Body composition measurements  
Body composition (total fat mass (FM), total fat free mass (FFM), abdominal fat 
mass, bone mineral density (BMD) and bone mineral content (BMC)) were measured 
with a dual-energy X-ray absorptiometer (DXA; model XR36, Norland). Rats were 
anesthetized with an i.p. injection of a 50/50 mix of Zoletil/Xylazile (0.1 mL/100g 
Adiponectin ELISA standard curve
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Lo
g 
ab
so
rb
an
ce
 (5
90
nm
-4
50
nm
)
Chapter 2 General Methods and Materials 
 
87 
 
 
body weight) and scanned in prone position. To avoid dryness of the eyes, saline 
was continuously applied onto the eyes with a syringe tube. Following the scan, rats 
received an intramuscular injection of 2-6 mL saline in the subscapular region to 
prevent dehydration and to facilitate recovery. Rats were allowed to recover in 
individual cages, with ad libitum access to tap water, hydrogels (Clear H2O, Portland, 
ME, USA) and moist rat chow. Scans were analysed using the manufacturer’s 
recommended software for use in laboratory animals (Small subject analysis 
software, version 2.5.3/1.3.1, Norland) (Figure 2.8). 
Figure 2.8 – DXA-scan of body composition                                         .      . 
An anesthetized rat undergoing a DXA-scan of body composition (A), an image of a control fed (B) 
and WD fed (C) male rat generated for analyze of body composition and abdominal fat content 
(square). 
2.9 Gene expression analysis 
Relative mRNA expression for a range of genes of interest (GOI) was determined by 
quantitative real-time polymerase chain reaction (qPCR) in a variety of tissues from 
E20 and offspring cohorts. 
2.9.1 RNA extraction 
For the purpose of this thesis, RNA was extracted from liver, placental labyrinth and 
junctional zones, and visceral intra-abdominal mesenteric adipose tissue. Extraction 
of these tissues required different protocols which are described in detail in the 
following sections.  
A B C
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2.9.1.1 RNA extraction from liver and placental compartments  
Total RNA was extracted from frozen tissues (20-30 mg) using an RNeasy Mini Kit 
(QIAGEN, Doncaster VIC, Australia). The homogenization buffer contained 1% (v/v) 
of β-mercaptoethanol for every mL of RLT buffer. Frozen samples were 
homogenized for 45-60 seconds in 600 µL of the RLT buffer using an Ultra-Turrax T8 
homogenizer (IKA, Labtek, Brendale, QLD, Australia). Between each sample, the 
probe was cleaned in distilled water and by 100% EtOH to prevent cross 
contamination. The homogenized samples were centrifuged using a refrigerating 
Eppendorf microcentrifuge 5417R (Quantum scientific, Eppendorf South Pacific, 
NSW, Australia) at 14,000 rpm for 3 minutes at room temperature to allow for 
separation of the RNA containing aqueous phase from the DNA/protein containing 
pellet. The supernatant was transferred to a sterilized 1.5 mL Eppendorf tube. One 
volume of 70% EtOH was added and mixed by pipetting. 600 µL aliquots were 
pipetted out and transferred to an RNA spin column (pre-inserted into a collection 
tube) and centrifuged at 14,000 rpm for 30 seconds at room temperature. This step 
was repeated with the remaining 600 µL of supernatant/EtOH mix. 350 µL provided 
wash buffer was added to the spin column and samples centrifuged again at 14,000 
rpm for 30 seconds. 80 µL of deoxyribonuclease (DNase) in RDD (12.5 % (v/v)) were 
pipetted directly on to the membrane of the spin column and samples were rested for 
15 minutes at room temperature. Spin columns were washed again in 350 µL wash 
buffer and two times in 500 µL provided RPE buffer. RNA was then eluted from the 
spin column using two aliquots of 30 µL of ribonuclease (RNase)/DNase free water 
(InvitrogenTM) centrifuged through the column at 14,000 rpm for 1 minute. A total of 
60 µL of RNA was obtained from each sample and stored in -80oC prior to 
performing complementary Deoxyribonucleic acid (cDNA) synthesis. 
2.9.1.2 RNA extraction from visceral abdominal adipose tissue 
For adipose tissue, total RNA was extracted from frozen tissues (80-90 mg) using an 
RNeasy Mini Kit (QIAGEN, Doncaster VIC, Australia). Adipose tissue was 
homogenized in 1000 µL Trizol lysis reagent for 20-40 seconds using an Ultra-Turrax 
T8 homogenizer (IKA, Labtek, Brendale, QLD, Australia). The homogenate was 
rested in room temperature for 5 minutes. 200 µL chloroform was added to the 
homogenate and samples vigorously shaken for 20 seconds. Samples were 
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incubated in room temperature for another 3 minutes before being centrifuged at 
14,000 rpm for 15 minutes at 4oC. The chloroform allows the sample to separate into 
a clear upper aqueous layer (containing the RNA), an interphase, and a pink/red 
lower layer (containing the DNA and proteins). The upper phase was carefully 
transferred to a sterilized 1.5 mL Eppendorf tube and one volume (~600 µL) of 70% 
EtOH was added. Samples were mixed by pipetting and aliquots were transferred to 
a RNA spin column (pre-inserted into a collection tube) and centrifuged at 14,000 
rpm for 30 seconds at room temperature. From this step onwards, the procedure 
followed the same protocol as described for liver and placental compartment RNA 
extraction (see section 2.9.1.1). However, due to very low yield of RNA, only 30 µL of 
RNase/DNase free water (InvitrogenTM) was added to elute the RNA from the spin 
column. Thus a total of 30 µL of RNA was obtained from each adipose sample and 
stored in -80oC prior to performing cDNA synthesis. 
2.9.2 RNA concentration and purity 
The concentration and purity of RNA were measured using a NanoDrop ND1000 
spechtrophotometer (NanoDrop Technologies, Wilmington, DE, USA) (Figure 2.9). 
Calibration was performed by adding 1 µL of RNase-free water onto the measure-
ment pedestal sensor of the NanoDrop in order to blank the system to zero. 1 µL of 
extracted RNA per sample was placed onto the measurement pedestal sensor to 
create a reading. Sample and blank intensities were used by the NanoDropto 
calculate the sample absorbance wavelengths at 260 nm and 280 nm (ND-1000 
Data Viewer). Although we did not check the integrity of all RNA samples by running 
them on a gel, any samples that did not give the expected 260:280 ratio or gave a 
value for 18S outside the expected range was either re-extracted or excluded from 
the analysis. 
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Figure 2.9 – Measurement of RNA concentrations using a Nanodrop spectrophotometer     .     .     . 
The curve generated when measuring ribonucleic acid (RNA) concentration using a Nanodrop 
spectrophotometer. The concentration of RNA is calculated from the A260/A280 ratio. 
The Beer-Lambert equation is used to correlate the calculated absorbance with 
concentration: 
𝐶 =
(𝐴260 𝑥 𝑒𝑐)
𝐵
 
Where:  
C = concentration of RNA (ng/µL) 
A260 = absorbance at 260 nm 
ec = wavelength-dependent extinction coefficient (a constant: 40 ng-cm/µL for RNA) 
B = the path length of the NanoDrop (1 mm) 
Both RNA and protein absorbs light at distinct wavelengths (i.e. 260 nm and 280 
nm). Therefore, the purity was also evaluated by obtaining an A260/A280 ratio. By 
comparing the absorbance values at 260 nm and 280 nm, the proportion of RNA 
relative to protein in the sample can be calculated. Samples with A260/A280 ratio 1.8-
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2.1 μg/μL were considered as a relatively pure RNA sample and used for cDNA 
synthesis. 
2.9.3 Reverse transcription of RNA to cDNA 
cDNA synthesis from RNA was performed using the iScriptTM Reverse Transcription 
Supermix for RT-qPCR (Bio-Rad). 1 µg of total RNA was combined with 2 µL of 5x 
iScript reverse transcription supermix and made up to 10 µL with nuclease-free 
water. The cDNA synthesis step also contained a No-RT control to reveal the 
presence of genomic DNA (gDNA). This reaction contained the same amount of 
RNA as the reverse transcription reaction to allow similar carryover of cDNA 
synthesis components in qPCR, but the 5x iScript reverse transcription supermix 
was replaced by a negative reverse transcriptase. Samples were incubated at 25oC 
for 10 minutes for enzyme activation, followed by 42oC for 30 minutes extension 
phase. The reaction was terminated at 85oC for 5 minutes to allow for denaturation 
using a PCR Express Thermal Cycler (Thermo Fisher Scientific, Wilmington, DE, 
USA). Samples were stored in -20oC until quantifying gene expression by qRT-PCR 
assay.  
2.9.4 Quantifying gene expression 
Gene expression was quantified via TaqMan® or SYBR® Green-based detection 
chemistry. As almost all genes examined in this thesis were quantified using 
Taqman®in the following sections, whereas the SYBR® Green-based detection 
chemistry is only described briefly.  
2.9.4.1 TaqMan® detection chemistry 
mRNA expression is measured by the fluorescence emitted during the polymerase 
chain reaction (PCR) as an indicator of amplicon (i.e. the PCR product) production 
during each PCR cycle in ‘real-time’. A laser is directed to each sample well with 
fluorescence emission data collected once every few seconds for each sample as 
the PCR product is being generated. A fluorescent reporter detects and measures 
the amount of PCR product formation by the number of copies of the nucleic acid 
target. As the starting copy number is determined by when the PCR product is first 
detected, the higher the starting copy number, the more fluorescence will be emitted 
and this in turn indicates a higher gene expression of the nucleic target. The 
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fluorescence signal, which increases exponentially, is measured by the cycle 
threshold (CT) (PCR cycle number at which the reporter dye fluorescence exceeds 
background level and is proportional to the level of gene expression in a given 
tissue). 
Taqman® probes are oligonucleotides which contain a reporter dye at the 5’ end and 
a quenching dye at the 3’ end (Figure 2.10). For the purpose of this thesis, 18s 
ribosomal RNA (Rn18s) was used as the endogenous control (labelled at the 5′ end 
with VIC; 2′-chloro-7′-phenyl-1,4-dichloro-6-carboxyfluorescein). All probes were 
labelled at the 3’ end with the florophore FAM; V6-carboxyfluorescein (TaqMan® 
Ribosomal RNA Control Reagents kit, Applied Biosystems, Mulgrave, VIC, 
Australia). When excited by the cycler’s light source, the quenching molecule 
quenches the fluorescence emitted by the reporter dye via FRET (Bustin, 2000). 
During the extension phase, when the Taq polymerase replicates a template DNA 
strand on which a TaqMan® probe is bound, its 5’exonuclease activity will cleave the 
probe, causing the probe to cleave, and the fluorescent and quenching dyes to 
decouple, thus terminating the FRET. The increased fluorescence in each cycle is 
therefore directly proportional to the amount of probe cleaved and PCR product 
formed. When well designed, TaqMan® probe chemistry provides the highest level 
of specificity for the PCR and requires very little optimization. It is the most 
commonly used detection chemistry for reverse transcription polymerase chain 
reaction (RT-PCR). TaqMan® detection chemistry and assay on demand (AOD) 
(Applied Biosystems, Foster City, CA, USA) assays were used to determine relative 
gene expression of various genes throughout this thesis (Table 2.8).  
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Figure 2.10 – The principle of Taqman® detection chemistry 
A schematic presentation of the principle of Taqman® polymerization, strand displacement, cleavage 
and completion of cycle. Adapted from (Yuan et al., 2000). 
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2.9.4.2 SYBR®Green-based detection chemistry 
SYBR® Green is a non-sequence specific double stranded (ds) intercalating dsDNA 
binding dye which fluoresces once bound to the dsDNA (Figure 2.11). The target 
gene is amplified using a pair of specific primers and the amount of dye incorporated 
is proportional to the amount of generated target. When the dye emits at 520 nm, 
fluorescence emitted is detected and related to the amount of target. As SYBR® 
Green will bind to any dsDNA, primers needs to be very specific to the target, which 
generally requires sufficient optimization. The specificity of the system is validated at 
the end of the PCR run by creating a melt curve (Figure 2.12). As every product has 
a specific dissociation temperature, depending on the size and base content, the 
melt curve is an indication of the number of products amplified. An optimized SYBR® 
Green reaction will produce one single unique, well defined peak on the melt curve. 
The first step of a SYBR® Green reaction is DNA denaturation. This is followed by 
primers anneal and the free SYBR® Green molecules in the reaction mix binds to 
the dsDNA. DNA polymerase then elongates the template during the extension 
phase and allows for more SYBR® Green molecules to bind to the product. 
Subsequently, this results in an exponential increase in the fluorescent level.  
  
 
Figure 2.11 – The principle of 
SYBR® Green detection chemistry 
A schematic presentation of the 
principle of SYBR® Green 
detection chemistry. The initial 
annealing phase is followed by an 
extension phase, in which free 
SYBR® Green molecules bind to 
the dsDNA to produce an 
exponential increase in the 
fluorescence level.  Adapted from 
(van der Velden et al., 2003).  
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Figure 2.12 – A melt curve generated with SYBR® Green detection chemistry                      . 
The melt curve generated in a SYBR® Green reaction is dependent on each products’ size and base 
content. When optimized, the reaction produces one unique, well defined peak on the melt curve. 
2.9.5 Real-time PCR 
Real-time PCR was performed using a StepOne™ Real-Time PCR system (Applied 
Biosystems, VIC, Australia) in 10 µL reactions (2.5 µL of 1:10 dilution of cDNA (1:5 
dilution for adipose tissue)) as shown in Table 2.6. Before measuring gene 
expression for the GOI with Taqman®, reactions were tested with (multiplex) and 
without 18s (singleplex) at different sample concentrations (1:10, 1:100 and 1:1000) 
for each primer set and tissue in duplicates. In cases were 18s did not significantly 
affect the amplification of the primer set, reactions were multiplexed (Figure 2.13). In 
all other cases, reactions were singleplexed.  
All reactions were run in duplicates. The thermal cycling conditions for Taqman® 
consisted of: 1) an incubation step at 50oC for 2 minutes; 2) an initial denaturation 
stage at 95oC for 10 minutes; 3) 40 cycles of 95oC for 15 seconds to denature the 
cDNA into single strands; and 4) annealing/extension at 60oC for 1 minute. For 
SYBR® Green, the thermal cycling parameters consisted of: 1) 10 minutes at 95oC; 
2) a 40 cycle denaturation stage for 15 seconds at 95oC; and 3) an 
annealing/extension phase at 60oC for 1 minute. The melt curve for SYBR® Green 
was generated at the end of the thermal cycling using the Applied Biosystems real-
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time PCR system. Data obtained from the RT-PCR reactions were analyzed using 
the StepOne™ sequence detection system (StepOne™ Software v2.2.2, Applied 
Biosystems, VIC, Australia). Each PCR template contained three calibration 
samples, one water and four negative controls prepared during the cDNA synthesis 
to monitor gDNA, contamination and non-specific binding. 
Table 2.6 Recipe for real-time PCR reactions with Taqman® and SYBR® Green 
Taqman® Amount per well (µL) SYBR® Green Amount per well (µL) 
Mastermix 5 Mastermix 5 
18s 0.1 18s 1* 
AOD 0.25 Probe/primer set (4ng/ml) 1* 
1:10 cDNA (sample) 2.5 1:10 cDNA (sample) 2.5 
Rnase free H2O 2.15 Rnase free H2O 1.5 
Total 10  10 
 
18s, 18s ribosomal ribonucleic acid; AOD, assay on demand; cDNA, complementary Deoxyribonucleic 
acid. Recipe for a real-time PCR reaction with Taqman® and SYBR® Green detection chemistry per 
reaction well. When singleplexed, reaction volume was adjusted with RNase free water (H2O). *, All 
SYBR® Green were singleplexed with each reaction containing either 18s or the probe/primer set. 
 
Figure 2.13 – An amplification plot generated by the real-time PCR system     .     .     .    .   . 
An amplification plot of a multiplexed reaction (left curve 18s, right curve gene of interest). The 
plateau phase (a), linear phase (b), exponential phase (c), background (d) and threshold (e) are 
indicated for the curve showing the gene of interest.  
a
b
c
d
e
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2.9.6 Quantification of gene expression 
Relative gene expression results were analyzed using the comparative CT method in 
which the difference between the average CT-values of the gene of interest and the 
endogenous control 18s ribosomal RNA was calculated for each sample (ΔCT) 
according to: 
ΔCT = ACT(GOI) – ACT(18s) 
The ΔCT for each sample was further normalized to the ΔCT of a calibrator sample 
(i.e. the control group), creating a  ΔΔCT value: 
ΔΔCT = ΔCT (sample) - ΔCT (calibrator) 
The ΔΔCT value was transformed to an absolute value that allows for gene 
expression levels to be represented as a fold-change relative to the calibrator used. 
The formula used for the comparative expression level was: 
2- ΔΔCT 
 
2.9.7 Fetal genotyping 
Identification of DNA for the sex-determining region Y (Sry) sequence is the most 
accurate way to determine fetal sex as the use of this method has eliminated the 
possibility of contamination by maternal tissue.  
At the time of PMs for the E20 cohort, fetal tails were collected and snap frozen in 
liquid nitrogen for determination of fetal sex. Tails were incubated in lysis buffer 
(Table 2.7) containing 0.2 mg/mL proteinkinase K (Promega) overnight at 55oC. 
Proteinkinase K was deactivated by heating at 95oC for 10 minutes followed by 
vortexing of tissue samples. Samples were then centrifuged at 4oC at 10 000 rpm for 
10 minutes. A multiplexed RT-PCR reaction for the Sry gene (Sry, Mm00441712_s1) 
was performed directly on the supernatant as described in section 2.9.5 to detect 
gDNA.
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Table 2.7 Lysis Buffer  
Reagent Volume/weight 
KCl 1.15 g 
1M TRIS-HCl pH 8.3 2 mL 
1M MgCl2 0.4 mL 
Gelatin 20 mg 
Nonidet P-40 900 µL 
TWEEN 20 900 µL 
H20 200 mL 
  
HCl, hydrogen chloride; KCl, potassium chloride; MgCl2, magnesium chloride; TRIS, tris(hydroxyl-
methyl) aminomethane. 
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Table 2.8 Primers and probes used in thesis 
AOD ID number/ AOD Name Gene name Reaction type Chapter used 
Rn00593696_m1 Slc38a1 Solute carrier family 38, member 1, multiplex 1 
Mn00628416_m1 Slc38a2 Solute carrier family 38, member 2, multiplex 1 
Rn00593742_m1 Slc38a4 Solute carrier family 38, member 4, multiplex 1 
Rn1417099_m1 Slc2a1(Glut1) solute carrier family 2 (facilitated glucose transporter) member 1 multiplex 1 
Rn00567331_m1 Slc2a3(Glut3) solute carrier family 2 (facilitated glucose transporter) member 3 multiplex 1 
Rn00710306_m1 Igf1 Insulin-like growth factor 1 multiplex 1 
Rn01454518_m1 Igf2 Insulin-like growth factor 2 multiplex 1 
Rn01636937_m1 Igf2R Insulin-like growth factor 2 receptor multiplex 1 
Mm00437304_m1 Vegfa  Vascular endothelial growth factor A multiplex 1 
Rn00492539_m1 11βHsd2 Hydroxysteroid 11-beta dehydrogenase 2 multiplex 1 
Rn00585926_m1 Pgf Placental growth factor multiplex 1 
Rn00570815_m1 Flt1 fms-related tyrosine kinase 1 multiplex 1 
Mn01222421_m1 Kdr Kinase insert domain receptor multiplex 1 
Rn01476417_m1 Gys1 Glycogen synthase 1 multiplex 1 
Rn00570335_s1 Gjb3 Gap junction beta-3 protein multiplex 1 
Rn00583429_m1 Gsk3β Glycogen synthase kinase 3 beta multiplex 1 
Rn01529014_m1 Pck1 Phosphoenolpyruvate carboxykinase multiplex 2 
Rn00561265_m1 Gck Glukokinase  multiplex 2 
Rn00689876_m1 G6pc Glucose 6-phosphatase multiplex 2 
Rn00580241_m1 Ppargc1a Peroxisome proliferator-activated receptor gamma coactivator 1-alpha singleplex 2 
Rn01193634_g1 Hdac2 Histone deacetylase 2 multiplex 2 
F 5’-GATTAGGCTGCTTCAATCTC 
R 5’-CAGAGATGTTTCATATGTCCAG 
 
Hdac3* Histone deacetylase 3 singleplex 2 
F 5’-AAACAGCTTCTGAACCTAAC 
R 5’-GAGTCTGTAACATCCAGGG 
Hdac4* Histone deacetylase 4 singleplex 2 
Rn01528283_m1 Hdac6 Histone deacetylase 6 multiplex 2 
F 5’-AGAGACCAGGATAAGAACG 
R 5’-TTACTCGTTCAGGTTTCTCC 
Dnmt1* Deoxyribonucleic acid methyltransferase 1 singleplex 2 
F 5’-AATAGCCAAGTTCAGCAAAG 
R 5’-AAACACCCTTTCCATTTCAG 
Dnmt3a* Deoxyribonucleic acid methyltransferase 13A singleplex 2 
F 5’-GATGACAAGGAGTTTGGAATA 
R 5’-CAGCGATCTCAGAAAACTTG 
Dnmt3b* Deoxyribonucleic acid methyltransferase 13B singleplex 2 
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Table 2.8 Primers and probes used in thesis (cont.) 
AOD ID number/ AOD Name Gene name Reaction type Chapter used 
Rn00565158_m1 Lep Leptin multiplex 3 
F 5'-GAAACACACGAGACGCTGAA 
R 5'-GAAAGCCCATTGGAATCCTT 
 
 
Tnf-α* Tumor necrosis factor alpha  singleplex 3 
F 5'-ACTCATCTTGAAAGCACTTG 
R 5'-GTCCACAAACTGATATGCTTAG 
IL-6* Interleukin 6 singleplex 3 
     
F, forward probe; R, reverse probe; *, gene expression determined using SYBR® Green-based detection chemistry. All other genes were analysed with 
TaqMan® detection chemistry. 
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2.10 Protein expression analysis  
Protein expression was determined by Western Blotting and/or immunohisto-
chemistry (see section 2.10.3 and 2.11.3) in placental, muscle and adipose tissue.  
2.10.1 Protein extraction  
Total protein was extracted from placenta (30-40 mg), visceral intra-abdominal 
mesenteric adipose tissue (70-90 mg) and skeletal muscle (10-15 mg). RIPA lysis 
buffer (Table 2.9) was added (~350-500 µL depending on tissue weight). Samples 
were homogenized with an Ultra-Turrax T8 homogenizer (IKA, Labtek, Brendale, 
QLD, Australia) for 20-30 seconds (maximum 2 bursts). Samples were centrifuged at 
11,000 rpm for 30 minutes at 4oC in an Eppendorf microcentrifuge 5417R (Quantum 
scientific, Eppendorf South Pacific, NSW, Australia) to allow for separation of the 
cellular debris and supernatant.  
Table 2.9 RIPA buffer recipe  
Reagent Concentration  Volume (ml) Final Concentration  
MQ H20 - 85.6   
Tris-Hcl pH7.5 2 M 2.5 0.05 M 
NaCl 5 M 2 0.1 M 
EDTA pH8 0.5 M 0.4 0.002 M 
NaF 1 M 5 0.05 M 
SDS 10% 1 0.1% 
Deoxycholic acid 20% 2.5 0.5% 
Triton x 100 100% 1 1% 
Aprotin 2 mg/mL 0.05  
Leupeptin 2 mg/mL 0.25  
Pepstatin 2 mg/mL 0.035  
Total volume  100.34   
Add fresh -     
NaF  0.01 M 50 uL per 5 mL 0.01 
Na Vanadate 0.01 M 50 uL per 5 mL 0.01 
Na pyrophosphate 0.005 M 22.5 uL per 5 mL 0.0045 
 
EDTA, ethylenediaminetetraacetic acid; HCl, hydrogen chloride; KCl, potassium chloride; MgCl2, 
magnesium chloride; MQ H20, milli-Q water;  NaF, sodium fluoride; SDS, sodium dodecyl sulphate; 
TRIS, tris(hydroxymethyl) aminomethane. 
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2.10.2 Protein concentration 
The concentration of protein was determined using the Bio-Rad RC DC protein 
assay kit (Bio-Rad, Gladesville, NSW, Australia) which uses a colometric assay for 
protein quantitation. All samples were tested in triplicates and compared to a 
standard curve generated using bovine serum albumin. 5 µL sample/standard per 
well was loaded in a flat bottomed 96 well reaction plate. 75 µL provided reagent A 
(containing 0.02% reagent S) were added to each well followed by 200 µL reagent B. 
The plate was gently agitated and incubated in room temperature for 20-45 minutes 
to allow for color change of the standards. Absorbance was measured at 650 nm in a 
Tecan SunriseTM Micro plate Absorbance reader (Tecan Australia Pty, Ltd., Port 
Melbourne, VIC, Australia). 
2.10.3 Western blotting 
Following the protein concentration assay, samples were diluted in 
radioimmunoprecipitation (RIPA) buffer to a final concentration of 20 µL. 20% sodium 
dodecyl sulfate (SDS) was added to each sample before heating samples for 5 
minutes at 95oC. Even concentrations of samples were then subjected to a sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 10-12% 
resolving gels (depending on the molecular weight of the protein of interest) and run 
at 90 V for 2-3 hours. Proteins were then transferred to an Immun-Blot® LF poly-
vinylidene fluoride (PVDF) membrane (Bio-Rad, Gladesville, NSW, Australia) at 30 V 
at 4oC overnight. Following protein transfer, the membrane was blocked for 1.5-3 
hours in blocking buffer (3% fish gelatin from cold water fish (Sigma Aldrich, St 
Louis, MO, USA) in phosphate buffered saline (1 x PBS), using 2% horse or goat 
serum as appropriate. The membrane was then incubated with the first primary 
antibody overnight in 4oC. The antibody cocktail consisted of 3% fish gelatin in 1 x 
PBS, 2% horse or goat serum as appropriate, and 0.01% tween20. Following several 
washes in washing buffer, the membrane was incubated with an endogenous control 
as appropriate for 30 minutes in 4oC. After several washes, the membrane was 
subjected to secondary antibodies for 30-40 minutes in 4oC in a cocktail containing 
3% fish gelatin in 1 x PBS, 1% horse- and 2% goat serum, 0.01% tween20 and 
0.02% SDS. Membranes were washed again several times before being scanned 
with an Odyssey Infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA) 
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and densitometry performed using the Odyssey 2.0 software package (LI-COR 
Biosciences, Lincoln, NE, USA). All primary and secondary antibodies used in this 
thesis are summarized in Table 2.10. 
Table 2.10 Antibodies used for western blotting and/or immunohistochemistry in this thesis 
Name company/product# Host Dilution Duration MW (kDa) 
Chapter 
used 
Anti-GLUT-1 Millipore #07-1401 Rabbit 1:1000 ON 54  1 
Anti-IGF1R Santa Cruz #Sc-712 Rabbit 1:1000 ON 132 1 
Anti-GSK3α/β Upstate, Millipore #05-412 Mouse 1:400 ON 46, 51 2 
Anti-pGSK3α/βSer9/21 Cell signaling #9331 Rabbit 1:400 ON 46, 51 2 
Anti-pAKT2(thr309) Cell signaling #9275 Rabbit 1:600 ON 60 2 
Anti-pAKT2(ser474) Cell signaling  #8599 Rabbit 1:800 ON 60 2 
Anti-AKT2 Cell signaling #3063 Rabbit 1:1000 ON 60 2 
Anti-beta actin Sigma Aldrich #A1978  Mouse  1:25000 30 min 42 1+2 
Donkey-Anti-Mouse 2° Li-Cor 926-32210 Donkey 1:15000 30 min N/A  
Goat-Anti-Rabbit 2° Li-Cor 926-68071  Goat 1:20000 30 min N/A  
       
AKT, v-akt murine thymoma viral oncogene homolog; GLUT1, glucose transporter 1; GSK3, glycogen 
synthase kinase-3; IGF1R, insulin-like growth factor receptor 1; N/A, not applicable; ON, overnight. 
2.11 Histology 
At the time of PMs, some tissues were fixed in 4% PFA at 4oC overnight before 
being prepared for paraffin sectioning. Tissues were dehydrated in 70% EtOH 
overnight followed by a processing procedure of 90% EtOH, 100% EtOH and xylene. 
Following infusion of 60oC paraffin wax under vacuum (60 psi), tissues were 
embedded in paraffin blocks. Blocks were sectioned at 7 µm and transferred to 
Superfrost Ultra Plus® (Menzel Gläser). 
2.11.1 Hematoxylin and Eosin 
Slides were stained with hematoxylin and eosin (H&E) for basic morphological 
investigation. Hematoxylin stains nucleic acids deep blue-purple whereas eosin 
stains protein, cytoplasm and extracellular matrix in various degrees of pink. Paraffin 
slides were de-waxed in a series of xylene (3 x 2 minutes), and rehydrated in a 
series of EtOH (2 x 2 minutes of 100% EtOH; 2 minutes of 95% EtOH; 2 min of 90% 
EtOH; and 2 minutes of 70% EtOH) before being stained in hematoxylin for 6 
minutes. Following the stain in hematoxylin, slides were washed in running tap water 
for 2 minutes, placed in 90% EtOH for 2 minutes and the counterstained in eosin for 
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6 minutes. Slides were then washed in 70% EtOH for 2 minutes and dehydrated 
through a series of EtOH (2 minutes each in 70% EtOH; 95% EtOH; and 100% 
EtOH). Slides were re-waxed in a new series of xylene (3 x 2 minutes), mounted with 
DPX mounting medium (Merck, mounting medium, Darmstadt, Germany) and cover-
slipped. 
For this thesis, E20 placentas were stained with H&E to allow for identification of 
placental compartments for cross-sectional analyses (see section 2.11.4). Livers 
collected at 8 months were stained with H&E to allow for pathological analyses using 
the Kleiner scoring system (see section 2.11.5). 
2.11.2 Masson’s trichrome  
Masson’s trichrome stain is commonly used to identify increases in collagenous 
tissue. The three dyes used in this method is selectively staining nuclei dark 
blue/purple-black (Weigert’s working hematoxylin), collagen blue (aniline blue) and 
muscle, erythrocytes and cytoplasm red (Biebrish scarlet). Paraffin slides were de-
waxed and rehydrated according to the same protocol described in section 2.11.1. 
Slides were then mordant in Bouin’s solution at 60oC for 1 hour, followed by a 5 
minutes wash in running tap water to remove picric acid. Slides were then stained in 
Weigert’s working hematoxylin for 5 minutes, washed in running tap water for 5 
minutes and rinsed in distilled water. Slides were subjected to Bierbich scarlet stain 
for 5 minutes before being rinsed in distilled water again. Sections were flooded in 
2.5% phosphotungstic/phosphomolybdic acid solution for 30 minutes before being 
stained with aniline blue for 20 minutes. The third stain was followed by a wash in 
distilled water, a 1 minute wash in 1% acetic acid, another wash in distilled water and 
slides were finally dehydrated, cleared and cover-slipped as described in section 
2.11.1. 
For this thesis, Masson’s trichrome stain was used to stain livers to allow for 
evaluation of fibrosis using the Kleiner scoring system (see section 2.11.5).  
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2.11.3 Immunohistochemistry 
Immunocytochemistry is a common method in biomedical research which uses 
antibodies to identify and localize proteins and other macromolecules in tissues and 
cells (Burry, 2011).  
In this thesis, immunohistochemistry was used to identify GLUT1 in E20 placentas 
from 5 representative midline sections (7 µm). Sections were dehydrated as 
described in section 2.11.1, washed in distilled water for 2 minutes and placed in 
PBS. Endogenous peroxidase activity was blocked by placing the slides in 0.9% 
hydrogen peroxide (H2O2) in water for 40 minutes, followed by washes in 0.1 M 
phosphate buffer (PB) (3 x 5 minutes). Slides were then incubated in PB containing 
10% goat serum and 2% BSA for 30 minutes to block non-specific binding. A rabbit 
polyclonal GLUT1 antibody (1:1000, Millipore - cat. #07-1401) was put on the 
sections in a mixture containing 2% BSA and 0.3% triton in PB for 1 hour before 
washing in 0.1 M PB (3 x 5 minutes). This was followed by a 30 minute incubation 
with a bioinylated goat-anti-rabbit IgG secondary antibody (1:200, VECTASTAIN 
Elite avidin-biotin complex (ABC) Kit, PK-6101) containing 10% goat serum and 2% 
BSA in PB for 1 hour at 37oC and washes in 0.1 M PB (3 x 5 minutes). Slides were 
then incubated in ABC reagents (10 µL of reagent A and 10 µL of reagent B per 1 
mL of prep solution) at 37oC for 30 minutes, and washed again in 0.1 M PB (3 x 5 
minutes). 50 µL of 3’3 diaminobenzidine tetrahydrochloride (DAB) (ImmPACT DAB 
Peroxidase Substrate, SK4015, Vectorlabs., USA) (made up by adding 30 µL of 
DAM chromagen per 1 mL of DAB substrate buffer) was added to the slides and the 
reaction stopped by placing the slides in distilled water once the sections turned pale 
brown. Slides were finally counterstained in hematoxylin for 20 seconds, dehydrated 
and re-waxed as described in section 2.11.1 before being cover-slipped. Negative 
controls were generated to show that the labelling was a result of the label added 
and not the result of endogenous labelling. 
2.11.4 Cross-sectional area measurement  
For determining the cross-sectional area of the labyrinth vs. the junctional zones in 
E20 placenta, slides were scanned with an Aperio Scanscope XT scanning system 
(Aperio Technologies, Inc., Vista, CA, USA) and visualized using the associated 
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ImageScope software (version.10.2.2.2319). Thea area of each placental 
compartment was determined by carefully drawing around the outline of that specific 
zone on five different sections per placenta (Figure 2.14). The cross-sectional area 
of glycogen cells within the junctional layer was evaluated in the same way. All 
sections were assessed blinded. 
Figure 2.14 – Cross-sectional area of a placental section                     .         .     .          .   . 
The cross-sectional areas in placental sections were calculated using the ImageScope software. 
Drawings around each placental compartment were made at 2 x magnifications for the junctional 
layer (yellow) and the labyrinth layer (green) and at 5 x magnifications for glycogen cells (red). 
Placental section is shown at 2 x magnification.   
2.11.5 Kleiner scoring system for non-alcoholic fatty liver disease 
NAFLD is commonly seen together with insulin resistance. The Kleiner scoring 
system, developed by Kleiner and colleagues (Kleiner et al., 2005), is a commonly 
used semi quantitative scoring system for assessing a variety of histological features 
of NAFLD in slides stained with H&E and Masson’s trichrome.  
 
Five representative liver sections (6 µm) taken from the apex of the left lateral lobe of 
the liver per animal were stained with H&E (see section 2.11.1), and five were 
1000µm
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stained with Masson’s trichrome (see section 2.11.2) to assess histological features 
of NAFLD (Figure 2.15). All sections were scored blinded. Features assessed 
included steatosis, microvesicular steatosis, inflammation, microgranulomas (H&E), 
and fibrosis (Masson’s trichrome) (Table 2.11). 
 
Table 2.11 Kleiner scoring system 
 Severity Score 
Steatosis grade 
(Low- to medium- power 
evaluation) 
<5% 0 
5-33% 1 
>33-66% 2 
>66% 3 
Location of steatosis 
(predominant distribution 
pattern) 
Zone 3 0 
Zone 1 1 
Azonal 2 
Panacinar 3 
Microvesicular steatosis 
(contiguous patches) 
Absent  0 
Present 1 
Lobular inflammation (overall 
assessment of all inflammatory 
foci) 
No foci 0 
<2 foci per 200 x field  1 
2-4 foci per 200 x field 2 
>4 foci per 200 x field 3 
Microgranulomas (small 
aggregates of macrophages) 
Absent  0 
Present 1 
Stage of fibrosis None 0 
Perisinusoidal or periportal 1 
Mild, zone 3, perisinusoidal 1A 
Moderate, zone 3, 
perisinusoidal 
1B 
Portal/periportal 1C 
 
For description of hepatic zones, refer to Figure 2.15 A. 
Chapter 2 General Methods and Materials 
 
108 
 
 
 
Figure 2.15 – Traits of NAFLD assessed with the Kleiner scoring system     .  .     . 
Liver section stained with H%E of a healthy liver (A) with the hepatic zones defined (1, the area 
around the portal vein; 2, azonal; and 3, the area around the central vein). A liver with 
macrovesicular steatosis in zone 1 (black arrow), zone 3 (yellow arrow) and zone 2 (green arrow) (B). 
Macrovesicular steatosis in zone 1 exclusively receives a score of 1 (C), and macrovesicular steatosis 
in zone 3 exclusively receives a score of 0 (D). (E) is showing the presence of microgranuloma (yellow 
arrows) and severe lobular inflammation (>4 foci x 200 field) receiving a score of 3, and (F) the 
presence of microvesicular steatosis. For scoring the severity of macrovesicular steatosis, sections 
with 5-33% steatosis at low to medium power receives a score of 1 (G), 33-66% receives a score of 2 
(H), and >66% receives a score of 3.  A, B and G-I are shown at 5 x magnification and C-F at 10 x 
magnification. All inserted bars are 200 µm.  
C
A B
D
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G H I
1
2
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2
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2.12 Statistical analyses 
The statistical analyses for each data set are described in the relevant experimental 
chapters. All data are presented as mean ± standard error of the mean (SEM). The 
number of animals (n) used for each experiment is stated in the chapters. All graphs 
and statistical analyses were conducted with GraphPad Prism (v.6.0; GraphPad 
Software Inc., San Diego, CA, USA). Details of specific statistical analyses are found 
in each chapter. 
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Abstract 
Introduction: Alcohol consumption is a common social practice among women of 
childbearing age. With 50% of pregnancies being unplanned, many embryos are 
exposed to alcohol prior to pregnancy recognition and formation of the placenta. The 
effects of PC:EtOH-exposure on the placenta are unknown. 
Methods: Sprague-Dawley rats were exposed to alcohol (12.5% v/v ad libitum) from 
4 days prior to 4 days after conception and effects on placental growth, morphology 
and gene/protein expression examined at E20. 
Results: PC:EtOH-exposed fetuses were growth restricted and their placental/body 
weight ratio and placental cross-sectional area were increased. This was associated 
with an increase in cross-sectional area of the junctional zone and glycogen cells, 
especially in PC:EtOH-exposed placentas from female fetuses. 
Junctional Glut1 and insulin like growth factor 2 (Igf2) mRNA levels were increased. 
Labyrinth insulin like growth factor 1 (Igf1) mRNA levels were decreased in placentas 
from both sexes, but protein IGF1R levels were decreased in placentas from male 
fetuses only. Labyrinth mRNA levels of Slc38a2 were decreased and Vegfa were 
increased in placentas following PC:EtOH-exposure but only placentas from female 
fetuses exhibited increased Kdr expression. Augmented expression of the protective 
enzyme 11-beta hydroxysteroid dehydrogenase (11βHsd2) was found in PC:EtOH-
exposed labyrinth. 
Discussion: These observations are consistent with a stress response, apparent well 
beyond the period of EtOH-exposure and demonstrate that PC:EtOH alters placental 
development in a sex-specific manner. 
Conclusion: Public awareness should be increased to educate women about how 
excessive drinking even before falling pregnant may impact on placental 
development and fetal health. 
 
Chapter 3 
 
113 
 
 
3.1 Introduction 
It is increasingly accepted that IUGR is associated with chronic adult diseases that in 
many cases can be traced back to the quality of nutrition and health of the mother 
during pregnancy (McMillen and Robinson, 2005). A critical issue is the relative 
vulnerability of different stages of development to environmental insult and therefore 
potential developmental programming changes. Increasing evidence suggests that 
these programming events may be determined prior to implantation (Fleming et al., 
2004). Indeed, the period surrounding conception, or the periconceptional period, 
has been identified as a critical window of vulnerability for the embryo in both in 
vitro and in vivo studies from several species (Kwong et al., 2000, Sinclair et al., 
2007). Whilst previous studies have examined the impact of nutrition during the 
periconceptional period on development (Watkins et al., 2011, Zhang et al., 2011), 
little is known about the impact of maternal alcohol consumption during this period. 
This is of particular interest, as many women consume alcohol prior to pregnancy 
recognition (Edwards and Werler, 2006, Floyd et al., 1999) and both 
gestational (Gundogan et al., 2010) and periconceptional (Haycock and Ramsay, 
2009) EtOH-exposure is known to impair placentation by inhibition of vascular 
transformation and by reducing invasive trophoblastic cells (Gundogan et al., 2013). 
 
Developmental programming events are often sexually dimorphic but the 
mechanisms involved are poorly understood (Maloney et al., 2011). The placenta 
which is the major determinant of intrauterine growth (Harding and Johnston, 
1995) may be a key in mediating tissue responses to a dynamic maternal 
environment as it forms the interface between the maternal and fetal circulation. Sex 
differences in how the placenta responds to the same maternal milieu may contribute 
to the altered susceptibility of male and female fetuses to long-term programming 
outcomes observed in other animal models (O'Connell et al., 2011, O'Connell et al., 
2013a, Cuffe et al., 2011, Cuffe et al., 2012). 
 
This study examined the impact of moderate alcohol exposure during the 
periconceptional period in the rat. This time point was selected as it is during this 
period that the initiation of placental formation occurs and insults that occur at this 
time may have long lasting effects on later stage placental morphology and function. 
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This study also sought to establish whether changes in placental morphology and 
function were dependent upon fetal sex. 
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3.2 Materials and methods 
3.2.1 Ethics 
All animal experiments and procedures were approved by The University of 
Queensland Anatomical Bioscience Animal Ethics Committee (AEC approval 
number SBS/022/12/NHMRC) prior to commencement of this study. 
3.2.2 Animal treatment 
Outbred, nulliparous female Sprague Dawley rats were housed individually and kept 
under standard housing conditions, with controlled temperature, humidity and an 
artificial 12 hour light–dark cycle. Vaginal impedance was measured with an EC40 
estrous cycle monitor (Fine Science Tools, CA, USA). When the impedance was 
4.5 × 103 Ω or above, indicating estrous, dams were randomly allocated either a 
control liquid diet (n = 10) or a liquid diet containing 12.5% EtOH (v/v) (∼25% EtOH 
derived calories) (n = 11) on which they remained on during the periconceptional 
period (from 4 days prior to conception until 4 days after). The energy content of the 
EtOH diet was modified to give equal energy percentages of protein, fat and calories 
compared with the control diet. The dams had ad libitum access to the liquid diet 
21 hours daily, with water offered during the remaining 3 hours of the day. At the 
initiation of the next estrus cycle (4 days), dams were mated overnight. Mating was 
confirmed by the presence of a seminal plug and this day was designated as E1. On 
E5, the liquid diet was replaced with standardized rat chow. Food, water intake and 
maternal weight gain was monitored daily throughout gestation. On E20, dams were 
deeply anesthetized following i.p. administration of a mix of 50/50 Ketamine/Xylazile 
(0.1 mL/100 g body weight) and maternal blood collected from a tail vein. Fetuses 
and placentas were removed and weighed to the nearest 0.1 μg. Placental 
dimensions were measured to the nearest 0.01 mm. Fetal sex was confirmed by 
qPCR as previously described (Cuffe et al., 2012). Placentas were immediately 
separated into the labyrinth and junctional zone, snap frozen in liquid nitrogen and 
stored at −80 °C, or left intact and fixed in 4% PFA. Placental labyrinth and junctional 
zone dry weights were obtained by oven drying (Cuffe et al., 2012). All analyses 
were carried out in placentas from both male and female fetuses. 
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To avoid stressing the dams, a separate cohort of control fed dams and EtOH fed 
dams (n = 10 per group) where set up for determination of PAC. These dams were 
treated and mated in the same way as outlined previously. Blood was drawn from a 
tail vein into a lithium-heparinized collection tube (Sarstedt, SA, Australia), two days 
prior to mating (E-2) and on E2 at 0.5, 1, 3 and 5 hours after diet administration. 
Plasma samples were centrifuged at 3000 rpm for 10 minutes at 4°C. The plasma 
supernatant was collected and stored at −80 °C until assayed with an EnzyChrome 
EtOH kit (BioAssay Systems, CA, USA) according to manufacturer's instructions. 
3.2.3 Gene analyses 
RNA from each placental region was extracted separately using the RNeasy Mini-Kit 
(Qiagen, VIC, Australia), reverse transcribed into cDNA and gene expression 
assayed using qPCR with the following Assays-on-Demand primer/probe sets 
(Applied Biosystems., CA, USA): 11βHsd2 (Rn00492539_m1); Slc2a1 (Rn1411 
7099_m1); Slc2a3 (Rn00567331); Igf1 (Rn00710306_m1); Igf2 (Rn0145518 _m1); 
Igf1R (Rn01636937_m1); Slc38a1 (Rn00593696_m1); Slc38a2 (Mn00628416 
_m1); Slc38a (Rn00593742_m1); Pgf (Rn00585926_m1); Flt1 (Rn00570815_m1); 
Vegfa (Mm00437304_m1); Kdr  (Mn01222421_m1); Gsk3β (Rn00583429_m1); 
Gys1 (Rn01476417_m1) and Gjb3 (Rn00570335_s1). qPCR results were analyzed 
using the ΔΔCT method, Rn18s as the endogenous control and did not differ between 
groups. All groups were compared with the average of the male control group (Cuffe 
et al., 2011). qPCR results were analyzed using the ΔΔCT method.  Rn18s was used 
as the endogenous control because initial studies demonstrated the expression of 
the gene did not differ between groups. 
3.2.4 Protein analyses 
Total protein was extracted from placental labyrinth tissue (n = 5–6 per sex and 
treatment group) and subjected to SDS-PAGE and western blotting as described 
previously (Cuffe et al., 2011) to detect the expression of IGFR1 (Anti-IGF1R 1:1000, 
Santa Cruz – cat#Sc-712). 
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3.2.5 Immunohistochemistry 
Fixed placentas were processed to paraffin and 5 representative midline sections 
(7 μm) were taken from each placenta. Sections were stained with H&E, cover-
slipped and imaged using the ScanScope system (Aperio Technologies, USA). 
Cross-sectional areas of junctional zone, labyrinth and glycogen cells were 
measured using imagescope software (version.10.2.2.2319). Additional sections 
were used for immunohistochemical staining of GLUT1. Sections were dehydrated, 
blocked in BSA/goat serum and incubated with a rabbit polyclonal GLUT1 antibody 
for 1 hour (1:1000, Millipore – cat. #07-1401). This was followed by 30 minute 
incubation with anti-rabbit secondary antibody (ABC Vectastain Elite KIT, Vectorlabs, 
USA) and staining with Diaminobenzidine tetrahydrochloride (ImmPACT DAB 
Peroxidase Substrate, SK4015, Vectorlabs, USA). 
3.2.6 Plasma analyses 
Maternal and fetal plasma electrolytes were analyzed with a Cobas Integra 400 
Chemistry Analyzer (Block Scientific, NY, USA). Osmolality was determined using a 
Vapor Pressure Osmometer (5520 WESCOR, Helena Laboratories, Australia). 
3.2.7 Statistical analyses 
All results are presented as mean ± SEM. Fetal body and placenta weights were 
calculated as litter averages by sex. qPCR data represent 7–11 fetuses of each sex, 
collected from different litters. Statistical analyses were conducted with GraphPad 
Prism 5 software (GraphPad Software, CA, USA). Maternal measurements during 
pregnancy were analysed with a repeated measures analysis of variance (ANOVA) 
or with an unpaired student's t-test. All fetal/placental data were analyzed with a two-
way ANOVA for treatment (Ptrt) and sex (Psex) using Bonferroni's post hoc test as 
appropriate. 
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3.3 Results 
3.3.1 Maternal parameters and plasma alcohol levels 
There was no difference in maternal caloric intake or weight gain at any time during 
gestation, but EtOH-exposed dams consumed more water during exposure to the 
liquid diet (Table 3.1). The peak PAC was reached 30 minutes after provision of the 
EtOH containing diet on E-2 (0.18 ± 0.04%) and E2 (0.25 ± 0.04%). Levels thereafter 
declined and at 3 hours were ∼0.07 ± 0.02% and at 5 hours, 0.05 ± 0.02% (data not 
shown). Plasma osmolality and electrolyte concentration of sodium, potassium and 
chloride did not differ between groups on either E-2 or E2 (Table 3.1). The number of 
fetuses and the fetal sex ratio (data not shown) was similar between treatment 
groups, but EtOH-exposed dams had a higher rate of unviable fetuses (Table 3.1). 
 
Table 3.1. Maternal parameters 
Variables Control EtOH 
Calorie intake (liquid diet), cal/gbw/d (E-4-mating) 0.20 ± 0.01 0.18 ± 0.01 
Calorie intake (liquid diet), cal/gbw/d (mating-E4) 0.23 ± 0.01 0.21 ± 0.01 
Calorie intake (chow), cal/gbw/d (E5-E20) 0.27 ± 0.01 0.27 ± 0.00 
Water intake, ml/gbw/d (E-4-mating) 0.010 ± 0.002  0.015 ± 0.002* 
Water intake, ml/gbw/d (mating-E4) 0.010 ± 0.002  0.023 ± 0.003* 
Water intake, ml/gbw/d (E5-E20) 0.110 ± 0.003 0.120 ± 0.005 
Peak plasma alcohol level (%) (E-2) 0 0.18 ± 0.04 
Osmolality (mmol/kg) (E-2) 302 ± 4 300 ± 5 
Plasma sodium (mmol/L) (E-2) 136.8 ± 1.9 140.4 ± 1.2 
Plasma potassium (mmol/L) (E-2) 5.17 ± 0.16 5.37 ± 0.63 
Plasma chloride (mmol/L) (E-2) 101.2 ± 1.7 102.3 ± 1.8 
Peak plasma alcohol level (%) (E2) 0 0.25 ± 0.04 
Osmolality (mmol/kg) (E2) 292 ± 4 297 ± 1 
Plasma sodium (mmol/L) (E2) 136.9 ± 1.1 137.8 ± 1.3 
Plasma potassium (mmol/L) (E2) 6.62 ± 0.78 5.28 ± 0.31 
Plasma chloride (mmol/L) (E2) 101.1 ± 1.1 100.4 ± 1.1 
Body weight on (g) E0 254 ± 6 262 ± 8 
Total weight gain (g) 144.8 ± 8.6 141.2 ± 6.0 
Litter size (number) 15 ± 1 14 ± 1 
Number of pregnancies with at least one unviable fetus 1 of  9 6 of 11 
   
Bw, body weight; E, embryonic day, EtOH, ethanol; d, day. All data are presented as mean ± SEM and 
n(control) = 9, n(EtOH) = 11. *,P < 0.05 by unpaired t-test (P < 0.05). 
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3.3.2 Fetal weight, placental ratio and placental cross-sectional area 
At E20, the body weight of PC:EtOH-exposed fetuses was reduced (Ptrt < 0.009) and 
females of both treatment groups were lighter than their males counterparts 
(Psex < 0.04, Table 3.2). PC:EtOH-exposed fetuses were also shorter than controls 
(Ptrt < 0.004, Table 3.2). There was no difference in absolute placenta (Table 3.2), 
labyrinth or junctional zone wet weight (data not shown), but placenta-to-body 
weight-ratio was increased following PC:EtOH-exposure (Ptrt < 0.004, Table 3.2). 
Labyrinth zone dry weights were unaffected by PC:EtOH-exposure while junctional 
dry weight was increased (Ptrt < 0.002, Table 3.2). Placental depth was not different 
following PC:EtOH-exposure but length (Ptrt < 0.05) and width (Ptrt < 0.03) were 
increased (Table 3.2).  
H&E staining showed no gross morphological abnormalities in response to 
PC:EtOH-exposure, however there was an increase in junctional zone due to 
glycogen accumulation (Figure 3.1). Analysis of the cross-sectional areas of each 
placental zone in proportion to whole placenta showed a decrease in labyrinth 
(Ptrt < 0.03, Figure 3.1 A) and an increase in junctional (Ptrt < 0.03, Figure 3.1 B) 
region following PC:EtOH-exposure. In addition, the cross-sectional area of glycogen 
cells, both as a percentage of total placenta (Ptrt < 0.002; Psex < 0.01, Figure 3.1 C) 
and as absolute cross-sectional area (Ptrt < 0.009; Psex < 0.007, Figure 3.1 D) were 
greater following PC:EtOH-exposure. Post hoc analyses showed that the cross-
sectional area of glycogen cells were greater in PC:EtOH-exposed placentas from 
females compared with their control counterparts (P < 0.01). 
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Table 3.2 Fetal and placental weights and dimensions at E20 
  
     
Variables Male control Male EtOH Female Control Female EtOH  Statistics 
Fetal weight and dimensions      
Body weight, g 2.65 ± 0.05 2.45 ± 0.08 2.50 ± 0.05 2.33 ± 0.07 
P(trt) < 0.002 
P(sex) < 0.04 
P(trt x sex) = NS 
Snout-rump length, mm 40.37 ± 0.23 38.58 ± 0.76 39.55 ± 0.13 37.85 ± 0.68 
P(trt) < 0.004 
P(sex) = NS  
P(trt x sex) = NS 
 
Placental weights and dimensions          
 
Absolute placenta wet weight, g 0.56 ± 0.02 0.55 ± 0.02 0.55 ± 0.01 0.55 ± 0.02 
P(trt) = NS 
P(sex) = NS 
P(trt x sex) = NS 
Placenta:Body weight ratio, g/gbw 0.21 ± 0.01 0.23 ± 0.01 0.22 ± 0.01 0.24 ± 0.01 
P(trt) < 0.004 
P(sex) = NS  
P(trt x sex) = NS 
Absolute Labyrinth zone (dry), g 0.057 ± 0.011 0.065 ± 0.012 0.054 ± 0.005 0.057 ± 0.004 
P(trt) = NS 
P(sex) = NS 
P(trt x sex) = NS 
Absolute Junctional zone (dry), g 0.033 ± 0.003 0.042 ± 0.002 0.033 ± 0.003 0.045 ± 0.004* 
P(trt) < 0.002 
P(sex) = NS 
P(trt x sex) = NS 
Placental length, mm 13.55 ± 0.21 13.95 ± 0.20 13.54 ± 0.16 13.94 ± 0.18 
P(trt) < 0.05 
P(sex) = NS 
P(trt x sex) = NS 
Placental width, mm 12.18 ± 0.14 12.42 ± 0.18 12.02 ± 0.14 12.60 ± 0.19 
P(trt) < 0.03 
P(sex) = NS 
P(trt x sex) = NS 
Placental depth, mm 4.20 ± 0.10 4.22 ± 0.12 4.14 ± 0.09 4.18 ± 0.13 
P(trt) = NS 
P(sex) = NS 
P(trt x sex) = NS 
      
Bw, body weight; EtOH, ethanol; NS, not significantly different; trt, treatment. All data are presented as mean ± SEM and n = 9-11 for each group. *, P < 0.05 for Bonferroni 
post hoc compared with untreated controls of same sex.  
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Figure 3.1 – Placental morphology following periconceptional alcohol exposure                   . 
Effects of PC:EtOH-exposure (black bars) on cross-sectional area of labyrinth zone (A), junctional 
zone (B), glycogen cells (C) as a percentage of total placenta, and absolute cross-sectional area of 
glycogen cells (D) in placentas from male and female fetuses on E20 compared with untreated 
controls (white bars). Data are represented as litter means ± SEM, n = 9–11 per group, **, P < 0.01 
for Bonferroni post hoc compared with untreated controls of same sex. Representative sections of 
untreated control (E) and PC:EtOH-exposed (F) placenta from female fetuses ×1 (scale bars 1000 μm) 
with glycogen stores (appears white) shown in ×20 magnification (scale bars 100 μm). 
3.3.3 Placental gene and protein expression 
PC:EtOH-exposure did not alter mRNA levels of Glut1 in the labyrinth (Figure 3.2 A) 
but increased the expression in the junctional zone of the placenta (Ptrt < 0.05, Figure 
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3.2 B). This was confirmed by immunohistochemistry staining of GLUT1 in the 
junctional zone (Figure 3.2 E & F). There was a significant interaction between 
PC:EtOH and sex on the gene expression of Glut3 in both the labyrinth (Ptrt x 
sex < 0.02, Figure 3.2 C) and junctional zone (Ptrt x sex < 0.04, Figure 3.2 D). 
 
Figure 3.2 – The effect of periconceptional alcohol exposure on glucose transporters in the 
placenta 
Effects of PC:EtOH-exposure (black bars) on Glut1 gene expression in the labyrinth (A) and junctional 
(B) zone; and on Glut3 gene expression in the labyrinth (C) and junctional (D) zone of placenta from 
male and female fetuses on E20 compared with untreated controls (white bars). Data are 
represented as litter means ± SEM, n = 9–11 per group, *, P < 0.05 for Bonferroni post hoc compared 
with untreated controls of same sex. Representative sections of untreated control (E) and PC:EtOH-
exposed (F) placenta from female fetuses shown in ×20 magnification (scale bars 100 μm) 
quantitatively confirmed that the increase in Glut1 mRNA in the junctional zone also were translated 
into increases in GLUT1 protein levels (dark brown staining). Inserts shows sections stained with the 
appropriate sense probe as a control (×20 magnification, scale bars 100 μm). 
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PC:EtOH-exposure suppressed Igf1 gene expression in the labyrinth 
(Ptrt < 0.001, Figure 3.3 A), whereas the gene expression of Igf1 in the junctional 
zone was unaffected (Figure 3.3 B). Igf2 mRNA was not altered in the labyrinth 
(Figure 3.3 C) but increased in the junctional zone of PC:EtOH-exposed placentas 
(Ptrt < 0.03, Figure 3.3 D). mRNA levels of the insulin like growth factor 2 receptor 
(Igf2R) were similar between treatment groups (Figure 3.3 F). Relative protein 
expression of IGF1R was lower in PC:EtOH-exposed placenta from males, but not 
females, when compared with untreated controls (P < 0.01, Figure 3.3 E). 
PC:EtOH-exposure did not affect junctional mRNA levels of gap junction beta-3 
protein (Gjb3) and Gys1 but mRNA levels of Gsk3β were higher in PC:EtOH-
exposed placenta from females but not males (P < 0.05, Table 3.3). In addition, 
PC:EtOH caused multiple changes in mRNA expression in the labyrinth: increased 
mRNA levels of 11βHsd2  in both sexes (Ptrt < 0.0001, Table 3.3), increased mRNA 
levels of Slc38a1 in placentas from females fetuses regardless of treatment 
group (Psex < 0.03, Table 3.3) and decreased mRNA levels of Slc38a2 in placentas 
from both sexes (Ptrt < 0.003, Table 3.3), while Slc38a4 was unaffected (Table 
3.3). Vegfa mRNA levels were higher in PC:EtOH-exposed placentas 
(Ptrt < 0.03, Table 3.3) and in placentas from female fetuses (Psex < 0.03, Table 3.3), 
but there was no difference in mRNA levels of Pgf (Table 3.3). While Flt1 gene 
expression was higher in placentas from female fetuses (Psex < 0.02, Table 3.3), 
mRNA levels of Kdr were only increased in placentas from females following 
PC:EtOH-exposure (P < 0.05, Table 3.3). 
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Figure 3.3 – The effect of periconceptional alcohol exposure on gene and protein expression of placental 
insulin like growth factors                                                               . 
Effects of PC:EtOH-exposure (black bars) on Igf1 gene expression in the labyrinth (A) and junctional (B) zone; 
on Igf2 gene expression in the labyrinth (C) and junctional (D) zone, on relative protein expression in the 
labyrinth zone (E), and on relative gene expression of Igf2R (F) of placenta from male and female fetuses on 
E20 compared with untreated controls (white bars). Data are represented as litter means ± SEM, mRNA 
expression: *, P < 0.05 for Bonferroni post hoc compared with untreated controls of same sex, n = 9–11 per 
group. Protein expression: *, P < 0.05 by unpaired t-test comparing untreated controls and PC:EtOH-exposed 
placenta of the same sex, n = 5 per group. 
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Table 3.3 Relative gene expression     
  Male control Male EtOH Female Control Female EtOH  Statistics 
Labyrinth zone          
Slc38a1 1.03 ± 0.07 0.91 ± 0.08 1.06 ± 0.10 1.28 ± 0.14 
P(trt) = NS 
P(sex) < 0.04 
P(trt x sex) = NS 
Slc38a2 1.01 ± 0.06 0.76 ±0.06 0.92 ± 0.05 0.83 ± 0.04 
P(trt) < 0.003 
P(sex) = NS 
P(trt x sex) = NS 
Slc38a4 1.11 ± 0.13  1.06 ± 0.10 0.90 ± 0.05 1.11 ± 0.12 
P(trt) = NS 
P(sex) = NS 
P(trt x sex) = NS 
Vegfa 1.03 ± 0.09 1.23 ±0.11 1.23 ± 0.11 1.55 ± 0.13 
P(trt) < 0.03 
P(sex) < 0.03 
P(trt x sex) = NS 
Kdr 1.07 ± 0.14 0.97 ± 0.07 0.87 ± 0.05 1.39 ± 0.16* 
P(trt) = NS 
P(sex) = NS 
P(trt x sex) < 0.01 
Pgf 1.03 ± 0.09 0.97 ± 0.08 1.01 ± 0.08 1.15 ± 0.08 
P(trt) = NS 
P(sex) = NS 
P(trt x sex) = NS 
Flt1 1.02 ± 0.08 0.91 ± 0.10 1.14 ± 0.10 1.25 ± 0.09 
P(trt) = NS 
P(sex) < 0.02 
P(trt x sex) = NS 
11βHsd2 1.06 ± 0.14 2.03 ±0.21 1.38 ± 0.20 2.51 ± 0.29 
P(trt) < 0.0001 
P(sex) = NS 
P(trt x sex) = NS 
Junctional zone      
Glycogen cell markers      
Gys1 1.03 ± 0.09 0.98 ± 0.09 1.00 ± 0.11 1.11 ± 0.13 
P(trt) = NS 
P(sex) = NS 
P(trt x sex) = NS 
Gsk3β 1.02 ± 0.09  0.84 ± 0.04 0.82 ± 0.05 1.07 ± 0.09* 
P(trt) = NS 
P(sex) = NS 
P(trt x sex) < 0.006 
Gjb3 1.13 ± 0.20 1.09 ± 0.15 0.87 ± 0.09 1.15 ± 0.14 
P(trt) = NS 
P(sex) = NS 
P(trt x sex) = NS 
      
11βHsd2, 11-beta hydroxysteroid dehydrogenase; Flt1, fms-related tyrosine kinase 1; Gjb3, gap 
junction beta-3 protein; Gsk3β, glycogen synthase kinase 3 beta; Gys1, Glycogen synthase 1; Kdr, 
kinase insert domain receptor; NS, not significantly different; Pgf, placental growth factor; Slc38a, 
sodium-coupled neutral amino acid transporter; Vegfa, vascular endothelial growth factor A. All data 
are presented as mean ± SEM and n = 9-11 for each group. *, P < 0.05 for Bonferroni post hoc 
compared with untreated controls of same sex.  
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3.4 Discussion 
Our study shows for the first time that exposure of the rat to moderate levels of 
alcohol exclusively during the periconceptional period is sufficient to program growth 
restriction in both male and female fetuses in late gestation and cause significant 
changes in placental structure, morphology and gene expression. Whilst the primary 
stimulus was PC:EtOH-exposure, elevated levels of placental 11βHsd2  (Cuffe et al., 
2011) and (Cuffe et al., 2012) and GLUT1 (Langdown and Sugden, 2001) suggest a 
long-lasting stress response may be involved. Sex-specific differences such as the 
size of placental junctional zone in females, along with an increase in Glut3 mRNA 
levels, indicate dissimilar mechanisms of action. The observations from this study 
are consistent with other models of periconceptional perturbations, mainly focusing 
on maternal nutritional status (Kwong et al., 2000, Sinclair et al., 2007, Watkins et 
al., 2011, Zhang et al., 2011, Ikeda et al., 2012), in that it highlights the importance of 
the period around the time of conception as a critical window of development. These 
results are therefore of high clinical importance as they suggest that a woman's 
drinking habits, even prior to conception and preimplantation can have implications 
on the growth and development of the placenta and thus, the fetus. 
PC:EtOH-exposure results in fetal growth restriction 
It is well established that prenatal alcohol exposure causes fetal growth 
restriction (Chen and Nyomba, 2003b, Lopez-Tejero et al., 1989)  Many studies of in 
utero EtOH-exposure are however confounded by a modified energy intake (Chen 
and Nyomba, 2003a). Both maternal over- (Jones et al., 2009) and under-
nutrition (Vickers et al., 2000) causes alterations in fetal growth ultimately resulting in 
early onset of adult diseases (Vickers et al., 2000, Langley-Evans and Nwagwu, 
1998, Barker et al., 1990). Our model is not complicated by caloric restriction or 
overnutrition as energy intake was equivalent in both EtOH and control fed dams 
throughout preimplantation and later periods of gestation, as was maternal weight 
gain. Moreover EtOH-exposed dams drank more water, allowing maintenance of 
plasma osmolality and electrolytes. The PAC reported may appear high as they were 
determined following the period of maximal ingestion. The PAC generated is 
comparable with other models of EtOH exposure, which generally administer EtOH  
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via gavage (Chen and Nyomba, 2003a) (Gray et al., 2010). Importantly, these levels 
are only marginally higher than levels found in occasional alcohol users (Touquet et 
al., 2008) and as rats metabolize alcohol faster than humans (Zorzano and Herrera, 
1990), they should be considered clinically relevant. 
PC:EtOH-exposure introduced a long-lasting stress response in placentas from both 
sexes 
EtOH appeared to induce a long-lasting stress response in placentas from both 
sexes, as evidenced by increased expression of the gene 11βHsd2 in the labyrinth 
zone. Placental 11βHSD2 protects the fetus from maternally circulating 
glucocorticoids (cortisol or corticosterone) by enzymatic inactivation (Murphy et al., 
2007). Previous studies performed by our laboratory in the mouse (Cuffe et al., 2011, 
Cuffe et al., 2012) and others in the human (Clifton et al., 2006) have shown that the 
placenta can mediate a temporary increase in the expression level of 11βHsd2  in 
response to elevations in circulating maternal glucocorticoids. Although 
corticosterone levels were not measured in this model, other studies in rats have 
shown that chronic alcohol consumption throughout pregnancy does indeed increase 
maternal corticosterone concentrations (Wilcoxon and Redei, 2004). Furthermore, 
increases in placental Glut1 gene expression, similar to those measured in this 
study, have been observed in rats following maternal glucocorticoid 
administration (Langdown and Sugden, 2001). GLUT1 is a ubiquitous stress and 
growth factor responsive transporter that is expressed throughout preimplantation 
development (Pantaleon and Kaye, 1998). We therefore suggest the 
increased Glut1 expression in PC:EtOH-exposed placentas to be supportive for a 
role of stress and/or glucocorticoids in PC:EtOH-exposure. 
PC:EtOH-exposure caused sex-specific alterations in placental morphology and 
gene expression  
Abnormal placental weight, both absolute and as a ratio of fetal weight, are 
independently associated with adult disease (Barker et al., 1990). Although absolute 
placental weight was unchanged by PC:EtOH-exposure, there were changes in 
shape and an increase in body/placental ratio and junctional zone cross-sectional 
area. The increase in junctional cross-sectional area was due to an increase in the 
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area of apparent glycogen and this was more pronounced in placentas from females. 
This suggests a sexually dimorphic chance which ultimately may have contributed to 
other sex-specific alterations, as differences in placental shape and morphology 
affects transplacental transfer of nutrients, oxygen and hormones (Burton and 
Fowden, 2012). 
 
Neither IGF1 nor 2 can cross the placental barrier and are exclusively produced by 
the feto-placental unit to maintain fetal and placental growth (Lopez et al., 1996). As 
IGF1 deletion is known to cause fetal growth restriction (Fowden, 2003), we suggest 
that the lower labyrinth Igf1 mRNA levels in PC:EtOH-exposed placentas may have 
impacted on fetal growth. Junctional Igf2 mRNA levels on the other hand were 
elevated, whilst labyrinth mRNA levels of IGF2R were maintained. Given that the 
IGF2R predominantly acts to limit IGF2 action by internalization and degradation of 
the ligand (Baker et al., 1993), we suggest this may have contributed to the greater 
proportion of junctional zone area observed in PC:EtOH-exposed placentas from 
females. 
 
PC:EtOH-exposure also increased levels of labyrinth Vegfa gene expression. 
Numerous studies have previously shown that prenatal EtOH-exposure alters normal 
vascular adaptation during pregnancy (for review see (Ramadoss and Magness, 
2012)). Whilst the increase in Vegfa gene expression may appear to be inconsistent 
with the apparent growth restriction, similar results have been observed in placentas 
of mouse fetuses following prenatal dexamethasone administration (Cuffe et al., 
2011). As mRNA levels of Flt1 were higher in placentas from female fetuses 
regardless of treatment group and mRNA levels of Kdr were increased in placentas 
from PC:EtOH-exposed females only, it is likely that placentas from female fetuses 
are attempting to increase vasculogenesis to ensure adequate fetal nutrient supply. 
PC:EtOH-exposure and alterations in glycogen cross-sectional area 
Glycogen cross-sectional area was increased in placentas from female fetuses 
following PC:EtOH-exposure. Although the role of glycogen in the placenta is unclear 
we attempted to further approach this by investigating the levels of specific glycogen 
cell markers. Interestingly, whilst Igf2, a key regulator of placental glycogen 
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synthesis (Lopez et al., 1996, Esquiliano et al., 2009) was elevated in PC:EtOH-
exposed female placentas, mRNA levels of Gjb3 and Gys1 was 
unchanged. Gjb3 encodes a gap junction protein which is exclusively expressed in 
the membrane of vacuolated glycogen cells in mid to late gestation placenta (Coan 
et al., 2006) whilst Gys1 is the rate limiting enzyme involved in glycogen 
synthesis (Bevan, 2001). Intriguingly, mRNA levels of Gsk3β, a negative regulator of 
GYS1 activity (Ludwig et al., 1996), was only elevated in placentas from females, 
perhaps to limit further glycogen deposition. Furthermore, PC:EtOH-exposure 
increased junctional Glut3 mRNA levels in female placenta, which together with 
glycogen accumulation has also has been observed in placentas of diabetic 
rats (Boileau et al., 1995). While GLUT3 is involved in glucose delivery to the 
fetus (Boileau et al., 1995), it also transports glucose from the fetal circulation back 
into the placenta, as the placenta is the only tissue capable of storing excess fetal 
glucose (Schneider et al., 2003). In contrast, placentas from male fetuses expressed 
less Glut3 following PC:EtOH-exposure but also had a smaller placental area 
occupied by glycogen cells. Our data may suggest an early EtOH induced change in 
metabolism to favor glycogen accumulation. We propose that placentas, particularly 
from females, either have a reduced capacity for transplacental glucose transfer from 
mother to fetus and/or an augmented backflow of glucose from the fetal circulation to 
the placenta, which again is the case seen in placentas of diabetic rats (Thomas et 
al., 1990). 
PC:EtOH-exposure altered amino acid transporter abundance 
The decreased labyrinth expression of Slc38a2 following PC:EtOH-exposure seen in 
this study may have contributed to fetal growth restriction as seen in other models 
with changes in placental Na+-dependent system A transporters (Sinclair et al., 2007, 
Maloney et al., 2011). The system A amino acid transporters accept a wide range of 
amino acids, however only Slc38a2 transports the essential amino acid 
methionine (Mackenzie and Erickson, 2004). As methionine is involved in DNA and 
histone methylation it has been suggested to play an important role in epigenetic 
regulation of genes (Sinclair et al., 2007, Ikeda et al., 2012). The preimplantation 
embryo is very susceptible to epigenetic perturbations (Ikeda et al., 2012) and we 
cannot preclude the possibility of the alterations in Slc38a2 gene expression 
Chapter 3 
 
130 
 
 
contributing to faults in programming events involving epigenetic change. 
 
Conclusion 
 
Our study has for the first time shown that maternal alcohol intake exclusively around 
the time of conception alters placental weight and morphology and causes growth 
restriction in the late gestation fetus. Particularly interesting was the programmed 
stress response, indicated by the increase in placental 11βHsd2 and Glut1 gene 
expression. Our results suggest that the placenta exerts sex-specific mechanisms of 
actions, both structurally and functionally, with females perhaps being more 
protected. Future studies that determine postnatal sex-specific contributions to adult 
onset of programmed disease following PC:EtOH-exposure need to be carried out to 
establish this hypothesis. As alcohol consumption is common amongst women of 
childbearing age (Floyd et al., 1999) and half of all pregnancies are un-
planned (Colvin et al., 2007) it is important to address this by increasing public 
awareness about the implication of alcohol consumption even before becoming 
pregnant.
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Abstract 
Introduction: Alcohol consumption throughout pregnancy can cause metabolic 
dysregulation, including glucose intolerance in progeny. This study determined if 
alcohol consumed exclusively around conception caused similar outcomes. 
 
Methods and results: Periconceptional maternal alcohol intake (12% v/v in a liquid 
diet, PC:EtOH), from 4 days prior to conception until day 4 of gestation in the 
Sprague-Dawley rat, resulted in offspring with elevated fasting plasma glucose (~10-
25%, P < 0.05), impaired glucose tolerance (P < 0.05) and decreased insulin 
sensitivity (P < 0.01) at 6 months of age. This was associated with increased hepatic 
gluconeogenesis and sex-specific alterations in peripheral protein kinase B (AKT) 
signaling. These changes were accompanied by increased mRNA expression of 
DNA methyltransferases 1, 3a and 3b (1.5-1.9 fold, P < 0.05) in fetal liver in late 
gestation, suggesting that PC:EtOH may cause epigenetic changes that predispose 
offspring to metabolic dysfunction. Exposure to a postnatal high-fat diet (HFD) from 3 
months of age caused hyperinsulineamia (~2 fold increase, P < 0.001) and 
exacerbated the metabolic dysfunction in male offspring exposed to PC:EtOH but 
had no additive effects in females. Control rats were given a liquid diet containing no 
alcohol but matched to ensure equal caloric intake.  
Discussion and conclusion: Given many women may drink alcohol whilst planning a 
pregnancy, it is crucial to increase public awareness regarding the effects of alcohol 
conception. 
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4.1 Introduction 
Increasing evidence implicates the intrauterine environment in the development of 
chronic adult disease propensity and metabolic disorders (Godfrey and Barker, 
2000). Indeed, fetuses exposed to a range of adverse intrauterine environments 
including malnutrition (Ravelli et al., 1999), placental insufficiency (Siebel et al., 
2008), and alcohol (Chen and Nyomba, 2003b, Lopez-Tejero et al., 1989, Yao et al., 
2006, Probyn et al., 2013c) have an increased risk of adult onset metabolic 
dysfunction. Low birth weight, insulin resistance, and altered regulation of hepatic 
glucose output are commonly demonstrated in these models (Chen and Nyomba, 
2003b, Lopez-Tejero et al., 1989, Yao et al., 2006, Probyn et al., 2013c, Devaskar 
and Thamotharan, 2007, Chen and Nyomba, 2004). Intriguingly, these effects are 
often programmed in a sex-specific manner, with males consistently more adversely 
affected than females (Probyn et al., 2013c). The periconceptional period appears to 
be a particularly susceptible developmental window for programming of disease 
(McMillen et al., 2008). Given >50% of women consume alcohol prior to pregnancy 
(Colvin et al., 2007) and half of all pregnancies are reported to be unplanned (Colvin 
et al., 2007, Naimi et al., 2003), many embryos are potentially exposed to alcohol 
prior to pregnancy recognition. Despite recommendations of alcohol abstinence for 
women who are pregnant, or planning a pregnancy, a recent study reported that 
32% of women claim they would continue to drink despite trying to conceive (Peadon 
et al., 2011). 
We have previously shown that PC:EtOH-exposure causes fetal growth restriction 
and sex-specific placental abnormalities in late pregnancy in the rat (Gardebjer et al., 
2014). Both are risk factors for adult onset disease (Varvarigou, 2010, D J Barker, 
1990). Here, we examined the hypothesis that PC:EtOH-exposure programs glucose 
intolerance and insulin resistance in offspring. In addition, we explored the influence 
of a postnatal HFD as it has been suggested that lifestyle/dietary factors can unmask 
and/or exacerbate pre-programmed adult disease propensity (Chen and Nyomba, 
2003b). In order to elucidate potential mechanisms contributing to disease, we 
examined the effect of PC:EtOH-exposure on gluconeogenic genes in the liver and 
AKT-signaling in peripheral tissues in postnatal offspring (Yao et al., 2006, Devaskar 
and Thamotharan, 2007, Thompson et al., 2007). Additionally, we assessed 
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expression levels of key chromatin modifiers in fetal life since epigenetic changes 
are implicated in metabolic programming of adult disease following periconceptional 
perturbation (Sinclair et al., 2007). Specifically, we examined expression levels of 
histone deactylases (HDACs) and DNA methyltrasferases (DNMTs) in fetal liver as 
alterations in both these modifications are associated with metabolic disease.  
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4.2 Materials and methods 
4.2.1 Ethics 
All animal experimentation was approved by The University of Queensland 
Anatomical Bioscience Animal Ethics Committee (SBS/022/12/NHMRC) prior to 
commencement of the study. 
4.2.2 Rats and treatment 
Outbred nulliparous Sprague-Dawley rats were individually housed under an artificial 
12 hour light-dark cycle and treated as previously described (Gardebjer et al., 2014). 
Briefly, 12-13-week-old dams were randomly allocated to a liquid diet containing 
either 12.5% v/v (PC:EtOH) or an equal-caloric 0% EtOH diet (untreated, U) (n = 22 
per treatment group) for one full estrus cycle (4 days), prior to overnight mating. 
Animals that did not mate on the 4th or 5th day after being offered the diet were 
removed from the protocol. The liquid diet was composed of Sustagen® hospital 
formula (Mead Johnson® Nutritionals), reduced fat milk, corn flour and essential 
minerals (ferric citrate, copper II sulphate, selenium and magnesium sulphate. In 
preliminary experiments, we had identified that the EtOH-exposed dams consumed a 
lesser amount of the liquid diet, hence the energy density of the EtOH-diet was 
increased and the ingredients were modified to ensure an equal amount of macro- 
and micronutrients: (control diet composition: 11.3% fat, 17.0% protein, 68.2% 
carbohydrates, 7.7 MJ/kg; EtOH-diet: 11.9% fat, 13.6% protein, 50.7% 
carbohydrates, 11.8 MJ/kg). Dams had access to the liquid diet 21 hours daily ad 
libitum until E4, with water offered during the remaining 3 hours of the day. Liquid 
diets were replaced by standardized rat chow and water on E5 (4.0% fat, 13.6% 
protein 64.3% carbohydrates; 15.5 MJ/kg) (SF-08-020 Specialty feeds, Glenforrest, 
WA, Australia). One subset of dams (n = 10 per group) was killed on E20 for 
collection of fetal liver, whereas one subset (n = 12 per group) littered down 
naturally. Offspring were weighed daily until weaning on PN day 28. At 3 months, 
one subset of offspring was randomly assigned to a modified diet that contained 
increased fat and cholesterol (HFD: 21% fat, 0.15% cholesterol, 19% protein, 59.9% 
carbohydrates; 19.4MJ/kg) (SF00-219 Specialty feeds, Glenforrest, WA, Australia) 
whilst remaining animals were supplied with the same standardized chow as the 
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dams consumed (C). These diets are matched for micronutrient composition. This 
resulted in the generation of 8 treatment groups: U:C; U:HFD; PC:EtOH:C and 
PC:EtOH:HFD for both male and female offspring. Both the HFD and C diet were 
based on similar base ingredients for protein and carbohydrates (casein; and wheat 
starch, sucrose and cellulose); but the fat source was canola oil in the C-diet and 
clarified butter in the HFD. All groups had ad libitum access to allocated diet and 
water until the end of the study.  
4.2.3 Glucose and insulin tolerance test 
Glucose (1g/kg body weight) and insulin (0.75 U/kg body weight) tolerance tests 
(GTT & ITT) were performed at 6 months (n = 10-11 per group) as described 
previously (Probyn et al., 2013c). Plasma glucose levels were determined using a 
Cobas Integra 400 Plus Chemistry Analyzer and insulin concentrations by rat insulin 
RIA kit (Cat#RI-13K, Millipore Australia, Kilsyth, VIC, AUS). Insulin samples were run 
in duplicates, at 1:2 dilutions. Assay sensitivity was 28.0 pmol/L whilst inter- and 
intra-assay coefficients of variation were 14.9% and 9.9% respectively. 
4.2.4 Tissue collection 
Rats were euthanized at 8 months by i.p. administration of a 50/50 Ketamine/Xylazile 
mix (0.5 mL/100 g body weight) after a 15 hour fasting period. Tissues were snap-
frozen in liquid nitrogen and stored at -80oC (gastrocnemius muscle, white intra-
abdominal adipose tissue, and liver). Fetal liver was collected as previously 
described on E20 (Gardebjer et al., 2014). 
4.2.5 qPCR and Western blotting 
RNA from the left lateral lobe of the liver was extracted using RNeasy Mini-Kit and 
reversed transcribed into cDNA. Gene expression was analyzed using qPCR with 
the following Assay-on-Demand primer/probe sets (Applied Biosystems, CA, USA) 
Pck1, (Rn01529014_m1), Gck, Rn00561265_m1), G6pc, (Rn00689876_m1), 
Ppargc1a, (Rn00580241_m1), Hdac2 (Rn01193634_g1) and Hdac6 (Rn01528 
283_m1), or SYBR® Green detection chemistry using the following primers for: 
Hdac3 (F;5'-GATTAGGCTGCTTCAATCTC; R;5'-CAGAGATGTTTCATATGTCCAG), 
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Hdac4 (F;5'-AAACAGCTTCTGAACCTAAC; R;5'-GAGTCTGTAACATCCA-GGG), 
Dnmt1  (F;5'-AGAGACCAGGATAAGAACG; R;5'-TTACTCGTTCAGGTTT-CTCC), 
Dnmt3a  (F;5'-AATAGCCAAGTTCAGCAAAG; R;5'-AAACACCCTTTCCATT-TCAG) 
and Dnmt3b  (F;5'-GATGACAAGGAGTTTGGAATA; R;5'-CAGCGATCTCAGAAAA 
CTTG). qPCR results were analyzed with the ΔΔCT method. Rn18s, which did not 
differ between groups, was used as the endogenous control. All groups were 
compared with the average of the untreated control group (Gardebjer et al., 2014). 
Total protein was extracted from 80 mg abdominal adipose tissue and 15 mg 
gastrocnemius muscle. Tissues were homogenized in 0.4 mL RIPA buffer for 20 
seconds using an Ultra-Turrax T8 homogeniser (Labtek). Homogenates were 
centrifuged (11,000 rpm, 20 minutes, 4 °C) and resultant supernatant assayed using 
the Bio-Rad (Hercules, CA, USA) reducing agent and detergent compatible protein 
assay kit. Total protein (20 µg per sample; n = 5–6 per sex and PC-treatment) was 
subjected to SDS-PAGE on 12% gels and subsequently transferred to 
Immobilon® FL PVDF membranes (Millipore). Membranes were incubated overnight 
with one of the following polyclonal rabbit antibodies (all from Cell Signaling, 
Danvers, MA, USA); anti-total-AKT2 (1:1000, cat#3063), anti-phospho-AKT(Thr309) 
(1:600, cat#9275), anti-phospho-AKTSer474 (1:800, cat#8599), anti-phospho-
GSK3α/β(Ser21/9) (1:600, cat#9331), or a mouse monoclonal anti-GSK3α/β (1:600, 
cat#05-412, Upstate Biotechnology, Lake Placid, NY, USA). β-actin immunoreactivity 
was used for ratiometric purposes (1:25000, #A1978; Sigma Aldrich, St. Louis, MO). 
Protein expression was assayed using a LI-COR Odyssey infrared imaging system 
(LICOR Biosciences, Lincoln, NE, USA) following exposure to LI-COR IRDye 680 
goat anti-rabbit and IRDye 800CW goat anti-mouse secondary antibodies 
(Millennium Science, Mulgrave, Australia). 
4.2.6 Calculations and statistical analyses 
AUGC and AUIC concentration curves were calculated using the trapezius method 
with baseline defined as zero (Allison et al., 1995). AUGC following the GTT was 
calculated defining the baseline as zero and the positive incremental area (AUC of 
positive peaks) (Wolever and Jenkins, 1986). The ITT curves were inverted before 
calculating AUGC. Acute first-phase insulin secretion was calculated as the 
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incremental AUIC from basal to 5 minutes and second-phase insulin secretion as the 
incremental AUIC from 5 to 120 minutes. QUICKI was calculated as 1/[log(fasting 
insulin (μU/mL)) × log(fasting glucose (mg/dL))] (Katz et al., 2000). HOMA-IR was 
calculated using [fasting insulin (μU/mL) × fasting glucose (mmol/L)]/22.5 (Duncan et 
al., 1995). 
Three-way ANOVA analysis was conducted with IBM® SPSS® Statistics (version 
20.0) with main effects being PC-treatment, sex and diet. For most parameters there 
were significant (P < 0.05) main effects of PC-treatment, but also significant 
interactions with postnatal diet. Therefore, data was first analysed by two-way 
ANOVA examining the effects of PC-treatment between sexes [main effects of PC-
treatment (PPC:EtOH) and sex (PSex)]. Subsequently, the effect of HFD and PC:EtOH 
within each sex [main effects of PC-treatment (PPC:EtOH) and postnatal diet (PHFD)] 
was also assessed. Data were log transferred to remove heterogeneity of variance 
prior to performing ANOVA as required (Bartlett’s test). Means were further 
compared using a Tukey’s multiple comparison post-hoc test. Plasma glucose- and 
insulin concentrations over time were analysed with a two-way ANOVA repeated 
measurements [effects of PC-treatment (PPC:EtOH) and time (Ptime)]. Protein 
immunoblots were compared by Students t-test. P < 0.05 was considered statistically 
significant. Statistical analyses other than three-way ANOVAs were conducted with 
GraphPad Prism 6 software for Windows (GraphPad Software, San Diego, CA, 
USA). Results are presented as mean ± SEM. 
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4.3 Results 
4.3.1 Maternal parameters and postnatal growth 
Dams were of similar age (U: 87 ± 3 vs. PC:EtOH: 85 ± 3 days) and weight (U: 262 ± 
7 vs. PC:EtOH: 258 ± 7 g) at the start of the experimental protocol. There was no 
difference in caloric intake at any time during pregnancy as reported previously 
(Gardebjer et al., 2014). Gestational weight gain was similar between treatment 
groups (data not shown). The average and the peak PAC two days prior to mating 
was 0.07 ± 0.01% and 0.18 ± 0.04% respectively, and the peak PAC on E2 was 0.25 
± 0.04% (Gardebjer et al., 2014). There were no differences in gestational length (22 
days), litter size (15 ± 1 pups), or the male:female ratio (U: 1.13 vs. PC:EtOH: 1.17) 
between treatment groups. Body weight at weaning (PN28) was also similar between 
treatment groups (Table 4.1) with no apparent differences in body weight prior to 
initiation of the HFD at 3 months (Table 4.1). Whilst consumption of a HFD 
significantly increased weight gain between weeks 17-24 and weeks 25-32 in both 
male and female offspring of both treatment groups (P < 0.0001, Table 4.1), 
PC:EtOH-exposure alone or in conjunction with HFD did not significantly affect 
growth (Table 4.1). 
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Table 4.1 Offspring weights and weight gain of untreated (U) and PC:EtOH-exposed offspring fed a control (C) or a high-fat diet (HFD) 
 Treatment group Statistics (P values) 
 U:C PC:EtOH:C U:HFD PC:EtOH:HFD PC:EtOH HFD Interaction 
Male        
Body weight at weaning, g 75 ± 4 74 ± 3 N/A N/A NS N/A N/A 
Body weight at 16 weeks, g 475 ± 8 479 ± 8 490 ± 11 480 ± 14 NS NS NS 
Weight gain (week 17-24), g 104 ± 7 108 ± 4 156 ± 16 169 ± 8 NS <0.0001 NS 
Weight gain (week 25-32), g 54 ± 5 57 ± 4 105 ± 10 94 ± 9 NS <0.0001 NS 
Body weight at PM, (week 32) g 606 ± 16 607 ± 13 681 ± 22 727 ± 45 NS <0.001 NS 
Snout-rump length at PM, cm 28.5 ± 0.2 28.1 ± 0.3 28.8 ± 0.3 28.8 ± 0.5 NS NS NS 
 
 
 
 
 
       
Female 
 
 
Female 
       
Body weight at weaning, g 72 ± 3 66 ± 2 N/A N/A 0.06 N/A N/A 
Body weight at 16 weeks, g 283 ± 6 283 ± 4 286 ± 3 287 ± 6 NS NS NS 
Weight gain (week 17-24), g 47 ± 3 43 ± 3 73 ± 6 71 ± 8 NS <0.0001 NS 
Weight gain (week 25-32), g 20 ± 2 18 ± 2 47 ± 4 40 ± 6 NS <0.0001 NS 
Body weight at PM, (week 32) g 315 ± 16 309 ± 14 387 ± 20 354 ± 18 NS <0.01 NS 
Snout-rump length at PM, cm 23.8 ± 0.3 23.0 ± 0.3 24.2 ± 0.4 23.8 ± 0.3 0.06 <0.05 NS 
 
HFD, high-fat diet; N/A, no data available; NS, not statistically significant; PC:EtOH, periconceptional alcohol; PM, post mortem. Body weight at weaning was 
analyzed with an unpaired t-test. All other data was analyzed with a two-way-ANOVA within each sex with main effects of PC:EtOH and HFD. Data are 
represented as mean ± SEM.   
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4.3.2 GTT and ITT at 6 months 
Primarily we examined the effects of the periconceptional alcohol exposure on 
glucose tolerance and insulin sensitivity in animals on the control diet in male and 
female offspring. We found that PC:EtOH-exposure increased fasting glucose 
concentrations (P < 0.05), although this was significantly greater in males than 
females (Figure 4.1 A). This effect was associated with a non-significant increase in 
fasting insulin concentrations (PPC:EtOH < 0.07, Figure 4.1 B), and significantly altered 
HOMA-IR and QUICKI indices (PPC:EtOH < 0.05, Figure 4.1 C & D). However, there 
were significant sex differences, with females exhibiting lower fasting insulin 
concentrations than males, and correspondingly lower HOMA-IR and higher QUICKI 
indices (Psex < 0.05, Figure 4.1 B-D). In the GTT, glucose clearance was inhibited in 
both sexes by PC:EtOH-exposure, as indicated by increased AUGC (PPC:EtOH < 0.01, 
Figure 4.2 A & B). Furthermore, both sexes displayed increased pancreatic insulin 
output (AUIC) during the GTT (PPC:EtOH < 0.01, Figure 4.2 C & D). The increased 
insulin response was both acute first-phase (PPC:EtOH < 0.05, Figure 4.2 E) and 
second-phase (PPC:EtOH < 0.001, Figure 4.2 F). Correspondingly, the AUIC:AUGC-
ratio was increased by PC:EtOH-exposure (PPC:EtOH < 0.05, Table 4.2). In the ITT, 
glucose clearance from circulation in response to exogenous insulin was decreased 
by PC:EtOH in both sexes (PPC:EtOH < 0.01, Figure 4.2 G & H). 
Second, we ascertained whether there was an interaction between PC:EtOH and a 
PN HFD in metabolic outcomes. To examine this interaction, we analysed males and 
females separately. In males, consumption of a HFD augmented fasting glucose 
concentrations, to a similar degree in both untreated and PC:EtOH (PHFD < 0.001, 
Table 4.2). Similarly, fasting insulin concentrations were also increased following 
HFD exposure (PHFD < 0.001, Table 4.2). However, PC:EtOH-exposed males that 
consumed a HFD had 2-fold higher fasting insulin concentration compared with 
males of other treatment groups (Pinteraction < 0.01, Table 4.2). This interaction of HFD 
with PC:EtOH resulted in a marked increase in the HOMA-IR index. In the GTT, 
consumption of the HFD did not affect the overall glucose (AUGC) or insulin (AUIC) 
response, but the HFD diet did increase acute first-phase insulin secretion (PHFD < 
0.01), and further exacerbated (P < 0.05) the response to PC:EtOH-exposure (Table 
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4.2). In the ITT, the HFD did not affect the glucose clearance in response to 
exogenous insulin beyond the effect of PC:EtOH.  
In females, there were generally significant effects of consuming a postnatal HFD in 
the absence of outcomes following PC:EtOH-exposure  (Table 4.2). The HFD had no 
effect on fasting glucose concentrations, but increased fasting insulin concentrations 
(PHFD < 0.01, Table 4.2). This was associated with altered HOMA-IR and QUICKI 
indices (PHFD < 0.01, Table 4.2). Similarly in the GTT, the AUGC, AUIC, 
AUIC:AUGC-ratio, and  acute first-phase and second-phase insulin secretion, and 
the AUGC in the ITT were all increased by the HFD (PHFD < 0.05; < 0.01; < 0.01; < 
0.01; < 0.01, < 0.05 respectively), but there were no significant interactions between 
PC:EtOH and HFD in females for any of these measures (Table 4.2).  
Figure 4.1 – The effect of periconceptional alcohol exposure on fasting plasma glucose and insulin, 
HOMA-IR and QUICKI scores                                                                                           .. 
Effects of PC:EtOH-exposure (black bars) on (A) fasting plasma glucose and (B) insulin concentration 
in male and female offspring at 6 months of age. Corresponding homeostatic model assessment 
(HOMA) of insulin resistance (C) and quantitative insulin sensitivity check index (QUICKI) (D) 
compared with U:C (white bars). Data is represented as mean ± SEM and compared with the 
untreated male group. n = 8-12 per group. NS, not statistically significant.  
A
C
B
D
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Figure 4.2 – The effect of periconceptional alcohol exposure on glucose and insulin homeostasis 
Plasma glucose clearance following a glucose tolerance test (GTT) (A), area under the glucose curve 
(AUGC) generated from the GTT (B), plasma insulin secretion following a GTT (C), total area under 
the insulin curve (AUIC) generated from the GTT (D) with acute first- and second-phase insulin 
secretion shown in (E & F). Plasma glucose concentration following an insulin tolerance test (ITT) (G) 
and the inverted AUGC generated from the ITT (H).  All experiments were performed on male and 
female offspring at 6 months of age. n = 8-12 for PC:EtOH (black bars) and untreated (white bars) 
groups. For curves: untreated males (white circles), PC:EtOH males (black circles), untreated females 
(white squares) and PC:EtOH females (black squares). Data is represented as mean ± SEM and 
compared with the untreated male group. NS, not statistically significant. 
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Table 4.2 Plasma glucose and insulin chemistry of untreated (U) and PC:EtOH-exposed offspring fed a control (C) or a high-fat diet (HFD) 
 Treatment group Statistics (P values) 
 U:C PC:EtOH:C U:HFD PC:EtOH:HFD PC:EtOH HFD Interaction 
Male        
Fasting glucose (mmol/L) 7.0 ± 0.1 7.6 ± 0.2 7.8 ± 0.2 8.2 ± 0.2 <0.01 <0.001 NS 
Fasting insulin (pmol/L) 315.0 ± 70.0a 437.5 ± 70.0a 367.5 ± 52.5a 892.5 ± 105.0b <0.0001 <0.001 <0.01 
HOMA-IR index 0.57 ± 0.12a 0.86 ± 0.15a 0.75 ± 0.12a 1.92 ± 0.25b <0.0001 <0.001 <0.01 
QUICKI index 0.45 ± 0.03 0.40 ± 0.01 0.41 ± 0.01 0.35 ± 0.01 <0.01 <0.05 NS 
AUGC (GTT) 1020 ± 46 1206 ± 47 1054 ± 55 1217 ± 48 <0.01 NS NS 
Total AUIC (GTT)  238 ± 59 493 ± 86 285 ± 39 695 ± 88 <0.0001 NS NS 
AUIC (first-phase) (GTT) 26 ± 5a 40 ± 8a 30 ± 5a 78 ± 11b <0.001 <0.01 <0.05 
AUIC (second-phase) (GTT) 194 ± 51 422 ± 73 235 ± 34 565 ± 71 <0.0001 NS NS 
AUIC/AUGC 0.23 ± 0.05 0.41 ± 0.07 0.26 ± 0.04 0.55 ± 0.07 <0.001 NS NS 
AUGC (ITT) 1521 ± 57 1280 ± 94 1316 ± 58 1308 ± 63 <0.05 NS NS 
        
Female        
Fasting glucose (mmol/L) 6.9 ± 0.2 7.0 ± 0.2 7.5 ± 0.3 7.4 ± 0.4 NS NS NS 
Fasting insulin (pmol/L) 175.0 ± 35.0 227.5 ± 35.0 402.5 ± 87.5 455.0 ± 87.5 NS <0.01 NS 
HOMA-IR index  0.31 ± 0.07 0.42 ± 0.09 0.82 ± 0.18 0.93 ± 0.20 NS <0.01 NS 
QUICKI index 0.51 ± 0.03 0.46 ± 0.02 0.41 ± 0.05 0.42 ± 0.03 NS <0.01 NS 
AUGC (GTT) 1023 ± 21 1115 ± 57 1211 ± 65 1191 ± 57 NS <0.05 NS 
Total AUIC (GTT) 190 ± 39 277 ± 25 466 ± 94 502 ± 99 NS <0.01 NS 
AUIC (first-phase) (GTT) 17 ± 2 25 ± 4 42 ± 8 45 ± 9 NS <0.01 NS 
AUIC (second-phase) (GTT)  160 ± 37 231 ± 21 392 ± 85 424 ± 85 NS <0.01 NS 
AUIC/AUGC 0.20 ± 0.04 0.26 ± 0.03 0.37 ± 0.06 0.41 ± 0.07 NS <0.01 NS 
AUGC (ITT) 1544 ± 49 1357 ± 69 1263 ± 52 1168 ± 40 <0.01 <0.001 NS 
 
AUGC, area under the glucose curve; AUIC, area under the insulin curve; HOMA-IR, homeostatic model for assessment of insulin resistance; NS, not 
statistically significant; QUICKI, quantitative insulin sensitivity check index. Fasting glucose and insulin concentrations were prior to glucose tolerance test 
(GTT); basal glucose concentrations were prior to insulin tolerance test (ITT). Data was analysed with a two-way-ANOVA with post-hoc Tukey’s multiple 
comparison test. Values with different superscript letters are significantly different (P < 0.05). 
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4.3.4 Hepatic gluconeogenesis 
Having established that PC:EtOH-exposure resulted in metabolic dysfunction, we 
sought to determine if this was associated with changes in expression of genes 
regulating hepatic gluconeogenesis. We found that PC:EtOH-exposure increased 
mRNA-expression of G6pc (PPC:EtOH < 0.01, Figure 4.3 A), Pck1 (PPC:EtOH < 0.05, 
Figure 4.3 C), peroxisome proliferator-activated receptor gamma, coactivator 1α 
(Ppargc1a) (PPC:EtOH < 0.05, Figure 4.3 D) and decreased expression of Gck 
(PPC:EtOH < 0.01, Figure 4.3 B) in both sexes. Overall mRNA-expression of Ppargc1a 
was higher in females compared with males (Psex < 0.001, Figure 4.3 D), whereas 
Gck was expressed at lower levels in females than males (Psex < 0.01, Figure 4.3 B).  
The HFD did not affect the gene expression of G6pc, Pck1, or Ppargc1a in males 
(Table 4.3). HFD-fed males had increased gene expression of Gck (PHFD < 0.01), but 
there was no significant interaction of a HFD with PC:EtOH (Table 4.3). In females, 
the HFD had no effect on G6pc, Ppargc1a or Gck (Table 4.3). However the HFD 
decreased gene expression of Pck1 (PHFD < 0.01) and this decrease was greater in 
females exposed to PC:EtOH compared with control-fed females (PInteraction < 0.01, 
Table 4.3). 
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Figure 4.3 – The effect of periconceptional alcohol exposure on hepatic mRNA levels               . 
The effect of PC:EtOH-exposure (black bars) on hepatic mRNA levels of glucose-6-phosphatase 
(G6pc) (A), glucokinase (Gck) (B), phosphoenolpyruvate carboxykinase (Pck1) (C), and peroxisome- 
proliferator-activated receptor-gamma co-activator alpha (Ppargc1a) (D) compared with U:C (white 
bars) in male and female offspring at 8 months of age, n = 6-8 per group. Values are expressed as 
relative gene expression levels normalized to endogenous control ribosomal 18s. Data is represented 
as mean ± SEM and compared with the untreated male group. NS, not statistically significant. 
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Table 4.3 Relative mRNA levels of hepatic genes of untreated (U) and PC:EtOH-exposed offspring fed a control (C) or a high-fat diet (HFD) 
 
Treatment group Statistics (P values) 
 U:C PC:EtOH:C U:HFD PC:EtOH:HFD PC:EtOH HFD Interaction 
Male        
G6pc 1.09 ± 0.19 1.62 ± 0.39 1.15 ± 0.21 1.40 ± 0.28 NS NS NS 
Gck 1.08 ± 0.17 0.80 ± 0.34 1.82 ± 0.19 1.58 ± 0.37 NS <0.01 NS 
Pck1 1.08 ± 0.17 1.52 ± 0.18 1.05 ± 0.21 1.34 ± 0.21 0.07 NS NS 
Ppargc1a 1.29 ± 0.30 1.66 ± 0.34 1.78 ± 0.55 2.23 ± 0.56 NS NS NS 
 
Female        
G6pc 1.07 ± 0.13 2.08 ± 0.42 2.06 ± 0.40 1.48 ± 0.39 NS NS <0.05 
Gck 1.17 ± 0.24 0.72 ± 0.18 1.11 ± 0.25 0.86 ± 0.18 NS NS NS 
Pck1 1.07 ± 0.13ab 1.60 ± 0.20b 1.07 ± 0.15ab 0.80 ± 0.10a NS <0.01 <0.01 
Ppargc1a 1.14 ± 0.19 1.80 ± 0.22 0.84 ± 0.15 1.34 ± 0.22 <0.01 0.06 NS 
 
G6pc, glucose-6-phosphatase; Gck, glucokinase; Pck1, phosphoenolpyruvate carboxykinasel; Ppargc1a, peroxisome proliferator-activated receptor gamma, 
coactivator 1α; NS, not statistically significant. All data were analyzed with a two-way-ANOVA compared with the U/C group for each sex. Data are 
represented as mean ± SEM. Mean values with different superscript letters are significantly different with post-hoc Tukey’s multiple comparison test. 
Values with different superscript letters are significantly different (P < 0.05). 
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4.3.5 Peripheral insulin signaling  
As peripheral insulin insensitivity is often due to altered insulin signaling, we 
examined protein expression of AKT2 and GSK3β and their basal serine/threonine 
phosphorylation states in adipose tissue and skeletal muscle in control-fed offspring. 
PC:EtOH-exposed males had higher protein levels of tAKT2 (PPC:EtOH < 0.05, Figure 
4.4 A), basal pAKTThr309 (U: 0.71 ± 0.34 vs. PC:EtOH: 5.27 ± 0.90, P < 0.01), and 
pAKTThr309/tAKT ratio (PPC:EtOH < 0.05, Figure 4.4 A) in adipose tissue compared with 
untreated males. Neither pAKTSer474 (U: 1.00 ± 0.29 vs. PC:EtOH: 1.11 ± 0.31) or the 
pAKTSer474/tAKT ratio (Figure 4.4 A) were different in adipose tissue between 
untreated and PC:EtOH-exposed males. In skeletal muscle, there was no significant 
difference in tAKT2 (U: 1.00 ± 0.32 vs. PC:EtOH: 0.77 ± 0.11), pAKTSer474 (U: 1.00 ± 
0.27 vs. PC:EtOH: 0.70 ± 0.17) or the pAKTSer474/tAKT ratio (U: 1.00 ± 0.20 vs. 
PC:EtOH: 0.86 ± 0.19) between untreated and PC:EtOH-exposed males respectively 
(data not shown).  
In control-fed female offspring, protein levels of tAKT2 in adipose tissue were similar 
in PC:EtOH-exposed and untreated groups (Figure 4.4 B), but pAKTThr309 (U: 1.00 ± 
0.12 vs. PC:EtOH: 0.26 ± 0.16, P < 0.01), the pAKTThr309/tAKT ratio (P < 0.01, Fig. 
4B), pAKTSer474 (U: 1.00 ± 0.12 vs. PC:EtOH: 0.33 ± 0.08, P < 0.001), and the 
pAKTSer474/tAKT ratio (P < 0.001, Figure 4.4 B) were all significantly lower following 
PC:EtOH. In skeletal muscle, PC:EtOH-exposed females had higher protein levels of 
tAKT (U: 1.00 ± 0.19 vs. PC:EtOH: 1.49 ± 0.08, P < 0.05). Both pAKTSer474 (U: 1.00 ± 
0.24 vs. PC:EtOH: 0.58 ± 0.18) and the pAKTSer474/tAKT ratio (U: 1.00 ± 0.25 vs. 
PC:EtOH: 0.50 ± 0.30) lower following PC:EtOH-exposure but this did not reach 
statistical significance (P < 0.11) (data not shown).  
Protein levels of tGSK3β and pGSK3βSer9/tGSK3β in adipose tissue were similar 
between all control-fed groups (Figure 4.4 C & D). Similar results for GSK3β were 
found in skeletal muscle of both sexes (data not shown). 
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Figure 4.4 – The effect of periconceptional alcohol exposure on AKT and GSK3β-protein in adipose 
tissue 
The effect of PC:EtOH-exposure (black bars) on protein levels in white intra-abdominal adipose 
tissue in male and female offspring at 8 months of age compared with U:C (white bars), n = 4-6 per 
group. Total (t)AKT2 levels, phosphorylated (p)AKTThr309/tAKT ratio and the pAKTSer474/tAKT ratio in 
males (A) and females (B). tGSK3β and the pGSK3βSer9/tGSK3β ratio in males (C) and females (D). 
Values for the protein levels are normalised to β-Actin. Data is represented as mean ± SEM. * P < 
0.05; * P < 0.01; * P < 0.001 by Students t-test. 
     .    .       .  . 
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4.3.6 Fetal liver expression of chromatin modifiers  
An adverse environment during the 
periconceptional period may result in 
epigenetic changes and thus long-term 
alterations in gene expression, which have 
been implicated as an underlying mechanism 
in the development of metabolic disease 
(McMillen et al., 2008, Sinclair et al., 2007, 
Maloney et al., 2011). We therefore examined 
expression levels of key chromatin modifiers, 
namely HDACs and DNA DNMTs in fetal liver 
following periconceptional alcohol exposure. 
PC:EtOH-exposure increased mRNA-
expression of Dnmt1, Dnmt3a and Dnmt3b in 
liver from fetuses on E20 (PPC:EtOH < 0.05, 
Figure 4.5 A-C) but had no effect on Hdac2, 
Hdac3, Hdac4 or Hdac6 mRNA levels (data 
not shown).    
Figure 4.5 – The effect of periconceptional 
alcohol exposure on the expression of 
hepatic DNA methyltransferases on E20         .  
The effect of PC:EtOH-exposure (black bars) 
on fetal hepatic mRNA levels of DNA 
methyltransferase (Dnmt)1 (A), Dnmt3a (B) 
and Dnmt3b (C) compared with untreated 
offspring (white bars) in males and females 
on E20, n = 9-11 per group. Values are 
expressed as relative gene expression levels 
normalized to endogenous control ribosomal 
18s. Data is represented as mean ± SEM and 
compared with the untreated male group. NS, 
not statistically significant. 
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4.4 Discussion 
Our data demonstrate for the first time that maternal alcohol consumption for a short 
period exclusively during the periconceptional period impairs glucose tolerance and 
decreases insulin sensitivity in both male and female adult offspring at 6 months of 
age. This metabolic phenotype was associated with increased hepatic 
gluconeogenesis in both sexes, indicated by increased levels of G6pc, Pck1 and 
Ppargc1a, and decreased levels of Gck mRNA, although increased fasting glucose 
concentrations was only apparent in males. Furthermore, sex-specific alterations in 
AKT2 signaling were observed in peripheral tissues. Importantly, consumption of a 
postnatal HFD exacerbated both fasting insulin concentrations and acute first-phase 
insulin secretion during the GTT more than 2-fold in PC:EtOH-exposed male 
offspring relative to PC:EtOH-exposure or a HFD alone. Our data demonstrate that 
PC:EtOH-exposure around the time of conception is sufficient to cause a pre-
diabetic insulin insensitive state in both male and female offspring, with significant 
interactive effects of HFD and PC:EtOH in male, but not female offspring. Analysis of 
fetal liver mRNA in late gestation demonstrated altered expression of multiple DNA 
methyltransferases, suggesting that long term metabolic outcomes following 
PC:EtOH may partly derive from changes in methylation status. 
Several animal studies have previously linked maternal alcohol consumption during 
pregnancy to insulin resistance and glucose intolerance in offspring postnatally 
(Chen and Nyomba, 2003b, Chen and Nyomba, 2003a, Lopez-Tejero et al., 1989). 
Maternal EtOH-exposure throughout pregnancy (gavage of 2 g/kg EtOH twice daily, 
or ~13E% daily) impairs glucose tolerance in rat offspring at 3 months of age, 
despite hyperinsulinemia (Chen and Nyomba, 2003a). Indeed, persistent 
hyperinsulinemia is reported to occur from the first day of postnatal life in the rat 
following maternal EtOH-exposure throughout pregnancy (25% in drinking water, 
>30E%) (Lopez-Tejero et al., 1989). This is consistent with our own data that more 
moderate maternal alcohol consumption (6% v/v via a liquid diet, ~15E% daily) 
throughout pregnancy results in hyperinsulinemia in male, but not female rat 
offspring at 4 months of age (Probyn et al., 2013c). Collectively, these studies 
highlight that maternal alcohol consumption during pregnancy can alter glucose 
metabolism in offspring. Here for the first time, we report that alcohol consumption 
Chapter 4 
 
153 
 
 
(12.5% v/v, or ~22E%) solely during the periconceptional period (4 days prior to 
conception until day 4 of gestation) is sufficient to program similar metabolic 
responses in offspring later in postnatal life.  
Although insulin directly inhibits de novo glucose output from the liver to the 
bloodstream by supressing gluconeogenesis (Huang, 2009), it is well characterized 
that hepatic glucose output remains high in an insulin resistant state (Mitrakou et al., 
1992). Intriguingly, in our study, fasting plasma glucose concentrations were 
increased, especially in males following PC:EtOH-exposure, indicating increased 
hepatic gluconeogenesis (DeFronzo et al., 1981). In contrast, PC:EtOH-treated 
females were euglycaemic and exhibited better insulin sensitivity (lower HOMA-IR 
and higher QUICKI indices) than males. To further examine gluconeogenesis in our 
animals, we investigated alterations in hepatic gene expression. We found that 
PC:EtOH-exposure increased the relative gene expression of the rate-limiting 
gluconeogenic enzyme Pck1 (Rognstad, 1979). Relatively small increases in Pck1 
gene expression are known to be sufficient to increase hepatic gluconeogenesis and 
impair glucose tolerance (Sun et al., 2002). Interestingly, glucose intolerance 
associated with increased hepatic Pck1 expression has also been demonstrated in 
offspring following prenatal protein restriction (Desai et al., 1997) and maternal 
glucocorticoid administration (Drake et al., 2005). Levels of Ppargc1a mRNA, a 
transcription factor which stimulates the expression of Pck1 and G6pc (Yoon et al., 
2001), were also increased following PC:EtOH-exposure as were levels of G6pc 
mRNA, despite hyperinsulinemia. Increased gluconeogenesis associated with 
increased basal gene expression of both Pck1 and Ppargc1a has previously been 
demonstrated in rats prenatally exposed to alcohol throughout pregnancy (Yao et al., 
2013). Furthermore, Gck gene expression was decreased in PC:EtOH-exposed 
offspring, consistent with an insulin resistant phenotype (Caro et al., 1995). 
Collectively, our data suggest that increased hepatic glucose output contributes to 
the insulin insensitive phenotype in both PC:EtOH-exposed male and female 
offspring.  
Although debatable, insulin resistance often precedes any impairment of β-cell 
function (Warram et al., 1990). Blood glucose levels can be normal or near normal 
as the β-cells hypersecrete insulin to compensate for the developing insulin 
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resistance (Kasuga, 2006). In our study, PC:EtOH-exposed offspring displayed only 
minor increases in fasting insulin and no loss of either first- or second-phase insulin 
secretion during the GTT. Instead, hypersecretion of insulin in response to a glucose 
load was observed, indicative of β-cell compensation. Furthermore, reduced 
responsiveness of PC:EtOH-exposed offspring to exogenous insulin (ITT) confirmed 
an insulin insensitive phenotype. Our results therefore support the notion that the 
effect of PC:EtOH-exposure is most likely due to dysregulation in tissue-specific 
insulin signaling (insulin insensitivity) and resultant pancreatic β-cell compensation, 
rather than PC:EtOH-exposure causing a direct pancreatic defect, like β-cell failure 
(Thompson et al., 2007, Devaskar and Thamotharan, 2007).  
We consequently investigated AKT2 activation in adipose tissue and skeletal 
muscle, which is necessary for GLUT4 translocation and insulin-mediated glucose 
uptake (Huang, 2009, Devaskar and Thamotharan, 2007). Since consumption of the 
HFD did not exacerbate the already impaired insulin sensitivity, we quantified AKT2 
levels only in untreated and PC:EtOH-exposed control-fed offspring. Given the 
phenotypes of impaired glucose tolerance and insulin insensitivity in PC:EtOH 
offspring, we expected AKT2 activity to be decreased in peripheral tissues. Indeed, 
female offspring exposed to EtOH during the periconceptional period had decreased 
AKT2 phosphorylation in adipose tissue (Ser474 and Thr309), whilst in skeletal 
muscle Ser474 phosphorylation tended to be decreased. Such decreases in 
phosphorylation of AKT2 are consistent with lower basal kinase activity (Thr309) and 
reduced “full” kinase activity in response to insulin (Ser474) (Schultze et al., 2011). 
Paradoxically, in PC:EtOH-exposed male offspring, there was an increase in tAKT2 
in adipose tissue, which might improve insulin sensitivity (Bae et al., 2003). Similar 
increases in tAKT2 have been demonstrated in skeletal muscle of twin sheep 
offspring exposed to periconceptional undernutrition (Lie et al., 2014), and in male, 
but not female offspring of obese mice (Shelley et al., 2009). Such up-regulation of 
tAKT2 levels is possibly a compensatory mechanism, and may be a direct result of 
increased basal insulin levels (40% higher in PC:EtOH-exposed males). Moreover 
the ratio of Thr309 phosphorylation to total AKT2 was also increased in adipose 
tissue of PC:EtOH-exposed male offspring, affirming the idea of increased insulin 
signaling in this tissue. These apparently disparate results in adipose tissue of male 
PC:EtOH-exposed offspring require further investigation as increased phosphor-
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ylation at Thr309 together with tAKT2 may be related to signaling pathways 
mediating adipogenesis and/or angiogenesis (He et al., 2010, Shiojima and Walsh, 
2002). Notwithstanding these sex-specific effects on insulin signaling in peripheral 
tissues, our data suggest maternal alcohol consumption during the periconceptional 
period programs a phenotype that is consistent with metabolic dysfunction and 
insulin resistance. 
There is growing evidence that perturbations around periconception can result in 
epigenetic modifications such as DNA methylation or histone acetylation, which have 
been implicated as an underlying mechanism in the development of metabolic 
disease (McMillen et al., 2008, Sinclair et al., 2007, Maloney et al., 2011). Key 
effectors are DNMTs, histone acetyltransferases (HATs), and HDAC proteins, 
respectively. Maternal alcohol consumption (E1-E7) has previously been linked to 
increased adult hepatic gluconeogenesis in association with increased class II HDAC 
protein activity (Yao et al., 2013). Although we did not observe changes in fetal liver 
Hdac mRNA expression, we cannot rule out the possibility that protein activity of 
these chromatin modifiers is altered in our model to impact on chromatin 
accessibility. Levels of expression of Dnmt genes however, were significantly 
increased in the fetal liver at E20 suggesting long-term alterations in methylation 
status. This is consistent with other recently published data showing dysregulation of 
hippocampal DNMT activity without changes in HDAC activity in a rat model of early 
life alcohol exposure (Perkins et al., 2013). It is tempting to speculate that increased 
Dnmt expression and consequent hypermethylation may provide the link between 
PC:EtOH and alterations in gene expression associated with the metabolic 
phenotype observed. Consistent with our data, Ppargc1a expression is reduced by 
hypermethylation of the PPARGC1A-promoter in diabetic patients (Barres et al., 
2009), and correlates positively with fasting plasma insulin levels and HOMA-IR 
(Sookoian et al., 2010).  
Other studies have demonstrated altered insulin and glucose dynamics following 
maternal periconceptional methionine deficiency in sheep (Sinclair et al., 2007) and 
rats (Maloney et al., 2011). Methionine provides methyl groups for the production of 
S-adenosyl methionine, a substrate for DNMTs. Significantly, we have previously 
demonstrated decreased expression of the major methionine transporter, Slc38a2, in 
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the placenta following PC:EtOH (Gardebjer et al., 2014). Intriguingly, global DNA 
methylation is increased in response to either methionine or choline deficiency 
through pregnancy (Sinclair et al., 2007, Kovacheva et al., 2007) and this is 
associated with increased expression of Dnmts, which is driven by hypomethylation 
of the Dnmt1 promoter (Kovacheva et al., 2007). Data from mice suggest that a 
perturbed preimplantation environment can also alter levels of the de novo DNA 
methyl transferase Dnmt3l (Kafer et al., 2011). This potentially impacts on de novo 
genome-wide methylation following resetting of epigenetic marks that occurs during 
this stage are also consistent with our data. Early embryonic alcohol exposure has 
also been demonstrated to result in allele specific changes in methylation patterns of 
the H19/Igf2 domain in the placenta of mice which may contribute to growth 
restriction (Haycock and Ramsay, 2009).  
In conclusion, our data establish that maternal consumption of alcohol during the 
periconceptional period programs impaired glucose tolerance and insulin insensitivity 
in offspring, which was associated with altered expression of key modifiers of fetal 
methylation status. Whilst these conditions are evident in both males and females, 
dysregulation of peripheral insulin signaling appeared to be sexually dimorphic with 
male offspring being more susceptible to a combination of PC:EtOH-exposure and a 
postnatal high-fat diet than females. These novel findings have important clinical 
implications for women wanting to conceive and bear healthy children. 
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Abstract 
Introduction: The effects of maternal alcohol consumption around the time of 
conception – a critical window of development – on adult onset obesity are largely 
unknown. We examined if PC:EtOH affected the development of obesity and/or 
NAFLD in adult offspring. We also studied the interaction of PC:EtOH with a 
postnatal HFD.  
Methods: Female Sprague-Dawley rats were fed a control or EtOH-containing liquid 
diet (0% or 12.5% EtOH v/v) from 4 days prior to mating until 4 days of gestation (n = 
12 per group). A subset of offspring was fed a HFD between 3-8 months of age, 
resulting in 8 groups for analysis. Body composition was assessed with DXA at 7 
months. Plasma was collected at PN30 and at 8 months when animals were killed 
for tissue collection. Results were analyzed separately for each sex.  
Results: Both PC:EtOH and HFD increased total fat mass in males (PPC:EtOH < 0.05; 
PHFD < 0.0001); but only HFD increased fat mass in females (PHFD < 0.0001). 
PC:EtOH increased the incidence of microvesicular steatosis and hepatic 
inflammation in male offspring only. At PN30, plasma leptin was increased in male 
and triglycerides decreased in female PC:EtOH-exposed offspring (PPC:EtOH < 0.05). 
At 8 months, PC:EtOH-exposure increased plasma triglycerides, HDL and 
cholesterol in male offspring (PPC:EtOH < 0.05); and LDL, cholesterol and leptin in 
female offspring (PPC:EtOH < 0.05). HFD increased HDL (PHFD < 0.05) and leptin (PHFD 
< 0.01) in males and triglycerides, cholesterol and leptin (PHFD < 0.05) in females. 
mRNA levels of Tnf-α and Leptin in visceral adipose were increased in both sexes 
(PPC:EtOH < 0.05) following PC:EtOH-exposure.  
Discussion and conclusion: Consuming alcohol around conception increases the risk 
of obesity, alters the plasma lipid profile and induces adult steatosis in a sex-specific 
manner. PC:EtOH-programmed phenotypes were similar to those caused by 
consumption of a postnatal HFD, particularly in male offspring. These results have 
important implications for women who have consumed alcohol around the time of 
conception. 
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5.1 Introduction 
Accumulating evidence suggests that exposure to a suboptimal environment in 
utero, including maternal alcohol intake (Shen et al., 2014), can impact on fetal 
development and offspring health, and therefore partially explain the rapid increase 
in disorders such as obesity and NAFLD (McMillen and Robinson, 2005). The timing 
of exposure may be important in determining the severity of the outcome (Fleming et 
al., 2004). Most developmental programming studies have focused on maternal 
insults when present throughout gestation; but the time shortly prior to conception 
until embryonic implantation (the periconceptional period) may be equally important 
(Lie et al., 2014, Maloney et al., 2011, Zhang et al., 2011). Very little, however, is 
known about how alcohol intake during this period – when women are most likely to 
drink (Floyd et al., 1999, Mullally et al., 2011) – impacts on the long-term health of 
the offspring, as previous studies have focused on the effects of alcohol when 
consumed throughout gestation (Chen and Nyomba, 2003a, Chen and Nyomba, 
2004, Elton et al., 2002, Lopez-Tejero et al., 1989). 
Human data from the Dutch Famine have demonstrated the possibility of obesity to 
be programmed in utero (de Rooij et al., 2006, Ravelli et al., 1999). Animal models of 
undernutrition (Jaquiery et al., 2012), low protein diet (Bol et al., 2009) and utero-
placental insufficiency (Joss-Moore et al., 2010) in various species have confirmed 
this. Prenatal alcohol exposure has been extensively investigated in relation to 
alterations in glucose and insulin metabolism (Probyn et al., 2013c, Chen and 
Nyomba, 2003a, Chen et al., 2004). Considering the strong links between insulin 
resistance, obesity and inflammation (Peraldi and Spiegelman, 1998, Fantuzzi, 
2005), relatively less is known about the consequences of maternal alcohol 
consumption on adult obesity (Dobson et al., 2012), especially when consumed 
around conception only. In some cases, a mismatch between the pre- and postnatal 
environment can reveal or exacerbate an in utero-programmed phenotype (Chen 
and Nyomba, 2003b, Rueda-Clausen et al., 2011). This is particularly important as 
developmental programming generally affects male and female offspring differently. 
Neglecting the sex of the offspring in the analyses may therefore confound 
conclusions to be drawn, especially in cases where such mismatch occurs (Vickers 
et al., 2000). 
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 We have recently shown that maternal alcohol intake when limited to the time of 
conception (PC:EtOH-exposure) restricts fetal growth (Gardebjer et al., 2014) – a 
strong indicator of adult onset disease (Floyd et al., 1999) – and induces a pre-
diabetic state in adult offspring (Gardebjer et al., 2015). Here, using the same model, 
we aimed to determine: 1) if PC:EtOH-exposure contributes to obesity in the adult 
offspring; 2) if a postnatal HFD interacts with PC:EtOH to exacerbate the phenotype; 
and 3) to establish whether male and female offspring are affected differently. Our 
study has important clinical implications as it can provide evidence to the current 
recommendations given to women concerning alcohol and pregnancy and ultimately 
secure the future health of the baby.  
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5.2 Materials and methods 
5.2.1 Ethics 
All animal experimentation was approved by The University of Queensland 
Anatomical Bioscience Animal Ethics Committee (SBS/022/12/NHMRC) prior to 
commencement of the study. 
5.2.2 Animal treatment  
Nulliparous Sprague-Dawley rats (n = 12 per treatment group) were treated as 
described in detail previously (Gardebjer et al., 2015). Briefly, dams were given a 
liquid diet containing either 0% or 12.5% EtOH (v/v) with similar energy composition 
from 4 days prior to mating until 4 days of gestation (control diet composition: 11.3% 
fat, 17.0% protein, 68.2% carbohydrates, 7.7MJ/kg; EtOH-diet: 11.9% fat, 13.6% 
protein, 50.7% carbohydrates, 11.8MJ/kg). Standard chow was offered from day 5. 
At PN30 blood samples were collected from a subset of offspring. At 3 months of 
age, a subset of offspring were randomly assigned a HFD (21% fat, 0.15% 
cholesterol, 19% protein, 59.9% carbohydrates; 19.4 MJ/kg) while one remained on 
standardized chow (C; 4.0% fat, 13.6% protein 64.3% carbohydrates; 15.5 MJ/kg), 
generating four treatment groups: untreated U:C; U:HFD; PC:EtOH:C and 
PC:EtOH:HFD for both male and female offspring. 
5.2.3 Body composition measurements   
A dual-energy X-ray absorptiometer (DXA; model XR36, Norland Corp., Fort 
Atkinson, USA) was used to determine body composition total FM, total FFM, 
abdominal fat mass, BMD and BMC) at 7 months (n = 10-11/group). Rats were 
anesthetized with an i.p. injection of a 50/50 mix of Zoletil/Xylazile (0.1 mL/100 g 
body weight). Scan images were analysed using the manufacturer’s recommended 
software for use in laboratory animals (small subject analysis software, version 
2.5.3/1.3.1, Norland Corp., Fort Atkinson, USA). 
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5.2.4 Tissue collection   
Offspring (n = 12 per group) were sacrificed at 8 months following an overnight 
fasting period, with an i.p. administration of a mix of 50/50 Ketamine/Xylazile (0.5 
mL/100 g body weight). Snout-rump length and abdominal girth were measured. 
Liver and visceral abdominal adipose tissue were snap frozen in liquid nitrogen and 
stored in -80oC, and the apexes of the left lateral lobe of the liver were collected in 
4% PFA for histological analyses. 
5.2.5 Blood sampling and plasma chemistry   
Blood was collected via cardiac puncture on PN30 and at 8 months, immediately 
spun (3000 rpm, 15 minutes, 4oC) and plasma stored at -80oC. Triglycerides, HDL, 
LDL, total cholesterol and electrolytes were analysed with a Cobas Integra 400 Plus 
Chemistry Analyzer (Block Scientific, NY, USA). Leptin was analysed with a multi-
species leptin radioimmunoassay kit with an assay sensitivity of 0.2 ng/mL (Cat.# 
XL-85K, Millipore, Pty. Ltd., Kilsyth, VIC, Australia). The between and within assay 
CVs were <6% for two leptin quality controls samples at concentrations 3.3 and 15.9 
ng/mL. Adiponectin was analyzed by an enzyme-linked immunosorbent assay with 
an assay sensitivity of 0.4 ng/mL (Cat#EZRADP-62K, Millipore, Pty. Ltd., Kilsyth, 
VIC, Australia).  
5.2.6 Gene analyses 
RNA from the apex of the left lateral lobe of the liver was extracted using an RNeasy 
Mini-Kit and visceral adipose tissue was extracted using an RNeasy Lipid Tissue 
Mini Kit (Qiagen, VIC, Australia) and reversed transcribed into cDNA. Gene 
expression analyses were conducted via qPCR with the Taqman Assay-on-Demand 
primer/probe set for Leptin (Rn00565158_m1) (Applied Biosystems, CA, USA), or 
SYBR® Green detection chemistry using the following primers for Tnf-α (F, 5'-
GAAACACACGAGACGCTGAA; R, 5'-GAAAGCCCATTGGAATCCTT), and IL-6 (F, 
5'-ACTCATCTTGAAAGCACTTG; R, 5'-GTCCACAAACTGATATGCTTAG) (Sigma 
Aldrich). mRNA expression was calculated with the ΔΔCT method. Rn18s, which did 
not differ between groups, was used as the endogenous control (Gardebjer et al., 
2014).  
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5.2.7 Histological analyses  
One section of the left lateral lobe of the liver were processed to paraffin and 
sectioned at 6 µm. Five representative sections per liver (n = 8 animals/group) were 
stained with H&E and scored for steatosis, microvesicular steatosis, inflammation 
and microgranulomas; and five were stained with Masson’s trichrome for evaluation 
of fibrosis according to the semi-quantitative Kleiner scoring system for non-alcoholic 
steatohepatitis (NASH) (Kleiner et al., 2005). All scores were performed blinded.  
5.2.8 Statistical analyses  
Statistical analyses were conducted with GraphPad Prism 6 software for Windows 
(GraphPad Software, San Diego, CA, USA). PN30 data were analysed by a students 
t-test for males and females separately. Data for U:C, U:HFD, PC:EtOH:C and 
PC:EtOH:HFD were analysed by two-way ANOVAs for main effects of PC-treatment 
(PPC:EtOH) and postnatal diet (PHFD) with males and females being analysed in 
separate ANOVAs. Data were log transferred to remove heterogeneity of variance 
prior to performing the ANOVA analyses as appropriate (Bartlett’s test). In cases 
where interaction and/or either treatment effect were significant, means were 
compared using a Tukey’s multiple comparison post-hoc test to look at statistical 
differences within variables. P < 0.05 was considered statistically significant. All 
results are presented as mean ± SEM. 
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5.3 Results  
5.3.1 Animal model 
As previously reported, there were no differences in maternal weight, initial age, 
caloric intake, gestational length, weight gain or litter sizes between PC:EtOH-
exposed and untreated dams (Gardebjer et al., 2014). 
5.3.2 PN30 outcomes 
Body weight, abdominal circumference, ponderal index and liver:body weight-ratio 
were similar between treatment groups of both male and female offspring; however 
PC:EtOH-exposed offspring tended to weigh less than their untreated counterparts 
(PPC:EtOH = 0.06, Table 5.1). PC:EtOH-exposed male offspring had higher plasma 
leptin levels (PPC:EtOH < 0.05), and tended to have elevated plasma triglyceride levels 
(PPC:EtOH = 0.09) compared with untreated controls on PN30, but plasma cholesterol 
and HDL were similar between treatment groups (Table 5.1). Females had similar 
plasma levels of leptin, cholesterol and HDL, but but plasma triglyceride levels were 
lower following PC:EtOH-exposure (PPC:EtOH < 0.05, Table 5.1). 
5.3.3 Adult offspring outcomes 
5.3.3.1 Offspring body composition 
Figure 5.1 shows that HFD-fed offspring weighed more than control-fed offspring for 
both sexes at 7 months (PHFD < 0.001, Figure 5.1 A & B), but PC:EtOH-exposure did 
not affect body weight. At the time of tissue collection at 8 months, similar 
differences in body weight were observed (PHFD < 0.001 vs 0.01 for males and 
females respectively, Table 5.2). PC:EtOH-exposed males had lower % fat-free 
mass and higher % total- and abdominal fat mass compared with untreated groups 
(PPC:EtOH < 0.05, Figure 5.1 C, E & G). The weight of intra-abdominal fat pads as a 
proportion of body weight at the time of tissue collection also tended to be higher 
following PC:EtOH-exposure (PPC:EtOH = 0.06, Table 5.2). PC:EtOH-exposed males 
had a larger abdominal circumference compared with untreated males at 8 months 
(PHFD < 0.05, Table 5.2), despite a similar ponderal index (Table 5.2). Both PC:EtOH-
exposed and untreated males that were fed a postnatal HFD had lower percentage 
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FFM, and higher total- and abdominal FM (PHFD < 0.0001, Figure 5.1 C, E & G) and a 
larger amount of intra-abdominal fat per gram body weight (PHFD < 0.0001, Table 5.2) 
compared with those fed a control diet. HFD-fed male offspring also had a larger 
abdominal circumference (PHFD < 0.001) and ponderal index (PHFD < 0.01) (Table 
5.2) but a HFD did not potentiate the effects of PC:EtOH-exposure. 
The body composition of female offspring was unaffected by PC:EtOH, but HFD-fed 
females had a lower % FFM, higher total- and abdominal FM (PHFD < 0.0001, Figure 
5.1 D, F & H), and a larger amount of intra-abdominal fat per gram body weight (PHFD 
< 0.001, Table 5.2). Both abdominal circumference (PHFD < 0.001) and ponderal 
index (PHFD < 0.01) were higher in HFD-fed females (Table 5.2). Similar to male 
offspring, % BMC and BMD were unaffected by both PC:EtOH-exposure and HFD. 
Table 5.1. Body weight and plasma parameters at postnatal day 30 
Variables Untreated PC:EtOH 
Male 
 
  
Body weight (g) 76.5 ± 3.5 73.8 ± 2.2 
Abdominal circumference (cm) 11.2 ± 0.2 10.8 ± 0.2 
Ponderal index (g/(100xcm3)) 30.4 ± 1.4 28.9 ± 2.6 
Liver weight (g/gbw) 0.04 ± 0.001 0.04 ± 0.001 
Triglycerides (mmol/L) 0.7 ± 0.1 0.9 ± 0.1 
HDL (mmol/L) 1.49 ± 0.05 1.53 ± 0.07 
Cholesterol (mmol/L) 2.4 ± 0.1 2.5 ± 0.1 
Leptin (ng/mL) 1.68 ± 0.23 2.47 ± 0.31* 
   
Female 
 
  
Body weight (g) 71.8 ± 2.3 65.4 ± 2.2  
Abdominal circumference (cm) 10.6 ± 0.4 10.6 ± 0.2 
Ponderal index (g/(100xcm3)) 31.0 ± 1.8 30.3 ± 1.5 
Liver weight (g/gbw) 0.04 ± 0.001 0.04 ± 0.001 
Triglycerides (mmol/L) 1.0 ± 0.1 0.6 ± 0.1* 
HDL (mmol/L) 1.57 ± 0.08 1.58 ± 0.14 
Cholesterol (mmol/L) 2.6 ± 0.1 2.5 ± 0.2 
Leptin (ng/mL) 1.75 ± 0.18 1.70 ± 0.21 
   
C, control; HDL, high density lipoprotein; PC:EtOH, periconceptional alcohol; U, untreated. Data are 
presented as mean ± SEM and n(untreated) = 9, n(EtOH) = 11. *,P < 0.05 by unpaired t-test (P < 
0.05). 
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Figure 5.1 – Effects of periconceptional alcohol and high-fat diet on adult offspring weight and 
body composition                             .       .          .                  .               . 
Body weight for male (A) and female offspring (B); % fat-free mass for male (C) and female offspring 
(D); % of total body fat mass for male (E) and female offspring (F); and % abdominal fat mass for 
male (G) and female offspring (H) exposed to PC:EtOH (black bars) and/or a high-fat diet (HFD) at 7 
months compared with untreated offspring (white bars) on a control diet. n = 10-11 per group. Data 
were analysed with two-way ANOVAs and is represented as mean ± SEM. NS, not significant. 
C
A B
D
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Table 5.2 Body and organ measurements at tissue collection and during X-ray absorptiometry scan of body composition in male and female offspring 
aged 7-8 months   
 Treatment group Statistics (P values) 
Variable U:C PC:EtOH:C U:HFD PC:EtOH:HFD PC:EtOH HFD Interaction 
Male        
Body weight at PM (g) 606 ± 16 607 ± 13 681 ± 22 727 ± 45 NS <0.001 NS 
Abdominal circumference (cm) 22.0 ± 0.5 22.4 ± 0.3 23.4 ± 0.6 25.9 ± 1.1 <0.05 <0.001 NS 
Ponderal index (g/(100xcm3)) 2.6 ± 0.1 2.7 ± 0.1 2.8 ± 0.1 3.0 ± 0.1 0.08 <0.01 NS 
Liver weight (g/gbw) 0.02 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 NS NS NS 
Intra-abdominal fat weight (g/g bw) 0.04 ± 0.01 0.05 ± 0.01 0.06 ± 0.01 0.08 ± 0.01 0.06 <0.0001 NS 
Tibial length (mm) 51.1 ± 1.0 52.0 ± 1.2 50.6 ± 1.1 51.1 ± 1.2 NS NS NS 
BMC (%) 2.85 ± 0.05 2.93 ± 0.07 2.88 ± 0.05 2.85 ± 0.05 NS NS NS 
BMD (g/cm2) 0.19 ± 0.01 0.19 ± 0.01 0.19 ± 0.01 0.19 ± 0.01 NS NS NS 
        
Female        
Body weight at PM (g) 315 ± 16 309 ± 14 387 ± 20 354 ± 18 NS <0.01 NS 
Abdominal circumference (cm) 17.3 ± 0.6 17.1 ± 0.3 19.1 ± 0.7 19.3 ± 0.4 NS <0.001 NS 
Ponderal index (g/(100xcm3)) 2.3 ± 0.1 2.5 ± 0.08 2.7 ± 0.07 2.7 ± 0.1 NS <0.01 NS 
Liver weight (g/gbw) 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 NS NS NS 
Intra-abdominal fat weight (g/g bw) 0.05 ± 0.01 0.05 ± 0.01 0.07 ± 0.01 0.09 ± 0.01 NS <0.001 NS 
Tibial length (mm) 46.4 ± 1.1 43.9 ± 1.1 45.9 ± 1.2 45.7 ± 1.0 NS NS NS 
BMC (%) 3.42 ± 0.09 3.25 ± 0.08 3.27 ± 0.12 3.38 ± 0.08 NS NS NS 
BMD (g/cm2) 0.16 ± 0.01 0.17 ± 0.01 0.16 ± 0.01 0.17 ± 0.01 NS NS NS 
 
BMC, bone mineral content; BMD, bone mineral density; C, control; DXA, dual X-ray absorptiometry; HFD, high-fat diet; NS, not statistically significant; 
PC:EtOH, periconceptional alcohol; U, untreated. All data were analysed with a two-way-ANOVA for each sex.Data is represented as mean ± SEM, n = 10-11 
per treatment group.  
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5.3.3.2 Plasma biochemistry at 8 months 
Table 5.3 shows that PC:EtOH-exposed male offspring aged 8 months – regardless 
of postnatal diet – had increased plasma levels of triglycerides (PPC:EtOH < 0.05), HDL 
(PPC:EtOH < 0.05), and cholesterol (PPC:EtOH < 0.01). HFD-fed males had lower HDL 
(PHFD < 0.05, Table 5.3) and higher leptin levels (PHFD < 0.01, Figure 5.2 A) 
compared with control-fed males. PC:EtOH-exposed female offspring aged 8 months 
had higher plasma levels of LDL and cholesterol (PPC:EtOH < 0.05) as shown in table 
2. PC:EtOH-exposed females also had increased fasting leptin (PPC:EtOH < 0.05, 
Figure 5.2 B. Leptin (PHFD < 0.01, Figure 5.2 B) and triglycerides (PHFD < 0.01, Table 
5.3) were also increased in females fed HFD whereas HDL levels were decreased 
(PHFD < 0.05, Table 5.3). Adiponectin (Figure 5.2 C & D) and plasma electrolytes 
(data not shown) were not affected by either PC:EtOH-exposure or HFD in either 
sex.  
Figure 5.2 – Effects of periconceptional alcohol and high-fat diet on plasma leptin and adiponectin 
Circulating levels of fasting plasma adipokines following PC:EtOH-exposure (black bars) or untreated 
(white bars) offspring on a control or high-fat diet (HFD) at 8 months; n = 8-10 per group. Leptin (A) 
and adiponectin (C) plasma levels in male offspring and leptin (B) and adiponectin (D) plasma levels 
in female offspring. Data were analysed with two-way ANOVAs and represented as mean ± SEM.
A B
C D
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Table 5.3 Fasting plasma profile of  8 months old male and female offspring 
 
Treatment group Statistics (P values) 
Variable U:C PC:EtOH:C U:HFD PC:EtOH:HFD PC:EtOH HFD Interaction 
Male        
Triglycerides  0.9 ±  0.2 1.1 ±  0.1 0.9 ±  0.1 1.3 ±  0.1 <0.05 NS NS 
HDL  1.68 ± 0.12 1.81 ± 0.07 1.21 ± 0.14 1.6 ± 0.1 <0.05 <0.05 NS 
LDL  0.09 ± 0.03 0.10 ± 0.02 0.13 ± 0.04 0.16 ± 0.05 NS NS NS 
Cholesterol 1.7 ± 0.1 1.9 ± 0.1 1.5 ± 0.2 2.00 ± 0.1 <0.01 NS NS 
        
Female        
Triglycerides  0.5 ± 0.1 0.6 ± 0.1 1.2 ± 0.3 1.5 ± 0.3 NS <0.05 NS 
HDL  1.94 ± 0.15 2.01 ± 0.14 1.53 ± 0.16 1.72 ± 0.09 NS <0.05 NS 
LDL  0.10 ± 0.03 0.17 ± 0.05 0.09 ± 0.02 0.19 ± 0.03 <0.05 NS NS 
Cholesterol 2.0 ± 0.2 2.2 ± 0.2 1.9 ± 0.2 2.4 ± 0.4 <0.05 NS NS 
 
C, control; HDL, high density lipoprotein; HFD, high-fat diet; LDL, low density lipoprotein; NS, not 
significant; PC:EtOH, periconceptional alcohol; U, untreated. Data were analysed with a two-way-
ANOVA for each sex. Data is represented as mean ± SEM, n = 8-12 per treatment group.  
 
5.3.3.3 Adipose tissue gene expression 
PC:EtOH significantly increased mRNA-levels of Tnf-α, IL-6, and Leptin in abdominal 
adipose tissue in male offspring at 8 months (PPC:EtOH < 0.01, 0.05 and 0.05, Figure 
5.3 A, C & E). In females, PC:EtOH-exposure only increased mRNA-levels of Tnf-α 
and Leptin in abdominal abdominal tissue (PPC:EtOH < 0.05, Figure 5.3 B & E) 
whereas IL-6 was not different (Figure 5.3 D). The HFD had no effect on mRNA-
levels of Tnf-α, IL-6 or Leptin in adipose tissue.  
PC:EtOH did not affect the hepatic gene expression of Tnf-α in neither male of 
female offspring, however the HFD increased Tnf-α mRNA-levels in male (U:C 1.23 
± 0.13; EtOH:C 1.08 ± 0.13; U:HFD 3.22 ± 0.53; EtOH:HFD 2.28 ± 0.46,  PHFD < 
0.001) but not female liver (data not shown). Hepatic mRNA-levels of IL-6 was 
unaffected by both PC:EtOH and HFD.  
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Figure 5.3 – Effects of periconceptional alcohol and high-fat diet on gene expression in visceral 
abdominal adipose tissue                                                                        .       .      
Relative gene expression of Tnf-α (A), IL-6 (C), and Leptin (Lep) (E) in male offspring; and Tnf-α (B), IL-
6 (D), and Lep (F) in female offspring exposed to PC:EtOH (black bars) and/or a high-fat diet (HFD) on 
gene expression in visceral abdominal adipose tissue at 8 months, compared with untreated (white 
bars) offspring on a control diet. n = 7-8 per group. Data were analysed with two-way ANOVAs and 
represented as mean ± SEM.  
 
C
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D
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5.3.3.4 Assessment of non-alcoholic fatty liver disease 
PC:EtOH-exposure did not grossly affect hepatic morphology (Figure 5.4). Signs of 
macrovesicular steatosis were absent in control-fed offspring of both sexes. The 
HFD increased the prevalence of macrovesicular steatosis in both sexes, although 
male offspring were more affected than females. The macrovesicular steatosis was 
more likely to be located around the central vein (zone 3) in untreated males fed 
HFD, whereas PC:EtOH-exposed males consuming HFD had a greater percentage 
panacinar steatosis compared with any other treatment group. Signs of 
microvesicular steatosis were present in livers of both male and female offspring 
following both PC:EtOH and HFD, whereas this was not seen in control-fed 
untreated offspring. All PC:EtOH-exposed males had  lobular inflammation when fed 
a control diet compared with only 50% of untreated (U:C) and HFD-fed (U:HFD) 
males. Although not all HFD-fed animals had lobular inflammation, in male offspring, 
the severity of this condition was worsened regardless of PC-treatment. 
Microgranulomas were present in all groups, however this was more frequent 
following PC:EtOH and/or HFD. There were no signs of hepatic fibrosis in liver 
sections from any treatment group. 
Chapter 5 
 
173 
 
 
 
  Male Female 
  U:C EtOH:C U:HFD EtOH:HFD U:C EtOH:C U:HFD EtOH:HFD 
Steatosis 
grade 
 
<5 % 100 100 10 0 100 100 71 86 
5-33 % 0 0 50 60 0 0 29 0 
>33-66 % 0 0 20 20 0 0 0 0 
>66 % 0 0 20 20 0 0 0 14 
Location of  
steatosis 
Absent 100 100 10 0 100 100 71 86 
Central 0 0 40 40 0 0 14.5 0 
Portal 0 0 10 0 0 0 0 0 
Azonal 0 0 20 10 0 0 0 0 
Panacinar 0 0 20 50 0 0 14.5 14 
Micro-
vesicular 
steatosis 
Absent  100 67 20 0 100 71 0 29 
Present 0 33 80 100 0 29 100 71 
Lobular 
inflammation 
Absent 50 0 30 20 14 43 14 0 
Grade 1 50 100 50 60 86 43 86 100 
Grade 2 0 0 20 20 0 14 0 0 
Micro-
granulomas 
Absent  50 17 30 30 57 29 43 14 
Present 50 83 70 70 43 71 57 86 
Stage of 
fibrosis 
None 100 100 100 100 100 100 100 100 
 
A B 
C D 
Figure 5.4 – Effects of periconceptional alcohol and high-fat diet on the development of hepatic 
steatosis Representative H&E liver histology images from male untreated (A) and PC:EtOH-exposed 
(B) on a control diet, and for male untreated (C) and PC:EtOH-exposed (D) on a high-fat diet (HFD) at 8 
months, with quantification of non-alcoholic fatty liver disease according to the Kleiner-scoring 
system (panel E). Scale bars are 100 μm for inserts and 200 μm for large images, n = 8 per group. 
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5.4 Discussion 
Although total fat mass is strongly associated with morbidity and correlates with 
coronary artery disease and diabetes, visceral distribution of fat is an even stronger 
predictor of adverse health outcomes (Montague and O'Rahilly, 2000). This study 
demonstrates that alcohol, when consumed only around the time of conception, 
predisposes male offspring to visceral adiposity, associated with altered plasma 
biochemistry and increased gene expression of cytokines and leptin. PC:EtOH-
exposed female offspring also had altered plasma biochemistry and increased gene 
expression of inflammatory markers, despite no changes in body composition. 
PC:EtOH offspring of both sexes were more likely to exhibit signs of microvesicular 
steatosis, but overall the development of NAFLD was not severely affected by 
PC:EtOH. Although a postnatal HFD also significantly affected both body 
composition, plasma chemistry, gene expression and NAFLD, it did generally not 
exacerbate the effects of PC:EtOH. However, the zonal distribution of hepatic 
steatosis was more likely to be panacinar in PC:EtOH-exposed male offspring 
consuming HFD compared with either one treatment, suggesting that PC:EtOH had 
a more deleterious effect on NAFLD progression when male offspring were 
submitted to a mismatch in pre- and postnatal nutrition. The phenotype displayed by 
male offspring following PC:EtOH was often comparable to the one seen after 
consuming HFD for the major part of adult life (U:HFD-group). Contradictorily, female 
offspring were vulnerable to a postnatal HFD, but not to PC:EtOH-exposure.   
The increase in body fat seen in males at 8 months corroborates a previous study, in 
which ewes were periconceptionally undernourished from either 61 days before until 
the time of mating, from 61 days prior to mating until 30 days gestation, or from 2 
days before mating to 30 days gestation. Offspring were studied at 3-4 years of age, 
and it was shown that males, but not females of all groups exhibited increased %FM 
and a tendency to decreased % lean mass, despite similar body weights (Jaquiery et 
al., 2012). Similarly, mice fed a low-protein diet during gestation produced offspring 
with increased total and %FM at 9 months, and this was exacerbated in males that 
were fed a hypercaloric diet from weaning. Females were not studied (Bol et al., 
2009). The ability of prenatal alcohol (30% v/v in tap water) to increase visceral and 
subcutaneous adipose tissue in adult offspring has been demonstrated in guinea pig 
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(Dobson et al., 2012), although studies in rat have not shown any effect of prenatal 
alcohol consumption on offspring adipose tissue (Chen and Nyomba, 2003a). 
Human studies have demonstrated increased % body fat in intrauterine growth 
restricted males (Kensara et al., 2005). An increase in body fat, despite normal BMI 
(or ponderal index), is referred to as ‘normal weight obesity’ and is associated with 
cardiometabolic dysregulation and metabolic syndrome in humans (Romero-Corral 
et al., 2010). 
Adipocytes, were long considered as energy storage only, whereas now it is widely 
understood they play a role in endocrine functions. Adipose tissue secretes both 
hormones and inflammatory cytokines and adipokines, many of which have been 
implicated in the development of insulin resistance and obesity (Greenberg and 
Obin, 2006, Fantuzzi, 2005). TNF-α, when shown to be overexpressed in obese 
rodents, was the first molecular link between obesity and inflammation (Sethi and 
Hotamisligil, 1999, Hotamisligil et al., 1993). Since then, evidence has accumulated 
to suggest that inflammatory pathways – which recently have been shown to be 
affected in offspring following maternal perturbations (Alfaradhi et al., 2014, Pruis et 
al., 2014) – are critical in the mechanism underlying insulin resistance and adiposity 
(Weisberg et al., 2003, Uysal et al., 1997). TNF-α expression, which is increased in 
adiposity (Fantuzzi, 2005), increases plasma levels of TG, VLDL (Peraldi and 
Spiegelman, 1998) and is therefore a likely mediator to insulin resistance. Indeed, 
mice lacking TNF-α or its receptors exhibit improved insulin sensitivity compared with 
wild-type mice (Hotamisligil et al., 1993, Uysal et al., 1997). Increased levels of IL-6, 
which are induced by TNF-α (Kern et al., 1995), correlate with the prospect risk of 
developing type 2 diabetes – irrespective of amount body fat in undiagnosed 
subjects (Pradhan et al., 2001); and adipose gene expression of IL-6 is increased in 
obese and diabetic subjects compared with lean subjects (Fried et al., 1998). 
However, although the expression and circulating levels of cytokines correlates with 
obesity and diabetes (Fantuzzi, 2005), it is also established that inflammation can 
predict future adiposity (Engstrom et al., 2003) suggesting the early presence of 
inflammatory markers can also be the cause of obesity. Hence the increased levels 
of Tnf-α in females exposed to PC:EtOH, despite unaffected adiposity, may suggest 
that they are more likely to gain adipose tissue or weight compared with untreated 
females; a proposal that could be tested if DXA scans were repeated at a later age.  
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Both TNF-α and IL-6 reduces adiponectin secretion from adipocytes (Rotter et al., 
2003). Although high circulating adiponectin levels are associated with a relatively 
lower risk of type two diabetes (Spranger et al., 2003), it was not surprising that 
plasma levels of adiponectin were comparable between all groups in our study. 
Models of fetal programming often produce inconsistent results of adiponectin levels 
in metabolic phenotypes, and others have failed to correlate prenatal alcohol 
exposure with circulating adiponectin levels (Chen et al., 2004). Instead, we found 
plasma leptin levels to be increased in male but not female offspring on PN30, and in 
female but not male offspring at 8 months following PC:EtOH. Free plasma leptin 
generally positively correlates with adipose tissue mass (Maffei et al., 1995, Brabant 
et al., 2000) and therefore it is possible that PC:EtOH-exposed males had more 
adipose tissue on PN30 – or that they were resistant to leptin (Friedman, 2002). 
Without closer examination of body composition on PN30 and/or examination of the 
leptin receptor, we can only speculate about this. Although the mechanisms are still 
unclear, increased plasma leptin has previously been found in 4 months old females, 
but not male offspring of periconceptionally undernourished sheep (-15 days to +30 
days gestation), but fat content was not assessed in this study (Debus et al., 2012). 
Owing to the close relationship between leptin levels and fat mass, it was expected 
to see increased plasma leptin levels in HDF-fed offspring – however surprisingly, 
adipose Leptin mRNA was only increased following PC:EtOH. The fact that we only 
examined gene expression in one fat depot may explain this, as this may not be 
representative of the level of Leptin expression across all fat cells. It is also possible 
that the plasma leptin levels found in the HFD-fed animals reflects the increased 
amount of total body fat, without affecting leptin mRNA. 
In addition to regulation of insulin, increased circulating leptin levels are associated 
with NAFLD in children (Nobili et al., 2006), and an increased susceptibility to 
NAFLD following intrauterine growth restriction has recently been demonstrated 
(Alisi et al., 2012). The prevalence of NAFLD is, just as obesity, increasing at an 
alarming rate and is closely associated with obesity and insulin resistance (Alisi et 
al., 2012). Steatosis, or accumulation of triglycerides in hepatocytes, is considered 
the “first hit” in NAFLD, which increases the susceptibility to “second hits” cell injury, 
fibrosis and inflammation, subsequently leading to NASH (Carter-Kent et al., 2011). 
Histological examination is the accepted standard for diagnosis of NAFLD. Maternal 
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obesity is known to cause NAFLD in offspring, despite no differences in body weight 
or adiposity (Alfaradhi et al., 2014). Shen et al (2014) demonstrated increased 
hepatic steatosis in female rat offspring when exposed to high doses of alcohol 
prenatally (E11-E20, dams reaching 87 mM (0.40% BAC)). Males were not 
examined in this study. The lower doses of alcohol used in this study (0.18-0.25% 
PAC) did not severely affect liver histology. The combination of PC:EtOH and HFD 
was however the more likely to, apart from steatosis around the central vein, cause a 
panacinar distribution of steatosis; whereas HFD alone did not induce panacinar 
steatosis (males only). Although we did not observe any major differences in other 
liver features between treatment groups, the presence of panacinar steatosis has 
been associated with a greater likelihood to cause ballooning injury and fibrosis, 
compared to when steatosis is present around the central and/or portal vein, which 
show no correlation with an early degree of fibrosis (Chalasani et al., 2008). We 
therefore suggest that the combination of PC:EtOH and a postnatal HFD has a more 
profound effect on the development of NAFLD.  
The available literature generally focuses on recognition of the problem and lifestyle 
interventions, including medication, dietary modifications and exercise to improve 
outcomes such as obesity or ‘normal weight obesity’. However, we and others have 
shown that adiposity and associated disorders are just as likely a result of 
unfavorable periconceptional and prenatal events. It is therefore essential to spread 
knowledge about the consequences alcohol consumption around conception may 
have on the future heath of the baby to women planning a pregnancy.  
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CHAPTER 6 
 
General discussion 
 
6.1 Thesis summary 
The primary focuses of this thesis were to identify the long-term metabolic 
consequences of maternal periconceptional alcohol exposure; and to determine if a 
postnatal western diet impacted on the in utero programmed phenotype. Secondly, 
this thesis investigated if the adult phenotype correlated with early changes in the 
placenta, including biochemistry, size, and morphology. The significant findings were 
that male and female fetuses of dams that consumed alcohol exclusively around the 
time of conception were growth restricted and had a relatively larger placenta – 
changes that have been strongly associated with adult onset disease in many other 
programming models. Indeed, adult offspring in our study became insulin insensitive, 
experienced glucose intolerance and increased adiposity (males only). Importantly 
the degree of disease was often equivalent to that seen after consuming a western 
diet for the major part of adult life. These changes are summarized in Table 6.1. 
Although we suggest the long-term metabolic dysfunction to have arisen via 
compromised placental function, and alterations in molecular and endocrine 
pathways, it should be emphasized that the alcohol may have induced epigenetic 
changes during the preimplantation development. It was beyond the scope of this 
thesis to investigate such changes but some primarily results including changes in 
DNMTs indicate the importance of pursuing this idea in future studies. This chapter 
summarizes the findings and conclusions drawn from the studies in this thesis and 
puts them into a broader context in view of the general literature. 
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Table 6.1 Summary of the major findings in fetuses and adult offspring following periconceptional alcohol 
exposure and a postnatal western diet 
                         Male          Female 
Area of  
investigation 
Measure PEtOH PWD PEtOH+WD PEtOH PWD PEtOH+WD 
Fetal 
Litter size ↔   ↔   
Body weight ↓   ↓   
Body length ↓   ↓   
Placenta:bw-ratio ↑   ↑   
Placental 
Weight and dimensions 
Placenta wet weight ↔ L, S   ↔ L, S   
Placenta dry weight ↔L ↑S   ↔L ↑S   
Depth ↔   ↔   
Width ↑   ↑   
Length ↑   ↑   
Cross-sectional area 
Glycogen cells ↑   ↑   
Labyrinth zone ↓   ↓   
Spongio zone ↑   ↑   
Gene and protein expression 
11βHsd2 ↑L   ↑L   
Igf1 ↓L ↔S    ↓L ↔S   
Igf2 ↔L ↑S   ↔L ↑S   
Igf2R ↔L   ↔L   
IGF1R *↓L   *↔L   
Glut1 ↔L ↑S   ↔L ↑S   
Glut3 ↔L ↓S   ↑L ↑S   
Slc38a1 ↔L   ↔L   
Slc38a2 ↓L   ↓L   
Slc38a4 ↔L   ↔L   
Vegfa ↑L   ↑L   
Kdr ↔L   ↔L   
Pgf ↔L   ↔L   
Flt1 ↔L   ↔L   
Gys1 ↔S   ↔S   
Gsk3β ↔S   ↑S   
Gjb3 ↔S   ↔S   
Hepatic 
Demethyltransferases (mRNA) 
Dnmt1 ↑   ↑   
Dnmt3a ↑   ↑   
Dnmt3b ↑   ↑   
*, compared to the same sex only; L, placental labyrinth zone; S, placental spongiotrophoblast zone.
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Table 6.1 Summary of the major findings in fetuses and adult offspring following periconceptional ethanol 
exposure and a postnatal western diet (cont.) 
  Male Female 
Area of  
investigation 
Measure PEtOH PWD PEtOH+WD PEtOH PWD PEtOH+WD 
Glucose and 
insulin 
homeostasis 
Glucose and insulin tolerance tests (6 months) 
Fasting glucose ↑ ↑ ↔ ↑ ↔ ↔ 
Fasting insulin ↔ ↑ ↑ ↔ ↑ ↔ 
HOMA-IR ↑ ↑ ↑ ↑ ↑ ↔ 
QUICKI ↓ ↓ ↔ ↓ ↓ ↔ 
Glucose intolerance (AUGC) ↑ ↔ ↔ ↑ ↑ ↔ 
(AUIC) Endogenous insulin 
insensitivity 
↑ ↔ ↔ ↑ ↑ ↔ 
(AUIC) first-phase ↑ ↑ ↑ ↑ ↑ ↔ 
(AUIC) second-phase ↑ ↔ ↔ ↑ ↑ ↔ 
(AUGC) Exogenous insulin 
insensitivity 
↑ ↔ ↔ ↑ ↑ ↔ 
Hepatic gluconeogenesis (mRNA) 
G6pase ↑ ↔ ↔ ↑ ↔ ↔ 
Pepck ↑ ↔ ↔ ↑ ↓ ↓ 
Pcg-1α ↑ ↔ ↔ ↑ ↔ ↔ 
Gk ↓ ↑ ↑ ↓ ↔ ↔ 
AKT2 signaling (protein expression) 
*tAKT2  ↑A ↔M   ↔A↑M   
*pAKT2Thr/tAKT2  ↑A↔M   ↓A↔M   
*pAKT2Ser/tAKT2  ↔A↔M   ↓A↔M   
Obesity 
Body composition (7 months) 
% fat free mass ↓ ↓ ↔ ↔ ↓ ↔ 
% fat mass ↑ ↑ ↔ ↔ ↑ ↔ 
Abdominal circumference ↑ ↑ ↔ ↔ ↑ ↔ 
Plasma profile 
Triglycerides ↑ ↔ ↔ ↔ ↑ ↔ 
Total cholesterol ↑ ↔ ↔ ↑ ↔ ↔ 
LDL ↔ ↔ ↔ ↑ ↔ ↔ 
HDL ↑ ↓ ↔ ↔ ↓ ↔ 
Leptin ↔ ↑ ↔ ↑ ↑ ↔ 
Adiponectin ↔ ↔ ↔ ↔ ↔ ↔ 
Inflammation and other mRNA expression 
Tnf-α (visceral adipose) ↑ ↔ ↔ ↑ ↔ ↔ 
IL-6 (visceral adipose) ↑ ↔ ↔ ↑ ↔ ↔ 
Leptin ↑ ↔ ↔ ↑ ↔ ↔ 
Tnf-α (hepatic) ↔ ↑ ↑ ↔ ↔ ↔ 
IL-6 (hepatic) ↔ ↔ ↔ ↔ ↔ ↔ 
 *, compared to the same sex only; A, adipose tissue; M, skeletal muscle. Differences between sex 
are not shown in this table. 
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6.2 Relevance of animal model, dietary Intervention and study design 
The rat is a good animal model to study the effects of the early maternal environment  
We sought to mimic maternal alcohol consumption around the time of conception 
(prior to embryonic implantation) using a rat model. As demonstrated in Figure 6.1, 
the preimplantation development more or less overlaps in rat and human until E4 – 
hence the rat is a suitable species to study impacts from the early in utero 
environment. 
 
Figure 6.1 – A comparison between the human and rat preimplantation development           .         .  
Rat (blue) and human (pink) embryonic development overlaps from fertilization until early blastocyst 
stage. The rat embryo implants between E5-E7 whereas the human embryo implants between E7-
E10. 
Importantly, our model does not aim to differentiate between pre-conception and pre-
implantation effects, but covers the periconceptional period as a whole. Others have 
demonstrated the significance of both periods in programming of adult disease 
(Watkins et al., 2010, Watkins et al., 2011, Watkins et al., 2008), demonstrating that 
the underlying mechanisms may vary as such the pre-conception period is more 
likely to affect the developing follicle in the ovary, whereas the post-conception 
period has a greater effect on the uterus and is likely to induce epigenetic changes in 
the blastocyst. In order to identify such differences in our study, future studies should 
compare the two periods separately by administering alcohol either exclusively 
ImplantationFertilization
Fertilization 2-cell
2-cell
Early blastocyst Implantation
0 1 2 3 4 5 6 7 8 9 10
Human preimplantation development
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during oocyte maturation (4 days prior to until conception) and exclusively during 
preimplantation development (until 4 days post conception).  
Administration of alcohol via a liquid diet is the best available method to study 
alcohol in animal models 
To study the effects of early alcohol consumption, Sprague-Dawley rats were offered 
an EtOH containing (12% v/v, ~22E%) nutritionally complete Sustagen based liquid 
diet. Untreated dams were given a similar diet in which the ingredients had been 
modified to give an equal amount of calories and similar E% of micro- and 
macronutrients. As a part of this thesis, I comprehensively developed this diet based 
on dietary data collected by others from a smaller pilot study of PC:EtOH-exposure 
in the Moritz’s lab. In the pilot study, control and EtOH-exposed dams consumed 
different volumes of the liquid diet (thereby receiving diets with different nutritional 
composition). Using this data, I was able to calculate how much of each ingredient 
that was needed to create a similar nutrient and caloric intake in both treatment 
groups. The procedure was however complicated by the fact that each modification 
made to the ingredients changed the viscosity and palatability of the diets, and 
therefore also the amount the dams consumed. Eventually, during a series of 
preliminary dietary experiments, I managed to produce an EtOH-diet, which 
compared to the control diet was less palatable (dams drank a smaller volume) but 
had higher energy density and a different ingredient composition (dams received the 
same amount of micro- and macronutrients) on average. Naturally, the dams did not 
drink an identical amount of diet (and therefore absolute EtOH); however this reflects 
the real life situation better as also women drink variable amounts.  
We choose to administer the alcohol via a liquid diet in order to limit confounding 
factors, and to secure the intake of vitamins and minerals. The alternatives would 
have been to give EtOH via drinking water (which rats have a natural aversion to); 
via gavage (which causes a lot of unnecessary stress); or intravenously via a pump 
(which apart from causing stress is unnatural as the EtOH skips the gastrointestinal 
system and goes straight out in the blood). In addition, when EtOH is given via 
drinking water or gavage, the EtOH-derived calories could create a surplus of 
calories (when added in addition to a normal diet) and compromise the results as 
they could arise from either EtOH, or overfeeding. The above models could also 
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reduce the daily calorie intake as a result of imposed stress or aversion, creating a 
similar problem. As we wanted to examine the effects of EtOH in vivo, without 
substituting other nutrients or calories, the liquid diet was the best available choice, 
and has previously been compared with a pair-fed control group (Lieber and DeCarli, 
1982).  
Our model created high – but realistic plasma alcohol levels 
The dams in our study reached PACs of 0.18 ± 0.04% 2 days before mating and 
0.25 ± 0.04% 2 days after (30 minutes after offering the diet). These levels of alcohol 
may be considered as fairly high but are only marginally higher than levels found in 
occasional alcohol users who undergo a drinking “binge” (Touquet et al., 2008). Rats 
also metabolize alcohol much faster than humans (Zorzano and Herrera, 1990) and 
indeed, the PAC in the dams in our model quickly declined and measured only 0.07 
± 0.02% 3 hours after; and 0.05 ± 0.02% 5 hours after diet administration. 
Furthermore, the E% alcohol derived calories (22E%) are quite similar to other 
alcohol studies in rat, ranging between 13-25E% (Chen and Nyomba, 2003a, Lopez-
Tejero et al., 1989, Probyn et al., 2012). 
6.3 Fetal weight and offspring growth 
PC:EtOH-exposure affected fetal weight but did not impact on offspring growth 
Chapter 3 demonstrated both male and female fetuses were growth restricted on 
E20 (8 and 9% lighter than their sex controls respectively), but were of similar 
weights to untreated offspring already at PN1. PC:EtOH-exposed female offspring 
tended to weigh less compared with untreated controls at weaning (P = 0.06) but 
thereafter, PC:EtOH had no effect on weight gain (Table 4.1). This is similar to a 
previous study by the Moritz’s lab in which dams were exposed to a low-moderate 
dose of alcohol (6% v/v) throughout pregnancy. In this study, EtOH-exposed females 
were 3% lighter and males 8% lighter compared with controls on E20, but the weight 
difference was no longer seen on PN1 (Probyn et al., 2012). This could either reflect 
a quick catch-up growth between E20 and PN1; or be due to subtle differences 
between different study cohorts. Interestingly, although offspring weight up until 8 
months were unaffected by PC:EtOH, PC:EtOH-exposed male offspring displayed 
increased abdominal circumference and increased weight of intra-abdominal fat 
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pads (Chapter 5), suggesting that PC:EtOH affected body composition in males. This 
is highly relevant as an abdominal distribution of fat is more harmful than for example 
total fat mass or absolute body weight (discussed in section 6.5). In contrast to our 
results, the low-moderate alcohol slowed growth in male offspring between 7-12 
month of age (Probyn et al., 2012) but did not affect body composition (Probyn et al., 
2013c). These dissimilar results are likely to recede in differences in the exposure 
periods and dosages used. As expected, WD-fed offspring weight more than control-
fed offspring at all times.    
6.4 The effects of periconceptional ethanol exposure on the placenta 
PC:EtOH-exposure affected placental weight and morphology 
Over the past decade, there has been a lot of attention on the placenta in 
developmental programming, as it shows strong correlations with adult disease. In 
this thesis, I examined the placenta to gain insight into the potential mechanisms 
which may have contributed to the programming of adult onset metabolic 
dysfunction. PC:EtOH-exposed male and female fetuses had a relatively larger 
placenta (specifically the spongiotrophoblast layer and glycogen cells) on E20 
compared with untreated controls. This finding is consistent with more recent data 
from others (O'Connell et al., 2013b), and from the Moritz’s lab, in which changes in 
glycogen cells have been identified following maternal hypoxia, glucocorticoids, and 
magnesium deficiency (unpublished data), suggesting that changes in glycogen cell 
content in the placenta may be indicative of fetal programming. Although the role of 
glycogen cells in placental development are still largely unknown, ALDH1A3 has 
recently been identified as a marker of glycogen trophoblast cells in the placenta in 
vitro (Outhwaite et al., 2014). ALDH1A3 is apart from detoxification of aldehydes in 
alcohol metabolism involved in oxidation of retinal to retinoic acid (Muzio et al., 2012) 
– which is essential for fetal and placental development (Kastner et al., 1995). As the 
early ectoplacental cone and later glycogen cells express Aldh1a3, it is possible that 
they can regulate early differentiation of junctional zone cell types, and provide the 
fetus with retinoic acid during development (Outhwaite et al., 2014). It is therefore 
tempting to speculate that increased glycogen cells in the placenta may serve as a 
protective mechanism by securing sufficient retinoic acid (and/or to protect the fetus 
from glucose toxicity as discussed in Chapter 3) during development. It would be 
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informative to elucidate retinoic acid signaling further in developmental programming 
models demonstrating altered placental glycogen content.  
PC:EtOH-exposure impaired the placental glucocorticoid barrier  
Another key finding in the placenta was the 2-fold increase in mRNA-levels of 
11βHsd2 in placentas from PC:EtOH-exposed fetsuses – something that also was 
demonstrated in a mouse model of endogenous glucocorticoid infusion (E14.5) by 
other members of Moritz’s lab (Cuffe et al., 2012). Alcohol is known to increase 
maternal levels of glucocorticoids (Liang et al., 2011, Weinberg et al., 2008) and 
have previously been shown to decrease placental mRNA levels of 11βHsd2 in mice 
(Liang et al., 2011). While contradictory to our findings, the mRNAs in the study of 
Liang et al (2011) were analysed in animals receiving very high doses of alcohol 
administration (40% EtOH v/v). The increased 11βHsd2 levels in our model were 
observed after the exposure period, and may therefore, as speculated in Chapter 3 
be an attempt to increase the placental barrier to protect the developing fetus. To 
confirm this, 11βHSD2 protein levels and maternal and fetal plasma levels of 
glucocorticoids would have to be measured. An earlier examination of the placenta 
(eg E10-15) may also provide insight. Some preliminary results from our lab do 
suggest that 11βHSD2 levels are reduced in the labyrinth zone of the (female) 
placenta on E20, where they were only 32% (P = 0.0013) of those in placenta from 
untreated females. While this would strengthen the argument, these analyses need 
to be repeated with a higher n-number and validated with better antibodies. 
6.5 Long-term consequences of periconceptional alcohol exposure and a 
western diet  
An abundance of studies have demonstrated that alcohol has the potential to affect 
different organs and organ systems in the body. Due to alcohols well known 
teratogenic effects, the brain has been extensively investigated, both in humans and 
animals (Jones et al., 1973, Clarren et al., 1978, Abel and Dintcheff, 1978, Maier and 
West, 2001). Over time however, evidence have accumulated to also suggest a 
strong correlation between prenatal alcohol and future risk for metabolic disorders. In 
agreement with the studies in this thesis, many other animal studies have 
demonstrated glucose intolerance and/or insulin insensitivity (Villarroya and Mampel, 
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1985, Elton et al., 2002, Chen and Nyomba, 2003b, Chen and Nyomba, 2003a, 
Chen and Nyomba, 2004, Chen et al., 2004, Yao et al., 2006, Yao et al., 2013, 
Probyn et al., 2013c); and a few have demonstrated increased adiposity (Dobson et 
al., 2012) in offspring following prenatal alcohol exposure (see Table 1.2 for further 
details). Our lab has previously contributed to the body of evidence suggesting that 
prenatal alcohol affects other organ systems, both when administered in a binge-like 
pattern; and when kept low-moderate throughout gestation. Primarily, these models 
have shown that alcohol decreases nephron endowment and consequently 
increases blood pressure in the offspring following binge (Gray et al., 2010). Our low-
moderate model (6% EtOH v/v) showed that prenatal alcohol at these levels altered 
protein composition in the breast milk without affecting the mammary gland (Probyn 
et al., 2013b). Additionally, offspring exposed to a low-moderate dose of alcohol 
prenatally developed pulmonary fibrosis over time (8-19 months old males), which 
would compromise respiratory lung capacity (Probyn et al., 2013a); exhibited left 
ventricular hypertrophy and fibrosis associated with decreased maximal aortic flow 
velocity (8 months) (Nguyen et al., 2014); and induced anxiety-like behaviour via 
structural changes in the basolateral amygdala (8 and 15 months) (Cullen et al., 
2013). 
Hence similar to our other alcohol models, the findings from this thesis should be 
seen as a part of a much larger picture. We are currently investigating the effects of 
PC:EtOH-exposure on cardiovascular and renal health, as well as the brain and 
behaviour. Many of the studies are ongoing but unpublished results suggest that also 
PC:EtOH-exposure compromise nephron number (PN30) and impair renal function. 
Adult PC:EtOH-exposed females (12 months) exhibit increased left ventricular 
internal diameter during systole and decreased cardiac output without any apparent 
blood pressure changes. This suggests that alcohol, also when periconceptionally 
administered has the potential to impair kidney development and influence renal and 
cardiovascular functions in adulthood. Other preliminary results indicate that 
PC:EtOH-exposed offspring may be neophobic, and the brain and other behavioural 
outcomes is currently under investigation. 
Bearing in mind potential changes in multiple organs and systems, it is difficult to 
elucidate which condition appears first as all the aforementioned diseases can be 
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programmed in utero; be epigenetically modified; and also affect the development of 
one another. Explicably, the development of diabetes and obesity as researched in 
this thesis is complexly intertwined with each other, as well as other metabolic 
outcomes. Obesity for example, is a major risk factor for both type 2 diabetes and 
CVD (Kopelman, 2007). In the same way, diabetes is a risk factor for obesity. The 
connection between the two is insulin resistance, and insulin resistance is 
characterized by chronic inflammation (Yu et al., 2002). To bring yet another 
dimension into consideration, interactions with the postnatal environment, in this 
case a WD (known to contribute to diabetes, obesity and CVD by itself) also causes 
inflammation (Manzel et al., 2014). The outcomes in Chapter 4 and Chapter 5 of this 
thesis are therefore strongly related not only to each other, but to other outcomes in 
this model. These interactions are summarized in Figure 6.2.   
Cleary, this figure is quite simplistic and only indicates associations between different 
parameters without explaining the mechanisms (which are discussed in section 
1.7.2.2.1). It should also be noted that some aspects of the disease picture are 
missing, limiting the conclusions we can draw from this data. For example, it would 
have been informative to histologically determine the size and number of adipocytes 
in adipose tissue in relation to closer examination of fat metabolism. In addition, data 
of the weight of subcutaneous fat pads would have been extremely valuable as it 
perhaps would explain some of the sex difference regarding the degree of insulin 
insensitivity, inflammation and hepatic steatosis. Obesity could be seen as a healthy 
response to high blood sugar (which is toxic). Storing glucose as fat in adipose 
tissue therefore protects other organs against glucose toxicity. Importantly, the 
capacity of subcutaneous fat to convert glucose to fat is larger compared with 
visceral fat (mainly because of the larger size and wider distribution); and visceral fat 
– apart from providing a smaller storage depot – also produce more pro-
inflammatory cytokines (Hamdy et al., 2006, van Harmelen et al., 2002); and are 
more susceptible to rupture which in turn causes inflammation (and therefore 
contributes to insulin resistance) (Monteiro and Azevedo, 2010). 
Chapter 4 provides a solid explanation to the insulin insensitivity seen in female 
offspring exposed to PC:EtOH. However, the same explanation did not apply to 
PC:EtOH-exposed male offspring, leaving room for speculation. It was clear that 
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insulin insensitivity did not arise from the same mechanism in both sexes. Perhaps in 
females it arose from dysfunctions in peripheral insulin signaling; but in males, the 
increase in visceral adiposity (that was not seen in females) (see Chapter 5) was a 
major cause of insulin insensitivity (i.e obesity preceded insulin insensitivity in 
males). This may also explain the faster progress of hepatic steatosis in males. 
When the adipocytes are unable to store more fat, other organs (in this case the 
liver) are likely to be affected. Because females generally have more subcutaneous 
fat and males more visceral fat (Hamdy et al., 2006), females are more ‘protected’ 
from metabolic outcomes caused by obesity. It is tempting to speculate that perhaps 
PC:EtOH-exposed female offspring could in a compensatory mechanism distribute 
more fat subcutaneously and thereby protect themselves, or at least postpone the 
development of steatosis. Although the percentage of total fat mass in females 
exposed to PC:EtOH speaks against this, it should be highlighted that: 1) the DXA 
scan did not consider the distribution of fat pads (other than an indication of 
abdominal fat); and 2) the argument still holds up for WD-fed females which despite 
of being fat (including more viscerally distributed fat) had milder signs of steatosis 
compared with WD-fed males. It is however important to remember that the lack of 
obesity in PC:EtOH-exposed females is no indication these animals are 
metabolically healthy, they still have increased levels of cholesterol, LDL and leptin 
in plasma. It should be noted however that the dissimilarities between rat and human 
lipid metabolism do complicate the comparison between rat and human lipid 
disorders. Therefore the altered plasma lipid profile in the PC:EtOH-exposed rats 
can only be compared with the plasma lipid profile of the untreated control rats – and 
not with humans. Additionally, we can not rule out the possibility of female offspring 
developing/exhibiting a stronger phenotype later in life (beyond this experimental 
protocol) as signs of metabolic syndrome and obesity tend to appear later in 
females, and because females live longer than males. Another important aspect to 
consider is the influence of the WD on the long-term disease picture. We introduced 
this ‘second hit’ when the offspring were 3 months old (corresponding to young 
people moving out of home) to mimic a realistic scenario during which many people 
change and establish their adult lifestyle. It is possible that introducing the WD 
earlier, perhaps after weaning as made by a number of other studies, may have 
influenced the severity and the type of the outcomes. 
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Figure 6.2 – A simplistic presentation of the relationship between periconceptional alcohol and its early and long-
term metabolic consequences.                                                                                                                             .  
Solid (black) arrows indicate a relationship/association that we have demonstrated within this model. Dashed arrows 
indicate that there is a relationship between the two parameters that has been shown in other models. It does not 
indicate in which order parameters arise.  
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6.6 Proposed mechanism – epigenetic modifications and initial development 
Having established a significant metabolic phenotype following PC:EtOH, it is 
important to consider the underlying mechanisms. The metabolic consequences in 
offspring exposed to alcohol periconceptionally are likely to arise from multifactorial 
mechanisms. The contribution of the placenta and our proposed ‘stress hypothesis’ 
has already been discussed in section 6.4. The primary research question of this 
thesis was to establish if PC:EtOH-exposure increases the susceptibility of adult 
metabolic disease; rather than elucidating how it occurred. Chapter 3 started to 
investigate the placenta’s role in programming of disease, and chapter 4 & 5 sought 
to explain the phenotype by examining programmed alterations in molecular 
pathways (gluconeogenesis, peripheral insulin signaling, and inflammation). 
Importantly, some initial investigation on the gene expression of Dnmt’s and Hdac’s, 
special targets for these genes (PGC-1α), and imprinted genes (Igf1) have provided 
us with some plausible indications of other underlying mechanisms that should be 
further addressed in future studies. Some of these are discussed in the following 
sections.  
Direct effects of alcohol via epigenetic regulation 
It is unlikely that alcohol directly impacted on organ development as it was 
administered prior to organogenesis; and teratogenic effects of alcohol consumption 
are generally only seen following excess alcohol consumption throughout gestation. 
The metabolites from alcohol can however influence on one-carbon metabolism and 
the methyl donor pathway, and thereby serve as a mediator of epigenetic 
modifications (El Hajj et al., 2014). For example, EtOH selectively acetylates histone 
H3 at lysine residue 9 (H3Ack9) (via an alcohol metabolism dependent process) in 
both cultured rat hepatocytes (Martus et al., 2005) and in vivo (Powles et al., 2013, 
Muzio et al., 2012). As a consequence, Adh1 gene expression increases (Martus et 
al., 2005); EtOH metabolism increases, and this in turn intensifies this cycle (Yan et 
al., 2014). Although maternal livers were not collected during the exposure period, 
unpublished data from our lab demonstrate such increase by which dams consuming 
EtOH had a ~40% increase in hepatic Adh1 gene expression on E20 compared with 
untreated dams (P < 0.05). This suggests that if Adh1 was increased as a 
consequence of increased H3 acetylation, the hepatic metabolism of EtOH may have 
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contributed to epigenetic responses in the dams in our study. This would need to be 
confirmed by chromatin immunoprecipitation assays as well as measurements of H3 
acetylation activity in maternal liver, preferably both on E20, and simultaneously with 
the exposure period.   
Epigenetic modifications of the placenta 
The first indication of epigenetic programming following PC:EtOH-exposure in fetal 
tissue was decreased gene expression of the methionine transporter Slc38a2 in the 
labyrinth zone of the late gestation placenta (Chapter 3). We speculated that 
PC:EtOH-exposed fetuses may have an aberrant methionine system, which in turn 
would influence on one-carbon metabolism, as methionine provides methyl groups 
for S-adenosyl methionine (SAM) production. Interestingly, SAM is a substrate for 
DNMTs (Kovacheva et al., 2007), and global DNA methylation is often increased in 
response to methionine (or choline), and associated with hypomethylation of the 
Dnmt1 promotor (Kovacheva et al., 2007). Intragrastric EtOH feeding in rat has been 
shown to cause hepatic methionine deficiency, reduced SAM activity and reduced 
DNA methylation (Outhwaite et al., 2014); and also we were able to link the reduced 
Slc38a2 expression to increased gene expression of hepatic Dnmts in the fetuses in 
Chapter 4. That PC:EtOH-exposure could induce epigenetic modifications is also 
supported by the fact that oxidative stress – a known consequence of alcohol 
consumption (Agudelo et al., 2011) – also alters DNA methylation (Lertratanangkoon 
et al., 1997).  Our findings so far are only sufficient for speculations; however they 
opened up for new questions and ideas that are currently being investigated in this 
model: 1) if the adult phenotype is partly a result of early epigenetic dysregulation, 
how does EtOH affect the preimplantation embryo, early trophoblast stem cell 
differentiation, and the allocation of placental linages? (discussed in the following 
sections); and 2) if one-carbon metabolism is affected, could the phenotype be 
reversed by an intervention of a methyl donor such as folate or choline 
administration? (discussed in section 6.7). 
Direct effects of periconceptional alcohol on the developing embryo 
As discussed in section 1.3.1.1, the preimplantation embryo is highly responsive to 
its surrounding environment because of the rapid development it is undergoing,  
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which includes a genome-wide demethylation, zygotic genome activation, and 
morphologic and metabolic differentiation (Fleming et al., 2004). These events all 
occurs during alcohol administration in our PC:EtOH model, and therefore it is 
plausible that both the uterus and the early blastocyst development are affected. We 
have recently started to examine how PC:EtOH affects the maternal uterine 
environment by isolating endometrial stromal cells from untreated and PC:EtOH-
exposed dams on E5. Following culture (in conditions inducing decidualization), we 
found that two key markers of decidualization, insulin like growth factor binding 
protein 1 (Igfbp1) and prolactin (Prl) were considerable reduced, being expressed at 
only ~5% and ~25% respectively compared with control levels (P < 0.05). This 
suggest that PC:EtOH directly affects the uterus and perhaps impacts on the ability 
of stromal cells to decidualize. Furthermore, we have preliminary results 
demonstrating that alcohol directly impacts on the trophoblast cells in vitro by 
reducing gene expression of Prl7b1, Prl7a2, and syncytin a (Syna) (P < 0.05) 
(trophoblast subtype-specific markers), suggesting EtOH could cause a delay in TS 
differentiation or alter cell allocation to specific lineages. Clearly, we have strong 
indications that EtOH has the ability to induce changes in both the uterine 
environment and the early blastocyst. This part of the study is under extensive 
investigation and we are planning to conduct embryo transfer studies to further 
determine the relative role of the maternal environment and the blastocyst, as faults 
in this early development are likely to contribute to the placental and fetal organ 
deficits observed from E20 and onwards. Data supporting this comes from human 
studies, demonstrating that children born following in vitro fertilization have higher 
blood pressure and fasting blood glucose levels (Ceelen et al., 2008). 
6.7 Limitations and future directions 
The studies in this thesis have provided novel, valuable insights regarding the 
consequences of periconceptional maternal alcohol consumption, but have also 
raised many new questions which remain to be answered. Some of these questions 
and ideas have already been covered previously whereas some others are 
discussed in the following paragraphs.  
Firstly, this study was set up to cover the periconceptional period in full. Therefore, it 
is difficult to recognize what day/process during this window that is the most critical 
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to in utero perturbations, as the consequences may have arisen from alcohol’s effect 
on the maternal ovaries and/or alcohol’s effect on the uterus/preimplantation 
environment. Hence future studies should consider separating the pre- versus post 
conception period. Additionally, one should attempt to measure the concentration of 
alcohol and the composition of nutrients in the uterine fluid to confirm a direct effect 
of alcohol on preimplantation development, something that we did not have the 
technical capability of doing during the course of this thesis. It is possible, as 
suggested section 6.6, that alcohol (and/or secondary factors) may have 
compromised the embryonic development directly and/or indirectly (epigenetic 
modifications) which may contribute to the adult phenotype. Apart from the ongoing 
studies determining EtOH’s effect on blastocyst development, it would be informative 
to separate embryos by sex to elucidate if later sex differences could origin already 
in embryonic development.  
Choline as an intervention to reverse the effects from periconceptional alcohol 
The primary research question in this thesis was to establish if periconceptional 
alcohol consumption impacts on the future disease picture, which my studies have 
clearly demonstrated. Naturally, the next question would be to establish if these 
diseases are reversible or preventable. Our current hypothesis that choline 
supplementation may reverse the phenotypes programmed by PC:EtOH arose from 
several observations from this thesis. 
The pregnant woman has an increased demand of choline; however alcohol is 
known to reduce plasma choline. Some preliminary data from our lab have confirmed 
this for our model, demonstrated that maternal choline levels on E5 are ~50% 
reduced (P < 0.05). In addition, a human study demonstrated that choline 
supplementation during the third trimester of pregnancy decreased cortisol by 33% 
(Jiang et al., 2012), which would be an attractive outcome in our model considering 
the clear indications of maternal stress (see section 6.4). Additionally, choline 
deficiency has been demonstrated to induce alterations in the fetal epigenetic marks 
(Waterland et al., 2008, Jiang et al., 2012), and affect the function and 
vascularization in cultured placental trophoblast cells from human (Jiang et al., 
2014). Again, considering the changes in placental Slc38a2 (and thereby possibly 
one-carbon metabolism); changes in Dnmts; the lower maternal choline levels on E5; 
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and the indications that EtOH may delay TS differentiation and/or alter cell allocation 
to specific lineages in the embryo, supplementing with choline is an attractive 
intervention which could potentially reverse the adult metabolic phenotype. 
Paternal periconceptional alcohol consumption 
Finally, this project has only investigated the effects of maternal periconceptional 
alcohol consumption, although the scenario which this model aims to mimic is likely 
to include paternal drinking as well. Of interest would be to compare the effects of 
maternal vs. paternal periconceptional alcohol exposure individually as well as 
examining the combined outcome. Alcohol is known to impact on both sperm 
mobility and morphology (Langley-Evans and McMullen, 2010), and paternal alcohol 
consumption in mouse (5.92 g EtOH per kg body weight for 5 weeks by gavage) 
generated offspring with a compromised growth post weaning, associated with 
reduced DNA methylation at the H19 paternally imprinted control region (Knezovich 
and Ramsay, 2012). Paternal drinking has also been associated with congenital 
malformations, low birth weight and neonatal mortality (Friedler, 1996, Passaro et al., 
1998) but metabolic effects in the offspring following paternal periconceptional 
alcohol consumption remain to be explored. 
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6.8 Conclusion and clinical implications 
Overall, my PhD studies have developed and optimized a rat model of PC:EtOH-
exposure and used this to demonstrate that PC:EtOH causes fetal growth restriction 
and impacts on the late gestation placenta. In addition, I have shown that these early 
effects of PC:EtOH are associated with an adult diseased phenotype, including 
glucose intolerance, insulin insensitivity, adiposity and hepatic steatosis. These 
findings are of particular significance because they are the first to show that maternal 
drinking; limited to the time of conception can induce long-lasting metabolic 
outcomes in the offspring – often similar to those seen after consuming a western 
diet for major part of adult life. Hence this supports an underlying genetic factor to 
obesity and insulin resistance. Given the high number of women consuming alcohol 
during pregnancy planning, and the rapid rise in metabolic type disorders, it is 
plausible that alcohol is a contributing factor to this. It is therefore crucial to increase 
knowledge and awareness regarding the potential harm alcohol – when consumed 
around the time of conception – has on the health of the future baby. 
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Introduction: Alcohol consumption is a common social practice among women of childbearing age. With
50% of pregnancies being unplanned, many embryos are exposed to alcohol prior to pregnancy recog-
nition and formation of the placenta. The effects of periconceptional (PC) alcohol exposure on the
placenta are unknown.
Methods: Sprague-Dawley rats were exposed to alcohol (12.5% v/v ad libitum) from 4 days prior to 4 days
after conception and effects on placental growth, morphology and gene/protein expression examined at
embryonic day (E) 20.
Results: PC ethanol (EtOH)-exposed fetuses were growth restricted and their placental/body weight ratio
and placental cross-sectional area were increased. This was associated with an increase in cross-sectional
area of the junctional zone and glycogen cells, especially in PC EtOH-exposed placentas from female
fetuses. Junctional Glut1 and Igf2 mRNA levels were increased. Labyrinth Igf1 mRNA levels were
decreased in placentas from both sexes, but protein IGF1R levels were decreased in placentas from male
fetuses only. Labyrinth mRNA levels of Slc38a2 were decreased and Vegfa were increased in placentas
following PC EtOH-exposure but only placentas from female fetuses exhibited increased Kdr expression.
Augmented expression of the protective enzyme 11bHsd2 was found in PC EtOH-exposed labyrinth.
Discussion: These observations are consistent with a stress response, apparent well beyond the period of
EtOH-exposure and demonstrate that PC EtOH alters placental development in a sex specific manner.
Conclusion: Public awareness should be increased to educate women about how excessive drinking even
before falling pregnant may impact on placental development and fetal health.
! 2013 Elsevier Ltd. All rights reserved.
1. Introduction
It is increasingly accepted that intrauterine growth restriction is
associated with chronic adult diseases that in many cases can be
traced back to the quality of nutrition and health of the mother
during pregnancy [1]. A critical issue is the relative vulnerability of
different stages of development to environmental insult and
therefore potential developmental programming changes.
Increasing evidence suggests that these programming events may
be determined prior to implantation [2]. Indeed, the period sur-
rounding conception, or the periconceptional (PC) period, has been
identified as a critical window of vulnerability for the embryo in
both in vitro and in vivo studies from several species [3,4]. Whilst
previous studies have examined the impact of nutrition during the
PC period on development [5,6], little is known about the impact of
maternal alcohol consumption during this period. This is of
particular interest, as many women consume alcohol prior to
pregnancy recognition [7,8] and both gestational [9] and PC [10]
EtOH exposure is known to impair placentation by inhibition of
vascular transformation and by reducing invasive trophoblastic
cells [11].
Developmental programming events are often sexually dimor-
phic but the mechanisms involved are poorly understood [12]. The
placenta which is the major determinant of intrauterine growth
[13] may be a key in mediating tissue responses to a dynamic
maternal environment as it forms the interface between the
maternal and fetal circulation. Sex differences in how the placenta
responds to the samematernal milieumay contribute to the altered
susceptibility of male and female fetuses to long-term program-
ming outcomes observed in other animal models [14e17].
This study examined the impact of moderate alcohol exposure
during the PC period in the rat. This time point was selected as it is
during this period that the initiation of placental formation occurs
and insults that occur at this time may have long lasting effects on
later stage placental morphology and function. This study also
* Corresponding author. Tel.: þ61 7 33654598; fax: þ61 7 33651299.
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sought to establish whether changes in placental morphology and
function were dependent upon fetal sex.
2. Materials and methods
2.1. Ethics
All animal experiments and procedures were approved by The University of
Queensland Anatomical Bioscience Animal Ethics Committee (AEC approval number
SBS/022/12/NHMRC) prior to commencement of this study.
2.2. Animal treatment
Outbred, nulliparous female Sprague Dawley rats were housed individually and
kept under standardhousing conditions,with controlled temperature, humidityand an
artificial 12 h lightedark cycle. Vaginal impedancewasmeasuredwith an EC40 estrous
cycle monitor (Fine Science Tools, CA, USA). When the impedance was 4.5 ! 103 U or
above, indicating estrous, dams were randomly allocated either a control liquid diet
(n ¼ 10) or a liquid diet containing 12.5% EtOH (v/v) (w25% EtOH derived calories)
(n ¼ 11) on which they remained on during the PC period (from 4 days prior to
conception until 4 days after). The energy content of the EtOHdietwasmodified to give
equal energy percentages of protein, fat and calories compared to the control diet. The
dams had ad libitum access to the liquid diet 21 h daily, with water offered during the
remaining 3 h of the day. At the initiation of the next estrus cycle (4 days), dams were
mated overnight. Matingwas confirmed by the presence of a seminal plug and this day
was designated as E1. On E5, the liquid diet was replaced with standardized rat chow.
Food,water intakeandmaternalweightgainwasmonitoreddaily throughoutgestation.
On E20, dams were deeply anesthetized following i.p. administration of a mix of 50/50
ketamine/xylazile (0.1ml/100gbodyweight) (LyppardAustralia Ltd,QLD,Australia)and
maternal blood collected from a tail vein. Fetuses and placentas were removed and
weighed to the nearest 0.1 mg. Placental dimensions were measured to the nearest
0.01 mm. Fetal sex was confirmed by real time polymerase chain reaction (qPCR) as
previously described [17]. Placentaswere immediately separated into the labyrinth and
junctional zone, snap frozen in liquid nitrogen and stored at #80 $C, or left intact and
fixed in4%paraformaldehyde (PFA). Placental labyrinthand junctionalzonedryweights
were obtained by oven drying [17]. All analyseswere carried out in placentas fromboth
male and female fetuses.
To avoid stressing the dams, a separate cohort of control fed dams and EtOH fed
dams (n ¼ 10 per group) where set up for determination of plasma alcohol con-
centrations (PAC). These dams were treated and mated in the same way as outlined
above. Blood was drawn from a tail vein into a lithium-heparinized collection tube
(Sarstedt, SA, Australia), two days prior to mating (E-2) and on E2 at 0.5, 1, 3 and
5 h after diet administration. Plasma samples were centrifuged at 3000 rpm for
10 min at 4 $C. The plasma supernatant was collected and stored at #80 $C until
assayed with an EnzyChrome EtOH kit (BioAssay Systems, CA, USA) according to
manufacturer’s instructions.
2.3. Gene analyses
RNA from each placental regionwas extracted separately using the RNeasyMini-
Kit (Qiagen, VIC, Australia), reverse transcribed into cDNA and gene expression
assayed using qPCR with the following Assays-on-Demand primer/probe sets
(Applied Biosystems., CA,USA);Hsd11b2 (Rn00492539_m1), Slc2a1 (Rn1417099_m1),
Slc2a3 (Rn00567331), Igf1(Rn00710306_m1), Igf2 (Rn01454518_m1), Igf2R
(Rn01636937_m1), Slc38a1 (Rn00593696_m1), Slc38a2 (Mn00628416_m1), Slc38a4
(Rn00593742_m1), Pgf (Rn00585926_m1), Flt1 (Rn00570815_m1), Vegfa
(Mm00437304_m1), Kdr (Mn01222421_m1), Gsk3b (Rn00583429_m1), Gys1
(Rn01476417_m1) and Gjb3(Rn00570335_s1). qPCR results were analyzed using the
DDc(t) method, with Rn18s as the endogenous control. All groups were compared
with the average of the male control group [16].
2.4. Protein analyses
Total proteinwas extracted from placental labyrinth tissue (n ¼ 5e6 per sex and
treatment group) and subjected to SDS-PAGE and western blotting as described
previously [16] to detect the expression of IGFR1(Anti-IGF1R 1:1000, Santa Cruz e
cat#Sc-712).
2.5. Immunohistochemistry
Fixed placenta were processed to paraffin and 5 representative midline sections
(7 mm) were taken from each placenta. Sections were stained with hematoxylin and
eosin (H&E), coverslipped and imaged using the ScanScope system (Aperio Tech-
nologies, USA). Cross sectional areas of junctional zone, labyrinth and glycogen cells
were measured using imagescope software (version.10.2.2.2319). Additional sec-
tions were used for immunohistochemical staining of GLUT1. Sections were dehy-
drated, blocked in BSA/goat serum and incubated with a rabbit polyclonal GLUT1
antibody for 1 h (1:1000, Millipore e cat. #07-1401). This was followed by 30 min
incubation with anti-rabbit secondary antibody (ABC Vectastain Elite KIT, Vector-
labs, USA) and staining with Diaminobenzidine tetrahydrochloride (ImmPACT DAB
Peroxidase Substrate, SK4015, Vectorlabs, USA).
2.6. Plasma analyses
Maternal and fetal plasma electrolytes were analyzed with a Cobas Integra 400
Chemistry Analyzer (Block Scientific, NY, USA). Osmolality was determined using a
Vapor Pressure Osmometer (5520 WESCOR, Helena Laboratories, Australia).
2.7. Statistical analyses
All results are presented as mean % SEM. Fetal body and placenta weights were
calculated as litter averages by sex. qPCR data represent 7e11 fetuses of each sex,
collected from different litters. Statistical analyses were conducted with GraphPad
Prism 5 software (GraphPad Software, CA, USA). Maternal measurements during
pregnancy were analysed with a repeated measures ANOVA or with an unpaired
student’s t test. All fetal/placental data were analyzed with a two-way ANOVA for
treatment (Ptrt) and sex (Psex) using Bonferroni’s post hoc testing as appropriate.
3. Results
3.1. Maternal parameters and plasma alcohol levels
There was no difference in maternal caloric intake or weight
gain at any time during gestation, but EtOH-exposed dams
consumed more water during exposure to the liquid diet (Table 1).
The peak PAC was reached 30 min after provision of the EtOH
containing diet on E-2 (0.18 % 0.04%) and E2 (0.25 % 0.04%). Levels
thereafter declined and at 3 h were w0.07 % 0.02% and at 5 h,
0.05 % 0.02% (data not shown). Plasma osmolality and electrolyte
concentration of sodium, potassium and chloride did not differ
between groups on either E-2 or E2 (Table 1). The number of fetuses
and the fetal sex ratio (data not shown) was similar between
treatment groups, but EtOH-exposed dams had a higher rate of
unviable fetuses (Table 1).
3.2. Fetal weight, placental ratio and placental cross-sectional area
At E20, the body weight of PC EtOH-exposed fetuses was
reduced (Ptrt < 0.009) and females of both treatment groups were
lighter than their males counterparts (Psex < 0.04, Table 2). PC
EtOH-exposed fetuses were also shorter than controls (Ptrt < 0.004,
Table 2). There was no difference in absolute placenta (Table 2),
labyrinth or junctional zone wet weight (data not shown), but
placenta to body weight ratio was increased following PC EtOH-
Table 1
Maternal parameters.
Variables Control EtOH
Calorie intake (liquid diet), cal/gbw/d
(E-4-mating)
0.20 % 0.01 0.18 % 0.01
Calorie intake (liquid diet), cal/gbw/d
(mating-E4)
0.23 % 0.01 0.21 % 0.01
Calorie intake (chow), cal/gbw/d (E5-E20) 0.27 % 0.01 0.27 % 0.00
Water intake, ml/gbw/d (E-4-mating) 0.010 % 0.002 0.015 % 0.002*
Water intake, ml/gbw/d (mating-E4) 0.010 % 0.002 0.023 % 0.003*
Water intake, ml/gbw/d (E5-E20) 0.110 % 0.003 0.120 % 0.005
Peak plasma alcohol level (%) (E-2) 0 0.18 % 0.04
Osmolality (mmol/kg) (E-2) 302 % 4 300 % 5
Plasma sodium (mmol/L) (E-2) 136.8 % 1.9 140.4 % 1.2
Plasma potassium (mmol/L) (E-2) 5.17 % 0.16 5.37 % 0.63
Plasma chloride (mmol/L) (E-2) 101.2 % 1.7 102.3 % 1.8
Peak plasma alcohol level (%) (E2) 0 0.25 % 0.04
Osmolality (mmol/kg) (E2) 292 % 4 297 % 1
Plasma sodium (mmol/L) (E2) 136.9 % 1.1 137.8 % 1.3
Plasma potassium (mmol/L) (E2) 6.62 % 0.78 5.28 % 0.31
Plasma chloride (mmol/L) (E2) 101.1 % 1.1 100.4 % 1.1
Body weight on E0 (g) 254 % 6 262 % 8
Total weight gain (g) 144.8 % 8.6 141.2 % 6.0
Litter size (number) 15 % 1 14 % 1
Number of pregnancies with at least
one unviable fetus
1 of 9 6 of 11
All data are presented as mean % SEM and n(control) ¼ 9, n(EtOH) ¼ 11.
E ¼ embryonic day. *, P < 0.05 by unpaired t -test (P < 0.05).
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exposure (Ptrt < 0.004, Table 2). Labyrinth zone dry weights were
unaffected by PC EtOH-exposure while junctional dry weight was
increased (Ptrt < 0.002, Table 2). Placental depth was not different
following PC EtOH-exposure but length (Ptrt < 0.05) and width
(Ptrt < 0.03) were increased (Table 2).
H&E staining showed no gross morphological abnormalities in
response to PC EtOH-exposure, however there was an increase in
junctional zone due to glycogen accumulation (Fig. 1). Analysis of
the cross-sectional areas of each placental zone in proportion to
whole placenta showed a decrease in labyrinth (Ptrt < 0.03, Fig. 1A)
and an increase in junctional (Ptrt < 0.03, Fig. 1B) region following
PC EtOH-exposure. In addition, the cross-sectional area of glycogen
cells, both as a percentage of total placenta (Ptrt< 0.002, Psex< 0.01,
Fig. 1C) and as absolute cross sectional area (Ptrt < 0.009,
Psex < 0.007, Fig. 1D) were greater following PC EtOH-exposure.
Post hoc analyses showed that the cross-sectional area of
glycogen cells were greater in PC EtOH-exposed placentas from
females compared to their control counterparts (P < 0.01).
3.3. Placental gene and protein expression
PC EtOH-exposure did not alter mRNA levels of Glut1 in the
labyrinth (Fig. 2A) but increased the expression in the junctional
zone of the placenta (Ptrt < 0.05, Fig. 2B). This was confirmed by
immunohistochemistry staining of GLUT1 in the junctional zone
(Fig. 2E and F). The relative gene expression of Glut3was unaffected
by PC EtOH-exposure (Fig. 2C and D).
PC EtOH-exposure suppressed Igf1 gene expression in the lab-
yrinth (Ptrt < 0.001, Fig. 3A), whereas the gene expression of Igf1 in
the junctional zone was unaffected (Fig. 3B). Igf2 mRNA was not
altered in the labyrinth (Fig. 3C) but increased in the junctional
zone of PC EtOH-exposed placentas (Ptrt < 0.03, Fig. 3D). mRNA
levels of the Igf2Rwere similar between treatment groups (Fig. 3F).
Relative protein expression of IGF1Rwas lower in PC EtOH-exposed
placenta frommales, but not females, when compared to untreated
controls (P < 0.01, Fig. 3E).
PC EtOH-exposure did not affect junctional mRNA levels of Gjb3
and Gys1 but mRNA levels of Gsk3b were higher in PC EtOH-
exposed placenta from females but not males (P < 0.05, Table 3).
In addition, PC-EtOH caused multiple changes in mRNA expression
in the labyrinth: increased mRNA levels of 11bHsd2 in both sexes
(Ptrt < 0.0001, Table 3), increased mRNA levels of Slc38a1 in pla-
centas from females fetuses regardless of treatment group
(Psex < 0.03, Table 3) and decreased mRNA levels of Slc38a2 in
placentas from both sexes (Ptrt < 0.003, Table 3), while Slc38a4was
unaffected (Table 3). Vegfa mRNA levels were higher in PC EtOH-
exposed placentas (Ptrt < 0.03, Table 3) and in placentas from fe-
male fetuses (Psex < 0.03, Table 3), but there was no difference in
mRNA levels of Pgf (Table 3). While Flt1 gene expressionwas higher
in placentas from female fetuses (Psex < 0.02, Table 3), mRNA levels
of Kdr were only increased in placentas from females following PC
EtOH-exposure (P < 0.05, Table 3).
4. Discussion
Our study shows for the first time that exposure of the rat to
moderate levels of alcohol exclusively during the PC period is suf-
ficient to program growth restriction in both male and female fe-
tuses in late gestation and cause significant changes in placental
structure, morphology and gene expression. Whilst the primary
stimulus was PC EtOH-exposure, elevated levels of placental
11bHsd2 [16,17] and GLUT1 [18] suggest a long-lasting stress
response may be involved. Sex-specific differences such as the size
of placental junctional zone in females, along with an increase in
Glut3 mRNA levels, indicate dissimilar mechanisms of action. The
observations from this study are consistent with other models of PC
perturbations, mainly focusing on maternal nutritional status [3e
6,19], in that it highlights the importance of the period around
Table 2
Fetal and placental weights and dimensions at E20.
Variables Male control Male EtOH Female control Female EtOH Statistics
Fetal weight and dimensions
Body weight, g 2.65 ! 0.05 2.45 ! 0.08 2.50 ! 0.05 2.33 ! 0.07 P(trt) < 0.002
P(sex) < 0.04
P(trt " sex) ¼ NS
Snout-rump length, mm 40.37 ! 0.23 38.58 ! 0.76 39.55 ! 0.13 37.85 ! 0.68 P(trt) < 0.004
P(sex) ¼ NS
P(trt " sex) ¼ NS
Placental weights and dimensions
Absolute placenta wet weight, g 0.56 ! 0.02 0.55 ! 0.02 0.55 ! 0.01 0.55 ! 0.02 P(trt) ¼ NS
P(sex) ¼ NS
P(trt " sex) ¼ NS
Placenta:body weight ratio, g/gbw 0.21 ! 0.01 0.23 ! 0.01 0.22 ! 0.01 0.24 ! 0.01 P(trt) < 0.004
P(sex) ¼ NS
P(trt " sex) ¼ NS
Absolute labyrinth zone (dry), g 0.057 ! 0.011 0.065 ! 0.012 0.054 ! 0.005 0.057 ! 0.004 P(trt) ¼ NS
P(sex) ¼ NS
P(trt " sex) ¼ NS
Absolute junctional zone (dry), g 0.033 ! 0.003 0.042 ! 0.002 0.033 ! 0.003 0.045 ! 0.004* P(trt) < 0.002
P(sex) ¼ NS
P(trt " sex) ¼ NS
Placental length, mm 13.55 ! 0.21 13.95 ! 0.20 13.54 ! 0.16 13.94 ! 0.18 P(trt) < 0.05
P(sex) ¼ NS
P(trt " sex) ¼ NS
Placental width, mm 12.18 ! 0.14 12.42 ! 0.18 12.02 ! 0.14 12.60 ! 0.19 P(trt) < 0.03
P(sex) ¼ NS
P(trt " sex) ¼ NS
Placental depth, mm 4.20 ! 0.10 4.22 ! 0.12 4.14 ! 0.09 4.18 ! 0.13 P(trt) ¼ NS
P(sex) ¼ NS
P(trt " sex) ¼ NS
All data are presented as mean ! SEM and n ¼ 9e11 for each group. *, P < 0.05 for Bonferroni post hoc compared with untreated controls of same sex. NS ¼ not significantly
different.
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the time of conception as a critical window of development. These
results are therefore of high clinical importance as they suggest that
a woman’s drinking habits, even prior to conception and preim-
plantation can have implications on the growth and development
of the placenta and thus, the fetus.
4.1. PC-EtOH exposure results in fetal growth restriction
It is well established that prenatal alcohol exposure causes fetal
growth restriction [20,21]. Many studies of in utero EtOH-exposure
are however confounded by a modified energy intake [22]. Both
maternal over [23] and under nutrition [24] causes alterations in
fetal growth ultimately resulting in early onset of adult diseases
[24e26]. Our model is not complicated by caloric restriction or
overnutrition as energy intake was equivalent in both EtOH and
control fed dams throughout preimplantation and later periods of
gestation, as was maternal weight gain. Moreover EtOH-exposed
dams drank more water allowing maintenance of plasma osmo-
lality and electrolytes. The PAC reported may appear high as they
were determined following the period of maximal ingestion. The
PAC generated is comparable with other models of EtOH exposure,
which generally administer EtOH via gavage [22,27]. Importantly,
these levels are only marginally higher than levels found in
occasional alcohol users [28] and as rats metabolize alcohol faster
than humans [29], they should be considered clinically relevant.
4.2. PC EtOH-exposure introduced a long-lasting stress response in
placentas from both sexes
EtOH appeared to induce a long-lasting stress response in pla-
centas from both sexes, as evidenced by increased expression of the
gene 11bHsd2 in the labyrinth zone. Placental 11bHSD2 protects the
fetus from maternally circulating glucocorticoids (cortisol or
corticosterone) by enzymatic inactivation [30]. Previous studies
performed by our laboratory in the mouse [16,17] and others in the
human [31] have shown that the placenta can mediate a temporary
increase in the expression level of 11bHsd2 in response to eleva-
tions in circulating maternal glucocorticoids. Although corticoste-
rone levels were not measured in this model, other studies in rats
have shown that chronic alcohol consumption throughout preg-
nancy does indeed increasematernal corticosterone concentrations
[32]. Furthermore, increases in placental Glut1 gene expression,
similar to those measured in this study, have been observed in rats
following maternal glucocorticoid administration [18]. GLUT1 is a
ubiquitous stress and growth factor responsive transporter that is
expressed throughout preimplantation development [33]. We
Fig. 1. Effects of PC EtOH-exposure (black bars) on cross-sectional area of labyrinth zone (A), junctional zone (B), glycogen cells (C) as a percentage of total placenta, and absolute
cross-sectional area of glycogen cells (D) in placentas from male and female fetuses on E20 compared with untreated controls (white bars). Data are represented as litter
means ! SEM, n ¼ 9e11 per group, **, P < 0.01 for Bonferroni post hoc compared with untreated controls of same sex. Representative sections of untreated control (E) and PC EtOH-
exposed (F) placenta from female fetuses #1 (scale bars 1000 mm) with glycogen stores (appears white) shown in #20 magnification (scale bars 100 mm).
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therefore suggest the increased Glut1 expression in PC EtOH-
exposed placentas to be supportive for a role of stress and/or glu-
cocorticoids in PC EtOH-exposure.
4.3. PC EtOH-exposure caused sex specific alterations in placental
morphology and gene expression
Abnormal placental weight, both absolute and as a ratio of fetal
weight, are independently associated with adult disease [26].
Although absolute placental weight was unchanged by PC EtOH-
exposure, there were changes in shape and an increase in body/
placental ratio and junctional zone cross-sectional area. The in-
crease in junctional cross-sectional area was due to an increase in
the area of apparent glycogen and this was more pronounced in
placentas from females. This suggests a sexually dimorphic
chance which ultimately may have contributed to other sex-
specific alterations, as differences in placental shape and
morphology affects transplacental transfer of nutrients, oxygen
and hormones [34].
Neither IGF1 nor 2 can cross the placental barrier and are
exclusively produced by the feto-placental unit to maintain fetal
and placental growth [35]. As IGF1 deletion is known to cause
fetal growth restriction [36] we suggest that the lower labyrinth
Igf1 mRNA levels in PC EtOH-exposed placentas may have
impacted on fetal growth. Junctional Igf2 mRNA levels on the
other hand were elevated, whilst labyrinth mRNA levels of Igf2R
were maintained. Given that the IGF2R predominantly acts to
limit IGF2 action by internalization and degradation of the ligand
[37], we suggest this may have contributed to the greater pro-
portion of junctional zone area observed in PC EtOH-exposed
placentas from females.
PC EtOH-exposure also increased levels of labyrinth Vegfa gene
expression. Numerous studies have previously shown that pre-
natal EtOH-exposure alters normal vascular adaptation during
pregnancy (for review see [38]). Whilst the increase in Vegfa gene
expression may appear to be inconsistent with the apparent
growth restriction, similar results have been observed in placentas
of mouse fetuses following prenatal dexamethasone administra-
tion [16]. As mRNA levels of Flt1 were higher in placentas from
female fetuses regardless of treatment group and mRNA levels of
Kdr were increased in placentas from PC EtOH-exposed females
only, it is likely that placentas from female fetuses are attempting
to increase vasculogenesis to ensure adequate fetal nutrient
supply.
Fig. 2. Effects of PC EtOH-exposure (black bars) on Glut1 gene expression in the labyrinth (A) and junctional (B) zone; and on Glut3 gene expression in the labyrinth (C) and
junctional (D) zone of placenta from male and female fetuses on E20 compared with untreated controls (white bars). Data are represented as litter means ! SEM, n ¼ 9e11 per
group, *, P < 0.05 for Bonferroni post hoc compared with untreated controls of same sex. Representative sections of untreated control (E) and PC EtOH-exposed (F) placenta from
female fetuses shown in #20 magnification (scale bars 100 mm) quantitatively confirmed that the increase in Glut1 mRNA in the junctional zone also were translated into increases
in GLUT1 protein levels (dark brown staining). Inserts shows sections stained with the appropriate sense probe as a control (#20 magnification, scale bars 100 mm).
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4.4. PC EtOH-exposure and alterations in glycogen cross-sectional
area
Glycogen cross-sectional area was increased in placentas from
female fetuses following PC EtOH-exposure. Although the role of
glycogen in the placenta is unclear we attempted to further
approach this by investigating the levels of specific glycogen cell
markers. Interestingly, whilst Igf2, a key regulator of placental
glycogen synthesis [35,39], was elevated in PC EtOH-exposed fe-
male placentas, mRNA levels of Gjb3 and Gys1was unchanged. Gjb3
encodes a gap junction protein which is exclusively expressed in
the membrane of vacuolated glycogen cells in mid to late gestation
placenta [40] whilst Gys1 is the rate limiting enzyme involved in
glycogen synthesis [41]. Intriguingly, mRNA levels of Gsk3b, a
negative regulator of GYS1 activity [42], was only elevated in pla-
centas from females, perhaps to limit further glycogen deposition.
Furthermore, PC EtOH-exposure increased junctional Glut3
mRNA levels in female placenta, which together with glycogen
accumulation has also has been observed in placentas of diabetic
rats [43]. While GLUT3 is involved in glucose delivery to the fetus
[43], it also transports glucose from the fetal circulation back into
the placenta, as the placenta is the only tissue capable of storing
excess fetal glucose [44]. In contrast, placentas from male fetuses
expressed less Glut3 following PC EtOH-exposure but also had a
smaller placental area occupied by glycogen cells. Our data may
suggest an early EtOH induced change in metabolism to favor
Fig. 3. Effects of PC EtOH-exposure (black bars) on Igf1 gene expression in the labyrinth (A) and junctional (B) zone; on Igf2 gene expression in the labyrinth (C) and junctional (D)
zone, on relative protein expression in the labyrinth zone (E), and on relative gene expression of Igf2R (F) of placenta frommale and female fetuses on E20 compared with untreated
controls (white bars). Data are represented as litter means ! SEM, mRNA expression: *, P < 0.05 for Bonferroni post hoc compared with untreated controls of same sex, n ¼ 9e11 per
group. Protein expression: *, P < 0.05 by unpaired t-test comparing untreated controls and PC EtOH-exposed placenta of the same sex, n ¼ 5 per group.
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glycogen accumulation. We propose that placentas, particularly
from females, either have a reduced capacity for transplacental
glucose transfer from mother to fetus and/or an augmented back-
flow of glucose from the fetal circulation to the placenta, which
again is the case seen in placentas of diabetic rats [45].
4.5. PC EtOH-exposure altered amino acid transporter abundance
The decreased labyrinth expression of Slc38a2 following PC
EtOH-exposure seen in this study may have contributed to fetal
growth restriction as seen in other models with changes in placental
Naþ-dependent system A transporters [4,12]. The system A amino
acid transporters accept a wide range of amino acids, however only
Slc38a2 transports the essential amino acid methionine [46]. As
methionine is involved in DNA and histone methylation it has been
suggested to play an important role in epigenetic regulation of genes
[4,19]. The preimplantation embryo is very susceptible to epigenetic
perturbations [19] and we cannot preclude the possibility of the al-
terations in Slc38a2 gene expression contributing to faults in pro-
gramming events involving epigenetic change.
Our study has for the first time shown that maternal alcohol
intake exclusively around the time of conception alters placental
weight and morphology and causes growth restriction in the late
gestation fetus. Particularly interesting was the programmed stress
response, indicated by the increase in placental 11bHsd2 and Glut1
gene expression. Our results suggest that the placenta exerts sex-
specific mechanisms of actions, both structurally and functionally,
with females perhaps being more protected. Future studies that
determine postnatal sex-specific contributions to adult onset of
programmed disease following PC EtOH-exposure need to be car-
ried out to establish this hypothesis. As alcohol consumption is
common amongst women of childbearing age [8] and half of all
pregnancies are unplanned [47] it is important to address this by
increasing public awareness about the implication of alcohol con-
sumption even before becoming pregnant.
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ABSTRACT Alcohol consumption throughout preg-
nancy can cause metabolic dysregulation, including
glucose intolerance in progeny. This study determined
if periconceptional (PC) alcohol (12% v/v in a liquid
diet) (PC:EtOH) consumed exclusively around con-
ception results in similar outcomes in Sprague-Dawley
rats. Control (C) rats were given a liquid diet contain-
ing no alcohol but matched to ensure equal caloric in-
take. PC maternal alcohol intake (from 4 days before
conception until day 4 of gestation), resulted in off-
spring with elevated fasting plasma glucose (∼10–25%,
P < 0.05), impaired glucose tolerance (P < 0.05), and
decreased insulin sensitivity (P < 0.01) at 6 months of
age. This was associated with increased hepatic glu-
coneogenesis and sex-specific alterations in peripheral
protein kinase B (AKT) signaling. These changes were
accompanied by increased mRNA expression of DNA
methyltransferases (DNMTs) 1, 3a, and 3b (1.5- to 1.9-fold,
P<0.05) in fetal liver in late gestation, suggestingPC:EtOH
may cause epigenetic changes that predispose offspring to
metabolic dysfunction. Exposure to a postnatal (PN) high-
fat and cholesterol diet (HFD) from 3 months of age
caused hyperinsulinemia (∼2-fold increase, P < 0.001) and
exacerbated the metabolic dysfunction in male offspring
exposed to PC:EtOH but had no additive effects in
females. Given many women may drink alcohol while
planning a pregnancy, it is crucial to increase public
awareness regarding the effects of alcohol consumption
around conception on offspring health.—Ga˚rdebjer,
E. M., Anderson, S. T., Pantaleon, M., Wlodek, M. E.,
Moritz, K. M.Maternal alcohol intake around the time of
conception causes glucose intolerance and insulin in-
sensitivity in rat offspring, which is exacerbated by
a postnatal high-fat diet. FASEB J. 29, 000–000 (2015).
www.fasebj.org
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INCREASING EVIDENCE IMPLICATES the intrauterine environ-
ment in the development of chronic adult disease
propensity andmetabolic disorders (1). Indeed, fetuses
exposed to a range of adverse intrauterine environments
includingmalnutrition (2), placental insufficiency (3), and
alcohol (4–7) have an increased risk of adult onset meta-
bolic dysfunction. Low birth weight, insulin resistance, and
altered regulationof hepatic glucose output are commonly
demonstrated in thesemodels (4–9). Intriguingly, these
effects are often programmed in a sex-specific manner,
with males consistently more adversely affected than
females (7). The PC period appears to be a particularly
susceptible developmental window for programming of
disease (10). Given that.50%of women consume alcohol
before pregnancy (11) and half of all pregnancies are
reported to be unplanned (11, 12), many embryos are
potentially exposed to alcohol before pregnancy recogni-
tion. Despite recommendations of alcohol abstinence for
women who are pregnant, or planning a pregnancy, a re-
cent study reported that 32% of women claim that they
would continue to drink despite trying to conceive (13).
We have previously shown that PC:EtOH-exposure
causes fetal growth restriction and sex-specific placental
abnormalities in late pregnancy in the rat (14). Both
are risk factors for adult-onset disease (15, 16). Here,
we examined the hypothesis that PC:EtOH-exposure
programs glucose intolerance and insulin resistance in
offspring. In addition, we explored the influence of a PN
HFD as it has been suggested that lifestyle/dietary factors
can unmask and/or exacerbate preprogrammed adult
disease propensity (4). To elucidate potential mecha-
nisms contributing to disease, we examined the effect of
PC:EtOH-exposure on gluconeogenic genes in the liver
and AKT signaling in peripheral tissues in adult offspring
(5, 8, 17). Additionally, we assessed expression levels ofAbbreviations: AKT, protein kinase B; AUGC, area under the
glucose curve; AUIC, area under the insulin curve; bw, body
weight; C, control; DNMT, DNA methyltransferases; E%, energy
percentage; E, embryonic day; EtOH, ethanol; G6pc, glucose-6-
phosphatase; Gck, glucokinase; GSK3, glycogen synthase kinase
3; GTT, glucose tolerance test; HDAC, histone deactylases;
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key chromatin modifiers in fetal life because epigenetic
changes are implicated in metabolic programming of
adult disease following PC perturbation (18). Specifi-
cally, we examined expression levels of histone deacty-
lases (HDACs) andDNAmethyltransferases (DNMTs) in
fetal liver as alterations in both these modifications are
associated with metabolic disease.
MATERIALS AND METHODS
Ethics
All animal experimentation was approved by The University of
Queensland Anatomic Bioscience Animal Ethics Committee
(SBS/022/12/NHMRC)before the commencement of the study.
Rats and treatment
Outbred nulliparous Sprague-Dawley rats were housed in-
dividually under an artificial 12-hour light-dark cycle and treated
as described previously (14). In brief, 12- to 13-week-old dams
were randomly allocated to a liquid diet containing either 12.5%
v/v (PC:EtOH) or an equal-caloric 0% EtOH diet (untreated, U)
(n = 22 per treatment group) for 1 full estrus cycle (4 days) before
overnightmating.Animals thatdidnotmateon the fourthorfifth
day after being offered the diet were removed from the protocol.
The liquid diet was composed of Sustagen hospital formula
(Mead Johnson Nutritionals, Auckland, New Zealand), reduced
fat milk, corn flour, and essential minerals (ferric citrate, copper
II sulfate, selenium, and magnesium sulfate). In preliminary
experiments, we had identified that the EtOH-exposed dams
consumed a lesser amount of the liquid diet, hence the energy
density of the EtOH-diet was increased and the ingredients were
modified to ensure an equal amount of macro- and micro-
nutrients (C diet composition: 11.3% fat, 17.0% protein, 68.2%
carbohydrates, 7.7 MJ/kg; EtOH diet: 11.9% fat, 13.6% protein,
50.7%carbohydrates, 11.8MJ/kg). Damshad access to the liquid
diet 21hours daily ad libitumuntil embryonic day (E)4, with water
offered during the remaining 3 h of the day. Liquid diets were
replaced by standardized rat chow and water on E5 (4.0% fat,
13.6% protein 64.3% carbohydrates; 15.5 MJ/kg) (SF-08-020
Specialty feeds, Glenforrest, WA, Australia). One subset of dams
(n = 10 per group) were killed on E20 for collection of fetal liver,
whereas one subset (n = 12 per group) littered down naturally.
Offspring were weighed daily until weaning on PN day 28. At
3 months, one subset of offspring was randomly assigned to
a modified diet that contained increased fat and cholesterol
(21% fat, 0.15% cholesterol, 19% protein, 59.9% carbohydrates;
19.4 MJ/kg) (SF00-219 Specialty feeds) and the remaining ani-
mals were supplied with the same standardized chow as the dams
consumed (C). These diets are matched for micronutrient
composition. This resulted in the generation of 8 treatment
groups: U:C; U:HFD; PC:EtOH:C; and PC:EtOH:HFD for both
male and female offspring. Both the HFD and C diet were based
on similarbase ingredients forproteinandcarbohydrates (casein;
and wheat starch, sucrose, and cellulose); but the fat source
was canola oil in the C-diet and clarified butter in the HFD. All
groups had ad libitum access to allocated diet and water until the
end of the study.
Glucose and insulin tolerance tests
Glucose [1g/kg body weight (bw)] tolerance test (GTT) and in-
sulin (0.75 U/kg bw) tolerance test (ITT) were performed at
6 months (n = 10–11 per group) as described previously (7).
Plasma glucose levels were determined using a Cobas Integra 400
Plus Chemistry Analyzer and insulin concentrations by rat insulin
radioimmunoassay kit (catalog no.RI-13K, Millipore Australia,
Kilsyth, Victoria, Australia). Insulin samples were run in dupli-
cates, at 1:2 dilutions. Assay sensitivity was 0.16 ng/mL, and inter-
and intra-assay coefficients of variation were 14.9% and 9.9%,
respectively.
Tissue collection
Rats were euthanized at 8 months by intraperitoneal adminis-
tration of a 50/50 ketamine/xylazinemix (0.5ml/100g bw) after
a 15 h fast. Tissues were snap-frozen in liquid nitrogen and stored
at280°C (gastrocnemius muscle, white intra-abdominal adipose
tissue, and liver). Fetal liver was collected as described previously
on E20 (14).
Quantitative PCR and Western blotting
RNA from the left lateral lobe of the liver was extracted using
RNeasy Mini-Kit and reversed transcribed into cDNA. Gene ex-
pression was analyzed using quantitative PCR (qPCR) with the fol-
lowing Assay-on-Demand primer/probe sets (Applied Biosystems,
Foster City, CA, USA) phosphoenolpyruvate carboxykinase (Pck1)
(Rn01529014_m1), glucokinase (Gck) (Rn00561265_m1), glucose-
6-phosphatase (G6pc) (Rn00689876_m1), peroxisomeproliferator-
activated receptor g coactivator 1-a (Ppargc1a) (Rn00580241_m1),
Hdac2 (Rn01193634-g1), and Hdac6 (Rn01528283_m1), or SYBR
Green detection chemistry using the following primers for: Hdac3
(F: 59-GATTAGGCTGCTTCAATCTC; R: 59-CAGAGATGTTTCA-
TATGTCCAG), Hdac4 (F: 59-AAACAGCTTCTGAACCTAAC; R:
59-GAGTCTGTAACATCCAGGG), Dnmt1 (F: 59-AGAGACCAGG-
ATAAGAACG; R: 59-TTACTCGTTCAGGTTTCTCC), Dnmt3a (F:
59-AATAGCCAAGTTCAGCAAAG;R:59-AAACACCCTTTCCATTT-
CAG), and Dnmt3b (F:59-GATGACAAGGAGTTTGGAATA;
R:59-CAGCGATCTCAGAAAACTTG).qPCRresultswereanalyzed
with the DDc(t) method, using Rn18s as the endogenous control.
All groups were compared to the average of the U:C group (14).
Total protein was extracted from 80 mg abdominal adipose
tissue and 15mg skeletalmuscle. Tissues were homogenized in
0.4 ml RIPA buffer for 20 seconds using an Ultra-Turrax T8
homogenizer (Labtek, Brendale, Australia). Homogenates
were centrifuged (11,000 rpm, 20 min, 4°C) and resultant
supernatant assayed using the Bio-Rad (Hercules, CA, USA)
reducing agent and detergent compatible protein assay kit.
Total protein (20 mg per sample; n = 5–6 per sex and PC
treatment) was subjected to SDS-PAGE on 12% gels and sub-
sequently transferred to Immobilon FL PVDF membranes
(Millipore). Membranes were incubated overnight with one
of the following polyclonal rabbit antibodies (all from Cell Sig-
naling, Danvers, MA, USA); anti-total-AKT2 (1:1000, catalog
no. 3063), anti-phospho-AKTThr309 (1:600, catalog no. 9275),
anti-phospho-AKTSer474 (1:800, catalog no. 8599), anti-phospho-
glycogen synthase kinase 3 (GSK3)a/bSer21/9 (1:600, catalog no.
9331), or amousemonoclonal anti-GSK3a/b (1:600, catalog no.
05-412, Upstate Biotechnology, Lake Placid, NY, USA). b-Actin
immunoreactivity was used for ratiometric purposes (1:25000,
#A1978; Sigma-Aldrich, St. Louis, MO). Protein expression was
(continued from previous page)
HFD, high-fat and cholesterol diet; HOMA-IR, homeostasis
model assessment-estimated insulin resistance; ITT, insulin tol-
erance test; PC, periconceptional; Pck1, phosphoenolpyruvate
carboxykinase; Ppargc1a, peroxisome proliferator-activated re-
ceptor g coactivator 1-a; PN, postnatal; qPCR, quantitative
PCR; QUICKI, quantitative insulin sensitivity check index;
U, untreated
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assayed using a LI-COR Odyssey infrared imaging system (LI-
COR Biosciences, Lincoln, NE, USA) following exposure to
LI-COR IRDye 680 goat anti-rabbit and IRDye 800CW goat
anti-mouse secondary antibodies (Millennium Science, Mul-
grave, Australia).
Calculations and statistical analyses
Area under glucose (AUGC) and insulin (AUIC) concentra-
tion curves were calculated using the trapezius method with
baseline defined as 0 (19). AUGC following the GTT was cal-
culated defining the baseline as 0 and the positive incremental
area (AUC of positive peaks) (20). The ITT curves were inverted
before calculating AUGC. Acute first-phase insulin secretion
was calculated as the incremental AUIC frombasal to 5min and
second-phase insulin secretion as the incremental AUIC
from 5 to 120 min. Quantitative insulin sensitivity check index
(QUICKI) was calculated as 1/{log[fasting insulin (mU/ml)]3
log[fasting glucose (mg/dl)]} (21). The homeostasis model
assessment-estimated insulin resistance (HOMA-IR) was
calculated using [fasting insulin (mU/ml) 3 fasting glucose
(mmol/L)]/22.5 (22).
Three-way ANOVA analysis was conducted with IBM SPSS
(Chicago, IL, USA) Statistics (version 20.0) with main effects
being PC treatment, sex, and diet. For most parameters, there
were significant (P , 0.05) main effects of PC treatment, but
also significant interactions with PNdiet. Therefore, data were
first analyzed by 2-way ANOVA examining the effects of
PC treatment between sexes [main effects of PC treatment
(PPC:EtOH) and sex (PSex)]. Subsequently, the effect of HFD
and PC:EtOH within each sex [main effects of PC treatment
(PPC:EtOH) and PN diet (PHFD)] was also assessed. Data were
log transferred to remove heterogeneity of variance before
performing ANOVA as required (Bartlett’s test). Means were
further compared using a Tukey’s multiple comparison post hoc
test. Plasma glucose and insulin concentrations over time were
analyzed with a 2-way ANOVA repeatedmeasurements [effects of
PC treatment (PPC:EtOH) and time (Ptime)]. Protein immunoblots
were compared by Student’s t test. P , 0.05 was considered
statistically significant. Statistical analyses other than 3-way
ANOVAs were conducted with GraphPad Prism 6 software for
Windows (GraphPad Software, San Diego, CA, USA). Results
are presented as mean 6 SEM.
RESULTS
Maternal parameters and PN growth
Damswereof similar age (U: 8763 vs.PC:EtOH: 8563d)
andweight (U: 2626 7 vs. PC:EtOH: 2586 7 g) at the start
of the experimental protocol. There was no difference in
caloric intake at any time during pregnancy as reported
previously (14). Gestational weight gain was similar be-
tween treatment groups (data not shown). The average
and the peak plasma alcohol concentration 2 days before
mating was 0.07 6 0.01% and 0.18 6 0.04%, respectively,
and the peak plasma alcohol concentration on E2 was
0.25 6 0.04% (14). There were no differences in gesta-
tional length (22 d), litter size (156 1 pups), or the male:
female ratio (U: 1.13 vs. PC:EtOH: 1.17) between treat-
ment groups. Body weight at weaning (PN28) was also
similar between treatment groups (Table 1) with no ap-
parent differences in body weight before initiation of the
HFD at 3 months (Table 1). Although consumption of an
HFD significantly increased weight gain between weeks 17
and 24 and weeks 25 and 32 in both male and female
offspring of both treatment groups (P, 0.0001, Table 1),
PC:EtOH-exposure alone or in conjunction with HFD did
not significantly affect growth (Table 1).
GTT and ITT at 6 months
Primarily we examined the effects of the PC:EtOH-
exposure on glucose tolerance and insulin sensitivity in
animals on the C diet in male and female offspring. We
found that PC:EtOH-exposure increased fasting glucose
concentrations (P, 0.05), although this was significantly
greater in males than females (Fig. 1A). This effect
was associated with a nonsignificant increase in fasting
insulin concentrations (PPC:EtOH , 0.07, Fig. 1B) and
significantly altered HOMA-IR and QUICKI indices
(PPC:EtOH , 0.05, Fig. 1C, D). However, there were signifi-
cant sex differences, with females exhibiting lower fasting
insulin concentrations than males, and correspondingly
TABLE 1. Offspring weights and weight gain of U and PC:EtOH-exposed offspring fed a C diet or a HFD
Treatment group Statistics (P values)
U:C PC:EtOH:C U:HFD PC:EtOH:HFD PC:EtOH HFD Interaction
Male
Body weight at weaning (g) 75 6 4 74 6 3 N/A N/A NS N/A N/A
Body weight at 16 wk (g) 475 6 8 479 6 8 490 6 11 480 6 14 NS NS NS
Weight gain wk 17–24 (g) 104 6 7 108 6 4 156 6 16 169 6 8 NS ,0.0001 NS
Weight gain wk 25–32 (g) 54 6 5 57 6 4 105 6 10 94 6 9 NS ,0.0001 NS
Body weight at PM, wk 32 (g) 606 6 16 607 6 13 681 6 22 727 6 45 NS ,0.001 NS
Snout-rump length at PM (cm) 28.5 6 0.2 28.1 6 0.3 28.8 6 0.3 28.8 6 0.5 NS NS NS
Female
Body weight at weaning (g) 72 6 3 66 6 2 N/A N/A 0.06 N/A N/A
Body weight at 16 wk (g) 283 6 6 283 6 4 286 6 3 287 6 6 NS NS NS
Weight gain wk 17–24 (g) 47 6 3 43 6 3 73 6 6 71 6 8 NS ,0.0001 NS
Weight gain wk 25–32 (g) 20 6 2 18 6 2 47 6 4 40 6 6 NS ,0.0001 NS
Body weight at PM, wk 32 (g) 315 6 16 309 6 14 387 6 20 354 6 18 NS ,0.01 NS
Snout-rump length at PM (cm) 23.8 6 0.3 23.0 6 0.3 24.2 6 0.4 23.8 6 0.3 0.06 ,0.05 NS
Body weight at weaning was analyzed with an unpaired t test. All other data was analyzed with a 2-way-ANOVA within each sex with main
effects of PC:EtOH and HFD. Data are represented as mean 6 SEM. PM, postmortem; N/A, no data available; NS, not statistically significant.
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lower HOMA-IR and higherQUICKI indices (Psex, 0.05,
Fig. 1B–D). In theGTT, glucose clearancewas inhibited in
both sexes by PC:EtOH exposure, as indicated by in-
creasedAUGC(PPC:EtOH, 0.01,Fig. 2A,B). Furthermore,
both sexes displayed increased pancreatic insulin output
(AUIC)during theGTT (PPC:EtOH, 0.01, Fig. 2C,D). The
increased insulin response was both acute first-phase
(PPC:EtOH , 0.05, Fig. 2E) and second phase (PPC:EtOH ,
0.001, Fig. 2F). Correspondingly, the AUIC:AUGC ratio
was increased by PC:EtOH exposure (PPC:EtOH , 0.05,
Table 2). In the ITT, glucose clearance fromcirculation in
response to exogenous insulin was decreased by PC:EtOH
in both sexes (PPC:EtOH, 0.01, Fig. 2G, H).
Second, we ascertainedwhether there was an interaction
between PC:EtOH and a PN HFD in metabolic outcomes.
Toexamine this interaction,weanalyzedmales and females
separately. In males, consumption of a HFD augmented
fastingglucoseconcentrations, toa similardegree inbothU
and PC:EtOH (PHFD , 0.001, Table 2). Similarly, fasting
insulin concentrations were also increased following HFD
exposure (PHFD , 0.001, Table 2). However, PC:EtOH-
exposed males that consumed a HFD had 2-fold higher
fasting insulin concentration comparedwithmales of other
treatment groups (Pinteraction , 0.01, Table 2). This in-
teraction of HFD with PC:EtOH resulted in a marked in-
crease in theHOMA-IR index. In theGTT, consumptionof
the HFD did not affect the overall glucose (AUGC) or in-
sulin (AUIC) response, but theHFDdiet did increase acute
first-phase insulin secretion (PHFD , 0.01), and further
exacerbated (P, 0.05) the response to PC:EtOHexposure
(Table 2). In the ITT, the HFD did not affect the glucose
clearance in response to exogenous insulin beyond the
effect of PC:EtOH.
In females, there were generally significant effects of
consuming a PN HFD in the absence of outcomes follow-
ing PC:EtOH exposure (Table 2). The HFD had no effect
on fasting glucose concentrations, but increased fasting
insulin concentrations (PHFD , 0.01, Table 2). This was
associated with altered HOMA-IR and QUICKI indices
(PHFD , 0.01, Table 2). Similarly in the GTT, the AUGC,
AUIC, AUIC:AUGC ratio, and acute first-phase and
second-phase insulin secretion, and theAUGC in the ITT
were all increasedby theHFD(PHFD, 0.05;,0.01;, 0.01;
, 0.01; , 0.01, , 0.05, respectively), but there were no
significant interactions between PC:EtOH and HFD in
females for any of these measures (Table 2).
Hepatic gluconeogenesis
Having established that PC:EtOH exposure resulted in
metabolic dysfunction, we sought to determine whether
this was associated with changes in expression of genes
Figure 1. Effects of PC:EtOH-exposure (black bars) on (A) fasting plasma glucose and (B) insulin concentration in male and
female offspring at 6 months of age. Corresponding homeostatic model assessment (HOMA) of insulin resistance (C) and
QUICKI (D) compared to U:C (white bars). n = 8–12 per group. Data are represented as mean 6 SEM and compared with the
U male group. NS, not significant.
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Figure 2. Plasma glucose clearance following a GTT (A), AUGC generated from the GTT (B), plasma insulin secretion following
a GTT (C), total AUIC generated from the GTT (D) with acute first- and second-phase insulin secretion (E and F). Plasma
glucose concentration following an ITT (G) and the inverted AUGC generated from the ITT (H). All experiments were
performed on male and female offspring at 6 months of age. n = 8–12 for PC:EtOH (black bars) and U (white bars) groups. For
curves: U males (white circles), PC:EtOH males (black circles), U females (white squares) and PC:EtOH females (black squares).
Data are represented as mean 6 SEM and compared with the U male group. NS, not significant.
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regulating hepatic gluconeogenesis. We found that PC:
EtOH exposure increased mRNA expression of G6pc
(PPC:EtOH, 0.01, Fig. 3A), Pck1 (PPC:EtOH, 0.05, Fig. 3C),
Ppargc1a (PPC:EtOH , 0.05, Fig. 3D), and decreased ex-
pression of Gck (PPC:EtOH , 0.01, Fig. 3B) in both sexes.
Overall mRNA expression of Ppargc1a was higher in
females compared with males (Psex , 0.001, Fig. 3D),
whereas Gck was expressed at lower levels in females
than males (Psex , 0.01, Fig. 3B).
The HFD did not affect the gene expression of G6pc,
Pck1, or Ppargc1a in males (Table 3). HFD-fed males had
increased gene expression ofGck (PHFD, 0.01), but there
was no significant interaction of a HFD with PC:EtOH
(Table 3). In females, the HFD had no effect on G6pc,
Ppargc1a, or Gck (Table 3). However, the HFD decreased
gene expression of Pck1 (PHFD , 0.01), and this decrease
was greater in femalesexposed toPC:EtOHcomparedwith
C-fed females (PInteraction, 0.01, Table 3).
Peripheral insulin signaling
As peripheral insulin insensitivity is often due to altered
insulin signaling,weexaminedproteinexpressionofAKT2
and GSK3b and their basal serine/threonine phosphory-
lation states in adipose tissue and skeletal muscle in C-fed
offspring. PC:EtOH-exposed males had higher protein
levels of tAKT2(PPC:EtOH,0.05,Fig. 4A), basal pAKTThr309
(U: 0.71 6 0.34 vs. PC:EtOH: 5.27 6 0.90, P , 0.01), and
pAKTThr309/tAKT ratio (PPC:EtOH , 0.05, Fig. 4A) in adi-
pose tissue compared with U males. Neither pAKTSer474
(U: 1.00 6 0.29 vs. PC:EtOH: 1.11 6 0.31) or the
pAKTSer474/tAKT ratio (Fig. 4A) were different in
adipose tissue between U and PC:EtOH-exposed males.
In skeletal muscle, there was no significant difference in
tAKT2 (U: 1.00 6 0.32 vs. PC:EtOH: 0.77 6 0.11),
pAKTSer474 (U: 1.00 6 0.27 vs. PC:EtOH: 0.70 6 0.17),
or the pAKTSer474/tAKT ratio (U: 1.00 6 0.20 vs. PC:
EtOH: 0.86 6 0.19) between U and PC:EtOH-exposed
males, respectively (data not shown).
In C-fed female offspring, protein levels of tAKT2 in ad-
ipose tissuewere similar inPC:EtOH-exposedandUgroups
(Fig. 4B), but pAKTThr309 (U: 1.00 6 0.12 vs. PC:EtOH:
0.26 6 0.16, P , 0.01), the pAKTThr309/tAKT ratio
(P , 0.01, Fig. 4B), pAKTSer474 (U: 1.00 6 0.12 vs. PC:
EtOH: 0.33 6 0.08, P , 0.001), and the pAKTSer474/
tAKT ratio (P , 0.001, Fig. 4B) were all significantly
lower following PC:EtOH. In skeletal muscle, PC:EtOH-
exposed females had higher protein levels of tAKT
(U: 1.006 0.19 vs. PC:EtOH: 1.496 0.08, P, 0.05). Both
pAKTSer474 (U: 1.006 0.24 vs. PC:EtOH: 0.586 0.18) and
the pAKTSer474/tAKT ratio (U: 1.00 6 0.25 vs. PC:EtOH:
0.506 0.30) were lower following PC:EtOH exposure but
this did not reach statistical significance (P , 0.11) (data
not shown).
Protein levels of tGSK3b and pGSK3bSer9/tGSK3b in
adipose tissue were similar between all C-fed groups (Fig.
4C, D). Similar results for GSK3b were found in skeletal
muscle of both sexes (data not shown).
Fetal liver expression of chromatin modifiers
An adverse environment during the PC periodmay result
in epigenetic changes and thus long-term alterations
TABLE 2. Plasma glucose and insulin chemistry of U and PC:EtOH-exposed offspring fed a C diet or a HFD
Treatment group Statistics (P values)
U:C PC:EtOH:C U:HFD PC:EtOH:HFD PC:EtOH HFD Interaction
Male
Fasting glucose (mmol/L) 7.0 6 0.1 7.6 6 0.2 7.8 6 0.2 8.2 6 0.2 ,0.01 ,0.001 NS
Fasting insulin (pmol/L) 315.0 6 70.0a 437.5 6 70.0a 367.5 6 52.5a 892.5 6 105.0b ,0.0001 ,0.001 ,0.01
HOMA-IR index 0.57 6 0.12a 0.86 6 0.15a 0.75 6 0.12a 1.92 6 0.25b ,0.0001 ,0.001 ,0.01
QUICKI index 0.45 6 0.03 0.40 6 0.01 0.41 6 0.01 0.35 6 0.01 ,0.01 ,0.05 NS
AUGC (GTT) 1020 6 46 1206 6 47 1054 6 55 1217 6 48 ,0.01 NS NS
Total AUIC (GTT) 238 6 59 493 6 86 285 6 39 695 6 88 ,0.0001 NS NS
AUIC (first phase) (GTT) 26 6 5a 40 6 8a 30 6 5a 78 6 11b ,0.001 ,0.01 ,0.05
AUIC (second phase) (GTT) 194 6 51 422 6 73 235 6 34 565 6 71 ,0.0001 NS NS
AUIC/AUGC 0.23 6 0.05 0.41 6 0.07 0.26 6 0.04 0.55 6 0.07 ,0.001 NS NS
AUGC (ITT) 1521 6 57 1280 6 94 1316 6 58 1308 6 63 ,0.05 NS NS
Female
Fasting glucose (mmol/L) 6.9 6 0.2 7.0 6 0.2 7.5 6 0.3 7.4 6 0.4 NS NS NS
Fasting insulin (pmol/L) 175.0 6 35.0 227.5 6 35.0 402.5 6 87.5 455.0 6 87.5 NS ,0.01 NS
HOMA-IR index 0.31 6 0.07 0.42 6 0.09 0.82 6 0.18 0.93 6 0.20 NS ,0.01 NS
QUICKI index 0.51 6 0.03 0.46 6 0.02 0.41 6 0.05 0.42 6 0.03 NS ,0.01 NS
AUGC (GTT) 1023 6 21 1115 6 57 1211 6 65 1191 6 57 NS ,0.05 NS
Total AUIC (GTT) 190 6 39 277 6 25 466 6 94 502 6 99 NS ,0.01 NS
AUIC (first phase) (GTT) 17 6 2 25 6 4 42 6 8 45 6 9 NS ,0.01 NS
AUIC (second phase) (GTT) 160 6 37 231 6 21 392 6 85 424 6 85 NS ,0.01 NS
AUIC/AUGC 0.20 6 0.04 0.26 6 0.03 0.37 6 0.06 0.41 6 0.07 NS ,0.01 NS
AUGC (ITT) 1544 6 49 1357 6 69 1263 6 52 1168 6 40 ,0.01 ,0.001 NS
Fasting glucose and insulin concentrations were before GTT, and basal glucose concentrations were before ITT. Data were analyzed with
a 2-way ANOVA with post hoc Tukey’s multiple comparison test. NS, not statistically significant. a,bValues with different superscript letters are
significantly different from each other (P , 0.05).
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in gene expression, which have been implicated as an
underlying mechanism in the development of meta-
bolic disease (10, 18). We therefore examined expres-
sion levels of key chromatin modifiers, namely HDACs
and DNMTs in fetal liver following PC:EtOH exposure.
PC:EtOH exposure increased mRNA expression of
Dnmt1, Dnmt3a, and Dnmt3b in liver from fetuses on
E20 (PPC:EtOH , 0.05, Fig. 5A–C) but had no effect
on Hdac2, Hdac3, Hdac4, or Hdac6 mRNA levels (data
not shown).
DISCUSSION
Our data demonstrate for the first time that maternal al-
cohol consumption for a short period exclusively during
the PC period impairs glucose tolerance and decreases
insulin sensitivity in both male and female adult offspring
at 6 months of age. This metabolic phenotype was associ-
atedwith increased hepatic gluconeogenesis in both sexes,
indicated by increased levels of G6pc, Pck1, and Ppargc1a
and decreased levels of Gck mRNA, although increased
fasting glucose concentrations was only apparent in
males. Furthermore, sex-specific alterations in AKT2 sig-
naling were observed in peripheral tissues. Importantly,
consumption of a PN HFD exacerbated both fasting
insulin concentrations and acute first-phase insulin
secretion during theGTTmore than 2-fold in PC:EtOH-
exposed male offspring relative to PC:EtOH exposure
or a HFD alone. Our data demonstrate that PC:EtOH
exposure around the time of conception is sufficient to
cause a prediabetic insulin insensitive state in bothmale
and female offspring, with significant interactive effects
of HFD and PC:EtOH in male but not female offspring.
Analysis of fetal liver mRNA in late gestation demon-
strated altered expression of multiple DNMT, suggest-
ing that long-term metabolic outcomes following
PC:EtOH may partly derive from changes in methyla-
tion status.
Several animal studies have previously linked mater-
nal alcohol consumption during pregnancy to insulin
resistance and glucose intolerance in offspring post-
natally (4, 6, 23). Maternal EtOH exposure throughout
pregnancy [gavage of 2g/kg EtOH twice daily, or;13%
of energy as EtOH (E%) daily] impairs glucose toler-
ance in rat offspring at 3 months of age, despite hyper-
insulinemia (23). Indeed, persistent hyperinsulinemia
is reported to occur from the first day of PN life in the
rat following maternal EtOH exposure throughout
pregnancy (25% in drinking water,.30E%) (6). This is
Figure 3. The effect of PC:EtOH-exposure (black bars) on hepatic mRNA levels of G6pc (A), Gck (B), Pck1 (C) and peroxisome
proliferator-activated receptor-g coactivator a (Ppargc1a) (D) compared with U:C (white bars) in male and female offspring at
8 months of age, n = 6–8 per group. Values are expressed as relative gene expression levels normalized to endogenous control
ribosomal 18s. Data are represented as mean 6 SEM and compared with the U male group. NS, not significant.
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consistent with our own data that more moderate ma-
ternal alcohol consumption (6% v/v via a liquid diet,
;15E% daily) throughout pregnancy results in hyper-
insulinemia in male but not female rat offspring at
4 months of age (7). Collectively, these studies highlight
that maternal alcohol consumption during pregnancy
can alter glucose metabolism in offspring. Here for the
first time, we report that alcohol consumption (12.5%v/v,
or ;22E%) solely during the PC period (4 days before
conception until day 4 of gestation) is sufficient to
program similar metabolic responses in offspring later
in PN life.
Although insulin directly inhibits de novo glucose
output from the liver to the bloodstream by suppressing
gluconeogenesis (24), it is well characterized that he-
patic glucose output remains high in an insulin-resistant
state (25). Intriguingly, in our study, fasting plasma
glucose concentrations were increased, especially in
males following PC:EtOH exposure, indicating in-
creased hepatic gluconeogenesis (26). In contrast, PC:
EtOH-treated females were euglycemic and exhibited
better insulin sensitivity (lower HOMA-IR and higher
QUICKI indices) than males. To further examine glu-
coneogenesis in our animals, we investigated alterations
in hepatic gene expression. We found that PC:EtOH
exposure increased the relative gene expression of the
rate-limiting gluconeogenic enzyme Pck1 (27). Rela-
tively small increases in Pck1 gene expression are known
to be sufficient to increase hepatic gluconeogenesis and
impair glucose tolerance (28). Interestingly, glucose
intolerance associated with increased hepatic Pck1 ex-
pression has also been demonstrated in offspring fol-
lowing prenatal protein restriction (29) and maternal
glucocorticoid administration (30). Levels of Ppargc1a
mRNA, a transcription factor that stimulates the ex-
pression of Pck1 and G6pc (31), were also increased
following PC:EtOH exposure as were levels of G6pc
mRNA, despite hyperinsulinemia. Increased gluconeo-
genesis associated with increased basal gene expres-
sion of both Pck1 and Ppargc1a has previously been
demonstrated in rats prenatally exposed to alcohol
throughout pregnancy (5). Furthermore, Gck gene ex-
pression was decreased in PC:EtOH-exposed offspring,
consistent with an insulin-resistant phenotype (32).
Collectively, our data suggest that increased hepatic
glucose output contributes to the insulin insensitive
phenotype in both PC:EtOH-exposed male and female
offspring.
Although debatable, insulin resistance often pre-
cedes any impairment of b-cell function (33). Blood
glucose levels can be normal or near normal as the b
cells hypersecrete insulin to compensate for the de-
veloping insulin resistance (34). In our study, PC:EtOH-
exposed offspring displayed only minor increases in
fasting insulin and no loss of either first- or second-
phase insulin secretion during the GTT. Instead, hy-
persecretion of insulin in response to a glucose load was
observed, indicative of b-cell compensation. Further-
more, reduced responsiveness of PC:EtOH-exposed
offspring to exogenous insulin (ITT) confirmed an
insulin-insensitive phenotype. Therefore, our results
support the notion that the effect of PC:EtOH exposure
is most probably attributed to dysregulation in tissue-
specific insulin signaling (insulin insensitivity) and re-
sultant pancreatic b-cell compensation, rather than PC:
EtOH exposure causing a direct pancreatic defect, such
as b-cell failure (8, 17).
We consequently investigated AKT2 activation in
adipose tissue and skeletal muscle, which is necessary
for GLUT4 translocation and insulin-mediated glucose
uptake (8, 24). Because consumption of the HFD did
not exacerbate the already impaired insulin sensitivity,
we quantified AKT2 levels only in U and PC:EtOH-
exposed C-fed offspring. Given the phenotypes of im-
paired glucose tolerance and insulin insensitivity in
PC:EtOH offspring, we expected AKT2 activity to be
decreased in peripheral tissues. Indeed, female off-
spring exposed to EtOH during the PC period had
decreased AKT2 phosphorylation in adipose tissue
(Ser474 and Thr309), and in skeletal muscle Ser474
TABLE 3. Relative mRNA levels of hepatic genes of U and PC:EtOH-exposed offspring fed a C or a HFD
Treatment group Statistics (P values)
U:C PC-EtOH:C U:HFD
PC-EtOH:
HFD
PC-
EtOH HFD Interaction
Male
G6pc 1.09 6 0.19 1.62 6 0.39 1.15 6 0.21 1.40 6 0.28 NS NS NS
Gck 1.08 6 0.17 0.80 6 0.34 1.82 6 0.19 1.58 6 0.37 NS ,0.01 NS
Pck1 1.08 6 0.17 1.52 6 0.18 1.05 6 0.21 1.34 6 0.21 0.07 NS NS
Ppargc1a 1.29 6 0.30 1.66 6 0.34 1.78 6 0.55 2.23 6 0.56 NS NS NS
Female
G6pc 1.07 6 0.13 2.08 6 0.42 2.06 6 0.40 1.48 6 0.39 NS NS ,0.05
Gck 1.17 6 0.24 0.72 6 0.18 1.11 6 0.25 0.86 6 0.18 NS NS NS
Pck1 1.07 6 0.13a,b 1.60 6 0.20b 1.07 6 0.15a,b 0.80 6 0.10a NS ,0.01 ,0.01
Ppargc1a 1.14 6 0.19 1.80 6 0.22 0.84 6 0.15 1.34 6 0.22 ,0.01 0.06 NS
All data were analyzed with a 2-way-ANOVA compared with the U:C group for each sex. Data are
represented as mean 6 SEM. NS, not statistically significant. a,bMean values with different superscript letters
are significantly different with post hoc Tukey’s multiple comparison test. Values with different superscript
letters are significantly different to each other (P , 0.05).
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phosphorylation tended to be decreased. Such de-
creases in phosphorylation of AKT2 are consistent
with lower basal kinase activity (Thr309) and reduced
“full” kinase activity in response to insulin (Ser474)
(35). Paradoxically, in PC:EtOH-exposed male off-
spring, there was an increase in tAKT2 in adipose tis-
sue, which might improve insulin sensitivity (36).
Similar increases in tAKT2 have been demonstrated
in skeletal muscle of twin sheep offspring exposed to
PC undernutrition (37), and in male but not female
offspring of obese mice (38). Such up-regulation of
tAKT2 levels is possibly a compensatory mechanism
and may be a direct result of increased basal insulin
levels (40% higher in PC:EtOH-exposed males).
Moreover, the ratio of Thr309 phosphorylation to total
AKT2 was also increased in adipose tissue of PC:EtOH-
exposed male offspring, affirming the idea of increased
insulin signaling in this tissue. These apparently disparate
results in adipose tissue of male PC:EtOH-exposed off-
spring require further investigation as increased phos-
phorylation at Thr309 together with tAKT2 may be
related to signaling pathways mediating adipogenesis
and/or angiogenesis (39, 40).Notwithstanding these sex-
specific effects on insulin signaling in peripheral tissues,
Figure 4. The effect of PC:EtOH exposure (black bars) on protein levels in white intra-abdominal adipose tissue in male and
female offspring at 8 months of age compared to U:C (white bars), n = 4–6 per group. Total (t)AKT2 levels, phosphorylated (p)
AKTThr309/tAKT ratio and the pAKTSer474/tAKT ratio in males (A) and females (B). tGSK3b and the pGSK3bSer9/tGSK3b
ratio in males (C) and females (D). Values for the protein levels are normalized to b-actin. Data are represented as mean 6 SEM.
*P , 0.05; **P , 0.01; ***P , 0.001 by Student’s t test.
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our data suggest maternal alcohol consumption during
the PC period programs a phenotype that is consistent
with metabolic dysfunction and insulin resistance.
There is growing evidence that perturbations
around periconception can result in epigenetic mod-
ifications such as DNA methylation or histone acetyla-
tion, which have been implicated as an underlying
mechanism in the development of metabolic dis-
ease (10, 18, 41). Key effectors are DNMTs, histone
acetyltransferases, and histone deacetylase (HDAC)
proteins, respectively. Maternal alcohol consumption
(E1–E7) has previously been linked to increased adult
hepatic gluconeogenesis in association with increased
class II HDAC protein activity (42). Although we did
not observe changes in fetal liver Hdac mRNA expres-
sion, we cannot rule out the possibility that protein
activity of these chromatin modifiers is altered in our
model to impact on chromatin accessibility. Levels of
expression of Dnmt genes, however, were significantly
increased in the fetal liver at E20 suggesting long-term
alterations inmethylation status. This is consistent with
other recently published data showing dysregulation of
hippocampal DNMT activity without changes inHDAC
activity in a rat model of early life alcohol exposure
(43). It is tempting to speculate that increased Dnmt
expression and consequent hypermethylation may
provide the link between PC:EtOH and alterations in
gene expression associated with the metabolic phe-
notype observed. Consistent with our data, Ppargc1a
expression is reduced by hypermethylation of the
PPARGC1A promoter in patients with diabetes (44)
and correlates positively with fasting plasma insulin
levels and HOMA-IR (45).
Other studies have demonstrated altered insulin and
glucose dynamics following maternal PC methionine
deficiency in sheep (18) and rats (41). Methionine pro-
vides methyl groups for the production of S-adenosyl
methionine, a substrate for DNMTs. Significantly, we
have previously demonstrated decreased expression of
the major methionine transporter, Slc38a2, in the pla-
centa following PC:EtOH (14). Intriguingly, global DNA
methylation is increased in response to either methio-
nine or choline deficiency through pregnancy (18, 46),
and this is associated with increased expression of Dnmts,
which is driven by hypomethylation of the Dnmt1 pro-
moter (46). Data from mice suggest that a perturbed
preimplantation environment can also alter levels of the
de novo Dnmt3l (47). This potentially impacts on de novo
genomewide methylation following resetting of epige-
netic marks that occurs during this stage are also consis-
tent with our data. Early embryonic alcohol exposure
has also been demonstrated to result in allele-specific
changes in methylation patterns of theH19/Igf2 domain
in the placenta of mice, which may contribute to growth
restriction (48).
In conclusion, our data establish that maternal con-
sumption of alcohol during the PC period programs
impaired glucose tolerance and insulin insensitivity in
offspring, whichwas associatedwith altered expression of
key modifiers of fetal methylation status. Although these
conditions are evident in both males and females, dysre-
gulation of peripheral insulin signaling appeared to be
sexually dimorphic with male offspring being more sus-
ceptible than female offspring to a combination of PC:
EtOHexposure and a PNHFD.These novelfindings have
important clinical implications for women wanting to
conceive and bear healthy children.
The authors acknowledge the funding provided by the
National Health and Medical Research Council of Australia
(1046137), and thank Kerri Tyrell, School of Biomedical
Sciences, The University of Queensland, for expert assistance
with the insulin assay.
Figure 5. The effect of PC:EtOH exposure (black bars) on
fetal hepatic mRNA levels of DNA methyltransferase (Dnmt)1
(A), Dnmt3a (B), and Dnmt3b (C) compared with U offspring
(white bars) in males and females on E20, n = 9–11 per group.
Values are expressed as relative gene expression levels normal-
ized to endogenous control ribosomal 18s. Data are represented
as mean 6 SEM and compared with the U male group. NS, not
significant.
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